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Preface
The work presented in this thesis was carried out during my Ph.D. studies at Technical
University of Denmark (DTU), the first year under the supervision of former Professor
Thomas Eiland Nielsen (Director at Novo Nordisk), and subsequently under the super-
vision of Senior Researcher Katrine Qvortrup. A six-month external stay was carried out
under the supervision of Assistant Professor Liang Yang and Research Director Professor
Michael Givskov at the Singapore Centre for Environmental Life Sciences Engineering
(SCELSE), and Professor Choon-Hong Tan at the Division of Chemistry and Biological
Chemistry at the School of Physical and Mathematical Sciences, Nanyang Technological
University (NTU).
The dissertation covers four projects and illustrates a multidisciplinary Ph.D. divided into
three Chapters. In Chapter 2, the development of an UV-labile protecting group for hy-
droxylamines is presented: its use for the synthesis of N-alkylated hydroxamic acids and
an orthogonality study. The synthesis of N-alkylated hydroxamic acids, is an extension of
my master project, where the methodology was developed. Chapter 3 describes the de-
velopment of a synthetic approach towards histone deacetylase inhibitors. The inhibitors
are based on a sub-class selective substrate previously found. The histone deacetylase
enzymes are important for the regulation of a variety of diseases, especially cancer. We
wanted to use this information to transform the substrate into an inhibitor. The research
covered in Chapter 4 was carried out in collaboration with the Yang and Tan group at
NTU, Singapore, to synthesize itaconimides with novel quorum sensing inhibitor prop-
erties.
During my Ph.D. I have been involved in other projects, which I have decided not to
include in this dissertation. The projects comprise of a synthesis of novel oligopeptides
as efflux pump inhibitors, synthesis of pyrazolones, a total synthesis of Desferal, and the
synthesis of 2-mercaptobenzothiazole building blocks for quorum sensing inhibitors.
Kim Thollund Mortensen Date
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Abstract
Photo-cleavable protecting groups are highly applicable for the synthesis of structural
complex and sensitive compounds, including biological important molecules. Herein, we
present the development of a novel O-hydroxylamine photo-cleavable protecting group,
based on the methyl-6-nitroveratryl moiety. We demonstrate the application of the pro-
tected hydroxylamine derivative for the synthesis of N-alkylated hydroxamic acids. We
have shown that the construct is stable toward a diverse set of reaction conditions, as
well as orthogonal with conventional protection groups. The O-protected hydroxylamine
derivative was applied to synthesize a small collection of N-alkylated hydroxamic acids
as inhibitors of the histone deacetylase enzymes, an important class of enzymes for the
treatment of a range of diseases, most importantly cancer.
During my external stay at Nanyang Technological University, Singapore, I worked on
a project with the aim of synthesizing compounds that target the quorum sensing net-
work in Pseudomonas aeruginosa, important for the treatment of bacterial infections. The
structure was based on a recent found hit compound, by our collaborators in Singapore,
showing high activity.
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Resume´
Lysfølsomme beskyttelsesgrupper er attraktive til syntese af komplekse, sensitive kemiske
forbindelser, heriblandt biologisk interessante molekyler. Dette projekt præsenterer ud-
viklingen af en ny O-hydroxylamin lyskløvbar beskyttelsesgruppe baseret pa˚ methyl-
6-nitroveratryl gruppen. Vi demonstrerer anvendelsen af det beskyttede hydroxylamin
derivat til dannelse af N-alkylerede hydroxamsyrer. Vi demonstrerer, at denne gruppe
er stabil overfor forskellige reaktionsbetingelser, sa˚ vel som ortogonal overfor konven-
tionelle beskyttelsesgrupper. O-Beskyttet hydroxylamin derivatet blev brug til at syn-
tetisere en stofsamling af N-alkylererede hydroxamsyrer med det forma˚t at identificere
selektive histon deacetyltransferase enzymer inhibitorer. Histon deacetyltransferase en
vigtig klasse af enzymer for behandlingen af en række lidelser, ikke mindst kræft.
Under mit udlandsophold pa˚ Nanyang Teknologiske Universitet, Singapore, arbejdede
jeg pa˚ et projekt, hvor ma˚let var at fremstille forbindelser, som inhiberer quorum sensing
netværket i Pseudomonas aeruginosa. Sa˚danne stoffer er vigtige til behandling af bakterielle
infektioner. Den strukturelle opbygning af inhibitorerne var baseret pa˚ en forbindelse,
som vores samarbejdspartner for nylig identificerede.
v
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Chapter 1
Introduction
Hydroxamates are an important class of compounds owing to their presence in numer-
ous biologically active molecules. Therefore, the implication of chemical strategies for
high-throughput generation of structurally diverse hydroxamic acids is self-evident. Hy-
droxamic acids represent the largest class of histone deacetylase inhibitors. These com-
pounds are important because histone acetylation affects both chromatin packing and
recruitment of transcription factors and thus affecting gene expression in the cell. Sev-
eral potent histone deacetylase inhibitors have entered clinical trials for treatment of var-
ious types of cancer. Furthermore, individual histone deacetylase enzymes have also
been linked to a variety of non-cancerous diseases, including neurodegenerative disor-
ders, chronic pain, and cystic fibrosis, as well as affect learning and memory. Therefore,
substrates for efficient and accurate profiling of histone deacetylase subtypes are highly
desirable. The present dissertation aims to develop mild and reliable chemical strategies
for high-throughput synthesis of a broad range of structurally diverse hydroxamic acids.
While, hydroxamic acids may be obtained by the use of acid- or base-cleavable protecting
groups, these strategies are not compatible with structurally elaborate hydroxamic acids.
The application of strong acids and bases with these strategies limit the range of chem-
ical transformations that are applicable for the synthesis of hydroxamic acids and other
protecting group principles are necessary to provide a further dimension to the chemi-
cal diversity. Completely orthogonal protection systems are only offered with relatively
few sets of cleavage conditions, photolysis being one of them. Furthermore, photolytic
cleavage offers a chemoselective and mild method of cleavage, which is particularly at-
tractive when synthesizing highly functionalized biologically active compounds, which
may not be tolerant of more harsh conditions, such as acidic- or basic-labile or metal-
catalyzed hydrogenation. A key goal of the project will be to develop a hydroxamic acid
photo-cleavable protecting group for the synthesis of highly functionalized biologically
relevant hydroxamic acids.
1

Chapter 2
Development of a Hydroxylamine
Photo-labile Protecting Group for the
Synthesis of Hydroxamic Acids
2.1 Introduction
Protecting groups (PGs) are a vital tool in organic chemistry, but also pose several dis-
advantages. In order to synthesize molecules with various functional groups, the ability
to block and unblock reactivity in a controlled way is essential. However, two steps are
added to the total step count, the protection and the deprotection. The protecting group
will limit the type of chemistry that can be conducted on the scaffold, as conditions that
will result in deprotection cannot be employed. Furthermore, the desired end product
need to be stable towards the deprotection conditions.
UV-light removable protecting groups pose several advantages such as mild release of
functionalized molecules and high orthogonality to most functional groups. The de-
velopment of PGs which are cleaved upon UV-exposure, so-called photo-labile protect-
ing group s, have been employed for several decades. The mild photolytic cleavage
conditions have been utilized to protect anything from adenosine triphosphate (ATP)
(”caged ATP”)2 to highly complex molecules showcased by the K. C. Nicolaou3 synthesis
of Calicheamicin-γ-1I . In the Nielsen group and Qvortrup group, photo-labile protecting
groups have been developed for the synthesis of bioactive molecules.
For an introduction to photo-labile protecting groups and an overview of the diverse
photo-mediated deprotection strategies, a review written by Petr Kla´n is recommended.4
The ortho-nitrobenzyl group have attracted much attention in the last decades. We uti-
lized this scaffold to produce an O-photo protected hydroxylamine for the generation of
protected hydroxamates which liberates hydroxamic acids upon UV-light exposure. Hy-
droxamic acids have attracted much attention as inhibitors of metalloenzymes involved
in the regulation of cancer. The biological importance of the hydroxamic acids are ex-
plained in greater detail in Chapter 3.
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2.2 The Use of ortho-Nitrobenzyl as an Efficient
Photo-labile Protecting Group
”Release” from ortho-nitrobenzyl compounds were reported already in the beginning of
the 20th century.5 This was further investigated by Barltrop and Schofield, who worked
on the ortho-nitrobenzyl alcohol and showed the release of carboxylic acids under mild
conditions from the corresponding esters.6 However, the authors experienced low yields
and the formation of a by-product. The photolytic by-product, ortho-nitroso benzalde-
hyde self-condensate which decreased the accessibility of the UV-light. The authors
quickly realized that this could be prevented by introducing a substitution in the ben-
zylic position, to afford the less reactive ortho-nitroso ketone by-product. As well the in-
troduction of a carbamate group to selectively release amines proved to be advantageous.
Woodward employed the 6-nitroveratryloxycarbonyl (NVOC) and 2-nitrobenzyloxycar-
bonyl (NBOC), Figure 2.1, to protect and liberate amine functionalities.7 However, the
photo-release performed poorly. This was rationalized to be a consequence of the un-
desired imine formation between the nitroso benzaldehyde by-product and the amino
group. To prevent this, again a substitution in the benzylic position showed to be bene-
ficial. The introduction of two methoxy groups in the phenyl ring, MeNV, provided an
improved energy absorption profile with a rapid deprotection.8
O
NO2
X
NO2
X
O
X
NO2
MeO
MeO
O
NO2
MeO
MeO
X
O
NVOC NBOCoNB MeNV
Figure 2.1: Literature reported UV-removable protecting groups
Knowledge from previous work gave inspiration for a protecting group useful in this
work.9–12 In this study a photo-protected hydroxylamine derivative was developed based
upon MeNV, Figure 2.1. In my master project, we aimed to apply this photo-labile group
for a synthesis of a broad range of hydroxamic acids. The aim was to synthesize and eval-
uate N-alkylated hydroxamic acids based on the construct of suberoylanilide hydroxamic
4
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acid (SAHA) and furthermore, to use a photo-labile protecting group for the synthesis of
diverse hydroxamic acids. Two papers were published last year by two different groups,
one with the photo-protection of SAHA and the other with the synthesis of N-alkylated
SAHA analogues.13,14
O-MeNV hydroxylamine 2.5 was previously developed in the Nielsen group.12 The syn-
thesis commenced from the commercially available 3’-4’-dimethoxyacetophenone 2.1,
Scheme 2.1. The nitration performed in high yield (79%) using HNO315 to give 2.2, which
was further reduced to the alcohol 2.3 with NaBH4 in excellent yield (97%). Chlorination
of the resulting alcohol, and introduction of the hydroxylamine moiety was performed
in high yield over two steps (72%). This afforded the N-hydroxylamine phthalimide 2.4
in a few steps without the need of flash column chromatography starting from a cheap
starting material. The phthalimide group was removed by hydrazine to the free O-MeNV
hydroxylamine 2.5, or precipitated as its O-MeNV hydroxylamine hydrochloride salt 2.7.
Moreover, the Boc-protected O-MeNV hydroxylamine 2.6 could also be obtained in ex-
cellent yield (93%).
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O
OMe
MeO
O
OMe
MeO
NO2
OH
OMe
MeO
O
OMe
MeO
NO2
O
OMe
MeONPhth
NH2
NO2
NO2 1) SOCl2, CH2Cl2
2) PhthN-OH, Et3N
DMF, 82 oC
0 oC to rt
79%
HNO3
MeOH, 0 oC to rt
97%
NaBH4
71% (two steps)
O
OMe
MeO
NH2HCl
NO2
1) H2NNH2  H2O
EtOH, reflux
98%
EtOH, reflux
1) H2NNH2  H2O
2) HCl (1.0 M in Et2O)
96% (two steps)
PhthN =
O
O
N
O
OMe
MeO
NHBoc
NO2Boc2O, 1 M NaHCO3 (aq.)
dioxane
93%
2.1 2.2 2.3
2.4
2.5 2.6
2.7
Scheme 2.1: Synthesis of O-hydroxylamine protecting group
During my Ph.D. I chose to precipitate the crude photo-protected O-hydroxylamine deriva-
tive 2.5 as its hydrochloride salt, which was easier to handle.
2.2.1 Synthesis of N-Alkylated Hydroxamic Acids
Hydroxamic acids are important bioactive compounds that has shown inhibition activity
against histone deacetylase (HDAC) enzymes. Unregulated activity of these enzymes has
been linked to various cancer types. Biological importance of HDACs and their role in
the epigenetic machinery is described in Chapter 3. SAHA was the first United States
Food and Drug Administration (FDA) approved hydroxamic acid for treatment of cuta-
neous T-cell lymphoma (CTCL). SAHA is recognized as a pan-inhibitor, which may be
the reason for the observed adverse effects. We wanted to explore the effects of intro-
ducing N-alkylated hydroxamic acids, as we hoped it would result in higher selectivity
profile. The synthetic strategy is illustrated in Scheme 2.2.
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O
NHPh
O
HO
O
OMe
MeO
NH
NO2
R
+
O
NHPh
O
O
OMe
MeO
N
NO2
R
O
NHPh
O
HN
OH
SAHA
N-alkylated O-photo-protected SAHA library
O-photo-protected hydroxylamines
2.8
Scheme 2.2: Synthetic overview for N-alkylated hydroxamic acids
Suberanilic acid 2.8 was synthesized using a reported procedure by Mai et al.16 To ob-
tain the desired N-alkylated hydroxylamines, we first investigated the reductive alky-
lation approach using commercially available aldehydes and ketones. During my mas-
ter project, I prepared mono-alkylated O-MeNV hydroxylamines by a one-pot approach.
Oximes were in situ generated from the hydroxylamine 2.5 with aldehydes and ketones
under acidic conditions and subsequently reduced with the addition of NaBH3CN. The
pH is crucial for selective mono-alkylation.17
The oxime formation and the following reduction of the oxime performed well with
aliphatic aldehydes and ketones. However, we experienced that aryl oximes were dif-
ficult to reduce. When using benzaldehyde, we had to add several portions of NaBH3CN
(5.0 equiv. in total) to obtain full conversion. Therefore, we changed the strategy for the
synthesis of substituted N-benzylated hydroxylamines to use a direct alkylation strat-
egy from N-Boc O-MeNV hydroxylamine 2.6. Maria Birgitte Routhe Rasmussen and
Kasper Juul Møller joined the group and helped me to extend the substrate scope of the
N-alkylated SAHA analogues by a reductive alkylation approach with aliphatic aldehy-
des or a direct alkylation approach with substituted benzyl halides or O-mesylates (Ms).
All the reactions are summarized in Table 2.1.
To obtain the N-alkylated hydroxamic acids, the N-alkylated O-MeNV hydroxylamines
were acylated with suberanilic acid 2.8. When the O-MeNV hydroxylamines were alky-
lated, if not a Me group, it was impossible to obtain efficient acylation with the standard
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coupling reagent, (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate
(PyBOP). BTC (bis-(trichloromethyl)carbonate) has been described to facilitate reactions
on hindered substrates or substrates where standard SPS coupling reagents were found
to be inefficient.18–20 BTC is also known under the name triphosgene, due to the conver-
sion into three phosgene molecules. An overview of all the synthesized SAHA analogues
are shown in Table 2.1.
Table 2.1: Overview of N-alkylated SAHA compound collection
NR'R''
O
NO2
OMe
MeO
NR''''
O
NO2
OMe
MeO
R'''
N
O
NO2
OMe
MeO
R''' O
CONHPh
or
MeCN, 0 oC
2) R'''CH2X
rt or heat
TFA, EtOH
2) NaBH3CN, rt PyBOP, NEM, DMF
C)
or
BTC, 2,4,6-collidine
THF
D)B) 1) NaH (60%)
A) 1) R'''CHO
3) CH2Cl2:TFA
2.8
2.8
Entry R’ R” X Alkylation R”’ R”” Yield (%) Acylation Yield (%)
A or B C or D
1 H H - -a H2.8 H 73 C 69
2 H H - Ab 2.8 H 86 D 77
3c H H ·HCl - Ad 2.8 H 71 D 54
4c H H ·HCl - Ad,e F3C2.8 H 50 D 51
5 H H - A 2.8 H 68 D 93
6c H H ·HCl - Ad 2.8 H 29 D 74
7c H H ·HCl - Ad,e 2.8 H 87 D 57
8c H H ·HCl - Ad O2.8 H 63 D 73
9f Boc H Br A O2.8 H 87 D 61
10f Boc H Br A OO2.8 H 69 D 70
11 H H - A 2.8 H 67 D 88
12 H H - Ab 2.8 H 97 D 69
continued on next page
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Entry R’ R” X Alkylation R”’ R”” Yield (%) Acylation Yield (%)
A or B C or D
13 H H - Ab 2.8 H 88 D 54
14 H H - A 2.8 H 74 D 91
15 H H - A 2.8 H 97 D 63
16c H H ·HCl - Ad,e 2.8 H 85 D 76
17c H H ·HCl - Ad,e 2.8 H 79 D 60
18c H H ·HCl - Ad,e 2.8 H 76 D 84
19c H H ·HCl - Ad,e 2.8 H 60 D 50
20 H H - A 2.8 H 89 D 69
21g Boc H Br B
F
2.8 H ·TFA 83 D 43
22g Boc H Br B
CF3
2.8 H ·TFA 81 D 62
23g Boc H OMsh B
OMe
2.8 H ·TFA 88 D 66
24g Boc H OMsi B
SMe
2.8 H ·TFA 89 D 54
25g Boc H Clj B N2.8 H ·TFA 67 D 45
continued on next page
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Entry R’ R” X Alkylation R”’ R”” Yield (%) Acylation Yield (%)
A or B C or D
26g Boc H OMsh B
N
H2.8 H ·TFA 81 D 74
27g H H - A S2.8 H 43 D 79
28 Boc H Brh B 2.8 H ·TFA 55k D 26
Procedure A (reductive alkylation): aldehyde and 2.5 or 2.7 were mixed together in EtOH with TFA. Corresponding oxime was
reduced with the addition of NaBH3CN. Procedure B (direct alkylation): N-Boc O-MeNV hydroxylamine 2.6 was alkylated under
NaH-conditions with an alkylating agent. Boc-Deprotection: Boc-protected hydroxylamines were dissolved in CH2Cl2 and added
TFA. Procedure C (acylation): the N-methyl O-MeNV hydroxylamine was acylated with suberanilic acid 2.8 mediated by PyBOP and
NEM in DMF. Procedure D (acylation): the N-alkylated O-MeNV hydroxylamines were acylated with suberanilic acid 2.8 mediated
by BTC and 2,4,6-collidine in THF (a) oxime formation utilizing a literature procedure.21 (b) oxime formation was performed under
reflux (c) performed by Maria Birgitte Routhe Rasmussen (d) heat was applied to obtain full conversion to the oxime (e) oxime
formation carried out at 50 °C (f) made in the collaboration with Katrine Qvortrup (g) performed by Kasper Juul Møller (h) from the
commercially available alcohol and mesylated22 (i) obtained by reduction of the commercially available aldehyde and reduced with
NaBH4 in EtOH and mesylated22 (j) from the commercially available hydrochloride salt (k) refluxed for 3 days
We have previously observed that photolytic cleavage of this type of compounds result
in a mixture of the hydroxamic acid and the corresponding amide (unpublished results).
During my master thesis, I show that acceptable selectivity for the hydroxamic acid over
the amide could be obtained with a solvent mixture of iPrOH:1 M HCl (aq.) (10:1). Using
acidic conditions limits the substrate scope and therefore, the goal was to find non-acidic
solvent mixtures affording hydroxamic acid selectivity during photolytic cleavage.
10
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2.3 Investigation of the O-MeNV Hydroxylamine
Protecting Group Stability
To demonstrate the compatibility of the photo-labile protecting group, we synthesized
a library of compounds, Table 2.4 and Table 2.5, containing various conventionally used
protecting groups, Table 2.3, and demonstrated selective removal of one protecting group
over another.
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Table 2.3: Applied conventional protecting groups
Entry PG Abbreviation Structure
1 benzyl Bn
2 allyl All
3 methoxymethyl MOM O
4 acetyl Ac
O
5 tert-butyldimethylsilyl TBS
Si
6 tetrahydropyranyl THP O
7 benzyloxycarbonyl Cbz
O
O
8 9-fluorenylmethoxycarbonyl Fmoc
O
O
9 allyloxycarbonyl Alloc
O
O
10 tert-butoxycarbonyl Boc
O
O
12
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Table 2.4: Synthesis of hydroxamates containing conventional protecting groups
NH2
O
NO2
OMe
MeO
PyBOP, NEM, DMF
HN
O
NO2
OMe
MeO
O
X
PGO
X
PGHO R
R
s2.5
Entry Carboxylic acid R X PG Product Yield (%)
1 2.14 2.5 O Bn 2.15 91
2 2.16
S
2.5 O All 2.17 78
3 2.18 2.5 O MOM 2.19 80
4 2.20 2.5 O Ac 2.21 67
5 2.22 2.5 NH Cbz 2.23 84
6 2.24
S
2.5 NH Fmoc 2.25 73
7 2.26 I
(S)
2.5 NH Alloc 2.27
8 2.28 2.5 NH Boc 2.29 95
13
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To obtain the TBS and THP protected compounds, 5-(hydroxymethyl)thiophene-2-car-
boxylic acid and 4-(hydroxymethyl)benzoic acid (HMBA) were coupled to the protecting
group 2.5 resulting in the hydroxy-functionalized hydroxamates. The hydroxy group was
afterwards protected by TBSCl or 3,4-dihydro-2H-pyran (DHP), Table 2.5.
Table 2.5: Synthesis of TBS- and THP-containing hydroxamates
NH2
O
NO2
OMe
MeO
PyBOP, NEM, DMF
HN
O
NO2
OMe
MeO
O
O
OH
HO or
imidazole, CH2Cl2
A) TBSCl, Et3N
B) DHP, p-TsOH
THF
HN
O
NO2
OMe
MeO
O
OH O PG
R
RR
1
2.5
Entry R Alcohol Yield PG Protected alcohol Yield
1
S
2.5 2.30 67% TBS 2.31 75%
2 2.5 2.32 27% THP 2.33 51%
With all the compounds in hand, we investigated the orthogonality of the O-MeNV pro-
tected hydroxamates. Boc, THP, TBS, Fmoc, Ac, and MOM were removed by standard
conditions, TFA in CH2Cl2, 10% HCl (aq.) in THF, TBAF in THF, 5% piperidine in DMF,
K2CO3 in MeOH, and TFA in CH2Cl2, respectively. Alloc was found to be selectively
removed by Pd(PPh3)4 and pyrrolidine in CH2Cl2.23
2.3.1 Selective Removal of Benzyl Ethers
Protection of hydroxy groups with a benzyl group is one of the most applied protecting
groups in organic chemistry.24 The tested deprotection for the testing of the removal of
the benzyl ether protecting group are listed in Table 2.6.
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Table 2.6: Overview of tested clevage conditions for Bn
HN
O
NO2
OMe
MeO
O
OBn
HN
O
NO2
OMe
MeO
O
OH
trs
Reaction
conditions
2.15 2.34
Entry Reaction conditions Conversion (2.15:2.34)a
125 TFA 100:00b
226 1) TFA, Ac2O -c
2) NaOMe, MeOH
327 FeCl3, CH2Cl2, 0 °C -c
428 LiCl, DMF, 160 °C -c
529 Pd(OH)2/C (0.5 equiv.), iPrOH, reflux 100:00
630 1) CSI, Na2CO3, CH2Cl2, -78 °C -c
2) NaOMe, MeOH
7 Pd(OH)2/C (2.0 equiv.), EtOH:H2O (9:1), reflux 00:100
831 BCl3, CH2Cl2, -78 °C 100:00
932 DDQ, H2O:CH2Cl2 (1:2) 00:100
1033 AlCl3, PhNMe2, CH2Cl2 100:00
1134 PPh3 ·HBr, MeCN, reflux -c
1235 tBuNH2, tBuOH, K -c
10-crown-6, THF
13 10% Pd/C (10 mol%), H2, MeOH -d
14 MeSO3H, CHCl3 -c
15 6 M HCl (aq.), reflux -c
1636 catechol boron bromide 100:00b
1737 TMSI, thiourea, NMI, MeCN -c
(a) observed by LCMS (b) 2.15 and impurities (c) complex reaction mixture without the desired
product (d) chemoselective reduction of the nitro group was observed
The photo-labile protecting group did not withstand several of the tested procedures. The
use of Pearlman’s catalyst was first shown to cleave benzyl ethers in 1981 by Hanessian
and co-workers38 under catalytic transfer hydrogenation with cyclohexene as a hydrogen
donor.39 Later, Prugh et al. showed that the reaction could proceed in the absence of a hy-
drogen donor.40 In our case, adding small amounts of water to the reaction mixture turned
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out to be highly advantageous and afforded the free hydroxy group chemoselectively
(Entry 7). We also tested several non-hydrogenation conditions and found that oxidative
cleavage by 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) afforded the formation of
2.34 (Entry 9).
2.3.2 Selective Removal of Benzyl Carbamate
Other well-explored protecting groups are based on the carbamates functionality, for ex-
ample the Cbz group, which turned out to be more difficult to selectively remove. All the
tested conditions are listed in Table 2.7.
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Table 2.7: Overview of tested cleavage conditions for Cbz
HN
O
NO2
OMe
MeO
O
NHCbz HN
O
NO2
OMe
MeO
O
NH2
sax
Reaction
conditions
2.23 2.35
Entry Reaction conditions Conversion (2.23:2.35)a
141 AlCl3, anisole 100:00
2 40% (wt:wt) KOH (aq.), MeOH -d
342 30% HBr, AcOH -b
4 Pd(OH)2/C (1.0 equiv.), iPrOH, reflux 100:00
543 tBuNH2, MeOH, reflux 100:00
644 TFA, reflux 00:100
7 10% Pd/C (10 mol%), H2, MeOH -c
8 Pd(OH)2/C (1 equiv), EtOH:H2O (9:1), 90 °C 100:00
9 6.0 M KOH (aq.):EtOH (1:1), reflux -e
10 10% Pd/C (10 mol%), NH4COOH, MeOH 100:00
11 10% Pd/C (10 mol%), Et3SiH, MeOH -c
1245 6 M HCl (aq.), reflux -c
13 6 M HCl (aq.) -f
14 25% NH4OH 100:00
15 10% Pd/C (10 mol%), H2, EtOAc -c
16 iPrOH, reflux 100:00
17 catechol boron bromide -c
(a) observed by LCMS (c) complex reaction mixture without the desired product (d) methyl
carbamate was observed (b) impure mixture of by-products and 2.35 (e) impure mixture of
by-products and ethyl ester was observed (f) hydrolysis to the corresponding photo-protected
hydroxylamine 2.5
The Cbz group has been shown to be both acid- and base-labile. When we tried to use
standard acidic conditions with 30% HBr in AcOH, the desired amine 2.35 was observed
along with by-products. Changing to TFA at reflux led to fast deprotection to the desired
product (Entry 6). Several basic conditions were tested. A transformation was observed
with 40% (wt:wt) KOH (aq.) in MeOH (Entry 2). However, this turned out to be conver-
sion to the corresponding methyl carbamate.
17
Chapter 2. Development of a Hydroxylamine Photo-labile Protecting Group for the Synthesis of
Hydroxamic Acids
2.3.3 Selective Removal of Allyl Ether
Another ether protecting group is the All group. Isomerization and cleavage conditions
were tested. However, no reaction was observed, Entries 1-2 Table 2.8. Conditions using
Pd(OH)2/C was tested and resulted in selectively removal of the All group to afford the
free hydroxy group, Entries 5 and 6.
Table 2.8: Overview of tested clevage conditions for All
HN
O
NO2
OMe
MeO
O
sax
S
OAll
HN
O
NO2
OMe
MeO
O
S
OH
Reaction
conditions
2.17 2.36
Entry Reaction conditions Conversion (2.17:2.36:)a
146 tBuOK, DMSO, 100 °C 100:00
H2SO4
246 tBuOK, DMSO, 100 °C 100:00
NaOH, KMnO4
3 Pd(PPh3)4, pyrrolidine, CH2Cl2 100:00
447 Pd(PPh3)4, K2CO3, MeOH 100:00
529 Pd(OH)2/C (0.5 equiv.), iPrOH, reflux 27:73b
6 Pd(OH)2/C (1.1 equiv.), iPrOH, reflux 00:100b
(a) observed by LCMS (b) no reaction was observed (c) complex reaction mixture
2.3.4 Up-scaling the Selective Removal of Conventional Protecting
Groups
A few of the successful conditions were performed on a larger scale for NMR characteri-
zation, Table 2.9. To avoid the use of high-boiling DMF for the highly polar amine, Et2NH
in MeCN was used for Fmoc deprotection.48 The investigation showed that the protecting
group is stable towards a variety of reaction conditions.
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Table 2.9: Large scale cleavage of selected conventional protecting groups
HN
O
NO2
OMe
MeO
O
Deprotection
HN
O
NO2
OMe
MeO
O
X Y
PG
procedures
R R
procedures
Entry SM R X Conditions PG Y Product Yield
1 2.17
S
O All Pd(OH)2/C, iPrOH, reflux OH 2.37 52%
2 2.31
S
O TBS TBAF, THF OH 2.38 82%
3 2.33 O THP 10% HCl (aq.), THF OH 2.39 87%
4 2.25
S
NH Fmoc Et2NH, MeCN NH2 2.40 quant.
2.3.5 Photolysis Study to Release a broad range of Hydroxamic Acids
To identify conditions that allowed for the selective photolytic release of hydroxamic
acids, the hydroxamate 2.25 was used as a model compound. The previous established
conditions, iPrOH:1 M HCl (aq.) (10:1), afforded acceptable selectivityof the N-alkylated
hydroxamic acids over the amide, but the acidity of these conditions, limit the substrate
scope, and therefore a study was conducted to find milder conditions, Table 2.10.
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Table 2.10: Solvent screen for selective liberation of hydroxamic acid
HN
O
NO2
OMe
MeO
O
sax
S
NHFmoc
NHFmoc
S
O
OH
HN
hν (365 nm)
solvent NHFmoc
S
O
H2N
2.25 2.41 2.42
Entrya Solvent Concentration (nM) Reaction time (h) Conversion (2.25:2.41:2.42)b
1c iPrOH 28.5 10.0 42:28:30
2c iPrOH:H2O (10:1) 28.5 10.0 48:26:26
3c iPrOH:0.01 M HCl (aq.) (10:1) 28.5 50.5 00:52:48
4c iPrOH:0.1 M HCl (aq.) (10:1) 28.5 5.0 29:36:35
5c iPrOH:0.1 M HCl (aq.) (19:1) 28.5 26.0 21:49:30
6c iPrOH:0.5 M HCl (aq.) (10:1) 28.5 10.0 13:45:42
749 MeCN 14.2 7.5 18:42:42
850 MeOH 4.0 9.5 00:78:22
951 dioxane 10.0 3.5 00:36:64
10 THF 14.0 3.5 00:24:76
11 THF 28.5 5.0 00:25:75
12 THF 57.0 5.5 40:26:34
133 THF:H2O(10:1) 7.6 5.0 00:63:37
14 THF:H2O(4:1) 8.0 6.0 7:79:14
15 THF:H2O(1:1) 28.5 2.0 68:16:16
16 THF:p-TSOH ·H2Od 28.5 5.0 00:32:68
17 THF:0.01 M HCl (aq.) (10:1) 2.8 2.0 11:72:17
1852 mesitylene 28.5 19.0 44:00:56
1952 HFIP:mesitylene (1:1)c 28.5 5.0 42:58:00
2052 HFIPe,f 7.1 5.0 6:91:3
2152 HFIPe,f 14.0 5.5 19:78:3
2252 HFIPe,f 28.5 5.5 54:46:2
(a) all reactions conducted on 5 mg scale. Several impurities observed by LCMS could not be assigned (b) observed by LCMS (d)
a couple of seeds (c) conducted on 10 mg scale (e) new significant peak appeared (f) highly volatile, over an extended time period
HFIP evaporates
When HCl (aq.) was used in combination with iPrOH, a preference for the hydroxamic
acid was observed (Entry 1-6 Table 2.10). We found that THF:H2O gave high selectivity
(Entry 14). Moreover, we found high selectivity with HFIP (Entry 20-22), but with the
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formation of a side-product was observed.
As for the conventional protecting groups, the photolysis was scaled up from 5-10 mg to
50 mg scale reactions. A total of seven compounds were liberated by UV-radiation and
due to the high polarity of the free hydroxamic acid, PREP-TLC was used for purification.
Generally, excellent selectivity was obtained with acceptable yields, Table 2.11.
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Table 2.11: Large scale liberation of hydroxamic acid
HN
O
NO2
OMe
MeO
O
HN
OH
O
X
X
PG
PG
hν (365 nm)
THF:H2O (4:1)
R
R
THF:H2O (4:1)
Entry SM R X PG Product Yield
1 2.17
S
O All 2.43 31%
2 2.19 O MOM 2.44 27%
3 2.23 NH Cbz 2.45 19%
4 2.25
S
NH Fmoc 2.46 32%
5 2.27 I
(S)
NH Alloc 2.47 20%
6 2.29 NH Boc 2.48 57%
7 2.31
S
O TBS 2.49 34%
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2.4 Conclusion
UV-cleavable groups have been used for a vast amount of functionalities over several
decades. Their inherent mild cleavage conditions have made them useful in many ap-
plications, among these caging of ATP. During my master project, I developed a photo-
labile group, methyl-6-nitroveratryl, for O-protection of hydroxylamine allowing for the
synthesis of N-alkylated SAHA analogues in great yields. In this project, we wanted to
investigate the orthogonality of this O-hydroxylamine protecting group. Rewardingly,
the newly developed protecting group showed high stability, therefore we were able to
selectively remove a broad range of commonly used protecting groups. Furthermore, the
protecting group could be removed without affecting the protecting groups. Pearlman’s
catalyst proved to be efficient for removal of both Bn, 2.15, and All, 2.17. Furthermore,
conventional acid/base-labile protecting groups were removed by standard conditions.
We also worked on developing suitable mild photolytic cleaving conditions. We demon-
strated that this group allowed for the chemoselective photolytic release of either hydrox-
amates or carboxamates. The bi-detachable mode of the protecting group, may simply be
controlled by the choice of solvent. Hydroxamic acids obtained by performing photol-
ysis in THF:H2O (4:1). Whereas, photolysis in mesitylene or THF enables the release of
carbaxamides. Using the developed conditions we synthesized seven hydroxamic acids
having a broad structural diversity in good yields (19-57%).
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2.5 Experimental Section
2.5.1 General Methods
All solvents were of HPLC quality from SigmaAldrich, and all commercially available
reagents were used without further purification. Dry THF, CH2Cl2, Et2O, MeCN, toluene,
DMSO and DMF were obtained from a PureSolvTM MD-7 Solvent Purification System, In-
novative Technology with Al2O3 as stationary phase. Dry alcoholic solvents and CHCl3
were obtained by using preheated 3 A˚mol sieves. Et3N and pyridine was kept dry by
storage over KOH pellets.
For TLC, Merck aluminium sheets covered with silica gel C-60 F254 were used and de-
veloped using UV-light or a suitable stain. Flash chromatography was performed using a
glass column packed with Merck Geduran 60 silica gel (40-63 µm particles) as stationary
phase. For dry column vacuum chromatography (DCVC)53 the dry column was packed
with Merck Geduran 60 silica gel (15-40 µm particles). All liquid phases are specified in
experimental procedures.
PREP-TLC purification was performed with Merck silica gel 60 C-60 F254 (10-12 µm par-
ticles) plates with a coating thickness of 250 µM.
All novel compounds were characterized by 1H-NMR, 13C-NMR, IR, Rf , and when ap-
propriate UPLC-MS (ESI), optical rotation, and/pr melting point were measured. HRMS
sample was obtained for a representative collection of novel compounds. For all known
compounds on 1H-NMR is listed with a reference to reported values.
NMR spectra were recorded on either a Varian Mercury spectrometer operating at 300
MHz for 1H-NMR and 75 MHz for 13C-NMR or a Bruker Ascend spectrometer with a
Prodigy cryoprobe operating at 400 MHz for 1H-NMR and 101 MHz for 13C-NMR. For all
compounds containing the photo-labile protecting group, 13C-NMR was performed with
a delay of at least 3 seconds, compared to a standard 1.2 seconds, and 512-2048 scans due
to low or no observed intensity. HSQC, HMBC, H2BC, NOESY400, and HSQC-TOCSY
experiments were used to verify the structures when 1H-, 13C-NMR, and COSY were in-
adequate. The specific deuterated solvent is stated for each compound. Chemical shifts
(δ) are given in ppm and the coupling constants (J) in Hz.
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IR analysis was performed on a Bruker Alpha FT-IR spectrometer from 4000 cm-1 to 400
cm-1 of a neat sample.
Analytic UPLC-MS analysis was run on a Waters AQUITY UPLC system equipped with
PDA and SQD electrospray MS detector. Column: Kinetex 1.7 µm XB-C18, 2.1 x 50mm.
Column temperature: 50 °C. Flowrate: 0.6 mL/min. Solvent A: 0.1% HCOOH in H2O,
Solvent B: 0.1% HCOOH in MeCN. Gradient: 5% B to 100% B in 2.4 min, hold 0.1 min,
total run time 2.6 min. Analytical LC-HRMS (ESI) analysis was performed on an Agilent
1100 RP-LC system equipped with a diode array detector using a Phenomenex Luna C-18
column (d 3 µm, 2.1 x 50 mm; column temp: 40 °C; flow: 0.4 mL/min). Eluents A (0.1%
HCO2H in H2O) and B (0.1% HCO2H in MeCN) were used in a linear gradient (20% B to
100% B) in a total run time of 15 min. The LC system was coupled to a Micromass LCT
orthogonal time-of-flight mass spectrometer equipped with a Lock Mass probe operating
in positive electrospray mode.
Melting points were measured using a Stuart SMP30 melting point apparatus. Photo
cleavage was performed in a custom made aluminium box with a Omnilux UV-lamp
400W E-40 irradiating blue light at 360 nm.
Optical rotation was measured on a Perkin-Elmer 341polarimeter (polarimeter cell, 1.0
mL, 100 mm), with a Na-lamp (589.3 nm, 22 °C).
2.5.2 Synthetic Procedures
General Procedure: Direct Alkylation
In an oven-dried round-bottomed flask containing a magnetic stirring bar, NaH (60% in
oil) was portionwise added to a cold solution of N-Boc protected hydroxylamine 2.6 in
MeCN (0.2 M) under an inert atmosphere. When gas evolution stopped, the solution was
stirred for 10 min and the alkyl halide was added in one portion. The reaction mixture
was stirred at reflux. The reaction mixture was cooled and quenched by the addition
of cold H2O. The aqueous solution was extracted with CH2Cl2 (3 x) and the combined
organic organic phases were dried over Na2SO4, filtered, and concentrated in vacuo. The
compound was purified by flash chromatography.
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General Procedure: Coupling Reagent Acylation
In a round-bottomed flask containing a magnetic stirring bar, coupling reagent and base
were added to a solution of carboxylic acid in DMF. The carboxylic acid was activated
before hydroxylamine was added to the stirring solution. The reaction mixture was trans-
ferred to a separation funnel with H2O and EtOAc. The organic layer was washed accord-
ing to the description for each reaction and dried over Na2SO4, filtered, and concentrated
in vacuo. The product was purified either by flash chromatography or recrystallization.
General Procedure: Photo-Mediated Deprotection
In a small glass jar containing a magnetic stirring bar, photo-protected hydroxamic acids
were dissolved in the listed cleavage mixture. A quartz lid was placed on top of the glass
jar and stirred in a aluminium box under a UV-lamp at 365 nm. Due to elevated tem-
peratures and long reaction time, additionally cleavage mixture was added. The desired
hydroxamic acid was purified according to the description for each reaction.
O-(1-(4,5-dimethoxy-2-nitrophenyl)ethyl)hydroxylamine hydrochloride salt (2.7)
OMe
MeO
NO2
O
NH2HCl
In a round-bottomed flask containing a magnetic stirring bar,
H2NNH2 ·H2O (70%, 1.0 mL, 20.1 mmol, 1.2 equiv.) was added to a gray
suspension of N-hydroxylamine phthalimide 2.4 (5.00 g, 13.4 mmol, 1.0
equiv.) in EtOH (120.0 mL) and stirred at reflux. When full conversion
was observed (3 h), the reaction mixture was cooled, and the precipitate
was removed by filtration. The solution was evaporated under reduced pressure. The
residues were dissolved in EtOAc and precipitation occurred one more time. The precip-
itate was removed by filtration and the solution was evaporated under reduced pressure.
The dark brown oil was dissolved in Et2O (150.0 mL) and vigorously stirred during the
addition of HCl (1.0 M in Et2O, 33.6 mL, 33.6 mmol, 2.0 equiv.). To ensure full precipi-
tation, the gray solution was stirred for 30 min further. The hydrochloride salt 2.7 was
collected by filtration and washed with cold Et2O and placed under vacuum to afford
it as a gray solid (3.56 g, 95%). Rf = 0.78 (CH2Cl2:MeOH (19:1); UV); IR (neat) ν (cm-1):
3145, 2938, 2848, 2791, 2619, 1619, 1590, 1544, 1520, 1456, 1335, 1274; 1H-NMR (400 MHz,
DMSO-d6): δ 10.85 (br. s, 3H, ONH3Cl), 7.62 (s, 1H, ArH), 7.18 (s, 1H, ArH), 5.74 (q, J =
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6.3 Hz, 1H, ArCHCH3), 3.98 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 1.56 (d, J = 6.3 Hz, 3H,
ArCHCH3), 13C-NMR (101 MHz, DMSO-d6): δ 153.6, 148.1, 140.3, 130.3, 108.8, 107.8, 77.8,
56.23, 56.17, 21.3; MS (ESI) m/z: calcd. for C10H12NO4+ [M + H]+ 210.1, found 210.0.
tert-Butyl (1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)(4-methoxybutyl)carbamate (2.9)
O2N
OMe
OMe
O
O
N O
O According to the general procedure for direct alkylation, NaH (60%
in oil, 79.4 mg, 1.99 mmol, 1.7 equiv.) was added to a cold so-
lution of 2.6 (400 mg, 1.17 mmol, 1.0 equiv.) in MeCN (5.8 mL).
1-Bromo-4-methoxybutane (188 µL, 1.40 mmol, 1.2 equiv.) was
added and stirred at reflux overnight. Incomplete conversion was
observed by TLC and LCMS, additional NaH (60% in oil, 46.7 mg,
1.17 mmol, 1.0 equiv.) was added to the cooled reaction mixture followed by 1-bromo-4-
methoxybutane (157 µL, 1.17 mmol, 1.0 equiv.) and left overnight. The title compound
2.9 was purified by aqueous work-up and flash chromatography (EtOAc:heptane 3:7)
providing as a green oil (435 mg, 87%). Trace amount of CH2Cl2 was detected by H1-
NMR. Rf = 0.24 (EtOAc:heptane (3:7); UV); IR (neat) ν (cm-1): 2977, 2935, 2867, 2830,
1702, 1581, 1457, 1335, 1271; 1H-NMR (400 MHz, CDCl3): δ 7.53 (s, 1H, ArH), 7.41 (s,
1H, ArH), 5.63 (q, J = 6.4 Hz, 1H, ArCHCH3), 4.02 (s, 3H, OCH3), 3.94 (s, 3H, OCH3),
3.47–3.21 (m, 7H, CH3OCH2CH2CH2CH2NC(O)), 1.63–1.44 (m, 16H, 3 x CH3, ArCHCH3,
CH3OCH2CH2CH2CH2N); 13C-NMR (101 MHz, CDCl3): δ 156.9, 153.5, 148.1, 140.6, 133.9,
109.7, 107.4, 81.7, 77.4, 72.4, 58.7, 56.6, 56.5, 50.0, 28.3, 27.0, 23.7, 21.7; MS (ESI) m/z: calcd.
for C20H32N2NaO8+ [M + Na]+ 451.2, found 451.1.
tert-Butyl (1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)(4-methoxybutyl)carbamate (2.10)
NO2
OMe
MeO
O
N O
O
OO
According to the general procedure for direct alkylation, NaH (60%
in oil, 79.4 mg, 1.99 mmol, 1.7 equiv.) was added to a cold solution
of 2.6 (400 mg, 1.17 mmol, 1.0 equiv.) in MeCN (5.83 mL). 1-Bromo-
2-(methoxymethoxy)ethane (163.7 µL, 1.40 mmol, 1.2 equiv.) was
added and stirred at reflux overnight. Incomplete conversion was
observed by TLC and LCMS, additional NaH (60% in oil) (46.7 mg,
1.17 mmol, 1.0 equiv.) was added to the cooled reaction mixture followed by 1-bromo-
2-(methoxymethoxy)ethane (136 µL, 1.12 mmol, 1.0 equiv.) and refluxed overnight.
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The title compound 2.10 was purified by aqueous work-up and flash chromatography
(EtOAc:heptane 3:7) providing it as a green oil (349 mg, 69%). Trace amount of CH2Cl2
was detected by H1-NMR. Rf = 0.24 (EtOAc:heptane (3:7); UV); IR (neat) ν (cm-1): 2977,
2935, 2867, 2830, 1702, 1581, 1457, 1335, 1271; 1H-NMR (400 MHz, CDCl3): δ 7.54 (s, 1H,
ArH), 7.46 (s, 1H, ArH), 5.66 (q, J = 6.4 Hz, 1H, ArCHCH3), 4.56 (s, 2H, CH3OCH2OCH2),
4.03 (s, 3H, OCH3), 3.94 (s, 3H, OCH3), 3.75–3.47 (m, 4H, CH3OCH2OCH2CH2NHC(O)O),
3.32 (s, 3H, CH3OCH2OCH2), 1.58 (d, J = 6.4 Hz, 3H, ArCHCH3), 1.44 (s, 9H, 3 x CH3);
13C-NMR (101 MHz, CDCl3): δ 157.3, 153.6, 148.0, 140.6, 134.0, 109.8, 107.4, 96.4, 81.8,
77.3 (overlap with CDCl3), 63.4, 56.6, 56.5, 55.3, 50.3, 28.3, 21.7; MS (ESI) m/z: calcd. for
C19H30N2NaO9+ [M + Na]+ 453.2, found 453.2.
N1-(1-(4,5-Dimethoxy-2-nitrophenyl)ethoxy)-N1-(4-methoxybutyl)-N8-phenyl-octane-
diamide (2.11)
O
OMe
MeO
NO2
N
O H
N
O
O
According to the general procedure for Boc-deprotec-
tion, 2.9 (417 mg, 0.97 mmol, 1.0 equiv.) was stirred
in TFA:CH2Cl2 (1:1) (9.8 mL) for 1.33 h. The crude
TFA amine was placed under vacuum. According to
the general procedure for BTC acylation, in a flame-
dried round-bottomed flask, 2,4,6-collidine (900 µL,
6.81 mmol, 7 equiv.) was dropwise added over 2.0 h to a solution of BTC (202 mg, 0.68
mmol, 0.7 equiv.) and suberanilic acid 2.8 (315 mg, 1.27 mmol, 1.3 equiv.) in dry THF
(24.5 mL) followed by the addition of the crude TFA amine in THF (5 mL) and stirred
overnight. The organic phase was washed with H2O (2 x 100 mL), sat. NaHCO3 (aq.) (2
x 100 mL), 1 M HCl (aq.) (3 x 100 mL), and brine (2 x 100 mL). The title compound was
purified by flash column chromatography (EtOAc:heptane 1:1) to afford 2.11 (330 mg,
61%) as a green semi solid. Rf = 0.08 (EtOAc:heptane (1:1); UV); IR (neat) ν (cm-1): 3307,
2933, 2858, 1661, 1599, 1518, 1440, 1334, 1271; 1H-NMR (400 MHz, DMSO-d6): δ 9.83 (s,
1H, C(O)NHPh), 7.59–7.54 (m, 3H, ArH), 7.30–7.25 (m, 3H, ArH), 7.01 (t, J = 7.4 Hz, 1H,
ArH), 5.44 (q, J = 6.5 Hz, 1H, ArCHCH3), 3.94 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.56–
3.49 (m, 1H, CH2CH’H”NC(O)CH2), 3.21–3.16 (m, 5H, CH3COCH2CH2, CH3OCH2CH2),
3.05–2.97 (m, 1H, H2CH2CH’H”NC(O)CH2), 2.30–2.26 (m, 4H, CH2CH2, CH2C(O)), 1.60–
1.24 (m, 15H, OCH2CH2CH2CH’H”NC(O), NC(O)CH2CH2CH2CH2CH2CH2C(O)NHPh,
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ArCHCH3); 13C-NMR (101 MHz, DMSO-d6): δ 174.3, 171.2, 152.9, 148.2, 140.7, 139.3,
130.6, 128.6, 122.9, 119.0, 109.7, 107.3, 77.5, 71.4, 57.7, 56.2, 56.1, 46.3 36.4, 31.9, 28.5, 28.4,
26.2, 25.0, 24.1, 23.3, 20.9; MS (ESI) m/z: calcd. for C29H42N3O8+ [M + H]+ 560.3, found
560.3.
N1-(1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)-N1-(2-(methoxymethoxy)ethyl)-N8-
phenyloctanediamide (2.12)
O
OMe
MeO
NO2
N
O H
N
O
OO
According to the general procedure for Boc-deprotec-
tion, 2.10 (337.4 mg, 0.78 mmol, 1.0 equiv.) was stirred
in TFA:CH2Cl2 (9:11) (5.9 mL) for 1.0 h at 0 °C. The
crude TFA amine was placed under vacuum.
According to the general procedure for BTC acylation,
in a flame-dried round-bottomed flask, 2,4,6-collidine
(725 µL, 5.49 mmol, 7 equiv.) was dropwise added over 2.0 h to a solution of BTC (163
mg, 0.55 mmol, 0.7 equiv.) and suberanilic acid 2.8 (254 mg, 1.01 mmol, 1.3 equiv.) in
dry THF (15.0 mL) followed by the addition of the crude TFA amine in THF (7 mL) and
stirred overnight. The organic phase was washed with H2O (2 x 100 mL), sat. NaHCO3
(aq.) (2 x 100 mL), 1 M HCl (aq.) (3 x 100 mL), and brine (2 x 100 mL). The title compound
was purified by flash column chromatography (EtOAc:heptane 1:1) to afford 2.12 309
mg, 70%) as a green semi solid. Rf = 0.50 (EtOAc; UV); IR (neat) ν (cm-1): 3308, 2933,
2857, 1661, 1599, 1518, 1440, 1334, 1271; 1H-NMR (400 MHz, DMSO-d6): δ 9.82 (s, 1H,
C(O)NHPh), 7.59–7.54 (m, 3H, ArH), 7.32–7.25 (m, 3H, ArH), 7.02–6.99 (m, 1H, ArH),
5.49 (q, J = 6.4 Hz, 1H, ArCHCH3), 4.45 (s, 2H, CH3OCH2O), 3.93 (s, 3H, OCH3), 3.85
(s, 3H, OCH3), 3.69 (m, 1H, OCH2CH’H”NC(O)), 3.46 (m, 2H, OCH2CH2NC(O)), 3.36–
3.29 (overlap with H2O) (m, 1H, OCH2CH’H”NC(O)), 2.32–2.26 (m, 4H, NC(O)CH2CH2,
CH2C(O)NHPh), 1.59–1.37 (m, 7H, ArCHCH3, NC(O)CH2CH2CH2CH2CH2CH2), 1.29–
1.19 (m, 4H, NC(O)CH2CH2CH2CH2CH2); 13C-NMR (101 MHz, DMSO-d6): δ 174.6, 171.2,
152.9, 148.1, 140.7, 139.3, 130.6 (HMBC), 128.6, 122.9, 119.0, 109.8 107.2, 95.5, 77.4, 62.8,
56.2, 56.1, 54.5, 36.4, 31.9, 28.5, 28.3, 25.0, 24.1, 20.9; MS (ESI) m/z: calcd. for C28H40N3O9+
[M + H]+ 562.3, found 562.3.
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N1-(1-(4,5-Dimethoxy-2-nitrophenyl)ethoxy)-N1-neopentyl-N8-phenyloctanediamide
(2.13)
O
OMe
MeO
NO2
N
O H
N
O
According to the general procedure for BTC acylation, in
a flame-dried round-bottomed flask, 2,4,6-collidine (592
µL, 4.48 mmol, 7 equiv.) was dropwise added over 2.75
h to a solution of BTC (133 mg, 0.45 mmol, 0.7 equiv.)
and suberanilic acid 2.8 (192 mg, 0.77 mmol, 1.2 equiv.)
in dry THF (12.0 mL) followed by the addition of 3.92
(200 mg, 064 mmol, 1.0 equiv.) in THF (4.0 mL) and stirred overnight. The organic
phase was washed with H2O (2 x 100 mL), sat. NaHCO3 (aq.) (2 x 100 mL), 1 M HCl
(aq.) (3 x 100 mL), and brine (2 x 100 mL). The title compound was purified by flash
column chromatography (EtOAc:heptane 2:3) to afford 2.13 (317 mg, 91%) as a green
semi solid. Rf = 0.12 (EtOAc:heptane (2:3); UV); IR (neat) ν (cm-1): 3307, 2935, 2861,
1660, 1599, 1518, 1462, 1334, 1272, 1218; 1H-NMR (400 MHz, DMSO-d6): δ 9.82 (s, 1H,
C(O)NHPh), 7.58 (d, J = 7.9 Hz, 2H, ArH), 7.52 (s, 1H, ArH), 7.29–7.25 (m, 3H, ArH),
7.01 (t, J = 7.4 Hz, 1H, ArH), 5.51 (q, J = 6.4 Hz, 1H, ArCHCH3), 3.92 (s, 3H, OCH3), 3.85
(s, 3H, OCH3), 3.43 (d, J = 14.8 Hz, 1H, CH3CCH’H”NC(O)), 3.11 (d, J = 14.8 Hz, 1H,
CH3CCH’H”NC(O)), 2.29–2.20 (m, 4H, NC(O)CH2CH2CH2CH2CH2CH2C(O)N), 1.56–
1.17 (m, 11H, NC(O)CH2CH2CH2CH2CH2CH2C(O)N, ArCHCH3), 0.85 (s, 9H, C(CH3)3);
13C-NMR (101 MHz, DMSO-d6): δ 171.2, 152.7, 148.3, 141.1, 139.3, 128.6, 122.9, 120.9,
119.0, 110.2, 107.3, 75.4, 56.2, 56.1, 54.9, 36.3, 33.3, 28.4, 28.2, 25.0, 24.4, 20.4; MS (ESI) m/z:
calcd. for C29H42N3O7+ [M + H]+ 544.3, found 544.4.
4-(Benzyloxy)-N-(1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)butanamide (2.15)
OMe
MeO
O
NO2
HN
O
O
According to the general procedure for coupling reagent acy-
lation, PyBOP (645 mg, 1.23 mmol, 1.5 equiv.) and NEM (623
µL, 4.95 mmol, 6 equiv.) was added to a stirring solution of 4-
benzyloxybutyric acid (205 µL, 1.16 mmol, 1.4 equiv.) in DMF
(8.3 mL) and stirred for 10 min, before 2.5 (200 mg, 0.83 mmol,
1.0 equiv.) was added and the reaction mixture was stirred
overnight. The organic layer was washed with brine:H2O (1:1) (5 x 100 mL), sat. Na2SO4
(aq.) (50 mL), and brine (10 mL). The hydroxamate product 2.15 was isolated by flash
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chromatography (EtOAc:heptane 7:3) as a light green solid (316 mg, 91%). Rf = 0.13
(EtOAc:heptane 1:1; UV); IR (neat) ν (cm – 1): 3141, 2985, 2944, 2855, 2753, 1650, 1578, 1510,
1466, 1332, 1270, 1219, 1080; 1H-NMR (400 MHz, DMSO-d6): δ 10.80 (s, 1H, HNC(O)), 7.56
(s, 1H, ArH), 7.38 (s, 1H, ArH), 7.34–7.23 (m, 5H, ArH), 5.47 (q, J = 6.3 Hz, 1H, ArCHCH3),
4.29 (s, 2H, OCH2Ar), 3.95 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 3.23–3.20 (t, J = 6.5 Hz, 2H,
CHOCH2Ph), 1.94–1.90 (t, J = 7.0 Hz, 2H, C(O)CH2CH2CH2O), 1.67–1.60 (p, J = 6.5 Hz,
2H, C(O)CH2CH2CH2O), 1.48 (d, J = 6.3 Hz, 3H, ArCHCH3); 13C-NMR (101 MHz, DMSO-
d6): δ 168.8, 153.4, 147.7, 140.2, 138.5, 132.6, 128.2, 127.4, 127.3, 109.2, 107.4, 77.3, 71.8, 68.5,
56.04, 56.02, 28.9, 25.1, 21.0; MS (ESI) m/z: calcd. for C21H27N2O7+ [M + H]+ 419.2, found
419.3; HRMS (ESI) m/z: calcd. for C21H27N2O7+ [M + H]+ 419.1813, found 419.1817; mp.
= 120.7–121.7 °C.
Diethyl 2,5-thiophenedicarboxylate
S
O O
O O
In a round-bottomed flask containing a magnetic stirring bar and
equipped with a condenser, conc. H2SO4 (2.0 mL) was added to a
stirring solution of 2,5-thiophenedicarboxylic acid (25.0 g, 145 mmol,
1.0 equiv.) in EtOH (500 mL) and heated at reflux overnight. Incomplete conversion was
observed by TLC and LCMS, and therefore all volatiles were evaporated under reduced
pressure and co-evaporated with toluene. The white precipitation was redissolved in
EtOH (350 mL) and added H3PO4 (2.0 mL) followed by reflux for 2 days. The reaction
mixture was cooled and all volatiles were removed under reduced pressure. The white
solid was dissolved in EtOAc (500 mL) and the organic phase was washed with 2.0 M
NaOH (aq.) (300 mL), brine (300 mL), dried over Na2SO4, filtered, and concentrated in
vacuo to afford diethyl 2,5-thiophenedicarboxylate as a white crystalline solid, used with-
out further purification (25.24 g, 76%). Spectral data in correspondence with reported
literature values.54 1H-NMR (300 MHz, DMSO-d6): δ 7.79 (d, J = 0.4 Hz, 2H, ArH), 4.32
(q, J = 7.1 Hz, 4H, 2 x C(O)CH2CH3), 1.30 (t, J = 7.1 Hz, 6H, 2 x C(O)CH2CH3);
Ethyl 5-(hydroxymethyl)thiophene-2-carboxylate
S
O
OHO
In a round-bottomed flask containing a magnetic stirring bar, NaBH4
(5.53 g, 142 mmol, 1.3 equiv.) was portion wise added to diethyl
2,5-thiophenedicarboxylate (25.0 g, 110 mmol, 1.0 eqiuv.) in EtOH
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(300 mL) and heated at reflux. When the amount of thiophene-2,5-diyldimethanol
started to increase, observed by LCMS (2.5 h), the reaction mixture was cooled to rt
and slowly quenched by the addition of H2O (100 mL). EtOH was removed under re-
duced pressure and the aqueous phase was extracted with CH2Cl2 (3 x 100 mL). The
combined organic phases were dried over Na2SO4, filtered, and concentrated in vacuo.
Purification by by flash chromatography (EtOAc:heptane 1:9 → 1:4) afford ethyl 5-
(hydroxymethyl)thiophene-2-carboxylate (12.9 g, 63 %) as an oil. Spectral data in cor-
respondence with reported literature values.54 1H-NMR (300 MHz, DMSO-d6): δ 7.65 (d,
J = 3.9 Hz, 1H, C(O)CCHCHC), 7.02 (m, 1H, C(O)CCHCHC), 5.73 (t, J = 5.8 Hz, 1H,
CH2OH), 4.67 (m, 2H, CCH2OH), 4.26 (q, J = 7.1 Hz, 2H, C(O)CH2CH3), 1.28 (t, J = 7.1 Hz,
3H, C(O)CH2CH3);
5-(Hydroxymethyl)thiophene-2-carboxylic acid
S
HO
O
OH
To a round-bottomed flask containing a magnetic stirring bar, LiOH (416
mg, 17.3 mmol, 3 equiv.) was added to a stirring solution of ethyl 5-
(hydroxymethyl)thiophene-2-carboxylate in EtOH:H2O (2:1) (13.9 mL)
and refluxed. When full conversion was observed by TLC and LCMS (75 min), the re-
action mixture was cooled and evaporated under reduced pressure to almost dryness
and extracted with Et2O (50 mL). The aqueous phase was acidified to pH < 3 with
1.0 M HCl (aq.) (30 mL) and extracted with Et2O (3 x 100 mL). The combined or-
ganic phases were dried over Na2SO4, filtered, and concentrated in vacuo to collect 5-
(hydroxymethyl)thiophene-2-carboxylic acid (1.36 g, 87%) as a off-white solid that was
used without further purification. Spectral data in correspondence with reported litera-
ture values.55 1H-NMR (300 MHz, DMSO-d6): δ 12.92 (br. s, 1H, ArCOOH), 7.58 (d, J = 3.7
Hz, 1H, ArH), 7.00 (d, J = 3.7 Hz, 1H, ArH), 5.68 (m, 1H, CH2OH), 4.66 (s, 2H, ArCH2OH);
5-((Allyloxy)methyl)thiophene-2-carboxylic acid (2.16)
S
HO
O
O
In a flame-dried round-bottomed flask containing a magnetic stir-
ring bar, 5-(hydroxymethyl)thiophene-2-carboxylic acid (400 mg, 2.53
mmol, 1.0 equiv.) in DMF (8.4 mL) was slowly added to a cold stir-
ring solution of NaH (60% in oil) (253 mg, 6.32 mmol, 2.5 equiv.) in DMF (2.1 mL) under
argon atmosphere. AllBr (274 µL, 3.16 mmol, 1.25 equiv.) was added to the cold solu-
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tion and stirred at rt. When full conversion was observed by TLC and LCMS (3.5 h), the
reaction mixture was cooled and quenched by the addition of H2O (5 mL). The aqueous
phase was extracted with EtOAc (2 x 25 mL) and acidified to pH < 3 with 1.0 M HCl
(aq.). The acidic aqueous phase was extracted with EtOAc (3 x 25 mL). The combined
organic phases were washed with 0.5 M HCl (aq.) (5 x 50 mL), brine (10 mL), dried over
Na2SO4, filtered, and concentrated in vacuo. Residual DMF was removed by wash a Et2O
solution with brine:H2O (1:1) (6 x 30 mL), brine (10 mL), dried over Na2SO4, filtered, and
concentrated in vacuo. This afforded a white solid (321 mg, 64%) that was used without
further purification 1H-NMR (400 MHz, DMSO-d6): δ 13.10 (br. s, 1H, COOH), 7.61 (d, J
= 3.7 Hz, 1H, ArH), 7.10 (d, J = 3.7 Hz, 1H, ArH), 5.96–5.86 (m, 1H, OCH2CHCH2), 5.31–
5.26 (m, 1H, CH2CHCH’H”), 5.20–5.16 (m, 1H, CH2CHCH’H”), 4.67 (s, 2H, ArCH2OAll),
4.03–4.01 (dq, J = 5.4, 1.6 Hz, 2H, OCH2CHCH2); 13C-NMR (101 MHz, DMSO-d6): δ 162.8,
148.8, 134.7, 133.9, 133.0, 126.7, 116.9, 70.4, 66.1; MS (ESI) m/z: calcd. for C9H11O3S+ [M +
H]+ 199.0, found 199.0; HRMS (ESI) m/z: calcd. for C9H11O3S+ [M + H]+ 199.0423, found
199.0422.
5-((Allyloxy)methyl)-N-(1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)thiophene-2-carbox-
amide (2.17)
S
O
HN
O
NO2
OMe
MeO
O
According to the general procedure for coupling reagent acyla-
tion, PyBOP (929 mg, 1.78 mmol, 1.1 equiv.) and NEM (1.22 µL,
9.73 mmol, 6 equiv.) was added to a stirring solution of 2.16 (322
mg, 1.62 mmol, 1.0 equiv.) in DMF (18.0 mL) and stirred for 20
min, before 2.5 (432 g, 1.78 mmol, 1.1 equiv.) was added and the
reaction mixture was stirred overnight. The organic layer was
washed with brine:H2O (1:1) (5 x 100 mL). The hydroxamate product 2.17 was isolated by
flash chromatography (EtOAc:heptane 3:7) as a yellow solid (537 mg, 78%). Trace amount
of impurities were observed by 1H-NMR. Rf = 0.38 (EtOAc:heptane 1:1; UV); IR (neat) ν
(cm – 1): 3177, 2995, 2977, 2850, 1620, 1580, 1513, 1456, 1328, 1268, 1219, 1168, 1012; 1H-
NMR (400 MHz, DMSO-d6): δ 11.50 (s, 1H, HNC(O)), 7.56 (s, 1H, ArH), 7.48 (s, 1H, ArH),
7.38–7.37 (m, 1H, ArH), 7.00 (d, J = 3.7 Hz, 1H, ArH), 5.93–5.84 (m, 1H, CH2CHCH2), 5.66
(q, J = 6.4 Hz, 1H, ArCHCH3), 5.29–5.23 (dq, J = 17.3, 1.8 Hz 1H, CH2CHCH(E)H), 5.18–
5.15 (dq, J = 10.4, 1.8, 1.4 Hz, 1H, CH2CHCH(Z)H), 4.61 (s, 2H ArH2O), 3.99–3.97 (m, 5H,
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OCH2CHCH2, OCH3), 3.84 (s, 3H, OCH3), 1.55 (d, J = 6.38 Hz, 3H, ArCHCH3); 13C-NMR
(101 MHz, DMSO-d6): δ 159.6, 153.3, 147.7, 146.8, 140.2, 135.3, 134.7, 132.4, 128.4, 126.5,
116.9, 109.4, 107.4, 77.9, 70.3, 65.9, 56.1, 56.0, 21.1; MS (ESI) m/z: calcd. for C19H23N2O7S+
[M + H]+ 423.1, found 423.4; HRMS (ESI) m/z: calcd. for C19H23N2O7S+ [M + H]+ 423.1220,
found 423.1222. mp. = 97.9-101 °C.
3-(Methoxymethoxy)benzoic acid (2.18)
HO
O
O O
In a round-bottomed flask containing a magnetic stirring bar, 3.5 M
NaClO2 (aq.) (13.7 mL) was dropwise added over 40 min to a cold
mixture of 3-(methoxymethoxy)benzaldehyde (1.0 mL, 6.87 mmol, 1.0
equiv.), 0.7 M NaH2PO4 (aq.) (24.5 mL), and 35% H2O2 (2.4 mL, 34.4 mmol, 5 equiv.) in
MeCN (51.5 mL), to ensure reaction temperature below 10 °C. The reaction mixture was
stirred at 0 °C for 1.5 h, followed by stirring at rt. When full conversion was observed by
TLC and LCMS (4 h), the reaction mixture was cooled and carefully quenching by slow
addition of Na2SO3 (6.06 g, 48.1 mmol, 7.0 equiv.). Sat. NaHCO3 (aq.) was added to en-
sure basic pH before MeCN was removed under reduced pressure. The aqueous solution
was carefully acidified by the addition of 1.0 M HCl (aq.) (pH ≈ 3-4) and extracted with
EtOAc (3 x 100 mL). The combined organic phases were dried over Na2SO4, filtered, and
concentrated in vacuo to afford the title compound as a white solid in (1.21 g, > 95%) that
was used without further purification. Spectral data in correspondence with reported lit-
erature values.56 1H-NMR (400 MHz, DMSO-d6): δ 13.00 (br. s, 1H, COOH), 7.59–7.55 (m,
2H, ArH), 7.44–7.40 (m, 2H, ArH), 7.28–7.25 (m, 1H, ArH), 5.24 (s, 2H, ArOCH2OCH3),
3.38 (s, 3H, ArOCH2OCH3);
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N-(1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)-3-(methoxymethoxy)benzamide (2.19)
HN
O
O
NO2
OMe
MeO
O O
According to the general procedure for coupling reagent acyla-
tion, PyBOP (978 mg, 1.88 mmol, 1.3 equiv.) and NEM (1.09 µL,
8.67 mmol, 6 equiv.) was added to a stirring solution of 2.18 (316
mg, 1.73 mmol, 1.2 equiv.) in DMF (14.4 mL) and stirred for 15
min, before 2.5 (350 mg, 1.44 mmol, 1.0 equiv.) was added and
the reaction mixture was stirred overnight. The organic layer
was washed with brine:H2O (1:1) (5 x 100 mL) and sat. NaHCO3 (aq.) (100mL). The hy-
droxamate product 2.19 was isolated by flash chromatography (EtOAc:heptane 2:3) as a
light green solid (469 mg, 80%). Trace amount of EtOAc was observed by 1H-NMR. Rf =
0.21 (EtOAc:heptane 1:1; UV); IR (neat) ν (cm – 1): 3358, 3083, 3007, 2937, 2838, 1672, 1587,
1523, 1506, 1472, 1343, 1270, 1216, 1079; 1H-NMR (400 MHz, DMSO-d6): δ 11.49 (s, 1H,
HNC(O)), 7.56 (s, 1H, ArH), 7.50 (s, 1H, ArH), 7.35–7.31 (m, 1H, ArH), 7.22–7.14 (m, 3H,
ArH), 5.65 (q, J = 6.4 Hz, 1H, ArCHCH3), 5.19 (s, 2H, ArOCH2OCH3), 3.98 (s, 3H, OCH3),
3.84 (s, 3H, OCH3), 3.35 (s, 3H, OCH2OCH3), 1.56 (d, J = 6.4 Hz, 3H, ArCHCH3); 13C-NMR
(101 MHz, DMSO-d6): δ 163.9, 156.7, 153.3, 147.7, 140.3, 133.5, 132.4, 129.7, 120.2, 119.3,
114.7, 109.4, 107.4, 93.9, 77.5, 56.1, 56.0, 55.6, 21.1; MS (ESI) m/z: calcd. for C19H23N2O8+
[M + H]+ 407.1, found 407.2; HRMS (ESI) m/z: calcd. for C19H23N2O8+ [M + H]+ 407.1449,
found 407.1450. mp. = 138–140 °C.
4-Acetoxybenzoic acid (2.20)
O
HO
O
O
To a round-bottomed flask containing a magnetic stirring bar, H3PO4
(five drops) was added to a stirring suspension of 4-hydroxybenzoic
acid (3.00 g, 21.7 mmol, 1.0 equiv.) in Ac2O (6.00 ml, 63.6 mmol, 6 equiv.)
and heated at 90 °C. When full conversion was observed by TLC and
LCMS (20 min), the reaction mixture was cooled and poured slowly into cold H2O (150
mL). The off-white precipitate was collected by filtration and washed with cold H2O (20
mL). The precipitate was stirred with sat. NaHCO3 (100 mL) until gas evolution ceased.
The remaining precipitate was removed by filtration. To the filtrate was added 6 M HCl
(aq.) until constant precipitation was obtained. The white solution was cooled, and the
precipitate was collected by filtration and washed with cold H2O (20 mL), until neutral
pH. More product was observed in the acidic filtrate and therefore it was extracted with
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EtOAc (2 x 20 mL), followed by evaporation and the precipitation method repeated. The
two crops were mixed to afford 4-acetoxybenzoic acid as white-off solid (2.77 g, 71%) that
was used without further purification. Spectral data in correspondence with reported
literature values.57 1H-NMR (400 MHz, DMSO-d6): δ 13.01 (br. s, 1H, ArCOOH), 7.9 (m,
2H, ArH), 7.25 (m, 2H, ArH), 2.29 (s, 3H, C(O)CH3).
4-((1-(2-Amino-4,5-dimethoxyphenyl)ethoxy)carbamoyl)phenyl acetate (2.21)
O
HN
O
NO2
OMe
MeO
O
O
In a flame-dried Schlenk tube containing a magnetic stirring bar
and equipped with a condenser, DMF (two drops) was added to
a stirring solution of 2.21 (781 mg, 4.33 mmol, 3 equiv.) in SOCl2
(2.11 ml, 28.9 mmol, 20 equiv.) under inert atmosphere and heated
at 80 °C. When full conversion was observed by TLC and LCMS
(1.0 h), excess SOCl2 was removed under reduced pressure and the
crude 4-acetoxybenzoyl chloride placed under vacuum for a couple of hours and placed
under inert atmosphere. The crude intermediate was dissolved in Et2O (3 mL) and to the
white suspension was added K2CO3 (998 mg, 7.22 mmol, 5 equiv.) followed by 2.5 (350
mg, 1.45 mmol, 1.0 equiv.). When full conversion was observed by TLC and LCMS, the
reaction mixture was quenched by the addition of H2O (10 mL) and extracted with EtOAc
(30 mL). The organic layer was washed with sat. NaHCO3 (aq.) (20 mL), 1.0 M HCl (aq.)
(2 x 20 mL), brine (20 mL), dried over Na2SO4, filtered, and concentrated in vacuo. The
hydroxamate product 2.21 was isolated by flash chromatography (EtOAc:heptane 4:6) as
a brown oil (393 mg, 67%). Trace amount of impurities were observed by 1H-NMR. Rf =
0.15 (EtOAc:heptane 1:1; UV); IR (neat) ν (cm – 1): 3246, 2979, 2937, 2846, 1757, 1654, 1603,
1582, 1517, 1465, 1334, 1218; 1H-NMR (400 MHz, DMSO-d6): δ 11.52 (s, 1H, HNC(O)),
7.64–7.61 (m, 2H, ArH), 7.56 (s, 1H, ArH), 7.50 (s, 1H, ArH), 7.19–7.17 (m, 2H, ArH),
5.65 (q, J = 6.4 Hz, 1H, ArCHCH3), 3.98 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 2.26 (s, 3H,
C(O)CH3), 1.56 (d, J = 6.4 Hz, 3H, ArCHCH3); 13C-NMR (101 MHz, DMSO-d6): δ 168.9,
163.7, 153.3, 152.9, 147.7, 140.2, 132.4, 129.6, 128.7, 122.0, 109.4, 107.4, 77.6, 56.1, 56.0, 21.1,
20.8; MS (ESI) m/z: calcd. for C19H21N2O8+ [M + H]+ 405.1, found 405.2;
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5-(((Benzyloxy)carbonyl)amino)pentanoic acid (2.22)
O
HO N
H
O
O To a round-bottomed flask containing a magnetic stirring bar,
CbzCl (2.23 mL, 17.1 mmol, 1.0 equiv.) was dropwise added to
a cold solution of 5-aminopentanoic acid (2.00 g, 17.1 mmol. 1-0
equiv.) in 2.0 M NaOH (aq.) (17.1 mL) at 0 °C. pH was followed. The reaction mixture
was stirred for 1 h further and further at rt for 12 h. The light green aqueous solution was
extracted with Et2O (3 x 25 mL) and acidified to pH≈ 2 by the addition of 1.0 M HCl (aq.).
The white precipitate was collected by filtration and washed with a small amount of cold
H2O and dried to afford 2.22 as a white solid (3.3006 g, 77%) that was used without further
purification. Spectral data in correspondence with reported literature values.58 1H-NMR
(400 MHz, DMSO-d6): δ 12.00 (br. s, 1H, COOH), 7.38–7.24 (m, 6H, ArH, CH2NHCbz),
5.00 (s, 2H, OCH2Ar), 3.01–2.96 (m, 2H, CH2,CH2NHCbz), 2.22–2.18 (t, J = 7.2 Hz, 2H,
COOHCH2CH2), 1.52–1.36 (m, 4H, COOHCH2CH2CH2CH2NHCbz);
Benzyl (5-((1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)amino)-5-oxopentyl)carbamate
(2.23)
HN
O
O
NO2
OMe
MeO
N
H
O
O According to the general procedure for coupling reagent
acylation, PyBOP (1.86 g, 3.57 mmol, 1.3 equiv.) and NEM
(2.07 µL, 16.5 mmol, 6 equiv.) was added to a stirring so-
lution of 2.22 (828 mg, 3.30 mmol, 1.2 equiv.) in DMF (27.5
mL) and stirred for 20 min, before 2.5 (665 mg, 2.75 mmol,
1.0 equiv.) was added and the reaction mixture was stirred
overnight. The organic layer was washed with brine (5 x 150 mL). The product was iso-
lated by flash chromatography (EtOAc:heptane 4:1) to afford 2.23 (1.10 mg, 84% ) as a
yellow solid foam. A trace amount of impurities was observed by 1H-NMR. Rf = 0.36
(EtOAc; UV); IR (neat) ν (cm – 1): 3416, 3203, 2953, 2933, 2860, 1697, 1656, 1581, 1518, 1336;
1H-NMR (400 MHz, DMSO-d6): δ 10.76 (br. s, 1H, HNC(O)CH2), 7.56 (s, 1H, ArH), 7.37–
7.28 (m, 6H, ArH), 7.18–7.15 (t, 1H, CH2NHC(O)O), 5.45 (q, J = 6.3 Hz, 1H, ArCHCH3),
4.99 (s, 2H, CH2Ar), 3.95 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 2.88 (m, 2H, CH2NHC(O)),
1.85–1.81 (m, 2H, NC(O)CH2CH2), 1.48 (d, J = 6.3 Hz, 3H, ArCHCH3), 1.40–1.32 (m,
2H, NC(O)CH2CH2CH2), 1.24–1.17 (m, 2H, NC(O)CH2CH2CH2); 13C-NMR (101 MHz,
DMSO-d6): δ 169.0, 156.0, 153.3, 147.7. 140.2, 137.3, 132.6, 128.3, 127.7, 109.3, 107.4, 77.3,
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65.1, 56.1, 56.0, CH2NHC(O)O missing under DMSO-d6, 31.7, 28.6, 22.1, 21.0; MS (ESI)
m/z: calcd. for C23H30N3O8+ [M + H]+ 476.2, found 476.3; HRMS (ESI) m/z: calcd. for
C23H30N3O8+ [M + H]+ 476.2027, found 476.2035.
(9H-Fluoren-9-yl)methyl ((5-((1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)carbamoyl)-
thiophen-2-yl)methyl)carbamate (2.25)
S
O
HN
O
NO2
OMe
MeO
HN
O
O
According to the general procedure for coupling reagent
acylation, PyBOP (5.17 g, 1.78 mmol, 1.2 equiv.)
and NEM (6.25 mL, 49.7 mmol, 6 equiv.) was
added to a stirring solution of 5-(((((9H-fluoren-9-
yl)methoxy)carbonyl)amino)methyl)thiophene-2-carboxy-
lic acid (3.457 g, 9.11 mmol, 1.1 equiv.) in DMF (297.0 mL)
and stirred for 15 min, before 2.5 (2.00 g, 8.28 mmol, 1.0 equiv.) was added and the re-
action mixture was stirred overnight. The organic layer was washed with brine (5 x 300
mL). The hydroxmate product was purified by crystallization from hot acetone and hep-
tane. The mother liquor was evaporated to dryness and the residues were recrystallized.
The two combined crops afforded 2.25 as a greyish solid in (3.65 g, 73% yield). Rf = 0.10
(EtOAc:heptane 1:1; UV); IR (neat) ν (cm – 1): 3324, 3220, 3009, 2970, 2938, 2915, 2851, 1692,
1639, 1520, 1466, 1272; 1H-NMR (400 MHz, DMSO-d6): δ 11.46 (s, 1H, HNC(O)), 8.00 (t,
J = 6.0 Hz, 1H, ArCH2NHC(O)O), 7.88 (d, J = 7.5 Hz, 2H, ArH), 7.67 (d, J = 7.5 Hz, 2H,
ArH), 7.56 (s, 1H, ArH), 7.49 (s, 1H, ArH), 7.40 (t, J = 7.4 Hz, 2H, ArH), 7.32–7.28 (m, 3H,
ArH), 6.87 (d, J = 3.5 Hz, 1H, ArH), 5.61 (q, J = 6.5 Hz, 1H, ArCHCH3), 4.34 (d, J = 6.8 Hz,
2H, C(O)OCH2CH), 4.30 (d, J = 6.0 Hz, 2H, ArCH2NH), 4.22 (t, J = 6.8 Hz, 1H, OCH2CH),
3.97 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 1.55 (d, J = 6.5 Hz, 3H, ArCHCH3); 13C-NMR (101
MHz, DMSO-d6): δ 159.6, 156.1, 153.3, 148.8, 147.7, 143.8, 140.7, 140.1, 137.4, 132.5, 128.9,
127.6, 127.0, 125.5, 125.1, 120.1, 109.4, 107.4, 77.9, 65.5, 56.1, 56.0, 46.7, ArCH2NHC(O)O
under DMSO-d6, 21.1; MS (ESI) m/z: calcd. for C31H30N3O8S+ [M + H]+ 604.2, found 604.4;
HRMS (ESI) m/z: calcd. for C31H30N3O8S+ [M + H]+ 604.1748, found 604.1748; mp. =
174.6–177.4 °C.
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(S)-2-(((Allyloxy)carbonyl)amino)-3-(4-iodophenyl)propanoic acid (2.26)
(S)
O
HO
I
H
N O
O
In a round-bottomed flask containing a magnetic stirring bar, Al-
locCl (805 µL, 7.56 mmol 2 equiv.) was added to a cold slurry of
4-iodo-L-phenylamine (1.10 g, 3.78 mmol, 1.0 equiv.) in THF (14.2
mL), followed by 0.4 M Na2CO3 (aq.) (14.2 mL) and stirred at rt.
When full conversion was observed by TLC and LCMS (1.0 h), the reaction mixture was
transferred to a separation funnel with Et2O (100 mL) and NaHCO3 (sat. aq.) (40 mL).
The aqueous layer was acidified with 1.0 M HCl (aq.) (pH < 1) and extracted with Et2O
(3 x 100 mL). The combined organic phases were dried over Na2SO4, filtered, and concen-
trated in vacuo. This provided 2.26 (1.01 g, 71%) as a white solid that was used without
further purification. Rf = 0.40 (CH2Cl2:MeOH 19:1; UV); IR (neat) ν (cm
– 1): 3313, 3131,
2979, 2940, 1694, 1214; 1H-NMR (400 MHz, DMSO-d6): δ 12.78 (br. s, 1H, C(O)OH),
7.64–7.57 (m, 3H, OC(O)NHCH, 2 x ArH), 7.08–7.06 (m, 2H, ArH), 5.88–5.79 (m, 1H,
OCH2CHCH2), 5.23–5.12 (m, 2H, OCH2CHCH2), 4.45–4.35 (m, 2H, OCH2CHCH2), 4.16–
4.10 (m, 1H, HO(O)CCHNH), 3.04–2.98 (m, 1H, HO(O)CCHCH’H”Ar), 2.81–2.74 (m, 1H,
HO(O)CCHCH’H”Ar); 13C-NMR (101 MHz, DMSO-d6): δ 173.1, 155.8, 137.8, 136.9, 133.5,
131.6, 116.9, 92.3, 64.4, 55.2, 35.9; MS (ESI) m/z: calcd. for C13H15INO4+ [M + H]+ 376.0,
found 376.0; mp. = 97.8–101.5 °C.
Allyl ((2S)-1-((1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)amino)-3-(4-iodophenyl)-1-
oxopropan-2-yl)carbamate
(2.27)
NH
O
HN
I
O
NO2
OMe
MeO
O O According to the general procedure for coupling reagent acyla-
tion, PyBOP (878 mg, 1.69 mmol, 1.5 equiv.) and NEM (855 µL,
6.76 mmol, 6 equiv.) was added to a stirring solution of alloc-
4-iodo-phenylalanine 2.26 (591 mg, 1.575 mmol, 1.4 equiv.) in
DMF (12.4 mL) and stirred for 15 min, before 2.5 (273 mg, 1.13
mmol, 1.0 equiv.) was added and the reaction mixture was stirred
overnight. The organic layer was washed with brine (5 x 50 mL). The hydroxmate prod-
uct 2.27 was purified by column chromatography. Trace amount of impurities were ob-
served by 1H-NMR. A diastereomeric mixture of 1:1 ratio was observed in the NMR spec-
tra. Two resonances for nuclei denoted with a star(*) were observed and both chemical
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shifts are reported. Multiplicity for each diastereomer is reported if possible. Two com-
pounds were observed by TLC. IR (neat) ν (cm – 1): 3295, 3201, 3090, 3012, 2978, 2933, 1687,
1663, 1583, 1518, 1462, 1335, 1274, 1219, 1175, 1083, 1006; 1H-NMR (400 MHz, DMSO-
d6): δ 11.13/11.10* (s, 1H, HNC(O)), 7.64–7.49 (m, 3H, ArH), 7.37/7.32* (d, 1H, ArH),
6.93–6.86 (m, 2H, ArH), 5.86–5.75 (m, 1H, OCH2CHCH2), 5.54–5.39 (m, 1H, ArCHCH3),
5.22–5.11 (m, 2H, OCH2CHCH2), 4.37–4.33 (m, 2H, OCH2CHCH2), 3.96–3.85 (m, 7H, 2
x OCH3, HNC(O)CHNHC(O)), 2.63–2.57 (m, 2H, HNC(O)CHCH2Ar), 1.47–1.43 (m, 3H,
ArCHCH3); 13C-NMR (101 MHz, DMSO-d6): δ 168.2/168.1* 155.9, 153.9/153.8*, 148.1,
140.5, 137.7/137.5*, 137.25/137.19*, 133.9, 133.0/132.9* 131.8, 117.4, 109.7/109.6*, 107.9,
92.8, 77.7, 64.8, 56.55, 56.49, 54.1, 37.2/37.1*, 21.50/21.46*; MS (ESI) m/z: calcd. for
C23H27IN3O8+ [M + H]+ 604.1, found 604.4; mp. = 148.5–150.0 °C.
4-(((tert-Butoxycarbonyl)amino)methyl)benzoic acid (2.28)
O
HO H
N O
O
To a round-bottomed flask containing a magnetic stirring bar,
0.5 M NaOH (aq.) (16 mL) was added to a slurry of 4-
(aminomethyl)benzoic acid (1.00 g, 6.62 mmol, 1.0 equiv.) in diox-
ane (16 mL) at rt. The clear solution was cooled and added Boc2O
(1.60 g, 7.32 mmol, 1.1 equiv.) and stirred rt overnight. When full conversion was ob-
served by TLC and LCMS, dioxane was removed under reduced pressure. pH was ad-
justed to pH = 4 by the addition of 20% citric acid (aq.), and immediately extracted with
EtOAc (3 x 100 mL). The combined organic phases were washed with H2O (100 mL), brine
(100 mL), dried over Na2SO4, filtered, and concentrated in vacuo. This afforded 2.28 as
a white solid (2.265 g, quant.) which was used without further purification. Spectral
data in correspondence with reported literature values.59. 1H-NMR (400 MHz, DMSO-
d6): δ 12.85 (br. s, 1H, C(O)OH), 7.89 (d, J = 8.2 Hz, 2H, ArH), 7.47 (t, J = 6.1 Hz, 1H,
ArCH2NHC(O)O), 7.34 (d, J = 8.2 Hz, 2H, ArH), 4.19 (d, J = 6.1 Hz, 2H, ArCH2NHC(O)O),
1.39 (s, 9H, C(CH3)3);
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tert-Butyl (4-((1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)carbamoyl)benzyl)carbamate
(2.29)
HN
O
O
NO2
OMe
MeO
H
N O
O
According to the general procedure for coupling reagent acy-
lation, PyBOP (978 mg, 1.88 mmol, 1.3 equiv.) and NEM (1.09
µL, 8.67 mmol, 6 equiv.) was added to a stirring solution of
2.28 (871 mg, 3.48 mmol, 2.4 equiv.) in DMF (14.5 mL) and
stirred for 20 min, before 2.5 (350 mg, 1.44 mmol, 1.0 equiv.)
was added and the reaction mixture was stirred overnight.
The organic layer was washed with brine (5 x 100 mL), sat. NaHCO3 (aq.) (100 mL),
and brine (10 mL). The hydroxamate product 2.29 was isolated by flash chromatography
(EtOAc:heptane 1:1) as a yellow solid (651 mg, 95% ). Trace amount of EtOAc was ob-
served by 1H-NMR. Rf = 0.61 (EtOAc; UV); IR (neat) ν (cm
– 1): 3328, 3237, 3008, 2981, 2935,
2835, 1683, 1656, 1584, 1520, 1498, 1467, 1336, 1275, 1220, 1160, 1016, 793; 1H-NMR (400
MHz, DMSO-d6): δ 11.45 (br. s, 1H, HNC(O)), 7.56–7.51 (m, 4H, ArH), 7.42 (t, J = 6.0 Hz,
1H, CH2NHC(O)O), 7.25 (d, J = 8.1 Hz, 2H, ArH), 5.65 (q, J = 6.3 Hz, 1H, ArCHCH3), 4.11
(q, J = 6.0 Hz, 2H, ArCH2NHC(O)O), 3.98 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 1.56 (d, J =
6.3 Hz, 3H, ArCHCH3), 1.37 (s, 9H, C(CH3)3); 13C-NMR (101 MHz, DMSO-d6): δ 164.4,
155.8, 153.3, 147.7, 144.1, 140.2, 132.5, 130.5, 127.1, 126.8, 109.4, 107.4, 77.9, 77.5, 56.11,
56.01, 43.1, 28.2, 21.1; MS (ESI) m/z: calcd. for C23H30N3O8+ [M + H]+ 476.2, found 476.2;
mp. = 149–150 °C.
N-(1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)-5-(hydroxymethyl)thiophene-2-carbox-
amide (2.30)
S
O
HN
O OH
NO2
OMe
MeO
According to the general procedure for coupling reagent acyla-
tion, PyBOP (1.18 g, 2.26 mmol, 1.3 equiv.) and NEM (1.31
µL, 10.4 mmol, 6 equiv.) was added to a stirring solution of 5-
(hydroxymethyl)thiophene-2-carboxylic acid (330 mg, 2.08 mmol,
1.2 equiv.) in DMF (17.4 mL) and stirred for 15 min, before 2.5 (421
mg, 1.74 mmol, 1.0 equiv.) was added and the reaction mixture
was stirred overnight. The organic layer was washed with brine:H2O (1:1) (5 x 100 mL),
sat. NaHCO3 (aq.) (100 mL), and brine (10 mL). The hydroxamate product 2.30 was
isolated by flash chromatography (EtOAc:heptane 7:3) as a yellow solid (445 mg, 67%).
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Trace amount of impurities were observed by 1H-NMR. Rf = 0.46 (EtOAc; UV); IR (neat)
ν (cm – 1): 3245, 3142, 3005, 2966, 2935, 1634, 1579, 1544, 1518, 1505, 1459, 1333, 1272, 1219,
1174; 1H-NMR (400 MHz, DMSO-d6): δ 11.44 (s, 1H, HNC(O)), 7.56 (s, 1H, ArH), 7.48
(s, 1H, ArH), 7.35–7.34 (m, 1H, ArH), 6.90 (d, J = 3.7 Hz, 1H, ArH), 5.62–5.57 (m, 1H,
ArCHCH3), 4.60–4.59 (d, 2H ArCH2OH), 3.97 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 1.55 (d,
J = 6.4 Hz, 3H, ArCHCH3); 13C-NMR (101 MHz, DMSO-d6): δ 160.0, 153.3, 152.3, 147.7,
140.2, 133.9, 132.4, 128.5, 124.1, 109.4, 107.4, 77.9, 58.4, 56.1, 56.0, 21.1; MS (ESI) m/z: calcd.
for C16H19N2O7S+ [M + H]+ 383.1, found 383.1; HRMS (ESI) m/z: calcd. for C16H19N2O7S+
[M + H]+ 383.0907, found 383.0902. mp. = 176–177.1 °C.
5-(((tert-Butyldimethylsilyl)oxy)methyl)-N-(1-(4,5-dimethoxy-2-nitrophenyl)-
ethoxy)thiophene-2-carboxamide (2.31)
S
O
HN
O
NO2
OMe
MeO
O Si
In a flame-dried round-bottomed flask containing a magnetic
stirring bar, TBSCl (218 mg, 1.44 mmol, 1.3 equiv.) in CH2Cl2
(4.0 mL) was added to a stirring solution of 2.30 (425 mg, 1.11
mmol, 1.0 equiv.) in CH2Cl2 (12.0 mL) under inert atmosphere.
The resulting solution was stirred for 10 min before imidazole
(98 mg, 1.44 mmol, 1.3 equiv.) was added followed stirring
overnight. The reaction mixture was concentrated under reduced pressure and purified
directly by flash chromatography (heptane→ EtOAc:heptane 1:4) providing 2.31 (412 mg,
75 %) as a light green solid. Rf = 0.37 (EtOAc:heptane 1:1; UV); IR (neat) ν (cm
– 1): 3154,
2952, 2930, 2855, 1674, 1581, 1511, 1462, 1332, 1272, 1219, 1077, 836; 1H-NMR (400 MHz,
DMSO-d6): δ 11.46 (s, 1H, HNC(O)), 7.56 (s, 1H, ArH), 7.48 (s, 1H, ArH), 7.36–7.35 (m,
1H, ArH), 6.93–6.92 (d, J = 4.0 Hz, 1H, ArH), 5.60 (q, J = 6.3 Hz, 1H, ArCHCH3), 4.83 (s,
2H, ArCH2O), 3.97 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 1.55 (d, J = 6.3 Hz, 3H, ArCHCH3),
0.88 (s, 9H, SiC(CH3)3), 0.07 (s, 6H, OSi(CH3)2C); 13C-NMR (101 MHz, DMSO-d6): δ 160.3,
153.8, 151.4, 148.2, 140.6, 134.8, 132.9, 129.0, 124.5, 109.9, 107.9, 78.4, 60.7, 56.6, 56.5, 26.1,
21.6, 18.4, -4.9; MS (ESI) m/z: calcd. for C22H33N2O7SSi+ [M + H]+ 497.2, found 497.2;
HRMS (ESI) m/z: calcd. for C22H33N2O7SSi+ [M + H]+ 497.1772, found 497.1770. mp. =
106–107 °C.
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N-(1-(2-amino-4,5-dimethoxyphenyl)ethoxy)-4-(hydroxymethyl)benzamide (2.32)
HN
O
O OH
NO2
OMe
MeO
According to the general procedure for coupling reagent acy-
lation, PyBOP (1.12 g, 2.15 mmol, 1.3 equiv.) and NEM (1.25
mL, 9.91 mmol, 6 equiv.) was added to a stirring solution of 4-
(hydroxymethyl)benzoic acid (302 mg, 1.98 mmol, 1.2 equiv.) in
DMF (16.5 mL) and stirred for 20 min, before 2.5 (400 mg, 1.65
mmol, 1.0 equiv.) was added and the reaction mixture was stirred
overnight. The organic layer was washed with brine:H2O (1:1) (5 x 100 mL). The hydrox-
amate product 2.32 (171 mg, 27%) was isolated by flash chromatography (EtOAc:heptane
7:3) as a light green solid. Trace amount of impurities were observed by 1H-NMR. Rf =
0.39 (EtOAc; UV); IR (neat) ν (cm – 1): 3284, 3145, 2983, 2874, 1636, 1575, 1518, 1469, 1375,
1334, 1274, 1223, 1177, 1005; 1H-NMR (400 MHz, DMSO-d6): δ 11.46 (br. s, 1H, HNC(O)),
7.56–7.52 (m, 4H, ArH), 7.34 (d, J = 8.1 Hz, 2H, ArH), 5.65 (q, J = 6.3 Hz, 1H, ArCHCH3),
5.28 (t, J = 5.7 Hz, 1H, ArCH2OH), 4.50 (d, J = 5.7 Hz, 2H, ArCH2OH), 3.98 (s, 3H, OCH3),
3.84 (s, 3H, OCH3), 1.56 (d, J = 6.3 Hz, 3H, ArCHCH3); 13C-NMR (101 MHz, DMSO-d6): δ
164.4, 153.3, 147.7, 146.5, 140.2, 132.6, 130.4, 126.9, 126.1, 109.4, 107.4, 77.5, 62.3, 56.1, 56.0,
21.1; MS (ESI) m/z: calcd. for C18H21N2O7+ [M + H]+ 377.1, found 377.2; mp. = 172.1–173.4
°C.
N-(1-(4,5-Dimethoxy-2-nitrophenyl)ethoxy)-4-(((tetrahydro-2H-pyran-2-yl)oxy)me-
thyl)benzamide (2.33)
HN
O
O
NO2
OMe
MeO
O
O
In a flame-dried Schlenk tube containing a magnetic stirring
bar, 3,4-dihydro-2H-pyran (435 µL, 4.76 mmol, 8 equiv.) and
p-TsOH (11 mg, 0.059 mmol, 0.1 equiv.) was added to the alco-
hol (224 mg, 5.95 mmol, 1.0 equiv.) in THF (5 mL) under inert
atmosphere and stirred overnight. The brown reaction mix-
ture was evaporated to dryness and title compound was iso-
lated directly by flash chromatography (EtOAc:heptane 4:6) (140 mg, 51%) as a light green
foam. A trace amount of impurites were observed 1H-NMR. Rf = 0.20 (EtOAc:heptane 1:1;
UV); IR (neat) ν (cm – 1): 3202, 2939, 2868, 1648, 1576, 1517, 1463, 1333, 1271, 1218, 1173,
1120, 1013; 1H-NMR (400 MHz, DMSO-d6): δ 11.48 (s, 1H, HNC(O)), 7.58–7.56 (m, 3H,
ArH), 7.51 (s, 1H, ArH), 7.37 (d, J = 7.9 Hz, 2H, ArH), 5.66 (q, J = 6.3 Hz, 1H, ArCHCH3),
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4.69–4.63 (m, 2H, ArCH’H”O,CH2OCHO), 4.89–4.45 (m, 1H, ArCH’H”O), 3.98 (s, 3H,
OCH3), 3.84 (s, 3H, OCH3), 3.78–3.72 (m, 1H, CH2CH2CHOCH”’H””CH2), 3.47–3.43 (m,
1H, CH2CH2CHOCH”’H””CH2), 1.75–1.46 (m, 9H, CH2CH2CHOCH2CH2, ArCHCH3);
13C-NMR (101 MHz, DMSO-d6): δ 164.2, 153.3, 147.7, 142.2, 140.2, 132.5, 131.1, 127.3,
127.1, 109.4, 107.4, 97.3, 77.5, 67.4, 61.3, 56.1, 56.0, 30.1, 25.0, 21.1, 19.0; MS (ESI) m/z:
calcd. for C23H29N2O8+ [M + H]+ 461.2, found 461.2.
N-(1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)-5-(hydroxymethyl)thiophene-2-carbox-
amide (2.37)
S
O
HN
O OH
NO2
OMe
MeO
In a flame-dried Schlenk tube containing a magnetic stirring bar
equipped with a cold finger, Pd(OH)2/C (18.3 mg, 0.130 mmol,
1.1 equiv.) was added to a stirring solution of 2.17 (50 mg, 0.128
mmol, 1.0 equiv.) in iPrOH (1.2 mL) and refluxed overnight. The
dark reaction mixture was filtered through a pad of Celite® and
washed thoroughly with CH2Cl2 and concentrated under reduced
pressure. Trace impurities were observed so the alcohol was purified by flash column
chromatography (EtOAc:heptane 3:2) to afford 2.37 (32 mg, 71%) as a light green solid.
Trace amount of impurities were observed by 1H-NMR. Spectral data in correspondence
with 2.30. 1H-NMR (400 MHz, DMSO-d6): δ 11.45 (br. s, 1H, HNC(O)), 7.56 (s, 1H, ArH),
7.48 (s, 1H, ArH), 7.34 (d, J = 3.5 Hz, 1H, ArH), 6.90 (d, J = 3.5 Hz, 1H, ArH), 5.64–5.58 (m,
2H, ArCHCH3, CH2OH), 4.60 (d, J = 5.6 Hz, 2H, ArCH2OH), 3.97 (s, 3H, OCH3), 3.84 (s,
3H, OCH3), 1.55 (d, J = 6.2 Hz, 3H, ArCHCH3); MS (ESI) m/z: calcd. for C16H19N2O7S+ [M
+ H]+ 383.1, found 383.2;
N-(1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)-5-(hydroxymethyl)thiophene-2-car-
boxamide (2.38)
S
O
HN
O OH
NO2
OMe
MeO
In a Schlenk tube containing a magnetic stirring bar, TBAF (1 M
in THF, 55 µL, 0.0554 mmol, 1.1 equiv.) was dropwise added to a
stirring solution of 2.31 (25 mg, 0.0554 mmol, 1.0 equiv.) in THF
(200 µL). When full conversion was observed (8.0 h), the reac-
tion mixture was evaporated and purified directly by PREP-TLC
(CH2Cl2:MeOH 39:1). The silica was stirred in EtOAc before the
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organic solution was collected by filtration and co-evaporated with CH2Cl2 to afford 2.38
as a light green solid (16 mg, 82%). Trace amount of EtOAc was observed by 1H-NMR.
Spectral data in correspondence with 2.30. 1H-NMR (400 MHz, DMSO-d6): δ 11.44 (br.
s, 1H, HNC(O)), 7.56 (s, 1H, ArH), 7.48 (s, 1H, ArH), 7.34 (d, J = 3.4 Hz, 1H, ArH), 6.91
(d, J = 3.4 Hz, 1H, ArH), 5.62–5.58 (m, 2H, ArCHCH3, CH2OH), 4.60 (d, J = 5.9 Hz, 2H,
ArCH2OH), 3.97 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 1.55 (d, J = 6.4 Hz, 3H, ArCHCH3);
MS (ESI) m/z: calcd. for C16H19N2O7S+ [M + H]+ 383.1, found 383.2;
N-(1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)-4-(hydroxymethyl)benzamide (2.39)
HN
O
O OH
NO2
OMe
MeO
In a Schlenk tube containing a magnetic stirring bar, 10% HCl
(aq.) (110 µL) was added to a stirring solution of 2.33 (25 mg,
0.0543 mmol, 1.0 equiv.) in THF (545 µL). When full conver-
sion was observed (2.5 h), the reaction mixture was transferred
to a separation funnel with EtOAc (5 mL) and H2O. The organic
layer was extracted with EtOAc (2 x 5 mL) and the combined or-
ganic phases were washed with H2O (5 mL), dried over Na2SO4, filtered, concentrated in
vacuo. 2.39 was purified by PREP-TLC (EtOAc:heptane 3:2), extracted from the silica with
EtOAc, and twice co-evaporated with CH2Cl2 affording the alcohol as a yellow solid (18
mg, 87%). Trace amount of EtOAc and CH2Cl2 were observed by 1H-NMR. Spectral data
in correspondence with 2.32.
1H-NMR (400 MHz, DMSO-d6): δ 11.46 (br. s, 1H, HNC(O)), 7.56-7.52 (m, 4H, ArH),
7.34 (d, J = 8.8 Hz, 2H, ArH), 5.64 (q, J = 6.5 Hz, 1H, ArCHCH3), 5.28 (t, J = 5.7 Hz, 1H,
ArCH2OH), 4.51 (d, J = 5.7 Hz, 2H, ArCH2OH), 3.99 (s, 3H, OCH3), 3.84 (s, 3H, OCH3),
1.56 (d, J = 6.5 Hz, 3H, ArCHCH3); MS (ESI) m/z: calcd. for C18H21N2O7+ [M + H]+ 377.1,
found 377.2; HRMS (ESI) m/z: calcd. for C18H21N2O7+ [M + H]+ 377.1343, found 377.1354.
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5-(aminomethyl)-N-(1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)thiophene-2-carboxamide
(2.40)
S
O
HN
O NH2
NO2
OMe
MeO
In a Schlenk tube containing a magnetic stirring bar, 2.25 (48
mg, 0.078 mmol, 1.0 equiv) was added to a stirring solution of
MeCN:Et2NH (10:1) (3.1 mL). When full conversion was observed
(1.75 h), all volatiles were removed under reduced pressure and
directly purified by flash column chromatography (CH2Cl2 →
CH2Cl2:MeOH 17:3). 2.40 was obtained as a green oil (30 mg,
quant.). Trace amount of impurities were observed by 1H-NMR.
1H-NMR (400 MHz, DMSO-d6): δ 7.56 (s, 1H, ArH), 7.49 (s, 1H, ArH), 7.35 (d, J = 3.4 Hz,
1H, ArH), 6.88 (d, J = 3.4 Hz, 1H, ArH), 5.60 (q, J = 6.3 Hz, 1H, ArCHCH3), 3.97 (s, 3H,
OCH3), 3.86-3.84 (m, 5H, OCH3, ArCH2NH2), 1.54 (d, J = 6.3 Hz, 3H, ArCHCH3); 13C-
NMR (101 MHz, DMSO-d6): δ 156.0, 154.4, 153.4, 147.7, 140.2, 133.4, 132.7, 128.6, 123.8,
109.5, 107.4, 77.8, 56.1, 56.0, 40.8, 21.1; MS (ESI) m/z: calcd. for C16H20N3O6S+ [M + H]+
382.1, found 382.2; HRMS (ESI) m/z: calcd. for C16H20N3O6S+ [M + H]+ 382.1067, found
382.1095.
General Photo-Cleavage Procedure
The MeNV-protected compound was dissolved in a solvent indicated under each com-
pound in a small glass jar and a quartz lid was placed on top. The jar was placed under
a UV-lamp at 365 nm inside a large customized aluminium box until full conversion was
observed by LCMS. Solvent was added every 10-12 h to prevent drying-out. The solution
was transferred to a separation funnel by the use of EtOAc and H2O. The aqueous layer
was extracted with EtOAc (3 x). The combined organic phases were dried over Na2SO4,
filtered, and concentrated in vacuo. The hydroxamic acids were purified by PREP-TLC.
The desired band was collected and the silica stirred in CH2Cl2:Et3N (2:1) (3 mL) for 30
min before it was filtrated. The mother liquor was concentrated under reduced pressure
and co-evaporated from toluene, filtrated and twice co-evaporated from CH2Cl2.
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N-Hydroxy-5-((prop-1-en-1-yloxy)methyl)thiophene-2-carboxamide (2.43)
S
O
HN
OH
O
According to the general photo-cleavage procedure, 2.17 (50 mg,
0.118 mmol, 1.0 equiv.) was placed under an UV-lamp and irradi-
ated for 44.5 h, extracted and purified by PREP-TLC (CH2Cl2:MeOH
9:1) to afford 2.43 as a brown oil (8 mg, 31%). A trace amount of
impurities and CH2Cl2 was observed by 1H-NMR. 1H-NMR (400 MHz, DMSO-d6): δ
11.18 (s, 1H, HNC(O)), 9.10 (s, 1H, HONHC(O)), 7.48 (s, 1H, ArH), 7.04 (d, J = 3.6 Hz,
1H, ArH), 5.95–5.86 (m, 1H, OCH2CHCH2) 5.28 (m, 1H, OCH2CHCH’H”), 5.18 (m, 1H,
OCH2CHCH’H”), 4.63 (s, 2H, ArCH2O), 4.01 (dt, J = 5.4, 1.5 Hz, 2H, OCH2CHCH2; 13C-
NMR (101 MHz, DMSO-d6): δ 159.5, 145.6, 136.9, 134.8, 127.2, 126.6, 116.9, 70.3, 66.0; MS
(ESI) m/z: calcd. for C9H12NO3S+ [M + H]+ 214.1, found 214.1;
N-hydroxy-3-(methoxymethoxy)benzamide (2.44)
HN
O
OH
O O
According to the general photo-cleavage procedure, 2.19 (50 mg, 0.123
mmol, 1.0 equiv.) was placed under an UV-lamp and irradiated for
47.0 h, extracted with EtOAc (3 x 5 mL) and purified by PREP-TLC
(CH2Cl2:MeOH 9:1) to afford 2.44 as a brown oil (7 mg, 27%). A trace
amount of impurities and CH2Cl2 was observed by 1H-NMR. 1H-NMR (400 MHz, DMSO-
d6): δ 11.20 (s, 1H, NHC(O)), 9.03 (s, 1H, HONHC(O)), 7.39–7.36 (m, 3H, ArH), 7.17–7.14
(m, 1H, ArH), 5.22 (s, 2H, OCH2OCH3), 3.38 (s, 3H, OCH2OCH3); 13C-NMR (101 MHz,
DMSO-d6): δ 163.8, 156.7, 134.2, 129.6, 120.1, 119.0, 114.6, 93.9, 55.6; MS (ESI) m/z: calcd.
for C9H12NO4+ [M + H]+ 198.1, found 198.1; HRMS (ESI) m/z: calcd. for C9H12NO4+ [M +
H]+ 198.0761, found 198.0766.
5-(((tert-Butyldimethylsilyl)oxy)methyl)-N-hydroxythiophene-2-carboxamide (2.49)
HN
O
OH
S
O Si
According to the general photo-cleavage procedure, 2.31 (50 mg,
0.101 mmol, 1.0 equiv.) was placed under an UV-lamp and irradi-
ated for 47.0 h, extracted with EtOAc (3 x 5 mL) and purified by
PREP-TLC (CH2Cl2:MeOH 39:1) to afford 2.49 as a brown film (10
mg, 34%). A trace amount of impurities and CH2Cl2 was observed by 1H-NMR. 1H-NMR
(400 MHz, DMSO-d6): δ 11.15 (s, 1H, NHC(O)), 9.07 (s, 1H, HONHC(O)), 7.49 (m, 1H,
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ArH), 6.95 (d, J = 3.3 Hz, 1H, ArH), 4.85 (s, 2H, ArCH2O), 0.89 (s, 9H, SiC(CH3)3), 0.08
(s, 6H, OSi(CH3)2C); 13C-NMR (101 MHz, DMSO-d6): δ 159.6, 149.7, 135.8, 127.2, 124.1,
60.2, 25.7, 17.9, -5.3; MS (ESI) m/z: calcd. for C12H22NO3SSi+ [M + H]+ 288.1, found 288.1;
HRMS (ESI) m/z: calcd. for C12H22NO3SSi+ [M + H]+ 288.1084, found 288.1080.
Benzyl (5-(hydroxyamino)-5-oxopentyl)carbamate (2.45)
HN
O
OH
N
H
O
O According to the general photo-cleavage procedure, 2.23 (50
mg, 0.105 mmol, 1.0 equiv.) was placed under an UV-lamp
and irradiated for 47.0 h, extracted with EtOAc (3 x 5 mL) and
purified by PREP-TLC (CH2Cl2:MeOH 39:1) to afford 2.45 as
a brown film (5 mg, 19%). A trace amount of impurities and CH2Cl2 was observed
by 1H-NMR. 1H-NMR (400 MHz, DMSO-d6): δ 10.33 (s, 1H, HNC(O)), 8.66 (s, 1H,
HONHC(O)), 7.38–7.24 (m, 1H, ArH, CH2NHC(O)CH2Ph), 5.00 (s, 2H, C(O)OCH2Ph),
2.99-2.94 (m, 2H, CH2CH2NHCbz), 1.93 (t, J = 7.2 Hz, 2H, HNC(O)CH2), 1.51–1.34 (m,
4H, CH2CH2CH2CH2); 13C-NMR (101 MHz, DMSO-d6): δ 167.0, 156.1, 137.3, 128.4, 127.7,
65.1, under DMSO, 31.9, 29.0, 22.5; MS (ESI) m/z: calcd. for C13H19N2O4+ [M + H]+ 267.1,
found 267.2. HRMS (ESI) m/z: calcd. for C13H19N2O4+ [M + H]+ 267.1339, found 267.1357.
(9H-Fluoren-9-yl)methyl ((5-(hydroxycarbamoyl)thiophen-2-yl)methyl)carbamate
(2.46)
HN
O
OH
S
N
H O
O
According to the general photo-cleavage procedure, 2.25 (50
mg, 0.0828 mmol, 1.0 equiv.) was placed under an UV-lamp
and irradiated for 24.0 h, extracted with EtOAc (3 x 5 mL)
and purified by PREP-TLC (CH2Cl2:MeOH 39:1) to afford 2.46
as a brown film (11 mg, 32%). A trace amount of impurities
and CH2Cl2 was observed by 1H-NMR. 1H-NMR (400 MHz, DMSO-d6): δ 11.15 (s, 1H,
NHCO), 9.07 (s, 1H, HONHCO), 8.02 (t, J = 5.8 Hz, 1H, CH2NHC(O)O), 7.88 (d, J = 7.4
Hz, 2H, ArH), 7.69 (d, J = 7.4 Hz, 2H, ArH), 7.41 (d, J = 7.3 Hz, 2H, ArH), 7.32 (m, 3H,
ArH), 6.90 (d, J = 3.0 Hz, 1H, ArH), 4.36–4.33 (m, 4H, ArCH2NHC(O)OCH2CH), 4.25–
4.21 (m, 1H, C(O)OCH2CH); 13C-NMR (101 MHz, DMSO-d6): δ 159.6 156.2, 147.7, 143.8,
140.8, 127.7, 127.1, 125.5, 125.2, 120.1, 65.6, 46.7, 39.2 (overlap with DMSO-d6); MS (ESI)
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m/z: calcd. for C21H19N2O4S+ [M + H]+ 395.1, found 395.2. HRMS (ESI) m/z: calcd. for
C21H19N2O4S+ [M + H]+ 395.1060, found 395.1058.
Allyl (1-(hydroxyamino)-3-(4-iodophenyl)-1-oxopropan-2-yl)carbamate (2.47)
N
H
O
HO
I
H
N O
O
According to the general photo-cleavage procedure, 2.27 (50 mg,
0.0834 mmol, 1.0 equiv.) was placed under an UV-lamp and ir-
radiated for 38.0 h, extracted with EtOAc (3 x 5 mL) and puri-
fied by PREP-TLC (CH2Cl2 → CH2Cl2:MeOH 9:1) to afford 2.47 as
a brown film (7 mg, 20%). A trace amount of impurities and CH2Cl2 was observed
by 1H-NMR. 1H-NMR (400 MHz, DMSO-d6): δ 10.68 (s, 1H, HNC(O)), 8.88 (s, 1H,
HONHC(O)), 7.63–7.61 (m, 2H, ArH), 7.53 (d, J = 8.2 Hz, 2H, ArH), 7.06 (d, J = 8.8 Hz,
1H, CHNHC(O)O), 5.87–5.77 (m, 1H, C(O)OCH2CHCH2), 5.19 (m, 1H, CH2CHCH’H”),
5.12 (m, 1H, CH2CHCH’H”), 4.42–4.33 (m, 2H, C(O)OCH2CHCH2), 4.07–4.01 (m, 1H,
HNC(O)CHNHC(O)O), 2.85–2.70 (m, 2H, HNC(O)CHCH2Ar); 13C-NMR (101 MHz,
DMSO-d6): δ 167.9, 155.5, 137.8, 136.8, 133.5, 131.7, 116.9, 92.3, 64.3, 53.8, 37.1; MS (ESI)
m/z: calcd. for C13H18N2O4 [M + H]+ 266.1, found 266.2.
tert-Butyl (4-(hydroxycarbamoyl)benzyl)carbamate (2.48)
HN
O
OH
H
N O
O
According to the general photo-cleavage procedure, 2.29 (50 mg,
0.105 mmol, 1.0 equiv.) was placed under an UV-lamp and irradi-
ated for 47.0 h, extracted with EtOAc (3 x 5 mL) and purified by
PREP-TLC (CH2Cl2:MeOH 39:1) to afford 2.48 as a brown film (16
g, 57%). A trace amount of impurities and CH2Cl2 was observed by 1H-NMR. 1H-NMR
(400 MHz, DMSO-d6): δ 11.16 (s, 1H, HNC(O)), 8.99 (s, 1H, HONHC(O)), 7.69 (d, J = 7.9
Hz, 2H, ArH), 7.44 (t, J = 5.5 Hz, 1H, ArCH2NHC(O)O), 7.29 (d, J = 7.9 Hz, 2H, ArH),
4.15 (d, J = 5.5 Hz, 2H, ArCH2NHC(O)O), 1.39 (s, 9H, C(CH3)3); 13C-NMR (101 MHz,
DMSO-d6): δ 164.2, 155.8, 143.5, 131.20 126.9, 126.8, 77.9, 43.1, 28.2; MS (ESI) m/z: calcd.
for C13H19N2O4+ [M + H]+ 266.1, found 266.2. HRMS (ESI) m/z: calcd. for C13H19N2O4+
[M + H]+ 267.1339, found 267.1345.
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A Guided Design of Selective HDAC
Inhibitors Based on Substrate Profiling
3.1 Introduction
Cancer remains one of the most fatal diseases in the developed parts of the world. Con-
sequently, there is a massive focus on this area.60 An early diagnose and treatment, are
key factors for recovery. Therefore, the danish non-governmental organization (NGO),
the Danish Cancer Society, works to raise public awareness of cancer by the use of infor-
mation campaigns, but also supports through research grants.61 In many cases, cancer is
treated with highly potent compounds, most of which are non-selective towards cancer
cells making them toxic. Better treatments are in the pipeline, one promising method is
delivery of the drug specifically to cancer cells by various methods for targeted treatment
with fewer adverse effects.
For decades, new compounds have been taken into clinical tests, but only a few of them
have been approved to fill this unmet need. Our goal is to synthesize compounds that
are sub-type selective for vital enzymes shown to be up-regulated in several cancer types.
Based on a substrate profiling study performed previous in our group, a hit compound
was identified as being selective for HDAC3 (3.1), Figure 3.1. We set out to investigate
the possibility of converting this substrate into a sub-class selective inhibitor.
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Figure 3.1: HDAC3 selective substrate and activity profile
3.2 Histone Deacetylase
The genetic code of mammalian cells is built into DNA, which is primarily found in the
nucleus of the cells. The nuclein was isolated by Friedrich Miescher in 1869,62 but the
structure of DNA was first characterized in 1953 by James Watson and Francis Crick.63
Watson, Crick, and Wilkins received the Nobel Prize for Physiology in 1962. The human
DNA is organized in a highly condensed structure called the chromosomes, Figure 3.2.
DNA coils around histones, positively charged proteins with a high amount of lysine
residues in the protruding histone N-amino tails. The ε-amino groups are protonated
at physiological pH, hence form strong electrostatic bonds with the negatively charged
phosphate group in the backbone of the coiled DNA. Histones are sites for post-trans-
lational modifications (PTMs) including phosphorylation, methylation, acetylation, bi-
otinylation, etc. This has been well-described in some excellent papers [65–67]. PTMs
alter DNA-histone interactions and binding of transcription factors.68 Our primary focus
is deacetylation, because the balance of chromatin acetylation-deacetylation is linked to
various cancer types.69
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Figure 3.2: Overview of the chromosome and its component. Adapted from Annunziato.64
Two enzymes are responsible for this balance, a epigenetic writer (histone acetyltrans-
ferase, HAT) and an epigenetic eraser (HDAC). HAT are responsible for acetylation of
lysine residues, whereas HDAC removes the attached acetyl group. Acetylation of lysine
results in a neutral residue at physiological pH, which cannot bind strongly to the phos-
phate group of DNA, overall affording a less condensed structure/arrangement. The
acetylation also operates as a recognizable tag for epigenetic readers with bromodomains
to recruit replication factors.70 Not only replication factors but also HAT contain a bro-
modomain to recognize acetylated lysine residues.71 HDAC removal of the acetyl group
restores the electrostatic interaction between protonated lysine-rich histone tails and neg-
ative phosphate in DNA. All the histone proteins can be acetylated, but the most im-
portant lysine residues are positioned on H3 and H4.72 Recent studies show that, HDAC
enzymes have proven them efficient not only to remove acetyl groups from various sub-
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strates, but also small acyl groups, which we also will highlight later in this dissertation.
3.2.1 HDAC Isozymes
The mammalian genome consists of 18 HDAC isozymes,73 which can be organized in
four classes based on their yeast equivalent, with a further sub-class division for class II:
class I (HDAC1, HDAC2, HDAC3, and HDAC8), class IIa (HDAC4, HDAC5, HDAC7,
and HDAC9) and class IIb (HDAC6 and HDAC10), class III accommodates the sirtuins
family (Sirt1-7), and class IV (HDAC11). The class III enzymes are different from the
other classes, due to the nicotinamide adenine dinucleotide (NAD+)-dependent nature,
whereas HDAC1-11 are zinc-dependent. As they distinctly differ from HDAC1-11, sirtu-
ins will not be further described.
HDAC1 and HDAC2 have a high sequence identity (86%), and compared to HDAC1:
HDAC3 and HDAC8 have 63% and 43%, respectively. In comparison HDAC10 have a se-
quence identity with HDAC7 and HDAC6 of 34% and 49% respectively, and for the three
other class II enzymes (HDAC4, HDAC5, and HDAC9) have an equal 34% sequence iden-
tity.74,75 The tissue distribution of HDAC in the body varies and they are found in many
different organs as shown in Table 3.1.
Table 3.1: Distribution HDAC isozymes throughout the body. Modified from Ruijter et al.76
Tissue HDAC1 HDAC2 HDAC3 HDAC8 HDAC4 HDAC5 HDAC7 HDAC9 HDAC6 HDAC10
Brain + + + - - + + + + +
Breast - - + - - + + - + +
Colon + + - - - + - - + +
Kidney + + - - - - - - - +
Ovary + + + - - - + + + +
Pancreas + + + + - - + - + -
Prostate + + + - - + + + + -
Heart - + - - - + + + + -
HDAC11 was not included in this study, but when it was first described in 2002 by Gao et
al. high levels were found in heart, testicles, skeletal muscle, and kidney.77 In 2007, Broide
and co-workers found HDAC11 in the brain of rats.78
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3.2.2 Active site Construction and Enzymatic Mechanism
In 1999, Finnin et al. postulated how the enzyme pocket and the active site in HDAC are
organized, Figure 3.3 and Figure 3.4.79 The authors showed the presence of an internal
cavity positioned next to the active site in the enzymatic pocket, Figure 3.3a. In Figure
3.3b, the way of the incoming N-acetylated lysine and important residues in HDLP are
sketched.
(a) Structure of the enzymatic pocket and
internal cavity of histone deacetylase-like
protein (HDLP) and with bound tricho-
statin A (TSA)
(b) Approach of the incoming acetylated lysine-residue
and transport of the acetate out of the internal pocket
Figure 3.3: Illustration of HDLP internal cavity and construction of the pocket. Modified from Wang and co-workers.80
In the active site, a zinc atom is stabilized by two aspartic acids, one histidine, and a
water molecule, Figure 3.4 (a).79 In addition to the stabilizing residues, the active site
contains two aspartic acids, two histidines, and one tyrosine residue. Aspartic acid and
histidine forms a charge-relay system, that have been described for serine proteases.81
The two charge-relay histidine-aspartic acid systems in combination with tyrosine and
are important to facilitate deacetylation. One aspartic acid carboxylate hydrogen-binds
to the nitrogen of histidine, increasing pKa of the histidine. One of the charge-relay sys-
tems is buried deeper, in closer proximity to the zinc ion in the active site than the other
one. Furthermore, the charge-relay system facilitates optimal spatial orientation of the
substrate in the active site. After establishing the important residues, Finnin et al. pro-
posed a mechanism for the hydrolysis of acetylated lysine residues, Figure 3.4. However,
this mechanism is still debated and could differ from one HDAC to another.82
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Figure 3.4: Mechanism of deacetylation of N-acetylated lysine residue. A Incoming acetyl group is attacked by the
activated water molecule. B The tetrahedral intermediate is protonated and colapses. C Liberation of protonated lysine
residue. Modified from Finnin et al.79
3.2.3 HDAC Isozyme Cellular Localization and Active Multi-Protein
Complexes
Class I HDACs are primarily localized in the nucleus, although HDAC3 and HDAC8 can
be found in the cytoplasm. HDAC sub-class IIa is located in the nucleus where DNA
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replication factors are present. HDAC4 is relocated from the nucleus to cytoplasm by
PTM, serine-phosphorylation, to expose a 14-3-3 binding domain to facilitate nucleocyto-
plasmic transport hereby regulating its accessibility to DNA.83,84
McKinsey et al.85 described that HDAC5 contains multiple phosphorylation sites for cal-
cium/calmodulin-dependent protein kinase (CaMK), and some others have been found
recently.86 This regulation of HDACs affect the enzymatic activity. Binding of 14-3-3 to
HDAC4 and HDAC5 result in an inactivation of the two enzymes and are also incapable
of bind to importin α, a transporter complex for nuclear uptake of proteins.87,88 Verdal and
co-workers proved that HDAC6 also contains a highly potent nuclear export sequence
and was predominately found in the cytoplasm.89 HDAC10 is also found in the nucleus
and the cytoplasm.90
HDACs are often organized in multi-protein complexes in their active enzymatic form.
HDAC8 displays enzymatic activity as a single protein, this is linked to the absence of
a specific peptide sequence used for protein complex formation.91 Not only HDAC4 but
also HDAC5, HDAC7, and HDAC9 can interact with the HDAC3-silencing mediator for
retinoid and thyroid receptor (SMRT)/nuclear receptor corepressor (N-CoR) complex,
and have been suggested to serve as recruiters to deliver HDAC3 to act as a HDAC.92 Be-
sides a 14-3-3 binding site, class IIa also contain a MEF2-interacting transcription repres-
sor (MITR) domain close to the 14-3-3 domain recognized by myocyte enhancer factor-2
(MEF2). MEF2 binds to DNA and acts as a transcription factor and is important in muscle
differentiation.93
3.2.4 Regulation of Acetylation by HDAC and their Biology
Influences
The 11 isozymes are involved in a comprehensive network of biological targets, and
HDAC dysfunctional activity has been associated with a variety of diseases. As such,
the use of HDACis have been shown to be efficient in the treatment of cancer as well
as various non-cancer diseases such as HIV,94,95 Alzheimer’s disease,96 Parkinson’s dis-
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ease,97 inflammation,98–100 long-term memory loss,101 diabetes mellitus,102 heart failure,103
and Friedreich ataxia.104
HDACis have especially proved to be highly efficient against mature T-cell non-Hodgkin
lymphomas, both against the aggressive peripheral T-cell lymphomas (PTCL)105 and the
primary skin lymphoma, CTCL.106
Therefore, HDACis have a broad application profile and due to the amount of com-
pounds been advanced to clinical trials, more compounds are expected to be approved
for treatment in the future. Hydroxamic acids strongly chelate to divalent ions, the rea-
son why this functional group is the most applied for inhibition of HDAC enzymes. Al-
though, there are several concerns regarding the use of hydroxamic acid, as it show low
HDAC isozyme selectivity and poor pharmacokinetics, summarized by Kozikowski.107
One of the most potent HDACi identified so far is TSA.108 However, due to extensive
mutagenesis, it has little use in clinical settings. This has been postulated to arise from
the degradation of the hydroxamic acids to the corresponding isocyanates via the Lossen
rearrangement.107 Kozikowski has suggested that N-alkylated hydroxamic acids are not
as prone to rearrange and therefore, may not afford mutagenesis. Many have looked into
the use of other functional groups as HDACis, and in particular the ortho-aminoanilide
group has been shown to be highly activity.
3.3 From a Pan-Inhibitor to Isozyme-Selective
Compounds
The first reported HDACi was DMSO. Friend et al. found it to induce growth arrest
and terminal differentiation in murine erythroleukemia cells (MELC). These results ini-
tiated the HDACi research field and furthermore lead to the synthesis of SAHA by P. A.
Marks and R. Breslow, a compound which was approved by FDA in 2006 as an anticancer
drug.109,110 The generally accepted pharmacophore of HDACis composes of a cap group,
a linker moiety, and a ZBG, see Figure 3.5.
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Figure 3.5: Well-acknowledged pharmacophore of HDAC inhibitors
Since the discovery of TSA and SAHA as potent HDACis, an enormous amount of re-
search has been conducted within this field. However, so far only the four compounds,
highlighted in Figure 3.6, have been granted FDA approval, SAHA and Romidepsin (Is-
todax, 2009) for CTCL111,112, and Belinostat113 (Beleodaq, 2014) for PTCL. Furthermore,
Chidamide was approved against PTCL in 2014 by China Food and Drug Administra-
tion (CFDA).114 In 2011, Romidepsin was also approved for PTCL by FDA in 2011.115
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Figure 3.6: Clinical approved HDACi
SAHA, Belinostat, Romidepsin, and Panobinostat are all recognized as pan-inhibitors,
and therefore there is a need to find sub-class selective HDACis.
Due to high degree of homology of the active site of HDAC isozymes, it is difficult to
predict the structural requirements of a sub-class selective inhibitor. Only a few selective
HDACi have until now been published, Table 3.2, and there is definitely a need for a
better understanding to develop the next generation of HDACis.82,116–122
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Table 3.2: Overview of chosen HDACis and their IC50 values
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HDACi Selectivity Activity (IC50) HDACi Selectivity Activity (IC50)
Hydroxamic acids
3.2 HDAC8 70 nM123 3.3 HDAC6 115 nM124
3.4 HDAC8 23 nM125 Tubastatin A 3.5 HDAC1 16.4 µM126
HDAC6 4 nM126
3.6 HDAC4 20 nM127 3.7 HDAC6 36 nM128
HDAC5 4 nM127 HDAC8 2.10 µM128
HDAC7 30 nM127
HDAC9 40 nM127
3.8 HDAC4 16.3 nM129
HDAC5 2.31 nM129
HDAC6 26.9 nM129
o-Aminoanilide
Entinostat 3.9 HDAC1 0.51 µM130 3.10 HDAC3 0.26 µM131
HDAC3 0.20 µM132
3.11 HDAC1 48 nM133
HDAC2 0.9 µM133
Trifluoromethyl ketone Thiol
3.12 HDAC1 >50 M134 3.13 HDAC1 36 nM135
HDAC4 43 µM134 HDAC6 0.55 µM135
HDAC8 1.8 µM134 HDAC9 57 nM135
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3.4 High-Throughput In-Bead Screening of Substrates for
HDAC Enzymes Profiling
We wanted to further investigate a recently developed in-bead strategy9 to allow for
HDAC substrate profiling studies useful for identification of isozyme selective compounds.
A former master student, Daniel Madsen, applied the in-bead screening platform for the
identification of isozyme selective HDAC substrates from a split-and-mix compound li-
brary with acylated lysine oligopeptides.
3.4.1 Introduction to In-Bead Screening Technology
Several on-bead solid-supported screening papers have been published (references here-
in).9 To diminish the influence by the solid-support backbone, Qvortrup and Nielsen ra-
tionalized that releasing compounds from the solid-support in an aqueous media, could
retain the compounds inside the beads, due to the hydrophobic interior, hence the termi-
nology in-bead. Daniel Madsen synthesized a large library of substrates for a profiling
study of HDAC to find selective isozymes. The compounds where build on solid-support
by standard SPS chemistry with a photo-labile linker. After photolytic release of the sub-
strates, HDAC enzymes were added to the beads. If the acylated substrate was recog-
nized by HDAC, the acyl group would be cleaved and liberate protonated lysine residue.
Upon the addition of the endopeptidase, trypsin,136,137 the protonated substrate was rec-
ognized by this enzyme and due to its nature, it will cleave the C-terminal of protonated
residues. This will cleave a fluorophore from the C-terminal with a detectable change in
fluorescence. The photolytic cleavage conditions prevents the use of chemical reagents,
that could interfere with the enzymes-substrate interactions or the integrity of HDAC.
For the solid-support polyethylene glycol polyacrylamide (PEGA) was chosen, due to its
reported accommodation of larger proteins.138
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3.4.2 Substrate Profiling of HDAC Enzymes
Potent lysine-containing substrates used for HDAC profiling have been summarized by
the Olsen lab.139 7-amino-4-methylcoumarin (AMC) is a standard utilized fluorophore.
The applied profiling substrates contain an Ac-Leu-Gly-Lys-AMC backbone, and the iso-
zyme selectivity was found to depend on the nature of the acyl group.
3.4.3 Development and Functionalization of an ε-Lysine Bound
Photo-Labile Linker for High-Throughput Screening
To obtain potential sub-type selective HDAC substrates, we first synthesized a photo-
labile construct 3.19 based on the Holmes photo-linker.140
Synthesis of the linker construct, commenced with an alkylation reaction of commercially
available acetovanillone (3.14) with ethyl 4-bromobutanoate, A Scheme 3.1. After the at-
tachment of this handle moiety for immobilization to the solid-support, nitration of 3.15
was achieved by HNO3 and Ac2O, affording 3.16 in high yield (78%). 3.17 was synthe-
sized by a two-step procedure in high yields starting from commercially available Boc-
Lys(Fmoc)-OH, B Scheme 3.1. The construct 3.17 was then be introduced by reductive
alkylation affording 3.18 in high yields before quantitative hydrolysis of the ester with
LiOH providing 3.19. The reductive alkylation was performed with Ti(OEt)4. During
the hydrolysis of the ethyl ester partial hydrolysis of coumarin was observed, however
re-lactonization was achieved by stirring the crude compound at neutral pH for 2 h fol-
lowed by up-concentration under reduced pressure.
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Scheme 3.1: A Synthetic route toward the lysine-AMC containing photo-labile linker. B Synthesis of AMC-containing
lysine
Introduction of the base-labile HMBA linker to the immobilized construct allows for
LCMS analysis of the proceeding reactions, Scheme 3.2. Phenylalanine was coupled to
HMBA under 1-(mesitylene-2-sulfonyl)-3-nitro-1,2,4- triazole (MSNT) conditions. After
Fmoc deprotection the photo-labile linker, 3.19, was coupled to immobilized phenylala-
nine under O-(7-azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophos-
phate (HATU) conditions using only 1.1 equiv. of the photo-labile linker to obtain 3.21.
For the last steps, standard SPS Boc strategy was applied to obtain the ε-bound Ac-Leu-
Gly-Lys tripetide, 3.22.
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As for the final step, ε-lysine was acylated. Decreased reactivity of the nitrogen141 was
observed for the N-alkylated hydroxylamine O-photo-labile protecting group. The sec-
ondary amine of 3.22 is probably better shielded due to the substituted benzylic position.
Generally, large amounts of reagents were used, and in some cases, heat was required to
obtain full conversion. In Figure 3.7, the different acyl groups used are shown.
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Photo-mediated cleavage of the immobilized compounds was performed in excellent pu-
rity to release tripeptide substrates, Figure 3.8, ready for HDAC profiling studies.
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Figure 3.8: Liberation of acylated lysine-containing tripeptides
All substrates (Figure 3.8) were tested against the 11 HDACs. The cyclopropionamide
3.1 was a selective substrate for HDAC3. Can we redesign the selective tripeptide substrate to
generate a sub-type selective HDAC inhibitor At this point I was involved in the project.
3.5 Guided Inhibitor Synthesis Strategy
With the discovery of the substrate 3.1, we became interested in modulating the substrate
into an inhibitor with isozyme-selectivity. To have a good zinc-chelator, we wanted to
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introduce the hydroxamic acid functionality which is the strongest and most investigated
ZBG. We planned a collection of hydroxamic acid functionalized tripeptides. AMC was
exchanged to a aniline amide as this fluorophore is not needed for this assay type.
We wanted to investigate both the position of the hydroxamic acid carbonyl group and
the length of the linker. Finally, a range of acyl groups were chosen. For this study we
designed a set of inhibitors, seen in Figure 3.9.
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Figure 3.9: Overview of inhibitor scaffolds designed from the HDAC3 selective substrate, 3.1
We aimed to synthesize one analogue for C3 and C3*, the cyclopropaneacetyl or N-
cyclopropanemethyl, respectively. For C4 and C4*, all the analogues in Figure 3.9 was
designed to resemble to the hit substrate 3.1. The tert-butyl and 2-thiophene groups were
excluded for the C5 and C5* analogues.
A retrosynthetic analysis of one of the proposed structures 3.36 is seen in Scheme 3.3. We
planned to employ the newly developed hydroxylamine photo-labile protecting group
due to its stability and the mild release conditions. The desired hydroxamic acid would
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then originate from cleavage of the photo-protected hydroxamate 3.38. We envisioned
that 3.38 could be formed from coupling the dipeptide 3.37 with 3.39. The derivatization
of the scaffold, 3.40, could be performed by acylation of the hydroxylamine, 3.39. The
compound 3.40 was rationalized to arise from 6-oxo-norleucine 3.42, by coupling with
the photo-labile protecting group 2.7, followed by standard functional group intercon-
version.
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Scheme 3.3: Synthetic overview of desired hydroxamic acids
This combinatorial approach provides easy accessibility to a diverse set of compounds as
structural parameters such as the length of the C-terminal residue, the amide group on
the C-terminal, the dipeptide, and the acyl group can easily be changed.
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3.6 Investigation of a Synthetic Strategy for the
Norleucine-Derived Key Building Block
Natural amino acids constitute an attractive starting material, due to their inherent stereo-
center, ready availability, and low cost. Hereby, the stereocenter is set from the beginning
of the synthesis, and therefore, reaction conditions that do not result in epimerization, are
crucial. In the literature, synthesis of 6-oxo-norleucine 3.42 has not been reported, possi-
bly because of the chance for spontaneous cyclization. However, some 6-oxo-norleucine
derivatives were reported by Fanning et al.142 and Padro´n et al.143 starting from aspar-
tic acid 3.49. The authors took advantage of a two-carbon elongation with the Wittig
reagent, (triphenylphosphoranylidene)acetaldehyde. The Wittig reaction was first pub-
lished in 1954 by Georg Wittig and Ulrich Scho¨llkopf.144 Phosphonium ylides react with
aldehydes or ketones to generate alkenes. Ylides are formed from deprotonation of the
corresponding phosphonium salts. Stabilized ylides generally afford E-alkenes.145
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Figure 3.10: Mechanism of Wittg reaction
Changing the Wittig reagent provided a feasible approach to obtain all the desired amino
acids, from one single key precursor, Figure 3.11.
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Figure 3.11: Synthetic strategy of important intermediates from the key precursor 3.43
The Padro´n procedure was applied to synthesize 3.50 from aspartic acid in a three-step
approach.143 4.0 g of L-aspartic acid 3.49 was treated with TMSCl in MeOH, followed by
Boc protection with Boc2O and NaHCO3 in MeOH, Scheme 3.4. Lastly, 3.50 was obtained
by a 4-dimethylaminopyridine (DMAP) mediated Boc protection under dry conditions.
Overall, 3.50 was afforded in 62% over three steps.
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Scheme 3.4: Synthesis of the conjugated aldehyde from aspartic acid
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The reaction also performed well on large scale, and specific rotation was found to be
in accordance with the literature. As epimerization is a concern throughout the entire
synthesis, optical rotation was recorded for all pure enantiomers in this dissertation. For
novel compounds, optical rotation was recorded with a concentration of 1.00 in a suitable
solvent.
Optimizing the pace of N,N-diisobutylaluminium hydride (DIBAL-H) (1.1 equiv., 1 M in
hexanes) addition as well as stirring time was necessary for complete conversion of the
side-chain methyl ester. Optimized conditions: addition of DIBAL-H to 3.50 at -78 °C
over 30 min followed by 30 min stirring and subsequently quenched by the addition of
H2O. Generally, both the starting material and the corresponding alcohol were observed
in low quantities and separation of 3.51 was difficult.
Fanning et al. experienced low yield for the Wittig reaction of 3.51.142 The expected steric
hindrance of the Boc groups, was proven to be the case, as the corresponding mono-Boc
compound 3.52 afforded excellent yield under Wittig conditions. The mono-deprotection
was achieved by LiBr, a procedure developed in the Martı´n lab.146 Unfortunately these
conditions in our hands from 3.96 g of 3.51 afforded incomplete conversion and once
more difficult separation. Low yield (37%) of 3.52 was observed. With 3.52 in hand,
the Wittig reaction performed well under reflux to obtain 63% of the α,β-unsubstituted
aldehyde 3.53. Trace impurities were observed by NMR and the stereochemistry ratio of
the double bond was found by 1H-NMR to be (Z:E) 33:67.
Fanning et al.142 observed cyclization of the saturated aldehyde. To prevent this, we chose
to continue with the conjugated alkene. In Chapter 2, we performed reductive alkylations
on our developed photo-protected hydroxylamine 2.5 to synthesize N-alkylated hydrox-
ylamines. Aldehydes were reacted with the O-MeNV hydroxylamine hydrochloride salt
2.7 in EtOH to generate the oxime, which was then reduced with NaBH3CN (1.0 equiv.)
under acidic conditions. We changed the solvent to dry MeOH, to prevent transesterifi-
cation, and attempted neutral conditions, due to the risk of Boc-deprotection. However,
acidic conditions have been reported to be crucial for mono-alkylation of oximes with the
use of NaBH3CN.17 Full conversion to the oxime was observed within a couple of hours,
however after prolonged reaction time, starting material was detected, probably a con-
sequence of the reversible nature of oxime formation, Scheme 3.5. It was subsequently
found that complete conversion to the oxime was achieved with pyridine.147
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Scheme 3.5: Reversible oxime formation
The crude oxime was cooled to 0 °C and NaBH3CN was added, Scheme 3.6. The conju-
gated oxime proved to be highly stable under neutral conditions, even after the addition
of an excess of NaBH3CN (5 equiv.). After observing that neutral conditions was ineffi-
cient, we tried the previously developed reaction conditions using NaBH3CN (1.0 equiv.)
and TFA (pH < 3). This reaction afforded trace amounts of 3.55 but also the formation of
an unidentified by-product. pH was checked continuously for 12 h and reducing agent
was added in portions, a total of 22 equiv., without achieving complete reduction. Re-
duction of oximes has previously shown to be efficient using the borane-THF complex
BH3 ·THF, but also these conditions were unsuccessful.
(S) COOMe
NHBoc
(S) COOMe
NHBoc
N
OHC
O
NO2
OMe
MeO
reduction
(S) COOMe
NHBoc
HN
O
NO2
OMe
MeO
MeOH
3.53
2.7
3.54 3.55
Scheme 3.6: Coupling and attempted double reduction of the conjugated oxime
Useful reduction conditions of 3.54 were not found, and the synthetic strategy had to be
changed. First of all, we had to avoid the conjugated alkene, and thereby reintroduce the
di-Boc protection to prevent cyclization. These modifications also prevent the need for
the low yield mono-Boc deprotection. We wanted to use Wittig reagents with a termi-
nal oxygen-functionality that could be converted to the corresponding aldehyde and the
carboxylic acid. Commercially available benzyl(triphenylphosphoranylidene)acetate148
was found to be suitable reagent. We envisioned that reacting the aldehyde 3.51 with the
stabilized phosphonium ylide, would result in the conjugated benzyl ester which could
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be further derivatized to the corresponding saturated carboxylic acid or saturated benzyl
ester. The latter once more would again be regioselectively reduced to the corresponding
aldehyde. This approach would allows us to use a single precursor for the formation of
the desired building blocks for both the C4 and C4* analogues.
Only small modifications gave even more efficient reactions starting from aspartic acid
3.49: high yielding esterification was observed with SOCl2 instead of TMSCl and an ef-
ficient Boc-protection was seen with dioxane and sat. NaHCO3 (aq.). On a 5.0 g scale
reaction, this afforded 12.3 g of 3.50 (91% yield) over three steps. Encouraged by this, we
scaled-up to start with 20.0 g of aspartic acid 3.49, which provided 49.8 g of the product
(91%). DIBAL-H reduction afforded 14.7 g of 3.51 in excellent yield (89%). The two-
carbon elongation of 3.51 performed well with commercially available benzyl(triphenyl-
phosphoranylidene)acetate (1.5 equiv.) in refluxing THF to provide the conjugated benzyl
ester 3.56 in 96% yield, Scheme 3.8. The Boc groups were not a steric issue, as mentioned
earlier for the aldehyde substrate.
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(S) COOMe
NBoc2
MeOOC
(S) COOMe
NBoc2
89%
sat. NaHCO3 (aq.)
2) Boc2O, dioxane
1) SOCl2, MeOH, reflux
3) Boc2O, DMAP
MeCN
91% (three steps)
DIBAL-H
Et2O, -78 oC
96%
Ph3P=CHCOOBn
THF, reflux
(S) COOMe
NBoc2
BnOOC
3.49 3.50 3.51
3.56
Scheme 3.7: Synthesis of the conjugated benzyl ester 3.56 from aspartic acid
An optimized and high yielding five-step procedure for the key intermediate 3.56 had
been developed.
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3.6.1 Chemoselective-Controlled Hydrogenation or
Hydrogenation-Hydrogenolysis of the Key Conjugated Benzyl
Ester Intermediate
To obtain the saturated carboxylic acid, hydrogenation of the alkene bond and hydrogenol-
ysis of the benzyl ester 3.56 was desired. An overview of the tested reaction conditions is
listed in Table 3.3.
Table 3.3: Screening of hydrogenation-hydrogenolysis conditions
(S) COOMe
NBoc2
BnOOC
(S) COOMe
NBoc2
HOOC
r
hydrogenolysis
hydrogenation-
conditions
3.56 3.57
Entry Scale Pd Solvent Additives Atm. Temp. Time Yielda
(h)
1 25.4 mg Pd(OH)2/C (20 mol%)b EtOAc - H2 rt 25.5 88c,d
2 25.0 mg Pd(OH)2/C (20 mol%)b EtOAc - H2 reflux 10.0 87c,e
3 2.0 g Pd(OH)2/C (20 mol%)b EtOAc - H2 reflux 15.0 79c,f
4 6.9 g Pd(OH)2/C (40 mol%)b EtOAc - H2 reflux 10.2 85c,g
5 50.0 mg Pd/C (20 wt%)h MeOH Et3SiH (10 equiv.) argon rt 0.17 quant.c,f,i
6 50.0 mg Pd(OAc)2 (2.5 mol%) MeOH charcoalj H2 rt 14.0 94c,e
7 50.0 mg Pd(OAc)2 (5.0 mol%) iPrOH charcoalj H2 rt 14.5 98c,e
8 50.0 mg Pd(OAc)2 (5.0 mol%) MeOH charcoalj H2 rt 15.5 97c,e
9 50.0 mg Pd/C (10 wt%) MeOH - H2 rt 15.75 93c,e
10 1.0 g Pd(OAc)2 (5.0 mol%) MeOH charcoalj H2 rt 16.0 quant.c,k
(a) Isolated yield (b) 20% Pd (c) filtrated through a pad of Celite® (d) hydrogenated product indicated by 1H-NMR (e) trace amount of
3.56 (f) 8% 5-((Boc)amino)-6-methoxy-6-oxohexanoic acid was indicated by 1H-NMR based on the Boc group (g) 50% 5-((Boc)amino)-
6-methoxy-6-oxohexanoic acid was indicated by 1H-NMR based on the Boc group (h) 10% Pd (i) Et3SiH indicated by 1H-NMR (j)
Pd(OAc)2:charcoal 10:90 (wt:wt) (k) CH2Cl2 and other minor impurities observed by 1H-NMR
The first test reaction was carried out using Pearlman’s catalyst (20% Pd(OH)2/C)149 in
MeOH under a hydrogen atmosphere (Entry 1, Table 3.3). However, 1H-NMR showed
incomplete conversion. Increasing the temperature improved conversion (Entry 2). Up-
scaling to 2.0 g (Entry 3) afforded a small drop in yield with minor impurities observed
by 1H-NMR. Specific optical rotation was determined, [a]22D - 31.6° (c 1.00, MeOH). The
amount of Pd(OH)2/C was doubled to obtain full conversion on larger scale (Entry 4).
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Unfortunately, this led to the formation of the mono-Boc protected side-product. 1H-
NMR indicated a 1:1 ratio
Pd/C is known to facilitate catalytic transfer hydrogenation with Et3SiH as a hydrogen
donor.150 Changing to 20 wt% Pd/C from the reported conditions afforded 3.56 in quant.
yield, however impurities of Et3SiH were indicated by 1H-NMR (Entry 5).
The combination of methanol vapors with oxygen pose a high safety risk due to the
pyrophoric nature, not to mention having hydrogen-containing balloons in the fume
hood. The Fouquet group has developed a safer method for hydrogenation-hydroge-
nolysis.151,152 The group reported a hydrogenation-hydrogenolysis protocol with in situ
formation of Pd/C from Pd(OAc)2 and charcoal under hydrogen atmosphere (Entry 6-
8). Utilizing these conditions provided high yield (Entry 6). MeOH and iPrOH are both
well-tolerated solvents. Using a commercially available Pd/C gave similar yield (Entry
9). Up-scaling the in situ Pd/C-formation conditions on 1.0 g, gave the substituted car-
boxylic acid 3.57 in quantitative yield (Entry 10).
We next turned our attention to the hydrogenation of the α,β-unsaturated benzyl ester
3.56, to afford the saturated benzyl ester (3.58), a precursor for the desired aldehyde for
the synthesis of C4 analogues. Transition metal complexes have been reported to afford
hydrogenation of the conjugated alkenes. In special cases, Pd/C or Pd(OH)2 have been
reported to afford the saturated benzyl ester, but these conditions have already proved to
give the saturated carboxylic acid for our substrate, Table 3.3. One example of a useful
metal complex for this type of reaction, is the Wilkinson’s catalyst,153 Table 3.4.
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Table 3.4: Screening of hydrogenation conditions
(S) COOMe
NBoc2
BnOOC
r
(S) COOMe
NBoc2
BnOOC
hydrogenation
conditions
3.56 3.58
Entry Scale Reagent Solvent Atm. Temp. Time Yielda
(mol%) (h) (%)
1 20.0 mg RhCl(PPh3)3 (23.0 mol%) toluenea H2 50 °C 21.25 quant.b
2 0.5 g RhCl(PPh3)3 (5.0 mol%) toluenea H2 reflux 15.0 76c,d
3 1.0 g RhCl(PPh3)3 (8.0 mol%) toluenea H2 50 °C 15.0 80c,d
4 100.0 mg 10% Pd/C (10.0 wt%), Ph2S (1.0 mol%) MeOH H2 rt 40.0 99d
5 50.0 mg Pd(OAc)2 (2.5 mol%), Ph2S (1.0 mol%) MeOH H2 rt 36.0 -e
charcoalg
6 1.01 g 10% Pd/C (10.0 wt%), Ph2S (1.0 mol%) MeOH H2 rt 36.0 98g
7 3.05 g 10% Pd/C (10.0 wt%), Ph2S (1.0 mol%) MeOH H2 rt 36.0 98g
8 5.51 g 10% Pd/C (10.0 wt%), Ph2S (1.0 mol%) MeOH H2 rt 40.0 94g
9 6.48 g 10% Pd/C (10.0 wt%), Ph2S (1.0 mol%) MeOH H2 rt 36.0 97g
(a) dry condition (b) purified by glass pipette column chromatography (c) purified by flash column chromatography (d)
starting material observed after flash column chromatography (e) 94% recovered starting material (f) Pd(OAc)2:charcoal
10:90 (wt:wt) (g) filtered trough a pad of Celite® and evaporated to dryness, this procedure was repeated once
Initially, the reaction with Wilkinson’s catalyst showed excellent selectivity and quant.
yield (Entry 1, Table 3.4). Using 23 mol% catalyst turned out to be crucial (Entry 2 and
3). The need for flash column chromatography, made this approach undesirable. Sajiki
et al. decreased the Pd/C activity by the use of amine additives in order to increase the
chemoselectivity (hydrogenation over hydrogenolysis)154,155 and later sulfur-containing
additives were found to facilitate chemoselective Pd-complexes.156 Sulfur is notorious
known to reduce the activity of palladium and other noble metals, such as platinum, by
occupying catalytic sites.157 One of the most successful ”poisoned catalysts” applied in
organic synthesis is the Lindlar catalyst developed in 1966. It contains a combination of
Pd/CaCO3 and lead, and further addition of quinoline can be advantageous.158 Sajiki et
al. show diphenyl sulfide to be a good additive for chemoselective hydrogenation of α,β-
unsaturated benzyl esters.156 Using these conditions (Entry 4, 6-9), worked well on our
substrate resulting in a multi-gram hydrogenation of 3.56 to afford 3.58 in 97% yield (En-
try 9).
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We have established reaction conditions from commercially available aspartic acid 3.49,
to the key conjugated benzylic ester intermediate 3.56, and by manipulating the reaction
conditions, we were able to obtain either the saturated carboxylic acid 3.57 or benzyl ester
3.58, see Scheme 3.8.
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Scheme 3.8: Updated overview of the synthetic approach to the four-carbon carboxylic acid and benzyl ester
With a well-established approach in hand, the next step was the one-carbon elongation to
synthesize the three-carbon aldehyde 3.60 from the corresponding two-carbon aldehyde
precursor 3.51 by Wittig approach.
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3.7 Synthesis of Natural and Unnatural Amino Acids
from a Chiral Precursor
3.7.1 One-Carbon Elongation Mediated by Wittig reactions
One-carbon elongation of aldehydes can be achieved by using (methoxymethyl)triphe-
nylphosphonium chloride, followed by hydrolysis of the resulting enol ether. This method
was utilized in the attempt to to synthesize optical pure glutamate aldehyde 3.60, Ta-
ble 3.5.
From a modified literature procedure with (methoxymethyl)triphenylphosphonium chlo-
ride,159 lithium hexamethyldisilazane (LiHMDS) was added to the phosphonium salt at
-78 °C resulting in a dark red colored solution. This afforded enol ether 3.59 in 41% with
an E:Z ratio of 81:19.
Table 3.5: Tested conditions of the one-carbon elongation
OHC
(S) COOMe
NBoc2
COOMe
NBoc2
MeO
THF, -78 oC to rt
Ph3PCH2OMeCl
LiHMDS
conditions
hydrolysis COOMe
NBoc2
OHC
d
41%
3.51 3.59 3.60a
Entry Scale Reagent Solvent Temp. Time Conversiona
(equiv.) (h)
1 50.0 mg p-TsOH ·H2O (0.5) acetone rt 0.58 3.59 b
2 50.0 mg p-TsOH ·H2O (0.7) acetone and H2O rt 2.0 3.59 + 3.60a c,d
3 82.7 mg Cl3CCOOH (5.0) CHCl3 reflux 1.75 3.60a b,e
4 82.7 mg Amberlite 120f , LiBr (9.0) acetone rt 22.25 -
5 82.7 mg PPTS (1.5) acetone rt 21.25 3.59 + 3.60a c
6 0.58 g p-TsOH ·H2O (0.5) acetone rt 0.83 3.60a b,g
(a) indicated by TLC (b) full conversion by TLC (c) incomplete conversion by TLC (d) longer reaction time afforded
a highly polar compound (e) highly polar compound was observed (f) 26 mg (g) 65% yield isolated by flash column
chromatography
Several weak acids were explored in order to hydrolyze the enol ether, Table 3.5. p-
TsOH ·H2O160 provided the aldehyde selectively and fast (Entry 1). When additional
water was added,161 incomplete conversion was observed (Entry 2). The stronger acid,
Cl3CCOOH,162 resulted in full conversion to a polar side-product, observed by TLC (En-
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try 3). The acidic resin, Amberlite,163 and the pyridinium p-toluenesulfonate (PPTS) gave
incomplete conversion (Entry 4 and 5). Therefore, the p-TsOH ·H2O conditions (Entry 6)
were up-scaled to afford 3.60a in 65% yield. Unfortunately, it was not optically pure (ob-
served by comparison with a sample previously prepared in the lab). This was probably
a result of LiHMDS and an incomplete deprotonation of the ylide. Lithium is known to
have good chelation abilities and therefore, may increase the α-proton acidity by chelation
between the two Boc groups. This chelating effect was earlier used to facilitate mono-Boc
deprotection by LiBr.146 Improvement of the Wittig one-carbon extension by changing
base, varying the reaction temperature profile, as well as increasing the phosphonium
salt:base ratio did not lead to satisfying results.
3.7.2 Three-Carbon Elongation Mediated by Wittig reactions
We did not succeed to convert 3.51 into 3.60 by a one-carbon Wittig elongation procedure.
The three-carbon Wittig elongation was investigated with the same precursor. The full
overview is shown in Table 3.6.
Table 3.6: Wittig three-carbon elongation approach
RCOOMe(S)OHC
(S) COOMe
NBoc2NBoc2
X
base, temperature
THF
phosphonium reagent
3.51
Entry Reagent base Temp. Yielda
(equiv.) (equiv.) (°C) (%)
1 Ph3PCH2CH2COOHBr (2.2) NaHMDS (3.0) rt→ 0 °C → rtb quantc
2 Ph3PCH2CH2COOBnBr (1.5) NaHMDS (1.4) rt -d
3 Ph3PCH2CH2COOBnBr (1.8) NaHMDS (1.6) - 78 °C → 0 °C → refluxb -e
4 Ph3PCH2CH2COBnBr (1.5) NaHMDS (1.4) - 78 °C → 0 °C → - 78 °C → 0 °C → rtf 85%
(a) Based on isolated yield (b) base added slowly over 35 min and stirred for an additional 35 min at rt. The aldehyde was
added at 0 °C over 30 min and then allowed to reach rt (c) starting material, phosphonium salt, and Ph3PO was detected by
1H-NMR (d) 1H-NMR indicated no product (e) inconclusive 1H-NMR results (f) stirred at - 78 °C for 1 h after addition of
NaHMDS, slowly warmed to 0 °C and cooled back to - 78 °C before adding the aldehyde. After the addition of the aldehyde,
the reaction was stirred at 0 °C for 30 min before left overnight at rt
Starting from the commercially available (2-carboxyethyl)triphenylphosphonium bromi-
de164 and double deprotection using NaHMDS, followed by addition of 3.51, Table 3.6,
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led to only trace amount of the desired product. The corresponding benzyl ester phos-
phonium salt could be synthesized from benzyl 3-bromopropanoate 3.61 and Ph3P in a
one-pot fashion followed by deprotonation and addition of the aldehyde (Entry 2). We
also attempted to prepare a large amount of the benzyl ester phosphonium salt165 and
then deprotonated the crude reagent followed by the addition of the aldehyde (Entry 3).
Both of these reactions gave disappointing results. The α-proton of the ester may inter-
fere during deprotection because of its acidity. We hypothesized, that the corresponding
protected alcohol reagent would be a great alternative. Commercially available (3-ben-
zyloxypropyl)triphenylphosphonium bromide was reacted with NaHMDS. This afforded
the unsaturated benzyl ether in a high yield, Table 3.6. Unfortunately, the benzyl ether
was found to be unreactive under hydrogenation-hydrogenolysis conditions. Inspired
from the literature,166 we tried to change the benzyl to a silyl protecting group.167 How-
ever, the Wittig reaction was not successful at sub gram scale.
3.7.3 Synthesis of Key Building Blocks for Generation of C5 and C5*
Analogues
With these disappointing results, the previously established reaction conditions was a-
dapted to glutamic acid successfully. The approach also made it possible to obtain the
three-carbon aldehyde 3.60 for the C3 analogue, and further functionalized to the cor-
responding saturated carboxylic acid 3.65 and the saturated benzyl ester 3.66 building
blocks for the synthesis of the C5 and C5* analogues.
Starting from 15.0 g of dimethyl L-glutamate hydrochloride 3.62, afforded 23.9 g (90%) of
3.63, Scheme 3.9. The regioselective DIBAL-H reduction of 3.63 gave 3.60 in high yield
(85%). To 21.1 g of 3.60 was added benzyl(triphenylphosphoranylidene)acetate , afforded
26.9 g (92%) of 3.64. Hydrogenation of the α,β-saturated benzyl ester afforded high yield
on multi-gram scale to the corresponding saturated benzyl ester 3.66 (8.5 g, 96%).
When applying the hydrogenation-hydrogenolysis protocol to synthesize the five-carbon
saturated carboxylic acid 3.65. NMR studies clearly indicated the formation of the methyl
ester. The methyl ester formation was probably a consequence of the AcOH formation
during the in situ Pd/C generation. iPrOH is less reactive in a nucleophilic substitution
reaction, with decreased tendency of esterification. Changing to iPrOH resulted in a clean
conversion to the saturated carboxylic acid 3.65 starting from 6.5 g of starting material to
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the desired product in 96% yield. Using iPrOH instead of MeOH for the hydrogenation-
hydrogenolysis of the four-carbon α,β-unsaturated benzyl ester 3.56 afforded the four-
carbon saturated carboxylic acid 3.57 in excellent yield on multi-gram scale (4.3 g, 99%
yield).
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NBoc2
85%
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1) Boc2O, dioxane
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(E)
Pd(OAc)2, charcoal, H2
96%
(S) COOMe
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MeOOC MeOOC OHC
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NBoc2
BnOOC
96%
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MeOH, 36 h
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Scheme 3.9: Synthesis of the important five-carbon carboxylic acid and benzyl ester from dimethyl glutamate
3.8 Synthesis of Optically Pure Ac-Leu-Gly-OH (3.37)
3.37 has previously been reported by the Olsen lab.168 N,N’-diisopropylcarbodiimide
(DIC)/hydroxybenzotriazole (HOBt) coupling conditions of commercially available ace-
tyl-L-leucine and methyl glycinate hydrochloride followed by hydrolysis. However, the
risks related to anhydrous HOBt, made this procedure less favorable for the current syn-
thesis. We envisioned that changing from the methyl ester to the benzyl ester would
increase the lipophilicity of the compounds, thus giving easier purification.
The benzyl protecting group was introduced by a simple two-step approach169 in good
yields on multi-gram scale, 3.68 in Scheme 3.10. Standard HATU coupling conditions
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were found to afford the desired benzyl protected dipeptide in good yield (78%) on 10 g
scale, 3.69a.
COOHBocHN COOBnTFA  H2N
DMF, rt
1) Cs2CO3, BnBr
2) TFA:CH2Cl2 (1:9)
77%
DMF
HATU, DIPEA
Ac-Leu-OH
COOBn
H
N
O
AcHN
78%
3.67 3.68 3.69a
Scheme 3.10: Synthesis of racemic Ac-Leu-Gly-OH
For the overall three-step sequence, only a single flash column chromatography purifi-
cation was necessary starting from (tert-butoxycarbonyl)glycine 3.67. HATU is regarded
as a coupling reagent that afford low degree of epimerization.170 Surprisingly, the optical
rotation, α, of 3.69a was observed to be +0.002 (c 1.00 in CHCl3), which indicates racem-
ization.
Racemization may take place in peptide synthesis if the C-terminal is activated, which
result in the formation of a planar oxazolone anionic intermediate 3.72, Scheme 3.11.
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Scheme 3.11: Peptide couplings are prone to the oxazolone production that lead to a planar cyclic intermediate to
induce racemization
S-Oxazolone 3.71 is formed upon cyclization and accompanied by the formation of a
planar cyclic anionic intermediate under the basic reaction conditions, 3.72. This inter-
mediate can be protonated to afford either the S-Oxazolone (3.71) or the R-Oxazolone
3.73 that react with an incoming nucleophile with loss of chiral integrity.170,171 A liter-
ature procedure was reported by Zhang and co-workers.172 Herein, the authors syn-
thesized O-succinimide (OSu)-activated amino acids by N,N’-dicyclohexylcarbodiimide
(DCC)/HOSu coupling conditions, followed by stirring in dioxane and H2O under basic
conditions (NaHCO3) with a free N-terminal amino acid. We chose to use the commer-
cially available benzyl glycinate hydrochloride and with increased amount of NaHCO3.
To this solution, commercially available 2,5-dioxopyrrolidin-1-yl acetyl-L-leucinate (Boc-
Leu-OSu) was added. On 100 mg scale, excellent yield (88%) was obtained of 3.76, but
most importantly, the observed optical rotation was - 0.265 with a calculated specific op-
tical rotation of [a]22D - 26.5° (c 1.00 in CHCl3). The dipeptide has been reported in several
papers, although none of them reports optical rotation, though in some cases the corre-
sponding amine salt has been reported.172–174 A small amount of CH2Cl2 was observed
by 1H-NMR due to the high viscosity of the substance. With the proper reaction condi-
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tions in hand, the reaction was up-scaled and gave even better results on larger scale,
Scheme 3.12.
COOBn
H
NCOOBnHCl  H2N (S)
O
BocHN
H2O, dioxane
NaHCO3
Boc-Leu-OSu
94% 95%
COOBn
H
N(S)
O
AcHN
1) TFA:CH2Cl2 (3:7)
2) Ac2O, DIPEA
CH2Cl2, rt
3.75 3.76 3.69
Scheme 3.12: Synthesis of optical pure Ac-Leu-Gly-OH
Boc-removal and acetylation was inspired by the work of Huber et al.175 and slightly mod-
ified to perform excellently. Starting from 26.4 g (95%) of 3.76, afforded 21.2 g of the
N-acetylated dipeptide 3.69. A successful screening of hydrogenolysis conditions was
performed, Table 3.7.
Table 3.7: Screening hydrogenolysis conditions
COOBn
H
N(S)
O
AcHN
COOH
H
N(S)
O
AcHN
hydrogenolysis
conditions
conditions3.69 3.37
Entry Scale Pd source Solvent Time [a]22D
a Yieldb
(equiv.) (h) (%)
1 293 mg Pd(OAc)2, charcoal EtOAc:iPrOH (1:1) 17.15 -51.2 quant.
2 142 mg Pd(OAc)2, charcoal MeOH 15.5 -51.6 quant.c
3 103 mg Pd(OAc)2, charcoal THF 15.0 -49.4 93
4 86 mg Pd/Cd MeOH 14.0 -52.7 quant.
5 11.4 g Pd/Cd MeOH 14.75 -54.6 98
(a) [a]25D - 50.0° (c 2.00, MeOH) (b) Purified by filtration through a pad of Celite
® (c) trace amount of
starting material, 3.69 (d) 10% Pd/C, 50% wet with H2O, fluorochem product number 023236
Hydrogenolysis in both MeOH and THF gave good conversion (Entry 2-4). Also com-
mercially available wet 10% Pd/C afforded excellent yield (Entry 4 and 5).
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3.9 Synthesis of C3, C4, and C5 Analogues
Daniel Madsen showed that the acyl group was vital for isozyme selectivity. As already
described, a small collection of acyl groups were chosen based on his work and previous
results in the group. Synthesis of the four- and five-carbon benzyl ester (3.58 and 3.66,
respectively) resulted in excellent yields. The three-carbon aldehyde 3.60 was used as a
model substrate to investigate reaction conditions.
3.9.1 Development of a Synthetic Procedure for the Generation of
Photo-Protected δ-N-Hydroxy-L-Ornithine Derivatives
Aldehyde 3.60 was condensed with 2.7 in pyridine176 in high yield, Scheme 3.13.
(S) COOMe
NBoc2
NBoc2
COOMe(S)
N
OHC
O
NO2
OMe
MeO
86%
pyridine
3.60
2.7
3.77
Scheme 3.13: Three-carbon oxime formation
After condensation to form 3.77, we planned to reduce the oxime and hydrolyze the
methyl ester to introduce the aniline amide, before adding the acyl groups. Previously, we
illustrated that the secondary amine of the photo-labile protecting group is unreactive due
to steric hindrance, Section 2.2.1. Hydrolysis of the di-Boc protected amino acids without
epimerization was reported to be troublesome by Martı´n et al.143 To prevent epimerization
we removed the Boc groups before hydrolysis, inspired by the Martı´n lab. The oxime was
dissolved in MeOH under dry conditions: cooled to °C before the addition of NaBH3CN
(1.5 equiv.), followed by adjusting the pH < 3 with TFA, Scheme 3.14. After 1.5 h, nearly
full conversion was observed without any undesired Boc-deprotection. After work-up,
the Boc-groups were removed by the addition of TFA:CH2Cl2 (1:9). After full conver-
sion observed by LCMS and TLC, co-evaporation from toluene and CH2Cl2 afforded the
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TFA salt. The methyl ester was hydrolyzed by the addition of aqueous NaOH (1.0 M) in
MeOH and the amino group was afterwards Boc-protected by the addition of Boc2O to
afford the mono-Boc protected 3.78.
(S) COOMe
NBoc2
N
O
NO2
OMe
MeO
2) TFA:CH2Cl2 (1:9)
TFA (pH < 3), MeOH
1) NaBH3CN
3) NaOH, MeOH
then
(S) COOH
NHBoc
HN
O
NO2
OMe
MeOBoc2O
3.77 3.78
Scheme 3.14: Development of a four-step reaction sequence
The reactions gave full conversion, all LCMS-spectra included in Figure 3.12. Small im-
purities were observed after multiple steps. To further optimize the conditions a few
changes were implemented. The amount of NaBH3CN was increased to 2 equiv. for
a faster reduction. To speed-up the Boc-deprotection step, the amount of acid was in-
creased to 3:7 TFA:CH2Cl2. We also changed to LiOH (7 equiv.) to afford a clean and fast
hydrolysis.
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Openlynx Report - Kim Page 1 
File:KM-X-937-02 Date:03-Feb-2016 Time:19:43:51
Description: Method:C:\MassLynx\1_HCOOH_130_900.olp Vial:2:30
JobCode:KM-X-937-02
Printed: Wed Feb 03 19:47:45 2016
Sample Report:
Time
0.50 1.00 1.50 2.00 2.50
%
0
50
100
1.4e+0081: MS ES+ :TIC Smooth (Mn, 3x1) (9)
59%
2.37
(5)
18%
1.83
(4)
12%
1.69
(3)
8%
1.43
(7)
4%
2.18
%
Time
0.50 1.00 1.50 2.00 2.50
%
0
50
100
6.4e+0052: MS ES- :TIC Smooth (Mn, 1x1)
(6)
98%
2.15
(8)
2%
2.30
%
Time
0.50 1.00 1.50 2.00 2.50
A
U
0.0
5.0e+1
1.0e+2
1.033e+2
Range: 1.032e+2
3: UV Detector: TIC 
(9)
89%
2.38
A
U
Peak Number Compound Time AreaAbs Area %Total Width Height Mass Found
1 0.71 135051 6.03 0 2768553
2 0.83 29821 1.33 0 828431
4 1.70 75655 3.38 0 2683910
9 2.38 1997815 89.25 0 96877672
Peak ID Compound Time Mass Found
3 1.43
m/z
200.0 300.0 400.0 500.0 600.0 700.0 800.0 900.0
%
0
50
100
1:MS ES+ 
1.8e+006
3:(Time: 1.43) Combine (299:311-(250:261+337:348))
227.0
213.0
411.0
228.1
310.0 373.2
412.1
451.0
(a) Pure oxime
Openlynx Report - Kim Page 1 
File:KM-X-943-01 Date:11-Feb-2016 Time:18:47:38
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JobCode:KM-X-943-01
Printed: Thu Feb 11 18:51:31 2016
Sample Report:
Time
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A
U
Peak Number Compound Time AreaAbs Area %Total Width Height Mass Found
2 1.30 95266 3.25 0 6105146
4 1.73 23945 0.82 0 3873128
6 2.27 2813897 95.94 0135099360
Peak ID Compound Time Mass Found
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(b) Reduced oxime
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File:KM-X-943- 2 Date:11-Feb-2016 Time:23:03:22
Description: Method:C:\MassLynx\1_HCOOH_130_900.olp Vial:1:26
JobCode:KM-X-943-02
Printed: Thu Feb 11 23:07:15 2016
Sample Repor :
Time
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(8)
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1.86(5)
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1.29
(3)
1%
1.08
A
U
Peak Number Compound Time AreaAbs Area %Total Width Height Mass Found
1 0.89 11396308 83.59 0175228560
3 1.08 179532 1.32 0 6999894
4 1.21 99633 0.73 0 3941655
5 1.29 635010 4.66 0 21817654
6 1.49 74526 0.55 0 4316920
7 1.67 20268 0.15 0 2045828
8 1.86 1211253 8.88 0 63529356
9 1.95 17363 0.13 0 1482503
(c) Boc-deprotection
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Description: Method:C:\MassLynx\1_HCOOH_130_900.olp Vial:1:32
JobCode:KM-X-943-05
Printed: Fri Feb 12 08:14:05 2016
Sample Repor :
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A
U
Peak Number Compound Time AreaAbs Area %Total Width Height Mass Found
1 0.76 183876 1.19 0 8905001
2 0.85 13180921 85.59 0364439712
5 1.09 141961 0.92 0 8438772
6 1.19 196086 1.27 0 10211480
7 1.25 46372 0.30 0 3620780
8 1.30 147927 0.96 0 9128395
9 1.60 1478358 9.60 0 72486752
10 2.10 24080 0.16 0 5419347
(d) Hydrolysis of the methyl ester
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A
U
Peak Number Compound Time AreaAbs Area %Total Width Height Mass Found
2 0.93 16217 0.63 0 6046421
3 1.30 56969 2.22 0 4423860
4 1.59 2002441 78.06 0 98576072
5 1.72 130145 5.07 0 8178495
6 1.75 96966 3.78 0 6208168
8 1.87 17989 0.70 0 5801372
10 2.00 244644 9.54 0 13896281
(e) Mono-Boc protected amino acid
Figure 3.12: Overview of LCMS spectra for the developed four-step sequence
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To obtain the desired scaffold, amidation of the carboxylic acid was investigated. Two
reaction conditions were tested, Scheme 3.15.
(S) COOH
NHBoc
HN
O
NO2
OMe
MeO
aniline, PyBOP (S) CONHPh
NHBoc
HN
O
NO2
OMe
MeOCH2Cl2, 0 oC
1) EtOCOCl, Et3N
2) aniline
NEM, DMF
(S)
BocHN
N
O
NO2
OMe
MeO
O
Cyclized side-product
3.78 3.79 3.80
Scheme 3.15: Screened condition for the synthesis of aniline amide and the produced cyclic side-product
No formation of the desired aniline amide 3.79 was formed, but full conversion to a side-
product with the mass of the six-membered cyclization product was observed by LCMS.
Although this was not the desired product, this observation is interesting as the cyclized
1-hydroxy-2-oxo-3-piperidinyl 3.80 is a key component for the family of siderophores
(iron-chelating compounds), such as pseudobactin,177 heterobactins,178 and exochelin MN179.
To obtain the desired product, the order of the events was changed: the oxime was first
reduced, followed by acylation of the amino group, and then hydrolysis, Scheme 3.16. To
synthesize the aniline amide, different amidation protocols were tested on a sample of
3.81, Table 3.8.
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Table 3.8: Screening of reaction conditions for the synthesis of the aniline amide intermediate
(S) COOH
NHBocO
NO2
OMe
MeO
base, aniline
solvent
(S) CONHPh
NHBoc
N
O
NO2
OMe
MeO
O N O
solvent
coupling reagent
3.81 3.82
Entry Scale Coupling reagent Base Aniline Solvent Time Conversiona
(equiv.) (equiv.) (equiv.) (h) (3.81:3.82)
1 35 mg HATU (1.0) DIPEA (6) 1.1 DMF 5.50 17:83b
2 35 mg PyBOP (1.0) NEM (6) 1.1 DMF 5.50 00:100c,d
3 35 mg TBTUe (1.0) NEM (6) 1.1 DMF 5.50 00:100d
4 56 mg TBTU (1.0) DIPEA (6) 1.0 CH2Cl2 f 19.00 13:87
5 54 mg DCC (1.1) - 1.4 CH2Cl2 f 19.00 00:100c
6 147 mg TBTU (1.0) DIPEA (6) 1.0 CH2Cl2 f 25.00 17:83
(a) indicated by LCMS (b) impurities were observed (c) full conversion, but impurities from the coupling reagent
was observed (d) a non-identified side-product was identified (e) O-(benzotriazol-1-yl)-N,N,N’,N’-tetramethyl-
uronium tetrafluoroborate (f) dry conditions
A range of coupling reagents, including HATU, TBTU, and PyBOP170 were tested (En-
try 1-3, Table 3.8). The coupling reagents were pre-activated with base and 3.81 for 15
min before addition of the aniline. Full conversion was observed for TBTU and PyBOP.
A combination of TBTU and DIPEA in CH2Cl2180 afforded 3.82 with lower conversion
(Entry 4). Also a DCC coupling was tested.181 Good conversion, but several impurities
were observed by LCMS (Entry 5). The conditions described in Entry 4 were chosen as
standard protocol for the amidation with aniline. With the TBTU-DIPEA conditions, 3.82
was synthesized in excellent yield over six steps on large scale (79%), Scheme 3.16.
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(S) COOMe
NBoc2
N
O
NO2
OMe
MeO
dry CH2Cl2, 0 oC
2) cPr-COCl, pyridine
TFA (pH < 3), MeOH
3) TFA:CH2Cl2 (3:7)
4) LiOH, THF:H2O (4:1)
then Boc2O
1) NaBH3CN
5) TBTU, aniline
(S) CONHPh
NHBoc
N
O
NO2
OMe
MeO
O
DIPEA, CH2Cl2
79% (six steps)
3.77 3.82
Scheme 3.16: Synthesis of C3 inhibitor intermediate in excellent yield via an improved multi-step synthesis sequence
3.9.2 Synthesis of Photo-Protected ε-N-Hydroxy-L-Lysine and
δ-N-Hydroxy-L-Homolysine Derivatives
Next, the synthesis of 3.83 and 3.84 was investigated. The DIBAL-H reduction of the ben-
zyl esters to the corresponding aldehydes was unsuccessful, and both the starting mate-
rial and the alcohol were observed. Furthermore, the starting material proved difficult
to separate from the product. Thus, the crude aldehydes were directly coupled with the
hydroxylamine photo-labile protecting group 2.7 in pyridine to ease separation, Table 3.9.
Table 3.9: Synthesis of the four- and five-carbon oximes
BnOOC (S) COOMe
NBoc2
(S) COOMe
NBoc2
N
O
NO2
OMe
MeO
Et2O, -78 oC
1) DIBAL-H
2)
pyridine
n = 1,2
n = 1,2
pyridine
2.7
Entry Benzyl ester n Oxime Yield (%)
1 3.58 1 3.83 42–84
2 3.66 2 3.84 25–79
The four-carbon oxime 3.83 was synthesized in up to 84% yield on multi-gram scale (En-
try 1, Table 3.9). For the five-carbon oxime 3.84 the highest obtained yield was 79% (Entry
2). The oximes were observed to be unstable, resulting in degradation over time. Degra-
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dation was found to occur under purification by flash column chromatography.
Due to time-restrictions the number of analogues were reduced, Table 3.10.
Table 3.10: Utilization of the improved seven-step sequence on the degraded oximes
(S) COOMe
NBoc2
N
O
NO2
OMe
MeO
dry CH2Cl2, 0 oC to rt
2) R-COCl, pyridine
TFA (pH < 3), MeOH
3) TFA:CH2Cl2 (3:7)
4) LiOH, THF:H2O (4:1)
then Boc2O
1) NaBH3CN
5) TBTU, aniline
DIPEA, CH2Cl2
(S) CONHPh
NHBoc
N
O
NO2
OMe
MeO
n = 1,2 n = 1,2
O
R
DIPEA, CH2Cl2
Entry Oxime n R Hydroxamate Yield (%)
1 3.83 1 3.39 25
2 3.83 1 3.85 28
3 3.84 2 3.86 18
3.9.3 Synthesis of Photo-Protected C3, C4, and C5 Tripeptides
To finalize the synthesis of the C3, C4, and C5 analogues, we needed to couple the dipep-
tide 3.37 to the synthesized aniline amides, Table 3.11. We tested commonly applied SPS
coupling reagents, TBTU, PyBOP, and HATU with their respective bases applied in the
Qvortrup lab: NEM, NEM, and N,N-diisopropylethylamine (DIPEA), respectively. TBTU
was found to be the best choice, see Table 3.11.
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Table 3.11: Coupling of 3.37 with the C3, C4, and C5 inhibitor intermediater
RN
O
(S)N
H O
NHPh
OH
N
O
(S)AcHN
O
NO2MeO
MeO
n = 0-2
RN
O
(S)BocHN
O
NHPh
O
NO2MeO
MeO
n = 0-2
1) TFA:CH2Cl2 (3:7)
2)
TBTU, NEM, DMF
TBTU, NEM, DMF
3.37
Entry Hydroxamate n R Tripeptide Yield (%)
1 3.82 03.37 3.87 88
2 3.39 13.37 3.38 86
3 3.85 13.37 3.88 82
4 3.86 23.37 3.89 82
When characterizing the starting materials and products, two sets of resonances for iso-
lated protons, without neighboring protons, were observed. This trend was also reflected
in the 13C-NMR spectra, and for both instances, in a 1:1 ratio. For 1H-NMR, this was
frequently encountered for the aniline amide proton and or the methoxy group(s) reso-
nances. However, the multiplicity of two could also arise from two overlapping singlet
peaks, one resonance for each of the diastereomers, as a consequence of the racemic ben-
zylic proton. To exclude conformational isomers, NMR temperature experiment serie was
conducted on the synthesized tripeptide 3.38, in DMSO-d6, to investigate the occurrence
of diastereomers. Five 1H-NMR spectra were recording at different temperatures, rang-
ing from 22 °C to 77 °C. The results are listed in Figure 3.13.
A upfield shift of the aniline amide proton, from approx. 9.8 ppm to 9.2 ppm, was clearly
observed by 1H-NMR, a similar trend of displacement was also observed for the three
other amide protons. Over the temperature interval, no merging of the two resonance
signals for the aniline amide proton was observed, indicating a mixture of diastereomers
as suspected. Compounds where the two diastereomers can be differentiated by NMR is
marked with a star (*) in the experimental section, 3.13.
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N
(S)N
H O
H
N
OH
N
O
(S)N
H
O
O
NO2MeO
MeO
O
3.38
7.58.08.59.09.5 ppm
Figure 3.13: Selected expansion of 1H-NMR spectra from heat experiments for the investigation of the diastereomeric
nature of 3.38. Black = 22 °C, purple = 25 °C, blue = 37 °C, red = 57 °C, green = 77 °C
3.10 Synthesis of C3*, C4*, and C5* Analogues
For the C3*, C4*, and C5* analogues, the photo-labile protecting group 2.7 was alkylated
by a reductive alkylation approach with commercially available aldehydes and subse-
quently acylated with carboxylic acids.
3.10.1 Reductive Alkylation of Our Developed Hydroxylamine
Photo-Labile Protecting Group
Compound 2.7 (1.0 equiv.) was stirred under dry acidic conditions with commercially
available aldehydes (1.0 equiv.) in EtOH. The reaction mixture was heated for a short
period of time to dissolve the amine salt, and after additional three hours at rt, full con-
version to the corresponding oxime was observed by TLC and LCMS. The oximes were
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further reduced to obtain mono-alkylated O-protected hydroxylamines, Table 3.12.
Table 3.12: Reductive alkylation of O-MeNV hydroxylamine
NH2  HCl
O
NO2
OMe
MeO
TFA, EtOH,
2) NaBH3CN
0 oC to rt
1) R-CHO
NH
O
NO2
OMe
MeO
R
12.7
Entry R Hydroxylamines Yield (%)
1 2.7 3.90 85
2 2.7 3.91 61
3 2.7 3.92 74
4 2.7 3.93 87
5
S
2.7 3.94 oxime stable
The aliphatic aldehydes worked well (Entry 1-4). The 2-methylthiophene substituted
oxime was observed to be stable under the reductive conditions (Entry 5): after 12.5 equiv.
of NaBH3CN only a trace amount of the reduced oxime was observed by LCMS.
The desired thiophene-containing compound 3.96, was synthesized by alkylation of the
Boc-protected photo-labile protecting group 2.6 with 2-(chloromethyl)thiophene182 3.95,
followed by acidic cleavage of the Boc group affording 3.96 in 71% yield over two steps,
Scheme 3.17.
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NHBoc
O
NO2
OMe
MeO
1) NaH (60%), MeCN
2) TFA:CH2Cl2 (3:7)
71% (two steps)
NH  TFA
O
NO2
OMe
MeO
S
Cl
S
2.6
3.95
3.96
Scheme 3.17: Direct alkylation approach for the synthesis of the thiophen-2-ylmethyl alkylated hydroxylamine
3.10.2 BTC-Mediated Acylation of N-Alkylated Hydroxylamines
With the synthesized N-alkylated hydroxylamines in hand, the next step was to couple
them with the saturated carboxylic acids. As already described in Section 2.2.1, when-
ever our developed hydroxylamine photo-labile protecting group is alkylated, TBTU,
HATU, and PyBOP were inefficient. However, BTC was found to be an efficient acy-
lation reagent. The N-alkylated hydroxylamines were coupled to commercially available
methyl (tert-butoxycarbonyl)glycinate 3.45 and the prepared four- and five-carbon satu-
rated carboxylic acids (3.57 and 3.65) (Entry 1-10 Table 3.13).
For all the reactions full conversion of the hydroxylamines were observed by TLC and
LCMS, but a side-product was observed. However, it has not yet been possible to fully
determine the structures, but clearly contained both the N-alkylated hydroxylamines and
the carboxylic acid in a 2:1 ratio (Entry 7-10). For Entry 1, full conversion was also ob-
served, unfortunately several impurities and the corresponding side-product were too
observed for this entity.
95
Chapter 3. A Guided Design of Selective HDAC Inhibitors Based on Substrate Profiling
Table 3.13: Acylation of N-alkylated hydroxylamines mediated by BTC-coupling conditions
NR'
O
NO2
OMe
MeO
BTC, 2,4,6-collidine
(S) COOMe
NBocR''
N
O
NO2
OMe
MeO
n = 0, 1, 2
R
THF
R O
d
(S) COOMe
NBocR''
HOOC
n = 0, 1, 2
s
Entry Hydroxylamine R R’ R” Carboxylic acid n Hydroxamate Yield (%)
1 3.90 H H 3.45 0 3.97 0
2 3.91 H Boc 3.57 1 3.98 35
3 3.93 H Boc 3.57 1 3.99 34
4 3.100 H Boc 3.57 1 3.101 24
5 3.92 H Boc 3.57 1 3.102 30
6 3.96
S
H ·TFA Boc 3.57 1 3.103 32
7 3.90 H Boc 3.65 2 3.104 0
8 3.91 H Boc 3.65 2 3.105 0
9 3.100 H Boc 3.65 2 3.106 0
10 3.100 H Boc 3.65 2 3.107 0
Coupling of the carboxylic acids to the racemic N-alkylated hydroxylamine result in the
formation of two diastereomers as observed by NMR (denoted with a star (*) in the
experimental section 3.13). The acylation reactions were performed in the final stage
of my Ph.D. and time-limitations did not allow me to fully optimize these reactions,
Scheme 3.18. Due to the disappointing results, four reaction conditions were investigated
for the acylation of 3.92. The reactions were performed on a 100 mg scale and analyzed
by LCMS.
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N
(S) COOMe
NBoc2
O
O
NO2
OMe
MeO
NH
O
NO2
OMe
MeO
HOBt  H2O, 3 Å MS
DIC, MeCN
+ HOOC (S) COOMe
NBoc2
ClCOOEt, Et3N
DIC, DMAP
CH2Cl2
CH2Cl2
SOCl2, Et3N
CH2Cl2
3.92 3.65 3.108
Scheme 3.18: Screened alternative coupling conditions to provent side-product formation
HOBt ·H2O and 3.65 were stirred in dry MeCN for 15 min at rt with molecular sieves
before 3.92 was added and the mixture was cooled to 0 °C followed by the addition of
DIC.183 Full conversion to the side-product was observed by LCMS. 3.65 was treated with
ethyl chloroformate followed by the addition of 3.92. Only trace amount of the desired
compound 3.108 was detected by LCMS. The DIC184 and SOCl2185 test reactions both re-
sulted in formation of the side-product.
The last parameter we could change, was the number of Boc groups. The amount has pre-
viously been reported to give steric issues under other reaction conditions.142 Earlier, we
found that acylation with methyl (tert-butoxycarbonyl)glycinate 3.45 to the N-alkylated
hydroxylamine worked well, but extending the aliphatic carbon chain was found to af-
ford low - to no desired product. Another clear change, from the commercially available
carboxylic acid to our synthesized saturated carboxylic acids, is the double Boc-protected
amino group. Therefore, we investigated whether the double protection could be ac-
countable for the unsuccessful reaction. Mono-deprotection186 with 1.25 equiv. of TFA
in CH2Cl2 for 30 min followed by evaporation and drying before standard BTC cou-
pling conditions, proved to be efficient for a 150 mg scale reaction with low yield (36%).
On larger scale the selective mono-deprotection was slow and the amount of TFA was
changed to 1.4 equiv. Hereby, we isolated the hydroxamates 3.109 and 3.110 in 49% and
44% yield respectively, Table 3.14. Indeed, the desired products were obtained, but also
trace amount of a unidentified side-products were observed for the optimized reaction
conditions.
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Table 3.14: Improved synthetic strategy to obtain the C4* and C5* inhibitors
NHBoc
COOMe(S)N
O
NO2
OMe
MeO
O
(S) COOMe
NBoc2
HOOC
n = 1,2
1) TFA, CH2Cl2
2)
BTC, 2,4,6-collidine
THF
, BTC
n = 1,2
THF
3.90
Entry Carboxylic acid n Hydroxamate Yield (%)
1 3.57 1 3.109 49
2 3.65 2 3.110 44
3.10.3 Synthesis of Photo-Protected γ-(hydroxycarbamoyl)-L-Norvali-
ne, δ-(hydroxycarbamoyl)-L-Norleucine, and ε-(hydroxycarbamoyl)-L-
Homoleucine Derivatives
The mono- and di-Boc protected amino acids were converted into the corresponding ani-
line amide, Table 3.15. The mono-Boc amino acids were successfully hydrolyzed with 3
equiv. of LiOH187 (1a Table 3.15). For the remaining di-Boc protected compounds, the
already developed hydrolysis sequence (1b Table 3.15) was applied.
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Table 3.15: Synthesis of the aniline amides
(S) CONHPh
NHBoc
N
O
NO2
OMe
MeO
n = 0,1,2
R O
then Boc2O
(II) LiOH, THF:H2O (4:1)
1b) (I) TFA:CH2Cl2 (3:7)
2) TBTU, aniline
DIPEA, CH2Cl2
(S) COOMe
NX
N
O
NO2
OMe
MeO
n = 0,1,2
R O
1a) LiOH, THF:H2O (4:1)
or
DIPEA, dry CH2Cl23.90
Entry Methyl ester n X R Aniline amide Steps Yield (%)
1 3.109 1 HBoc3.90 3.111 2 88
2 3.101 1 Boc2 3.90 3.112 4 53
3 3.98 1 Boc2 3.90 3.113 4 34
4 3.102 1 Boc2 3.90 3.114 4 54
5 3.99 1 Boc2 3.90 3.115 4 59
6 3.103 1 Boc2
S
3.90 3.116 4 82
7 3.110 2 HBoc3.90 3.117 2 89
The results clearly indicate that the reactions with the highest yield were the ones using
the mono-Boc protected amino acids (Entry 1 and 7). Synthesizing compound 3.113 from
3.57 required five steps with an overall yield of 16%, whereas 3.111 was obtained in 43%
yield over four steps starting from 3.57.
3.10.4 Synthesis of Photo-Protected C4* and C5* Tripeptides
To complete the synthesis of the photo-protected analogues, the previously described
dipeptide coupling conditions were employed, Table 3.16. Synthesis of the desired photo-
protected C4* and C5* tripeptide analogues worked well in high yields (Entry 1-7).
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Table 3.16: Synthesis of protected tripeptides
RN
(S)N
H O
NHPh
OH
N
O
(S)AcHN
O
NO2MeO
MeO
n = 1, 2
RN
(S)BocHN
O
NHPh
O
NO2MeO
MeO
n = 1, 2
1) TFA:CH2Cl2 (3:7)
2) Ac-Leu-Gly-OH
TBTU, NEM, DMF
O O
TBTU, NEM, DMF
3.90
Entry Hydroxamate n R Tripeptide Yield (%)
1 3.111 13.90 3.118 70
2 3.112 13.90 3.119 87
3 3.113 13.90 3.120 75
4 3.114 13.90 3.121 88
5 3.115 13.90 3.122 89
6 3.116 1
S
3.90 3.123 84
7 3.117 23.90 3.124 79
3.11 Non-Substituted Hydroxamic Acid
In earlier projects, we have had great success coupling our photo-removable protect-
ing group with various acids promoted by PyBOP, to form the protected hydroxamates.
However, PyBOP proved to be inefficient for these compounds. Rewardingly, changing
to HATU gave full conversion on sub gram scale, Table 3.17.
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Table 3.17: Synthesis of O-protected hydroxamates
NH2  HCl
O
NO2
OMe
MeO
HATU, DIPEA, DMF
(S) COOMe
NBoc2
HN
O
NO2
OMe
MeO
n = 1, 2
O
(S) COOMe
NBoc2
HOOC
n = 1, 2
HATU, DIPEA, DMF
q
s
2.7
Entry Carboxylic acid n Hydroxamate Yield (%)
1 3.57 1 3.125 92
2 3.65 2 3.126 76
Deprotection of the Boc groups, hydrolysis, mono-Boc protection, TBTU-aniline coupling
was tested on 3.125, Scheme 3.19. Unfortunately, the amidation step failed due to the
formation of the cyclized side-product, 3.128, indicated by LCMS.
(S) COONHPh
NHBoc
HN
O
NO2
OMe
MeO
O
then Boc2O
2) LiOH, THF:H2O (4:1)
1) TFA:CH2Cl2 (3:7)
3) TBTU, aniline
DIPEA, dry CH2Cl2
(S) COOMe
NBoc2
HN
O
NO2
OMe
MeO
O (S)BocHN
N
O
NO2
OMe
MeO
O
Cyclic side-product
O
3.125 3.127 3.128
Scheme 3.19: Introduction of aniline amide
With the inefficient BTC-coupling conditions for the di-Boc protected compounds, HATU-
mediated acylation of 2.7 followed by N-alkylation could be an efficient method to pre-
vent the use of BTC. Mitsunobu alkylation conditions were tested with great success,
full conversion was observed of 3.125 to the N-alkylate O-MeNV hydroxamate 3.129,
Scheme 3.20.
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NBoc2
COOMe(S)N
O
NO2
OMe
MeO
ONBoc2
COOMe(S)HN
O
NO2
OMe
MeO
O
DIAD, PPh3
THF, reflux
OH
3.125 3.129
Scheme 3.20: Synthesis of N-alkylated O-MeNV hydroxamates via Mitsunobu conditions
Before this approach is pursued on large scale, eventual epimerization should be investi-
gated.
3.11.1 Alternative Synthesis of four- and five-Carbon Carboxylic
Acids
Due to the influence of the Boc-protecting groups described earlier, Section 3.10.2 Page
95, and the precautions we had to take to prevent epimerization/racemization as a conse-
quence of the increased α-proton acidity, along with the time-consuming synthesis, start-
ing from aspartic acid or glutamic acid is not advantageous. Therefore, we will give a
short introduction to some previously published alternative synthetic strategies here, for
the formation of the four- and the five-carbon carboxylic acids, (S)-5-((tert-butoxycarbo-
nyl)amino)-6-methoxy-6-oxohexanoic acid 3.130 and (S)-6-((tert-butoxycarbonyl)amino)-
7-methoxy-7-oxoheptanoic acid 3.139.
We also propose an alternative synthetic strategy for the mono-Boc protected saturated
carboxylic acids. First, deprotection of the Boc groups would be conducted, followed
by a mono-Boc protection, and the Pd(OAc)2-mediated hydrogenation-hydrogenolysis
affording the desired mono-Boc carboxylic acids, exemplified by the synthesis of 3.130
in Scheme 3.21. As reported by Fanning et al., the conjugated alkene would hinder cy-
clization. Optimization of either the TFA-mediated mono-Boc deprotection or the LiBr
approach could afford suitable reaction conditions.
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(S) COOMe
NBoc2
BnOOC
sat. NaHCO3 (aq), dioxane
2) Boc2O
1) TFA:CH2Cl2
3) Pd(OAc)2, charcoal
H2, EtOAc
(S) COOMe
NHBoc
HOOC
3.56 3.130
Scheme 3.21: Alternative synthesis of mono-Boc protected amino acids
Another method to synthesize 3.130 has been reported188 by RuO4-oxidation of (S)-methyl
1-Boc-piperidine-2-carboxylate 3.132 originating from the readily available Boc-L-pipecolic
acid 3.131189, Scheme 3.22.
HOOC
N
Boc
(S)
COOH N
Boc
(S)
COOMe
MeI, Cs2CO2
DMF
RuO4
t-BuOH
(S)
NHBoc
COOMe
3.131 3.132 3.130
Scheme 3.22: Literature procedure for the synthesis of 3.130 via a RuO4-oxidation approach
Yet another, but more time-consuming method involves the versatile diazotization reac-
tion of commercially available Cbz-Lys-OH 3.133, with sodium nitroprusside dihydrate
(Na2[Fe(CN)5NO] · 2 H2O)190 to afford Cbz-protected L-α-aminoadipic acid 3.134,
Scheme 3.23.
NHBoc
COOMe(S)HOOC
NHCbz
COOH(S)HO
NHCbz
Na2[Fe(CN)5NO]  2H2O
H2O, 4 M NaOH (aq.) (pH 9.5)
COOH(S)H2N
3.133 3.134 3.130
Scheme 3.23: Literature diazotization procedure for the synthesis of 3.130
One disadvantage of this approach is that the alkyl diazo compounds are explosive, and
L-α-aminoadipic acid is commercially available.
Synthesis of 3.139 has been reported in a patent191 filed by Miao et al., Scheme 3.24. Lit-
erature procedures192–194 were applied to synthesize our desired carboxylic acid, start-
ing from commercially available (S)-methyl-N-Boc-pyroglutamate (Boc-Pyr-OEt). In our
case, the even cheaper Boc-Pyr-OMe (3.135) could be used. The cyclic amide is reduced
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to the hemiaminal 3.136, Scheme 3.24. In the patent, the authors reacted the masked
aldehyde 3.137 with benzyl(triphenylphosphoranylidene)acetate, to obtain the α,β-un-
substituted benzyl ester 3.138. In the final step, a hydrogenation-hydrogenolysis reaction
was conducted in order to obtain the fully saturated mono-Boc protected carboxylic acid,
3.139.
N
Boc
(S)
O COOMe
DIBAL-H
N
Boc
(S)
HO COOMe BocHN
(S)O
COOMe
Ph3P=CHCOOBn
10% Pd/C, H2BnOOC COOMe(S)
NHBoc MeOH
COOMe(S)
NHBoc
HOOC
masked aldehyde
THF, -78 oC
3.135 3.136 3.137
3.138 3.139
Scheme 3.24: Literature procedure for the synthesis of 3.139
3.11.2 Screening of Photolytic Cleavage Conditions
Finally, the photo-mediated deprotection of our photo-labile protecting group was carried
out. In Chapter 2, photo-cleavage of the photo-labile protecting group was investigated.
For the first N-alkylated SAHA analogues a 1.0 M HCl (aq.):iPrOH (1:11) mixture was
used to get a good ratio between the hydroxamic acid and the corresponding amide. For
the non-substituted hydroxamates, we found that THF:H2O (4:1) afforded the desired
hydroxamic acid in high selectivity. Generally, N-alkylated hydroxamates require acidic
conditions to give high selectivity. From the work with the photo-labile protecting group,
several solvent systems afforded high selectivity, Table 2.10 20. 3.87 was chosen as a
model substrate for this step to afford the hydroxamic acid 3.140. It was not possible to
see separation of the hydroxamic acid and the corresponding amide on MS, but the mass
traces indicated selectivity.
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Table 3.18: Solvent screen for selective hydroxamic acid liberation
(365 nm)
solvent
N
O
(S)N
H
COONHPh
OH
N
O
(S)AcHN
O
NO2
OMe
MeO
νh
N
O
(S)N
H
COONHPh
OH
N
O
(S)AcHN
OH
2
3.87 3.140
Entrya Solventb Ratio Selectivityc
1 MeOH:H2O 1:1 -
2 MeOH:1.0 M HCl (aq.) 4:1 -
3 HFIP -
4d HFIP -
5 HFIP:THF 1:1 -
6 HFIP:H2O 1:1 -
7 HFIP:TFA 4:1 -
8 HFIP:TFA 3:2 -
9 HFIP:H2O 4:1 -
10 HFIP:1.0 M HCl (aq.) 4:1 -
11 HFIP:1.0 M Fe(OAc)3 (aq.) 1:1 A
12 HFIP:MeCN 1:1 -
13 HFIP:MeCN:TFA 1:1:1 -
14 HFIP:MeCN 4:1 -
15 HFIP:1.0 M FeCl3 · 7 H2O (aq.) 1:1 -
16 HFIP:MeCN:1.0 M FeCl3 · 7 H2O (aq.) 1:1:1 -
17 HFIP:1.0 M FeCl3 · 7 H2O (aq.) 9:1 A
18 MeCN:TFA 1:4 -
19 MeCN:TFA 1:1 -
20 MeCN:TFA 9:1 -
21 MeCN:H2O 4:1 -
continued on next page
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Entrya Solventb Ratio Selectivityc
22d MeCN:1.0 M FeCl3 · 7 H2O (aq.) 1:1 -
23 MeCN:1.0 M FeCl3 · 7 H2O (aq.) 1:1 -e
2413 DMSO -
25 DMSO:TFA 1:4 -
26 DMF -
27 iPrOH A
28 iPrOH:TFA 9:1 -
29 iPrOH:1.0 M HCl (aq.) 1:1 -
30 iPrOH:1.0 M HCl (aq.) 4:1 -
31 iPrOH:1.0 M HCl (aq.) 9:1 -
32 1.0 M HCl (aq.) -
33 iPrOH:1.0 M ZnSO4 · 7 H2O (aq.) 1:1 -
34 iPrOH:1.0 M FeSO4 · 7 H2O (aq.) 1:1 -
35 iPrOH:1.0 M ZnCl2 (aq.) 1:1 -
36 iPrOH:1.0 M FeCl3 · 7 H2O (aq.) 1:1 -
37 iPrOH:1.0 M Zn(OAc)2 · 2 H2O (aq.) 1:1 A
38 iPrOH:1.0 M FeCl2 (aq.) 1:1 -
39 iPrOH:1.0 M Fe(OAc)2 (aq.) 1:1 -
40 TFA HA
(a) Conducted on 5 mg scale (b) operating concentration 21.6 mM if otherwise reported (c) based on the positive mass trace, HA =
hydroxamic acid (3.140), A = amide, - no selectivity (d) 2.16 M (e) HA was degraded
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Photolytic cleavage in TFA displayed high selectivity, but as our goal was to find mild
conditions, more experiments are needed. Furthermore, we discovered, that Entry 7, 8,
13, 18, 19, 22, and 38 gave good selectivity based on the mass trace intensities. Although
due to time-constraints, these conditions were not further investigated. Because we did
not find proper conditions for the photolytic cleavage, we were not able, before writing
this dissertation, to conduct biological screening of the inhibitors. But it is our future per-
spectives to further investigate the solvent dependency for the hydroxamic acid release
and conduct a profiling study on these compounds in HDAC enzymes.
3.12 Conclusion
In a previous project in the Qvortrup group, a HDAC substrate profiling study was per-
formed and identified a HDAC subclass-3 selective substrate. The aim of my work was to
use this information and develop a subclass-3 selective inhibitor. HDACs are an impor-
tant class of enzymes and HDAC inhibitors have shown to be important in the treatment
of cancer as well as a range of non-cancer diseases. A selection of hydroxamic acid func-
tionalized peptides was successfully synthesized, consisting of a leucine-glycine dipep-
tide coupled to a lysine analogue. A hydroxamic acid functionality was introduced, as
this functionality has shown to result in good HDAC-inhibitor activity. Based on the
hit substrate, a selection of N-hydroxamate groups was chosen. To synthesize the de-
sired O-protected hydroxamate tripeptides, I developed a convergent synthetic route to
key intermediates starting from commercially available aspartic- and glutamic acid. A
preliminary test of photolytic cleavage conditions was conducted, which afforded the
desired hydroxamic acids.
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3.13 Experimental Section
General Methods
See Section 2.5.1 for general methods.
Due to instability of the oximes, 3.83 and 3.84 were characterized by LCMS alone.
General Procedure: Oxime Reduction
In a round-bottomed flask containing a magnetic stirring bar, the oxime was placed under
vacuum for a couple of hours before a nitrogen atmosphere was introduced. The oxime
was dissolved in MeOH (0.25 M) and cooled to 0 °C. To the cold stirring solution were
added NaBH3CN (1.3-2.0 equiv.) and a few drops of TFA (pH < 3) followed by stirring
at rt. When full conversion was observed by LCMS, the reaction mixture was quenched
by the addition of sat. NaHCO3 (aq.) and MeOH was removed under reduced pressure.
The aqueous phase was extracted with EtOAc and the organic phase was washed with
sat. NaHCO3 (aq.) (3 x), dried over Na2SO4, filtered, and concentrated in vacuo.
General Procedure: Acid Chloride Acylation
In a round-bottomed flask containing a magnetic stirring bar, the amine was placed un-
der vacuum for a couple of hours before a nitrogen atmosphere was established. The
hydroxylamine (1.0 equiv.) was dissolved in CH2Cl2 (0.22 M) and cooled to 0 °C. To the
cold stirring solution were dropwise added pyridine (10.0 equiv.) and acid chloride (1.0
equiv.) and stirred at rt. When full conversion was observed by TLC and/or LCMS, the
reaction mixture was concentrated under reduced pressure, and the residues were dis-
solved in sat. NH4Cl (aq.) and washed with CH2Cl2 (3 x). The organic phase was dried
over Na2SO4, filtered, and concentrated in vacuo.
General Procedure: Boc-Deprotection
In a round-bottomed flask containing a magnetic stirring bar, the Boc-protected amine
was dissolved in TFA:CH2Cl2. When full conversion was observed by TLC and/or LCMS,
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the reaction mixture was concentrated under reduced pressure, and co-evaporated twice
from toluene and CH2Cl2.
General Procedure: One-Pot LiOH Hydrolysis and Boc-Protection
In a round-bottomed flask containing a magnetic stirring bar, LiOH (7.0 equiv.) was
added to a stirring solution of the ester in THF:H2O (4:1) (0.04 M). When full conver-
sion to the carboxylic acid was observed by LCMS, Boc2O was added to the stirring basic
solution. When full Boc-protection was observed by TLC and/or LCMS, the reaction
mixture was diluted with EtOAc by half of the reaction volume and acidified to pH ≈
3-4 by the addition of 1.0 M HCl (aq.) and immediately extracted with EtOAc (3 x). The
combined organic phases were dried over Na2SO4, filtered, and concentrated in vacuo.
General Procedure: LiOH Hydrolysis
In a round-bottomed flask containing a magnetic stirring bar, LiOH (3.0 equiv.) was
added to a stirring solution of the ester in THF:H2O (4:1) (0.04 M). When full conver-
sion was observed by TLC and/or LCMS, the reaction mixture was diluted with EtOAc
by half of the reaction volume and acidified to pH ≈ 3-4 by the addition of 1.0 M HCl
(aq.) and immediately extracted with EtOAc (3 x). The combined organic phases were
dried over Na2SO4, filtered, and concentrated in vacuo.
General Procedure for BTC Acylation
In a dry round-bottomed flask containing a magnetic stirring bar, BTC was added to
a stirring solution of the carboxylic acid in THF (0.04 M) under nitrogen atmosphere.
To the solution was dropwise added 2,4,6-collidine to form a milky suspension with a
yellow shade over 1-2 h. N-Alkylated hydroxylamines were added to the milky mixture
in one portion and stirred. When full conversion was observed by TLC and/or LCMS,
the reaction mixture was quenched by the addition of H2O and transferred to a separation
funnel by the use of EtOAc. The organic phase was washed according to the description
for each specific reactions. The non-acidic phases were combined and extracted with
EtOAc. The combined organic phases were dried over Na2SO4, filtered, and concentrated
in vacuo. The title compound was purified by flash column chromatography.
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General TBTU-DIPEA Aniline Amidation180
A round-bottomed flask containing the Boc-protected carboxylic acid and a magnetic stir-
ring bar was placed under vacuum for a couple of hours before a nitrogen atmosphere
was established. TBTU was added to a stirring solution of the carboxylic acid in CH2Cl2
(0.07 M) and stirred. DIPEA and aniline were added to stirring solution. The reaction
mixture was evaporated under reduced pressure, and the organic layer was dissolved in
EtOAc and washed with H2O, sat. NaHCO3 (aq.), 1.0 M HCl (aq.), and brine. The organic
phase was dried over Na2SO4, filtered, and concentrated in vacuo. The title compound
was purified by flash column chromatography.
General Reductive Alkylation Procedure
To a dry round-bottomed flask containing a magnetic stirring bar, O-MeNV hydroxy-
lamine hydrochloride salt 2.7 was dissolved in an alcoholic solution (0.25 M). The alde-
hyde (1.0 equiv.) was added to the solution followed by TFA (pH < 3). The solution was
heated for a short period of time to followed by stirring at rt under a nitrogen atmosphere.
When full conversion was observed by TLC and/or LCMS, the solution was cooled to 0
°C and the oxime was reduced by the addition of NaBH3CN. When full reduction was
observed by TLC and/or LCMS, the reaction was quenched with H2O and the alcohol
was removed under reduced pressure. The residues were taken up in EtOAc and washed
with sat. NaHCO3 (aq.). The combined organic phases were dried over Na2SO4, filtered,
and concentrated in vacuo. This provided the crude N-alkylated O-MeNV hydroxylamine
which was purified by flash column chromatography.
Acetyl-L-leucylglycine (3.37)
(S)
O
H
N
O
OHN
H
O
In a round-bottomed flask containing a magnetic stirring bar, benzyl
acetyl-L-leucylglycinate (11.4 g, 35.7 mmol, 1.0 equiv.) was placed un-
der vacuum for an hour before a nitrogen atmosphere was established
and dissolved in MeOH (143 mL), and added 10% Pd/C (50% wetted
in H2O) (2.29 g, 10 wt%). Two vacuum/hydrogen cycles were performed before hydro-
gen was bubbled through the solution for 30 min. The reaction mixture was stirred un-
der hydrogen atmosphere overnight. The reaction mixture was filtered through a pad
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of Celite®, and washed thoroughly with CH2Cl2 and concentrated under reduced pres-
sure. This afforded acetyl-L-leucylglycine as a off-white solid (8.1002 g, 91%). Spectral
data in correspondence with reported literature values.195 1H-NMR (400 MHz, DMSO-
d6): δ 12.48 (br. s, 1H, C(O)OH), 8.19 (t, J = 5.9 Hz, 1H, C(O)NHCH2C(O)), 7.98 (d, J =
8.4 Hz, 1H, CH3C(O)NHCH), 4.34–4.29 (m, 1H, CH3C(O)NHCHC(O)), 3.77–3.65 (m, 2H,
NHCH2C(O)), 1.83 (s, 3H, CH3C(O)NH), 1.65–1.55 (m, 1H, CHCH2CH(CH3)2), 1.49–1.37
(m, 2H, CHCH2CH(CH3)2), 0.88–0.82 (m, 6H, CH(CH3)2); [a]22D - 54.6°(c 2.00, EtOH), lit.
[a]17D - 50.0°(c 2.00, CHCl3);196 [a]
22
D - 52.8°(c 1.00, EtOH).
N-((S)-5-(2-((S)-2-acetamido-4-methylpentanamido)acetamido)-6-oxo-6-(phenyl-
amino)hexyl)-N-(1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)cyclopropanecarboxamide
(3.38)
N
(S)N
H O
H
N
OH
N
O
(S)N
H
O
O
NO2MeO
MeO
O
According to the general procedure for Boc-deprotection, the
Boc-protected aniline amide 3.39 (648 mg, 1.03 mmol, 1.0
equiv.) was stirred in TFA:CH2Cl2 (3:7, 16.4 mL) for 1.5
h. Volatiles were removed under reduced pressure and co-
evaporated from toluene and CH2Cl2. The round-bottomed
flask was placed under vacuum for a couple of hours, be-
fore a nitrogen atmosphere was established. According to the general procedure for
coupling reagent acylation, TBTU (0.4305 g, 1.34 mmol, 1.3 equiv.) and NEM (908 µL,
7.21 mmol, 7.0 equiv.) was added to a stirring solution of acetyl-L-leucylglycine 3.37
(285 mg, 1.24 mmol, 1.2 equiv.) in DMF (2.0 mL) and stirred for 15 min, before the
crude TFA salt in DMF (8.3 mL) was added and stirred overnight. Incomplete conver-
sion was observed, and therefore a new batch of acetyl-L-leucylglycine 3.37, TBTU, and
NEM were prepared in DMF (2.0 mL) and after stirring for 15 min added to the reaction
mixture followed by stirring overnight. The reaction mixture was diluted with EtOAc
(25 mL), and the organic layer was washed with brine (5 x 25 mL), sat. NaHCO3 (aq.,
25 mL), and 1.0 M HCl (aq., 25 mL). The combined organic phases were dried over
Na2SO4, filtered, and concentrated in vacuo. The photo-protected tripeptide 3.38 was
isolated by flash column chromatography (CH2Cl2:MeOH 99:1 → 93:7) as a pale green
semi-solid (657 mg, 86%). A trace amount of CH2Cl2 was observed by 1H-NMR. A di-
astereomeric mixture of 1:1 ratio was observed in the NMR spectra. Two resonances
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for nuclei denoted with a star(*) were observed and both chemical shifts are reported.
Multiplicity for each diastereomer is reported if possible. Rf = 0.24 (CH2Cl2:MeOH
(19:1); UV); IR (neat) ν (cm-1): ; 1H-NMR (400 MHz, DMSO-d6): δ 9.88/9.87*
(s, 1H, C(O)NHPh), 8.27–8.24 (m, 1H, C(O)NHCH2C(O)), 8.07 (d, J = 7.4 Hz, 1H,
CH3C(O)NHCH), 7.93 (dd, J = 7.7, 4.7 Hz, 1H, C(O)NHCHC(O)NHPh), 7.61–7.60 (m, 2H,
ArH), 7.53 (s, 1H, ArH), 7.32–7.28 (m, 3H, ArH), 7.07–7.03 (m, 1H, ArH), 5.56–5.51 (m, 1H,
ArCHCH3), 4.35–4.28 (m, 1H, C(O)NHCHC(O)NHPh), 4.24–4.19 (m, 1H, H3C(O)NHCH),
3.91/3.90* (s, 3H, OCH3), 3.85/3.84* (s, 3H, OCH3), 3.76–3.65 (m, 2H, C(O)NHCH2C(O)),
3.61–3.52 (m, 1H, CH2CH’H”NC(O)), 3.17–3.03 (m, 1H, CH2CH’H”NC(O)), 2.10–
2.01 (m, 1H, C(O)NCH – CH2CH2 – ), 1.83/1.82* (s, 3H, CH3C(O)NH), 1.68–1.37 (m,
10H, CH3C(O)NHCHCH2CH, NHCHCH2CH2CH2, ArCHCH3), 1.27–1.09 (m, 2H,
CH2CH2CH2NC(O)), 0.88–0.61 (m, 10H, NC(O)CH – CH2CH2 – , CH(CH3)2); 13C-
NMR (101 MHz, DMSO-d6): δ 174.6, 172.8, 170.41/170.39*, 169.6, 168.8, 152.8, 148.2,
140.99/140.98*, 138.8, 130.1, 128.7, 123.4, 119.29/119.27*, 109.79/109.77*, 107.4, 76.9, 56.3
56.1, 53.3/53.2*, 51.4, 46.8, 42.0, 40.6, 31.6, 26.2/26.1*, 24.1, 22.9, 22.6/22.5*, 22.4, 21.6, 20.6,
10.6, 7.9, 7.7; MS (ESI) m/z: calcd. for C36H51N6O10+ [M + H]+ 727.4, found 727.8.
tert-Butyl ((2S)-6-(N-(1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)cyclopropanecarbox-
amido)-1-oxo-1-(phenylamino)hexan-2-yl)carbamate (3.39)
OMe
MeO
NO2
O
N (S)O
NHO
O
O
H
N
According to the general procedure for oxime reduction,
NaBH3CN (1.12 g, 17.8 mmol, 2.0 equiv.) was added to a
stirring cold solution of decomposed 3.83 (5.19 g, 8.89 mmol,
1.0 equiv.) in MeOH (35.6 mL) at 0 °C and pH was ad-
justed to pH< 3 with TFA. After 15 min, the reaction mixture
was quenched by the addition of sat. NaHCO3 (aq., 50 mL)
and volatiles were removed under reduced pressure. The
residues were dissolved in EtOAc (200 mL) and washed with sat. NaHCO3 (aq., 3 x 200
mL), dried over Na2SO4, filtered, and concentrated in vacuo. The crude mono N-alkylated
hydroxylamine was placed under vacuum with a magnetic stirring bar for an hour be-
fore a nitrogen atmosphere was established. According to the general procedure for acid
chloride acylation, pyridine (7.17 mL, 89.0 mmol, 10.0 equiv.) and cyclopropanecarbonyl
chloride (924 mL, 8.89 mmol, 1.0 equiv.) were added to a cold solution of the N-alkylated
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hydroxylamine in CH2Cl2 (46.7 mL) at 0 °C and stirred for 1.83 h. The concentrated re-
action mixture was washed added sat. NH4Cl (aq., 200 mL) and washed with CH2Cl2
(3 x 100 mL). The organic phase was dried over Na2SO4, filtered, and concentrated in
vacuo. According to the general procedure for Boc-deprotection, the di-Boc protected
compound was stirred in TFA:CH2Cl2 (3:7, 135 mL) overnight. Volatiles were removed
under reduced pressure and co-evaporated from toluene and CH2Cl2. According to the
general procedure for one-pot LiOH hydrolysis and Boc-protection, LiOH (1.49 g, 62.3
mmol, 7.0 equiv.) was added to a stirring solution of the crude TFA salt in THF:H2O
(4:1, 222 mL). After 3.0 h, Boc2O (3.88 g, 17.8 mmol, 2.0 equiv.) was added and stirred
overnight. The reaction mixture was diluted with EtOAc (100 mL), and pH adjusted to
≈ 3-4 by the addition of 1.0 M HCl (aq., 43.0 mL), and extracted with EtOAc (2 x 50
mL). The combined organic phases were dried over Na2SO4, filtered, and concentrated
in vacuo. The Boc-protected carboxylic acid was purified by flash column chromatogra-
phy (CH2Cl2:MeOH 99:1→ 19:1) and placed under vacuum for a couple of hours before
a nitrogen atmosphere was established. According to the general procedure for TBTU-
DIPEA aniline amidation, TBTU (2.07 g, 6.46 mmol, 1.0 equiv.) was added to a stirring
solution of the N-Boc protected amino acid (3.48 g, 6.46 mmol, 1.0 equiv.) in CH2Cl2 (30.8
mL). After 10 min, DIPEA (6.74 mL, 38.8 mmol, 6.0 equiv.) and aniline (647.3 µL, 7.10
mmol, 1.1 equiv.) were added and stirred overnight. Volatiles were removed under re-
duced pressure and taken up in EtOAc (100 mL) and washed with H2O (100 mL), sat.
NaHCO3 (aq., 100 mL), and 1.0 M HCl (aq., 2 x 100 mL). The organic phase was dried
over Na2SO4, filtered, and concentrated in vacuo. The residues were purified by flash col-
umn chromatography (EtOAc:heptane 2:3→ 11:9) to provide the aniline amide 3.39 (2.80
g, 51%) as a pale green foam. A trace amount of CH2Cl2 was observed by 1H-NMR. A
diastereomeric mixture of 1:1 ratio was observed in the NMR spectra. Two resonances
for nuclei denoted with a star(*) were observed and both chemical shifts are reported.
Multiplicity for each diastereomer is reported if possible. Rf = 0.14 (EtOAc:heptane (2:3);
UV); IR (neat) ν (cm-1): 3268, 2975, 2931, 1600, 1518, 1441, 1366, 1334, 1273; 1H-NMR
(400 MHz, DMSO-d6): δ 9.90/9.89* (s, 1H, C(O)NHPh), 7.58–7.53 (m, 3H, ArH), 7.31–
7.27 (m, 3H, ArH), 7.05–7.02 (m, 1H, ArH), 6.93–6.89 (m, 1H, CH2CHNHC(O)O), 5.56–
5.52 (m, 1H, ArCHCH3), 4.05–3.97 (m, 1H, C(O)CH2CH2CH2CHNBoc), 3.91/3.90* (s, 3H,
OCH3), 3.85/3.84* (s, 3H, OCH3), 3.62–3.52 (m, 1H, C(O)NCH’H”CH2CH2), 3.17–3.02
(m, 1H, C(O)NCH’H”HCH2CH2), 2.11–2.02 (m, 1H, – CH2CH2 – CHC(O)N), 1.62–1.15
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(m, 18H, C(O)NCH’H”CH2CH2CH2CHNHBoc, C(CH3)3, ArCHCH3), 0.86–0.62 (m, 4H,
– CH2CH2 – CH(O)N); 13C-NMR (101 MHz, DMSO-d6): δ 174.6 (observed by HMBC),
171.4, 155.4, 152.8, 148.2, 140.1, 139.0, 130.3, 128.7, 123.2, 119.2, 109.8, 107.4, 78.0, 77.9,
56.3, 56.11/56.10*, 54.9, 46.9 (observed by HSQC), 31.5, 28.2, 26.2/26.1*, 22.81/22.77*,
20.6, 10.4, 7.9, 7.6; MS (ESI) m/z: calcd. for C31H43N4O9+ [M + H]+ 615.3, found 615.8.
Dimethyl (S)-2-(bis(tert-butoxycarbonyl)amino)butane-1,4-dioate (3.50)143
(S)
O
O
OO
N O
O
O
O
To an oven-dried round-bottomed flask containing a magnetic stirring
bar and equipped with a condenser, SOCl2 (13.2 mL, 0.180 mol, 1.2
equiv.) was added dropwise to a suspension of L-aspartic acid 3.49 (20.0
g, 0.150 mol, 1.0 equiv.) in MeOH (200 mL) at 0 °C under nitrogen atmo-
sphere. The mixture was heated at reflux for 22 h. The reaction mixture
was cooled to rt and the solvent was removed under reduced pressure. The crude white
intermediated was dissolved in a solvent mixture of sat. NaHCO3 (aq., 200 mL) and diox-
ane (200 mL). (Boc)2O (39.4 g, 0.180 mol, 1.2 equiv.) was added and the reaction mixture
was stirred at rt overnight. The reaction mixture was extracted with EtOAc (3 x 400 mL).
The combined organic layer were dried over Na2SO4, filtered, and concentrated in vacuo.
The round-bottomed flask was placed under vacuum for a couple of hours, before a ni-
trogen atmosphere was established. The crude white powder was dissolved in MeCN
(250 mL). DMAP (3.67 g, 30.1 mmol, 0.2 equiv.) and (Boc)2O (55.8 g, 0.255 mol, 1.7 equiv.)
were subsequently added and the reaction mixture stirred for overnight. The resulting
red reaction mixture was evaporated to dryness. The residues were purified by DCVC
(EtOAc:heptane 1:99→ 3:7) to afford 3.50 (49.7 g, 91%) as a white solid. Spectral data in
correspondence with reported literature values.143 1H-NMR (400 MHz, CDCl3): δ 5.46 (t,
J = 6.8 Hz, 1H, CH’H”CHN), 3.72 (s, 3H, CHC(O)OCH3), 3.70 (s, 3H, CH3O(O)CCH’H”),
3.27–3.21 (m, 1H, CH’H”C(O)OCH3), 2.76–2.70 (m, 1H, CH’H”C(O)OCH3), 1.50 (s, 18H,
2 x C(CH3)3); [a]22D - 67.5°(c 2.00, CHCl3); lit. [a]
25
D - 61.0°(c 2.00, CHCl3).
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Methyl (S)-2-(di-tert-butoxycarbonylamino)-4-oxobutanoate (3.51)143
O
O
N O
O
O
O
OH In an oven-dried round-bottomed flask containing a magnetic stirring
bar, DIBAL-H (1 M in toluene, 10.8 mL, 9.13 mmol, 1.1 equiv.) was added
dropwise over a period of 30 min to a solution of the methyl ester 3.50
(3.00 g, 8.30 mmol, 1.0 equiv.) in Et2O (83.0 mL) at -78 °C under a ni-
trogen atmosphere. The reaction mixture was stirred for additional 30
min, before quenched by the addition of H2O (1.05 mL, 58.1 mmol, 7.0 equiv.) followed
by 30 min stirring. The solution was dried over MgSO4 and filtered through a pad of
Celite® and concentrated in vacuo. Six identical reactions were combined and purified
by one flash column chromatography (EtOAc:Heptane 1:9→ 2:3) to afford the aldehyde
3.51 (14.7 g, 89%) as a clear oil. Spectral data in correspondence with reported literature
values.143 1H-NMR (400 MHz, CDCl3): δ 9.79 (s, 1H, OHCCH2), 5.53 (t, J = 6.4 Hz, 1H,
CH’H”CHN), 3.73 (s, 3H, COOCH3), 3.45–3.38 (m, 1H, CH’HCHO), 2.86–2.80 (m, 1H,
CH’H”CHO), 1.50 (s, 18H, 2 x C(CH3)3); [a]22D - 56.9°(c 2.00, CHCl3); lit. [a]
25
D - 54.9°(c 2.00,
CHCl3).
Methyl (S)-2-(tert-butoxycarbonylamino)-4-oxobutanoate (3.52)146
(S)
O
O
HN O
O
H
O
In an oven-dried round-bottomed flask containing a magnetic stirring
bar, LiBr (3.12 g, 35.9 mmol, 3.0 equiv.) was added to a solution of di-Boc
aldehyde 3.51 (3.96 g, 12.0 mmol, 1.0 equiv.) in MeCN (135 mL) under ni-
trogen atmosphere and refluxed overnight. Incomplete conversion was
observed and the reaction mixture was concentrated under reduced pressure and directly
purified by flash column chromatography (EtOAc:Heptane 3:7) to afford the mono-Boc
protected aldehyde 3.52 (1.02 g, 37%) as an oil. A trace amount of impurities and 3.51
were observed by 1H-NMR. Spectral data in correspondence with reported literature val-
ues.146 1H-NMR (400 MHz, DMSO-d6): δ 9.59 (s, 1H, OHCCH2), 7.32 (d, J = 8.1 Hz, 1H,
CHNHC(O)), 4.51 (m, 1H, CH2CHNHC(O)), 3.62 (s, 3H, C(O)OCH3), 2.87–2.69 (m, 2H,
OHCCH2CH), 1.38 (s, 9H, C(CH3)3).
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Methyl (S,E)-2-((tert-butoxycarbonyl)amino)-6-oxohex-4-enoate (3.53)
O
O
HN O
O
H
O
In an oven-dried round-bottomed flask containing a magnetic
stirring bar equipped with a condenser, (triphenylphosphoranyli-
dene)acetaldehyde (2.11 g, 6.93 mmol, 2.0 equiv.) was added to a so-
lution of the mono-Boc protected aldehyde 3.52 (801 mg, 3.46 mmol,
1.0 equiv.) in THF (13.9 mL) and refluxed under nitrogen atmosphere for 26 h. The re-
action mixture was concentrated under reduced pressure. The residues were purified by
flash column chromatography (EtOAc:heptane 1:4 → 1:1) to afford the α/ β-conjugated
aldehyde 3.53 as a yellow oil (596.4 mg, 63%). Triphenylphosphineoxide was observed by
1H-NMR. Z:E ratio was found to be 33:67 by 1H-NMR. A trace amount of impurities was
observed by 1H-NMR. 1H-NMR (400 MHz, CDCl3): δ 9.55–9.50 (s, 1H, H(O)CCH), 7.09–
7.02 (m, 0.33H, H(O)CCHCH), 6.78–6.71 (m, 0.67H, H(O)CCHCH), 6.40–6.34 (m, 0.33H,
H(O)CCHCH), 6.18–6.07 (m, 0.67H, H(O)CCHCH), 5.16–5.09 (m, 1H, CH2CHNHC(O)O),
4.54–4.46 (m, 1H, CH2CHNHC(O)O), 3.77–3.75 (s, 3H, C(O)OCH3), 2.94–2.56 (m, 2H,
CH2CHNHC(O)O), 1.43 (s, 9H, C(CH3)3); 13C-NMR (101 MHz, CDCl3): δ 193.9/193.5,
172.1/171.8, 155.2, 151.5/151.4, 135.7 80.6, 52.9, 52.7/52.5, 36.6/36.2, 28.41/28.39.
1-Benzyl 6-methyl (S,E)-5-(bis(tert-butoxycarbonyl)amino)hex-2-enedioate (3.56)
(S)
(E)
N O
OO
O
O
O
O
O
In an oven-dried round-bottomed flask containing a mag-
netic stirring bar and equipped with a condenser, ben-
zyl(triphenylphosphoranylidene)acetate (19.36 g, 47.2 mmol,
1.5 equiv.) was added to a stirring solution of the di-Boc alde-
hyde 3.51 (10.42 g, 31.4 mmol, 1.0 equiv.) in THF (81.0 mL)
and refluxed overnight under a nitrogen atmosphere. The reaction mixture was cooled
to rt and diluted by the addition of sat. NH4Cl (aq., 300 mL) and extracted with
EtOAc (3 x 300 mL). The combined organic phases were dried over Na2SO4, filtered,
and concentrated in vacuo. The residues were purified by flash column chromatogra-
phy (heptane → EtOAc:heptane 4:6) providing the four-carbon α,β-conjugated benzyl
ester (14.06 g, 96%) as a clear oil. A trace amount of CH2Cl2 was observed by 1H-
NMR. Rf = 0.53 (EtOAc:heptane (2:3); UV); IR (neat) ν (cm
– 1): 2988, 2937, 1746, 1719,
1699, 1658, 1478, 1138; 1H-NMR (400 MHz, CDCl3): δ 7.36–7.31 (m, 5H, ArH), 6.98–6.91
(m, 1H, BnO(O)CCHCHCH’H”), 5.94–5.90 (m, 1H, BnO(O)CCHCHCH’H”), 5.15 (s, 2H,
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ArCH2O), 5.03 (dd, J = 9.8, 5.0 Hz, 1H, CH’H”CHN), 3.73 (s, 3H, CHC(O)OCH3), 3.04–
2.97 (m, 1H, CH’H”CHN), 2.87–2.79 (m, 1H, CH’H”CHN), 1.46 (s, 18H, 2 x C(CH3)3); 13C-
NMR (101 MHz, CDCl3): δ 170.4, 165.9, 151.8, 144.8, 136.0, 128.7, 128.4, 128.3, 124.0, 83.7,
66.3, 57.0 52.6, 33.2, 28.0; MS (ESI) m/z: calcd. for C24H33NNaO8+ [M + Na]+ 486.2, found
486.8; HRMS (ESI) m/z: calcd. for C24H33NNaO8+ [M + Na]+ 486.2098, found 486.2097.
[a]22D - 54.4°(c 1.00, CHCl3).
(S)-5-(bis(tert-butoxycarbonyl)amino)-6-methoxy-6-oxohexanoic acid (3.57)
(S)HO
O N
O
O O
O
O
O
In a round-bottomed flask containing a magnetic stirring bar, α,β-
conjugated benzyl ester 3.56 (5.35 g, 11.5 mmol, 1.0 equiv.) was
placed under vacuum for an hour before a nitrogen atmosphere
was established and dissolved in iPrOH (57.7 mL), and added
Pd(OAc)2 (64.8 mg, 0.288 mmol, 0.025 equiv.) and charcoal (584 mg,
Pd(OAc)2:charcoal 10:90 (wt:wt)). Two vacuum/hydrogen cycles were performed be-
fore hydrogen was bubbled through the solution over 45 min. The reaction mixture was
stirred under hydrogen atmosphere overnight. The reaction mixture was filtered through
a pad of Celite®, and washed thoroughly with CH2Cl2 and concentrated under reduced
pressure. This afforded the carboxylic acid 3.58 as a clear oil (4.29 g, 99%). A trace of
amount of CH2Cl2 was observed by 1H-NMR. Rf = 0.16 (CH2Cl2:MeOH (95:5); KMnO4);
IR (neat) ν (cm – 1): 3215, 2949, 2888, 1740, 1703, 1136, 1113; 1H-NMR (400 MHz, DMSO-
d6): δ 12.04 (br. s, 1H, HO(O)C), 4.82 (dd, J = 10.0, 4.9 Hz, 1H, CH’H”CHN), 3.62 (s, 3H,
C(O)OCH3), 2.30–2.16 (m, 2H, C(O)CH2CH2), 2.02–1.91 (m, 1H, CH2CH’H”CHN), 1.86–
1.77 (m, 1H, CH2CH’H”CHN), 1.48–1.40 (m, 20H, (O)CCH2CH2CH2CH, 2 x C(CH3)3);
13C-NMR (101 MHz, DMSO-d6): δ 174.6, 171.0, 152.0, 83.0, 57.7, 52.5, 33.6, 29.1, 27.9, 21.5;
MS (ESI) m/z: calcd. for C17H29NNaO8+ [M + Na]+ 398.2, found 398.6; HRMS (ESI) m/z:
calcd. for C17H29NNaO8+ [M + Na]+ 398.1791, found 398.1797; [a]22D - 33.6°(c 1.00, MeOH).
6-Benzyl 1-methyl (S)-2-(bis(tert-butoxycarbonyl)amino)hexanedioate (3.58)
(S)
N O
OO
O
O
OO
O
In a round-bottomed flask containing a magnetic stirring bar,
α,β-conjugated benzyl ester 3.56 (6.48 g, 17.8 mmol, 1.0 equiv.)
was placed under vacuum for an hour before a nitrogen atmo-
sphere was established and dissolved in MeOH (54.3 mL), fol-
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lowed by the addition of Ph2S (29.8 µL, 0.178 mmol, 0.01 equiv.) and 10% Pd/C (648
mg, 10wt%). Two vacuum/hydrogen cycles were performed before hydrogen was bub-
bled through the solution over 30 min. The reaction mixture was stirred under hydrogen
for 36 h. The reaction mixture was filtered twice through a pad of Celite®, and washed
thoroughly with CH2Cl2 and concentrated under reduced pressure each time. This af-
forded the benzyl ester 3.58 as a clear oil (6.28 g, 97%). Rf = 0.56 (EtOAc:heptane (1:1);
UV); IR (neat) ν (cm – 1): 2979, 2951, 1736, 1699, 1456, 1136; 1H-NMR (400 MHz, CDCl3): δ
7.38–7.29 (m, 5H, ArH), 5.11 (s, 2H, ArCH2O), 4.87 (dd, J = 9.5, 5.1 Hz, 1H, CH’H”CHN),
3.70 (s, 3H, C(O)OCH3), 2.47–2.33 (m, 2H, (O)CCH2CH2), 2.18–2.09 (m, 1H, CH’H”CHN),
1.99–1.89 (m, 2H, CH’H”CHN), 1.75–1.67 (m, 2H, (O)CCH2CH2CH2CH), 1.48 (s, 18H, 2
x C(CH3)3); 13C-NMR (101 MHz, CDCl3): δ 173.1, 171.3, 152.2, 136.1, 128.7, 128.3 (two
overlapping signals), 83.3, 66.3, 57.9, 52.3, 34.0, 29.5, 28.1, 21.8; HRMS (ESI) m/z: calcd. for
C14H20NO4+ [M - 2 x Boc + 3 x H]+ 266.1387, found ?; MS (ESI) m/z: calcd. for C14H20NO4+
[M - 2 x Boc + 3 x H]+ 266.1, found 266.6; [a]22D - 32.0°(c 1.00, CHCl3).
Benzyl 3-bromopropanoate (3.61)197
Br
O
O
In a flame-dried round-bottomed flask containing a magnetic stir-
ring bar and equipped with a Dean-Stark and a condenser, 3-
bromopropionic acid (7.50 g, 49.0 mmol, 1.0 equiv.), BnOH (5.48 mL,
52.7 mmol, 1.1 equiv.), and p-TsOH (466 mg, 2.45 mmol, 0.05 equiv.) were stirred in
toluene (52.7 mL) under a nitrogen atmosphere at reflux. When full conversion was ob-
served by TLC and LCMS (6.5 h), volatiles were removed under reduced pressure, and
the crude was directly purified by DCVC (heptane→ EtOAc:heptane 5:95) to obtain ben-
zyl 3-bromopropanoate as a clear oil (10.0 g, 84%). Spectral data in correspondence with
reported literature values.197 1H-NMR (400 MHz, DMSO-d6): δ 7.39–7.32 (m, 5H, ArH),
5.15 (s, 2H, OCH2Ar), 3.67 (t, J = 6.3 Hz, 2H, BrCH2CH2C(O)), 3.03 (t, J = 6.3 Hz, 2H,
BrCH2CH2C(O)).
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Dimethyl (2S)-2-(bis-tert-butoxycarbonylamino)pentane-1,5-dioate (3.63)143
(S)
O
O
NO
O
O
O
O
O
In a round-bottomed flask containing a magnetic stirring bar, (Boc)O2
(18.56 g, 85.0 mmol, 1.2 equiv.) was added to a solution of dimethyl
L-glutamate hydrochloride 3.62 (15.0 g, 70.9 mmol, 1.0 equiv.) in a
solvent mixture of sat. NaHCO3 (aq., 94.0 mL) and dioxane (94.0 mL)
and stirred overnight. The solution was extracted with EtOAc (3 x 300 mL). The combined
organic layer were dried over Na2SO4, filtered, and concentrated in vacuo. The crude
mono-Boc protected intermediate was placed under vacuum for a couple of hours, before
a nitrogen atmosphere was established. The crude oil was dissolved in MeCN (118 mL)
followed by the addition of DMAP (1.73 g, 14.2 mmol, 0.2 equiv.) and (Boc)2O (26.3 g, 120
mmol, 1.7 equiv.) were added and stirred overnight. The resulting red reaction mixture
was evaporated to dryness. The title compound (23.9 g, 90%) was obtained as a white
solid by DCVC (heptane → EtOAc:Heptane 1:9). Spectral data in correspondence with
reported literature values.143 1H-NMR (400 MHz, CDCl3): δ 4.95–4.91 (dd, J = 9.4, 4.6
Hz, 1H, CH’H”CHN), 3.71 (s, 3H, CH3O(O)CCH), 3.67 (s, 3H, CH3O(O)CCH2), 2.53–2.34
(m, 3H, CH3O(O)CCH2, CH’H”CHN), 2.23–2.14 (m, 1H, CH’H”CHN), 1.49 (s, 18H, 2 x
C(CH3)3); [a]22D - 39.0°(c 2.15, CHCl3); lit. [a]
25
D - 37.2°(c 2.15, CHCl3).
Methyl (S)-2-(di-tert-butoxycarbonylamino)-5-oxopentanoate (3.60)143
(S)
O
O
N O
O
O
O
O
H
In an oven-dried round-bottomed flask containing a magnetic stirring
bar, DIBAL-H (1.0 M in toluene, 8.79 mL, 8.79 mmol, 1.1 equiv.) was
added dropwise over a period of 30 min to a solution of the di-Boc
methyl ester (3.63 (3.00 g, 7.99 mmol, 1.0 equiv.) in dry Et2O (79.9 mL)
at -78 °C. The reaction mixture was stirred for a further 30 min, before it was quenched
by the addition of H2O (1.00 mL, 55.9 mmol, 7 equiv.)followed by 30 min stirring. The
solution was dried over MgSO4 and filtered through a pad of Celite® and concentrated
in vacuo. Nine identical reactions were combined and purified by one flash column
chromatography (EtOAc:Heptane 1:9 → 2:3) to afford the di-Boc aldehyde 3.60 (21.1 g,
85%) as a clear oil, that forms a semi solid over time. Spectral data in correspondence
with reported literature values.143 1H-NMR (400 MHz, CDCl3): δ 9.77 (s, 1H, OHC),
4.88 (dd, J = 9.5, 5.1 Hz, 1H, CH’H”CHN), 3.72 (s, 3H, C(O)OCH3), 2.63–2.45 (m, 3H,
OHCCH2CH’H”CH), 2.20–2.11 (m, 1H, CH’H”CH), 1.49 (s, 18H, 2 x C(CH3)3); [a]22D - -38.0
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°(c 1.0, CHCl3); lit. [a]25D - 35.3°(c 2.3, CHCl3).
1-Benzyl 7-methyl (S,E)-6-(di(tert-butoxycarbonyl)amino)hept-2-enedioate (3.64)
(S)(E)
O O
O
NO
O
O
O
O
In an oven-dried round-bottomed flask containing a magnetic
stirring bar, benzyl(triphenylphosphoranylidene)acetate (37.6
g, 91.6 mmol, 1.5 equiv.) was added to a stirring solution of di-
Boc aldehyde 3.60 (21.1 g, 61.1 mmol, 1 equiv.) in THF (156.7
mL) and refluxed overnight under a nitrogen atmosphere. The reaction mixture was
cooled to rt and diluted by the addition of sat. NH4Cl (aq., 500 mL) and extracted with
EtOAc (3 x 500 mL). The combined organic phases were dried over Na2SO4, filtered,
and concentrated in vacuo. The residues were purified by flash column chromatography
(heptane→ EtOAc:heptane 3:7) providing α,β-conjugated benzyl ester 3.64 (26.8 g, 92%)
as a clear oil. Rf = 0.26 (EtOAc:heptane (1:4); UV); R (neat) ν (cm
– 1): 2980, 2951, 1745, 1717,
1455, 1138; 1H-NMR (400 MHz, CDCl3): δ 7.37–7.32 (m, 5H, ArH), 7.00 (dt, J = 15.7, 6.5
Hz, 1H, O(O)CCHC(E)HCH2), 5.90 (d, J = 15.7 Hz, 1H, O(O)CC(E)HCHCH2), 5.17 (s, 2H,
ArCH2O), 4.86 (dd, J = 9.0, 4.1 Hz, 1H, CH’H”CHN), 3.71 (s, 3H, C(O)OCH3), 2.33–2.25
(m, 3H, CH2CH’H”CHN), 2.10–2.02 (m, 1H, CH2CH’H”CHN), 1.48 (s, 18H, 2 x C(CH3)3);
13C-NMR (101 MHz, CDCl3): δ 171.1, 166.3, 152.2, 148.4, 136.2, 128.7, 128.3, 128.3, 121.9,
83.5, 66.2, 57.6, 52.4, 29.1, 28.5, 28.1; MS (ESI) m/z: calcd. for C25H35NNaO8+ [M + Na]+
500.2, found 500.7; [a]22D - 28.0°(c 1.0, CHCl3).
(S)-6-(bis(tert-butoxycarbonyl)amino)-7-methoxy-7-oxoheptanoic acid (3.65)
(S)
NO
O
O
O
O
O
O
HO
In a round-bottomed flask containing a magnetic stirring bar, α,β-
conjugated benzyl ester 3.64 (6.52 g, 13.7 mmol, 1.0 equiv.) was
placed under vacuum for an hour before a nitrogen atmosphere
was established and dissolved in iPrOH (68.3 mL), and added
Pd(OAc)2 (77.9 mg, 0.3470 mmol, 0.025 equiv.) and charcoal (690 mg, Pd(OAc)2:charcoal
10:90 (wt:wt)). Two vacuum/hydrogen cycles were performed before hydrogen was bub-
bled through the solution over 45 min. The reaction mixture was stirred under a hydro-
gen atmosphere overnight. The reaction mixture was filtered through a pad of Celite®,
and washed thoroughly with CH2Cl2 and concentrated under reduced pressure. This
afforded the saturated carboxylic acid 3.58 as a clear oil (5.13 g, 96%). A trace amount
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CH2Cl2 was observed by 1H-NMR. Rf = 0.25 (CH2Cl2:MeOH (95:5); KMnO4); IR (neat) ν
(cm – 1): 3194, 2980, 2939, 1738, 1703, 1367, 1134; 1H-NMR (400 MHz, DMSO-d6): δ 11.99
(br. s, 1H, HOOC), 4.81 (dd, J = 9.9, 5.0 Hz, 1H, CH’H”CHN), 3.62 (s, 3H, C(O)OCH3),
2.18 (t, J = 7.3 Hz, 2H, CH’H”CHN), 2.01–1.92 (m, 1H, HO(O)CCH2), 1.83–1.73 (m, 1H,
CH2CH’H”HCHN), 1.55–1.37 (m, 20H, 2 x C(CH3)3, HO(O)CCH2CH2), 1.31–1.20 (m, 2H,
CH2CH2CHN); 13C-NMR (101 MHz, DMSO-d6): δ 174.3, 170.6, 151.6, 82.5, 57.4, 52.0, 33.5,
29.0, 27.5, 25.0, 24.1; MS (ESI) m/z: calcd. for C18H31NNaO8+ [M + Na]+ 412.2, found 412.6;
[a]22D - -31.0°(c 1.00, MeOH).
7-Benzyl 1-methyl (S)-2-(bis(tert-butoxycarbonyl)amino)heptanedioate (3.66)
(S)
O
O
O
O
NO
O
O
O
In a round-bottomed flask containing a magnetic stirring bar,
α,β-conjugated benzyl ester 3.64 (8.89 g, 18.6 mmol, 1.0 equiv.)
was placed under vacuum for two hour before a nitrogen at-
mosphere was established and dissolved in MeOH (74.4 mL)
followed by the addition of Ph2S (31.2 µL, 0.186 mmol, 0.01 equiv.) and 10% Pd/C (889
mg, 10wt%). Two vacuum/hydrogen cycles were performed before hydrogen was bub-
bled through the solution over 30 min. The reaction mixture was stirred under a hydrogen
atmosphere for 36 h. The reaction mixture was filtered twice through a pad of Celite®, and
washed thoroughly with CH2Cl2 and concentrated under reduced pressure each time.
This afforded the benzyl ester 3.66 as a clear oil (8.54 g, 96%). Rf = 0.60 (EtOAc:heptane
(1:1); UV); IR (neat) ν (cm – 1): 2979, 2937, 2871, 1736, 1699, 1456, 1133; 1H-NMR (400 MHz,
CDCl3): δ 7.38–7.30 (m, 5H, ArH), 5.10 (s, 2H, ArCH2O), 4.84 (dd, J = 9.4, 5.2 Hz, 1H,
CH’H”CHN), 3.70 (s, 3H, C(O)OCH3), 2.36 (t, J = 7.6 Hz, 2H, (O)CCH2), 2.17–2.08 (m, 1H,
CH’H”CHN), 1.93–1.83 (m, 1H, CH’H”CHN), 1.73–1.62 (m, 2H, CH2CH2CH2CH’H”CH),
1.48 (s, 18H, 2 x C(CH3)3), 1.42–1.34 (m, 2H, CH2CH2CH2CH’H”CHN); 13C-NMR (101
MHz, CDCl3): δ 173.4, 171.4, 152.2, 136.2, 128.7, 128.3, 128.3, 83.2, 66.3, 58.1, 52.3, 34.3,
29.8, 28.1, 26.0 24.7; MS (ESI) m/z: calcd. for C15H22NO4+ [M + 3 x H - 2 x Boc]+ 280.2, found
280.6; HRMS (ESI) m/z: calcd. for C25H37NNaO8+ [M + Na]+ 502.2411, found 502.2427.
[a]22D - 28.0°(c 1.00, CHCl3).
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Benzyl glycine TFA salt (3.68)
F3CCOOHH2N
O
O
In a flame-dried round-bottomed flask containing a magnetic
stirring bar, Cs2CO3 (18.6 g, 57.1 mmol, 1.0 equiv.) was added
to a stirring solution of (tert-butoxycarbonyl)glycine 3.67 (10.0
g, 57.1 mmol, 1.0 equiv.) in DMF (114 mL) at 0 °C and left for 60 min before BnBr
(6.45 mL, 54.2 mmol, 0.95 equiv.) was added followed by a further 30 min at this tem-
perature before leaving it overnight at rt. The reaction mixture was poured into H2O
(400 mL) and extracted with heptane (4 x 100 mL). Precipitation of (S)-5-(benzyloxy)-4-
((tert-butoxycarbonyl)amino)-5-oxopentanoic acid was observed during extraction and
collected by filtration. The combined organic phases were stored in the fridge overnight
and a second crop was collected. (S)-5-(Benzyloxy)-4-((tert-butoxycarbonyl)amino)-5-
oxopentanoic acid (11.6673 g) was dissolved in TFA:CH2Cl2 (1:10) (227 mL). When full
conversion was observed by TLC and LCMS (7 h), the reaction mixture was concentrated
under reduced pressure, and co-evaporated from toluene and two times CH2Cl2. This
afforded 3.68 as a off-white solid (11.6 g, 77%). Rf = 0.81 (CH2Cl2:MeOH (95:5); UV); IR
(neat) ν (cm – 1): 3324, 3066, 2981, 2936, 1749, 1681, 1540, 1169; 1H-NMR (400 MHz, DMSO-
d6): δ 8.33 (s, 3H, H3NCH2), 7.43–7.34 (s, 5H, ArH), 5.24 (s, 2H, OCH2Ar), 3.90 (s, 2H,
H3NCH2); 13C-NMR (101 MHz, ): δ 167.6, 135.2, 128.5, 128.4, 128.2, 66.8, H3NCH2 under
DMSO-d6); MS (ESI) m/z: calcd. for C9H12NO2+ [M + H - TFA]+ 166.1, found 166.0;
Benzyl acetyl-leucylglycinate (3.69a)
H
N
O
O
N
H
O
O
According to the general procedure for coupling reagent acyla-
tion, HATU (14.9 g, 39.4 mmol, 1.1 equiv.) and DIPEA (37.4 mL,
0.215 mol, 6.0 equiv.) were added to a stirring solution of N-
acetyl-L-leucine (7.44 g, 43.0 mmol, 1.2 equiv.) in DMF (358 mL)
and stirred for 25 min, before the crude TFA salt 3.68 was added and stirred overnight.
The reaction mixture was diluted with EtOAc (500 mL) and H2O (300 mL), and the or-
ganic layer was washed with brine (3 x 300 mL), sat. NaHCO3 (aq., 300 mL), and brine (25
mL). The combined organic phases were dried over Na2SO4, filtered, and concentrated in
vacuo. Racemic benzyl acetyl-leucylglycinate 3.69a was isolated by flash column chro-
matography (CH2Cl2:MeOH 95:5) as a white solid (8.96 g, 78%). A trace amount of impu-
rities were observed by 1H-NMR. 1H-NMR (400 MHz, CDCl3): δ 7.39–7.31 (m, 5H, ArH),
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6.81 (t, J = 5.0 Hz, 1H, NHCH2C(O)OBn), 6.09 (d, J = 8.2 Hz, 1H, CH3C(O)NHCH), 5.16 (s,
2H, OCH2Ar), 4.54–4.48 (m, 1H, CH3C(O)NHCHC(O)), 4.11–3.98 (m, 2H, NHCH2C(O)),
1.98 (s, 3H, CH3C(O)NH), 1.72–1.59 (m, 2H, NHCHCH’H”CH(CH3)2, CHCH2CH(CH3)2),
1.56–1.41 (m, 1H, CHCH’H”CHCH3), 0.92 (t, J = 6.3 Hz, 6H, CH(CH3)2); [a]22D + 0.002°(c
1.00, CHCl3).
Benzyl acetyl-L-leucylglycinate (3.69)
(S)
O
H
NN
H
O O
O
According to the general procedure for Boc-deprotection, benzyl
(tert-butoxycarbonyl)-L-leucylglycinate 3.76 (26.4 g, 69.6 mmol,
1.0 equiv.) was stirred in TFA:CH2Cl2 (3:7) (279 mL). The TFA salt
was placed under vacuum for a couple of hours before a nitrogen
atmosphere was introduced and dissolved in CH2Cl2 (126 mL). Subsequently, DIPEA
(36.4 mL, 0.209 mol, 3.0 equiv.) and Ac2O (9.90 mL, 0.104 mol, 1.5 equiv.) were added
and stirred overnight. The reaction mixture was concentrated under reduced pressure.
The residues were taken up in EtOAc (500 mL), and washed with with 1.0 M HCl (aq.,
2 x 250 mL), sat. NaHCO3 (aq., 2 x 250 mL), and brine (250 mL). The organic phase
was dried over Na2SO4, filtered, and concentrated in vacuo. The acetylated dipeptide
3.69 was purified by flash column chromatography (CH2Cl2 → CH2Cl2:MeOH 98:2) as
a off-white solid (21.2 g, 95%). Spectral data in correspondence with reported litera-
ture values.174 1H-NMR (400 MHz, CDCl3): δ 7.39–7.31 (m, 5H, ArH), 6.83 (t, J = 5.3 Hz,
1H, NHCH2C(O)OBn), 6.10 (d, J = 8.2 Hz, 1H, CH3C(O)NHCH), 5.16 (s, 2H, OCH2Ar),
4.55–4.49 (m, 1H, CH3C(O)NHCHC(O)), 4.11–3.98 (m, 2H, NHCH2C(O)), 1.98 (s, 3H,
CH3C(O)NH), 1.72–1.60 (m, 2H, NHCHCH’H”CH(CH3)2, CHCH2CH(CH3)2), 1.57–1.48
(m, 1H, CHCH’H”CHCH3), 0.92 (t, J = 6.3 Hz, 6H, CH(CH3)2); [a]22D - 56.5°(c 1.00, CHCl3).
Benzyl (tert-butoxycarbonyl)-L-leucylglycinate (3.76)
(S)
O
H
NN
H
O
O O
O
In a round-bottomed flask containing a magnetic stir-
ring bar, 2,5-dioxopyrrolidin-1-yl (tert-butoxycarbonyl)-L-
leucinate (26.9 g, 81.8 mmol, 1.1 equiv.) was added to solu-
tion of benzyl glycinate hydrochloride (15.0 g, 74.4 mmol, 1.0
equiv.) and NaHCO3 (13.7 g, 0.164 mmol, 2.2 equiv.) in H2O:dioxane (3:7) (434 mL) and
stirred overnight. The reaction mixture was extracted with EtOAc (3 x 500 mL). The com-
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bined organic phases were dried over Na2SO4, filtered, and concentrated in vacuo. The
residues were by flash column chromatography (EtOAc:heptane 2:8→ 4:6) to afford 3.76
it as a high viscosity clear oil (26.5 g, 94%). Rf = 0.38 (EtOAc:heptane (1:1); KMnO4); IR
(neat) ν (cm – 1): 3304, 3034, 2956, 2935, 1749, 1659, 1519, 1455, 1163; 1H-NMR (400 MHz,
CDCl3): δ 7.38–7.31 (s, 5H, ArH), 6.75 (br. s, 1H, (O)CNHCH2), 5.17 (s, 2H, OCH2Ar), 4.94
(d, J = 8.2 Hz, 1H, O(O)CNHCH), 4.17 (m, 1H, O(O)CNHCH), 4.07 (dd, J = 5.4, 1.9 Hz,
2H, NHCH2C(O)OCH2), 1.69–1.66 (m, 2H, CHCH’H”CHCH3, CHCH2CH(CH3)2), 1.50–
1.43 (m, 10H, CHCH’H”CHCH3, C(CH3)3), 0.93 (m, 6H, CH(CH3)2); 13C-NMR (101 MHz,
CDCl3): δ 173.0, 169.7, 155.6, 135.3, 128.8, 128.7, 128.5, 80.3, 67.3, 53.0, 41.4, 28.4, 24.8, 23.1,
22.0; MS (ESI) m/z: calcd. for C20H31N2O5+ [M + H]+ 379.2, found 379.7; [a]22D - 26.6°(c 1.00,
CHCl3).
Methyl (2S)-2-(bis(tert-butoxycarbonyl)amino)-5-((1-(4,5-dimethoxy-2-nitro-
phenyl)ethoxy)imino)pentanoate (3.77)
N
(S)
N
O
NO2
OMe
MeO
O
O
O
O
O
O
In a round-bottomed flask containing a magnetic stirring bar, the hy-
drochloride hydroxylamine 2.7 (3.73 g, 13.4 mmol, 1.0 equiv.) was
added to a stirring solution of the aldehyde 3.60 (4.62 g, 13.4 mmol,
1.0 equiv.) in pyridine (83.7 mL) and stirred overnight. The reaction
mixture was concentrated under reduced pressure and co-evaporated
with heptane. The residues were taken up in sat. NH4Cl (aq., 250 mL)
and extracted with EtOAc (3 x 250 mL). The combined organic phases were dried over
Na2SO4, filtered, and concentrated in vacuo. The residues were purified by flash column
chromatography (EtOAc:heptane 1:9 → 1:3) to provide the oxime 3.77 (6.58 g, 86%) as
a neon green oil. A diastereomeric mixture of 1:1 ratio was observed in the NMR spec-
tra. Two resonances for nuclei denoted with a star(*) were observed and both chemical
shifts are reported. Multiplicity for each diastereomer is reported if possible. Rf = 0.16
(EtOAc:Heptane (1:3); UV); IR (neat) ν (cm – 1): 2979, 2936, 1744, 1699, 1518, 1455, 1366,
1334, 1270; 1H-NMR (400 MHz, DMSO-d6): δ 7.58–7.55* (m, 1.5H, ArH, 0.5 x ONCHCH2),
7.02/6.95* (m, 1H, ArH), 6.80–6.75* (m, 0.5H, 0.5 x ONCHCH2), 5.68–5.59 (m, 1H,
ArCHCH3), 4.92–4.87/4.79–4.74* (m, 1H, CH2CHC(O)), 3.87–3.84 (m, 6H, 2 x OCH3),
3.64/3.61–3.60 (m, 3H, C(O)OCH3), 2.39–2.30 (m, 1H, CH’H”CHC(O)OCH3), 2.26–1.72
(m, 3H, CH2CH’H”CHC(O)OCH3), 1.53–1.49 (m, 3H, ArCHCH3), 1.42–1.37 (m, 18H, 2 x
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C(CH3)3); 13C-NMR (101 MHz, DMSO-d6): δ MS (ESI) m/z: calcd. for C26H39N3NaO11+
[M + Na]+ 592.2, found 592.8; HRMS (ESI) m/z: calcd. for C26H39N3NaO11+ [M + Na]+
592.2477, found 592.2498.
tert-Butyl ((2S)-5-(N-(1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)cyclopropanecarbox-
amido)-1-oxo-1-(phenylamino)pentan-2-yl)carbamate (3.82)
NH
(S)
N
O
NO2
OMe
MeO
O
O
N
HO
O
According to the general procedure for oxime reduction,
NaBH3CN (583 mg, 9.27 mmol, 2.0 equiv.) was added to a
stirring cold solution of 3.77 (2.64 g, 4.64 mmol, 1.0 equiv.) in
MeOH (18.5 mL) at 0 °C and subsequently pH was adjusted
to pH < 3 with TFA. After 25 min at rt, the reaction mixture
was quenched by the addition of sat. NaHCO3 (aq., 50 mL)
and volatiles were removed under reduced pressure. The residues were dissolved in
EtOAc (200 mL) and washed with sat. NaHCO3 (aq.) (3 x 200 mL), dried over Na2SO4,
filtered, and concentrated in vacuo. The crude mono N-alkylated hydroxylamine was
placed under vacuum with a magnetic stirring bar for an hour before a nitrogen at-
mosphere was established. According to the general procedure for acid chloride acy-
lation, pyridine (3.73 mL, 46.4 mmol, 10.0 equiv.) and cyclopropanecarbonyl chloride
(421 µL, 4.64 mmol, 1.0 equiv.) were added to a cold solution of the N-alkylated hydrox-
ylamine in CH2Cl2 (21.2 mL) at 0 °C. After 1.5 h at rt, the concentrated reaction mixture
was washed added sat. NH4Cl (aq.) (100 mL) and washed with CH2Cl2 (3 x 100 mL).
The organic phase was dried over Na2SO4, filtered, and concentrated in vacuo. Accord-
ing to the general procedure for Boc-deprotection, the di-Boc protected compound was
stirred in TFA:CH2Cl2 (3:7) (73.8 mL) overnight. The following day, volatiles were re-
moved under reduced pressure and co-evaporated from toluene and CH2Cl2. According
to the general procedure for one-pot LiOH hydrolysis and Boc-protection, LiOH (777
mg, 32.5 mmol, 7.0 equiv.) was added to a stirring solution of the crude TFA salt in
THF:H2O (4:1) (116 mL). After 2.5 h, Boc2O (2.02 g, 9.72 mmol, 2.0 equiv.) was added.
After 2.0 h, the reaction mixture was diluted with EtOAc (100 mL), and pH adjusted to
≈ 3-4 by the addition of 1.0 M HCl (aq., 31.0 mL), and extracted with EtOAc (2 x 100
mL). The combined organic phases were dried over Na2SO4, filtered, and concentrated in
vacuo. The Boc-protected carboxylic acid was purified by flash column chromatography
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(CH2Cl2 → CH2Cl2:MeOH 47:3) and placed under vacuum for a couple of hours before
a nitrogen atmosphere was established. According to the general procedure for TBTU-
DIPEA aniline amidation, TBTU (1.67 g, 5.72 mmol, 1.1 equiv.) was added to a stirring
solution of the N-protected amino acid in CH2Cl2 (24.6 mL). After 5 min, DIPEA (5.43
mL, 31.2 mmol, 6.7 equiv.) and aniline (521.0 µL, 5.72 mmol, 1.2 equiv.) were added
and stirred overnight. The reaction mixture was concentrated under reduced pressure,
and the residues were taken up in EtOAc (50 mL) and washed with H2O (50 mL), sat.
NaHCO3 (aq., 50 mL), 1.0 M HCl (aq., 2 x 50 mL), and brine (10 mL). The organic phase
was dried over Na2SO4, filtered, and concentrated in vacuo. The residues were purified by
flash column chromatography (EtOAc:heptane 2:3 → 11:9) to provide 3.82 (2.20 g, 79%)
as a green semi-sold. A trace amount of CH2Cl2 and EtOAc were observed by 1H-NMR.
A diastereomeric mixture of 1:1 ratio was observed in the NMR spectra. Two resonances
for nuclei denoted with a star(*) were observed and both chemical shifts are reported.
Multiplicity for each diastereomer is reported if possible. Rf = 0.25 (EtOAc:heptane (2:3);
UV); IR (neat) ν (cm-1): 3304, 2978, 2935, 2858, 1671, 1601, 1517, 1442, 1366, 1272; 1H-NMR
(400 MHz, DMSO): δ 9.88 (s, 1H, C(O)NHPh), 7.58–7.53 (m, 3H, ArH), 7.32–7.27 (m,
3H, ArH), 7.06–6.99 (m, 2H, ArH, CHNHC(O)O), 5.55 (q, J = 6.4 Hz, 1H, ArCHCH3),
4.03 (m, 1H, CH2CHNHC(O)O), 3.90/3.88* (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.62–
3.59 (m, 1H, C(O)NCH’H”CH2), 3.20–3.12 (m, 1H, C(O)NCH’H”CH2), 2.10–2.02 (m, 1H,
– CH2CH2 – CHC(O)), 1.62–1.50 (m, 7H, C(O)NCH’H”CH2CH2CHNH, ArCHCH3), 1.37
(s, 9H, C(CH3)3); 0.80–0.61 (m, 4H, – CH2CH2 – CHC(O)); 13C-NMR (101 MHz, DMSO): δ
174.6 (observed by HMBC), 171.0, 155.4, 152.88/152.85*, 148.2, 140.9/140.8*, 138.9, 130.3,
128.7, 123.3, 119.1, 109.7, 107.38/107.35*, 78.1, 76.5, 56.25/56.20*, 56.1, 54.7, 46.6, 29.2,
28.2, 23.2, 20.65/20.58*, 10.5, 7.9, 7.7; MS (ESI) m/z: calcd. for C30H41N4O9+ [M + H]+
601.3, found 601.8;
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Methyl (2S)-2-(bis(tert-butoxycarbonyl)amino)-6-((1-(4,5-dimethoxy-2-nitrophe-
nyl)ethoxy)imino)hexanoate (3.83)
(S)N
O
NO2
OMe
MeO
N O
O
O
O
O
O
In an oven-dried round-bottomed flask containing a magnetic
stirring bar, DIBAL-H (1 M in toluene, 5.27 mL, 5.27 mmol, 1.1
equiv.) was added dropwise over a period of 30 min to a so-
lution of the benzyl ester 3.58 (2.23 g, 4.79 mmol, 1.0 equiv.)
in Et2O (47.9 mL) at -78 °C under a nitrogen atmosphere.
The reaction mixture was stirred for additional 30 min, be-
fore quenched by the addition of H2O (604 µL, 33.5 mmol, 7.0
equiv.) followed by 30 min stirring. The solution was dried over MgSO4 and filtered
through a pad of Celite® and concentrated in vacuo. Hydrochloride hydroxylamine 2.7
(1.34 g, 4.79 mmol, 1.0 equiv.) was added to the crude aldehyde in pyridine (29.9 mL)
and stirred overnight. The reaction mixture was concentrated under reduced pressure
and co-evaporated with heptane. The residues were taken up in sat. NH4Cl (aq., 150 mL)
and extracted with EtOAc (3 x 150 mL). The combined organic phases were dried over
Na2SO4, filtered, and concentrated in vacuo. The residues were purified by flash column
chromatography (EtOAc:heptane 1:3→ 2:3) to provide the oxime 3.83 (5.01 g, 84%) as a
neon green oil. MS (ESI) m/z: calcd. for C27H41N3NaO11+ [M + H]+ 606.3, found 606.9.
Methyl (2S)-2-((tert-butoxycarbonyl)amino)-7-((1-(4,5-dimethoxy-2-nitrophe-
nyl)ethoxy)imino)heptanoate (3.84)
(S)
N
O
NO2
OMe
MeO
NO
O
O
O
O
O
In an oven-dried round-bottomed flask containing a magnetic
stirring bar, DIBAL-H (1 M in toluene, 9.91 µL, 9.91 mmol, 1.1
equiv.) was added dropwise over a period of 30 min to a so-
lution of the benzyl ester 3.66 (4.32 g, 9.01 mmol, 1.0 equiv.)
in Et2O (90.1 mL) at -78 °C under a nitrogen atmosphere.
The reaction mixture was stirred for additional 30 min, before
quenched by the addition of H2O (1.14 mL, 63.1 mmol, 7.0 equiv.) followed by 30 min
stirring. The solution was dried over MgSO4 and filtered through a pad of Celite® and
concentrated in vacuo. Hydrochloride hydroxylamine 2.7 (2.51 g, 9.02 mmol, 1.0 equiv.)
was added to the crude aldehyde in pyridine (56.3 mL) and stirred overnight. The reac-
tion mixture was concentrated under reduced pressure and co-evaporated with heptane.
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The residues were taken up in sat. NH4Cl (aq., 150 mL) and extracted with EtOAc (3 x 150
mL). The combined organic phases were dried over Na2SO4, filtered, and concentrated in
vacuo. The residues were purified by flash column chromatography (EtOAc:heptane 1:4
→ 3:2) to provide the oxime 3.84 (4.23 g, 79%) as a neon green oil. MS (ESI) m/z: calcd. for
C28H43N3NaO11+ [M + H]+ 620.3, found 620.9.
tert-butyl ((2S)-6-(N-(1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)butyramido)-1-oxo-1-
(phenylamino)hexan-2-yl)carbamate (3.85)
(S)N
O
NO2
OMe
MeO
O
NHO
O
O
H
N
According to the general procedure for oxime reduction,
NaBH3CN (474 mg, 7.54 mmol, 2.0 equiv.) was added to
a stirring cold solution of decomposed 3.83 (2.20 g, 3.77
mmol, 1.0 equiv.) in MeOH (15.1 mL) at 0 °C and subse-
quently pH was adjusted to pH < 3 with TFA. After 1.25
min at rt, the reaction mixture was quenched by the addi-
tion of sat. NaHCO3 (aq., 100 mL) concentrated under re-
duced pressure. The residues were taken up in EtOAc (200 mL) and washed with sat.
NaHCO3 (aq.) (3 x 200 mL), dried over Na2SO4, filtered, and concentrated in vacuo. The
crude mono N-alkylated hydroxylamine was placed under vacuum with a magnetic stir-
ring bar for an hour before a nitrogen atmosphere was established. According to the
general procedure for acid chloride acylation, pyridine (3.04 mL, 37.7 mmol, 10.0 equiv.)
and butyryl chloride (392 µL, 3.77 mmol, 1.0 equiv.) was added to a cold solution of the
N-alkylated hydroxylamine in CH2Cl2 (17.2 mL) at 0 °C. After 1 h, the concentrated reac-
tion mixture was washed added sat. NH4Cl (aq.) (200 mL) and washed with CH2Cl2 (3
x 200 mL). The organic phase was dried over Na2SO4, filtered, and concentrated in vacuo.
According to the general procedure for Boc-deprotection, the di-Boc protected compound
was stirred in TFA:CH2Cl2 (3:7) (59.9 mL) for 3.0 h before volatiles were removed under
reduced pressure and co-evaporated from toluene and CH2Cl2. According to the general
procedure for one-pot LiOH hydrolysis and Boc-protection, LiOH (632 mg, 26.4 mmol,
7.0 equiv.) was added to a stirring solution of the crude TFA salt in THF:H2O (4:1) (94.2
mL). The following day, Boc2O (1.65 g, 7.54 mmol, 2.0 equiv.) was added. After 2.5 h,
the reaction mixture was diluted with EtOAc, and pH adjusted to ≈ 3-4 by the addi-
tion of 1.0 M HCl (aq., 13.0 mL), and extracted with EtOAc (2 x 200 mL). The combined
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organic phases were dried over Na2SO4, filtered, and concentrated in vacuo. The Boc-
protected carboxylic acid was purified by flash column chromatography (CH2Cl2:MeOH
95:5→ 9:1) and placed under vacuum for a couple of hours before a nitrogen atmosphere
was introduced. According to the general procedure for TBTU-DIPEA aniline amidation,
TBTU (529 mg, 1.65 mmol, 1.0 equiv.) was added to a stirring solution of the N-protected
amino acid (892 mg, 1.65 mmol, 1.0 equiv.) in CH2Cl2 (7.8 mL). After 10 min, DIPEA (1.72
mL, 9.88 mmol, 6.0 equiv.) and aniline (165.1 µL, 1.81 mmol, 1.1 equiv.) were added and
stirred overnight. The reaction mixture was evaporated under reduced pressure, and
the organic layer was dissolved in EtOAc (50 mL) and washed with H2O (50 mL), sat.
NaHCO3 (aq., 50 mL), 1.0 M HCl (aq., 2 x 50 mL), and brine (10 mL). The organic phase
was dried over Na2SO4, filtered, and concentrated in vacuo. The residues were purified by
flash column chromatography (EtOAc:heptane 3:7→ 11:9) to provide 3.85 (572 mg, 28%)
as a neon yellow oil. A trace amount of EtOAc and CH2Cl2 were observed by 1H-NMR.
A diastereomeric mixture of 1:1 ratio was observed in the NMR spectra. Two resonances
for nuclei denoted with a star(*) were observed and both chemical shifts are reported.
Multiplicity for each diastereomer is reported if possible. Rf = 0.15 (EtOAc:heptane (3:7);
UV); IR (neat) ν (cm-1): 3306, 2973, 2934, 2871, 1667, 1600, 1517, 1334, 1272; 1H-NMR (400
MHz, DMSO-d6): δ 9.90/9.89* (s, 1H, C(O)NHPh), 7.58–7.52 (m, 3H, ArH), 7.31–7.27 (m,
3H, ArH), 7.05–7.02 (m, 1H, ArH), 6.92 (m, 1H, CHNHC(O)O), 5.45/5.44* (q, J = 6.4 Hz,
1H, ArCHCH3), 4.03–3.96 (overlap with EtOAc) (m, 1H, CH2CHNHC(O)O), 3.92/3.91*
(s, 3H, OCH3), 3.85/3.84* (s, 3H, OCH3), 3.57–3.48 (m, 1H, C(O)NCH’H”CH2), 3.09–2.97
(m, 1H, C(O)NCH’H”CH2), 2.26–2.22 (m, 2H, CH3CH2CH2C(O)N), 1.59–1.14 (m, 20H,
CH3CH2CH2, CH2CH2CH2CHNH, C(CH3)3, ArCHCH3), 0.80/0.79* (t, J = 7.4 Hz, 3H,
CH3CH2); 13C-NMR (101 MHz, DMSO-d6): δ 174.0 (observed by HMBC), 171.7, 155.9,
153.3, 148.6, 141.3/141.2*, 139.5, 131.2, 129.1, 123.6, 119.6, 110.2/110.1*, 107.8, 78.5, 77.5,
56.7 56.57/56.56*, 55.4 46.8, 34.3, 32.0, 28.6, 23.3/23.2*, 21.30/21.27*, 21.22, 18.1, 14.0; MS
(ESI) m/z: calcd. for C31H45N4O9+ [M + H]+ 617.3, found 617.9; HRMS (ESI) m/z: calcd. for
C31H45N4O9+ [M + H]+ 617.3181, found 617.3208.
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tert-Butyl ((2S)-7-(N-(1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)cyclopropanecarbox-
amido)-1-oxo-1-(phenylamino)heptan-2-yl)carbamate (3.86)
(S)
N
O
NO2
OMe
MeO
O
NH
O
O
O
N
H
According to the general procedure for oxime reduction,
NaBH3CN (890 mg, 14.2 mmol, 2.0 equiv.) was added to a
stirring cold solution of decomposed 3.84 (4.23 g, 7.1 mmol,
1.0 equiv.) in MeOH (28.3 mL) at 0 °C and subsequently
pH was adjusted to pH < 3 with TFA. After 20 min at rt,
the reaction mixture was quenched by the addition of sat.
NaHCO3 (aq., 100 mL) concentrated under reduced pressure. The residues were taken
up in EtOAc (200 mL) and washed with sat. NaHCO3 (aq.) (3 x 200 mL), dried over
Na2SO4, filtered, and concentrated in vacuo. The crude mono N-alkylated hydroxylamine
was placed under vacuum with a magnetic stirring bar for an hour before a nitrogen
atmosphere was established. According to the general procedure for acid chloride acyla-
tion, pyridine (5.70 mL, 70.8 mmol, 10.0 equiv.) and cyclopropanecarbonyl chloride (643
µL, 7.08 mmol, 1.0 equiv.) was added to a cold solution of the N-alkylated hydroxylamine
in CH2Cl2 (32.4 mL) at 0 °Cand stirred overnight at rt. The following day, the concentrated
reaction mixture was washed added sat. NH4Cl (aq.) (200 mL) and washed with CH2Cl2
(3 x 200 mL). The organic phase was dried over Na2SO4, filtered, and concentrated in
vacuo. According to the general procedure for Boc-deprotection, the di-Boc protected
compound was stirred in TFA:CH2Cl2 (3:7) (112.7 mL) for 2.5 h before volatiles were re-
moved under reduced pressure and co-evaporated from toluene and CH2Cl2. According
to the general procedure for one-pot LiOH hydrolysis and Boc-protection, LiOH (1.19 g,
49.6 mmol, 7.0 equiv.) was added to a stirring solution of the crude TFA salt in THF:H2O
(4:1) (177.0 mL). After 2.5 h, Boc2O (3.09 g, 14.2 mmol, 2.0 equiv.) was added. After 2 h,
full conversion was not observed, and therefore additional Boc2O (500 mg, 2.29 mmol, 0.3
equiv.) was added and stirred overnight. The reaction mixture was diluted with EtOAc,
and pH adjusted to ≈ 3-4 by the addition of 1.0 M HCl (aq.), and extracted with EtOAc
(2 x 200 mL). The combined organic phases were dried over Na2SO4, filtered, and con-
centrated in vacuo. The Boc-protected carboxylic acid was purified by flash column chro-
matography (CH2Cl2:MeOH 95:5→ 93:7) and placed under vacuum for a couple of hours
before a nitrogen atmosphere was introduced. According to the general procedure for
TBTU-DIPEA aniline amidation, TBTU (1.16 g, 3.61 mmol, 1.0 equiv.) was added to a stir-
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ring solution of the N-protected amino acid (2.00 g, 3.61 mmol, 1.0 equiv.) in CH2Cl2 (17.1
mL). After 10 min, DIPEA (3.77 mL, 21.7 mmol, 6.0 equiv.) and aniline (362 µL, 3.89 mmol,
1.1 equiv.) were added and stirred overnight. The reaction mixture was evaporated under
reduced pressure, and the organic layer was dissolved in EtOAc (50 mL) and washed with
H2O (50 mL), sat. NaHCO3 (aq., 50 mL), 1.0 M HCl (aq., 2 x 50 mL), and brine (10 mL). The
organic phase was dried over Na2SO4, filtered, and concentrated in vacuo. The residues
were purified by flash column chromatography (EtOAc:heptane 2:3 → 1:1) to provide
3.86 (696 mg, 18%) as a pale green foam. A trace amount of impurities and CH2Cl2 were
observed by 1H-NMR. A diastereomeric mixture of 1:1 ratio was observed in the NMR
spectra. Two resonances for nuclei denoted with a star(*) were observed and both chem-
ical shifts are reported. Multiplicity for each diastereomer is reported if possible. Rf =
0.21 (EtOAc:heptane (2:3); UV); IR (neat) ν (cm-1): 3305, 2978, 2935, 2859, 1667, 1600, 1518,
1441, 1366; 1H-NMR (400 MHz, DMSO-d6): δ 9.90 (s, 1H, C(O)NHPh), 7.59–7.53 (m, 3H,
ArH), 7.32–7.26 (m, 3H, ArH), 7.05–6.95 (m, 2H, ArH, CHNHC(O)O), 5.53 (q, J = 6.5 Hz,
1H, ArCHCH3), 4.04–3.98 (m, 1H, CH’H”CHNHC(O)O), 3.91/3.90* (s, 3H, OCH3), 3.85 (s,
3H, OCH3), 3.58–3.51 (m, 1H, C(O)NCH’H”CH2), 3.14–3.04 (m, 1H, C(O)NCH’H”CH2),
2.10–2.04 (m, 1H, – CH2CH2 – CHC(O)), 1.63–1.04 (m, 20H, NCH2CH2CH2CH2CH’H”,
C(CH3)3, ArCHCH3), 0.82–0.63 (m, 4H, – CH2CH2 – CHC(O)); 13C-NMR (101 MHz,
DMSO-d6): δ 174.4 (observed by HMBC), 171.4, 155.5, 152.8, 148.2, 140.97/140.95* (ob-
served by HMBC), 139.3/139.0*, 130.4 (observed by HMBC), 128.7/128.6*, 123.2/123.0*,
119.2/118.9*, 109.8, 107.3, 78.0, 77.1, 56.3, 56.1, 55.0, 47.3 (observed by HSQC), 31.8, 28.2,
26.3, 25.8, 25.3, 20.1, 10.5, 7.9, 7.6; MS (ESI) m/z: calcd. for C32H45N4O9+ [M + H]+ 629.3,
found 629.9; HRMS (ESI) m/z: calcd. for C32H45N4O9+ [M + H]+ 629.3181, found 629.3196.
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N-((S)-4-(2-((S)-2-acetamido-4-methylpentanamido)acetamido)-5-oxo-5-(phenyl-
amino)pentyl)-N-(1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)cyclopropanecarbox-
amide (3.87)
N
(S)N
H O
H
N
OH
N
O
(S)N
H
O
O
NO2
OMe
MeO
O
According to the general procedure for Boc-deprotection, the
Boc-protected aniline amide 3.82 (665 mg, 1.11 mmol, 1.0
equiv.) was stirred in TFA:CH2Cl2 (3:7) (17.6 mL) for 1.5
h. Volatiles were removed under reduced pressure and co-
evaporated from toluene and CH2Cl2. The round-bottomed
flask was placed under vacuum for a couple of hours before a
nitrogen atmosphere was established. According to the gen-
eral procedure for coupling reagent acylation, TBTU (462 mg,
1.44 mmol, 1.3 equiv.) and NEM (974 µL, 7.75 mmol, 7.0 equiv.) were added to a stir-
ring solution of acetyl-L-leucylglycine 3.37 (306 mg, 1.33 mmol, 1.2 equiv.) in DMF (2.0
mL) and stirred for 15 min, before the crude TFA salt in DMF (9.1 mL) was added and
stirred overnight. Incomplete conversion was observed, and therefore a new batch of
acetyl-L-leucylglycine 3.37, TBTU, and NEM were prepared in DMF (2.0 mL) and after
stirring for 15 min added to the reaction mixture followed by stirring overnight. The re-
action mixture was diluted with EtOAc (25 mL), and the organic layer was washed with
brine (5 x 25 mL), sat. NaHCO3 (aq., 25 mL), and 1.0 M HCl (aq., 25 mL). The combined
organic phases were dried over Na2SO4, filtered, and concentrated in vacuo. The photo-
protected tripeptide 3.87 was isolated by flash column chromatography (CH2Cl2:MeOH
99:1 → 23:2) as a light green semi-solid (500 mg, 84%). A trace amount of CH2Cl2 was
observed by 1H-NMR. A diastereomeric mixture of 1:1 ratio was observed in the NMR
spectra. Two resonances for nuclei denoted with a star(*) were observed and both chem-
ical shifts are reported. Multiplicity for each diastereomer is reported if possible. Rf =
0.20 (CH2Cl2:MeOH (19:1); UV); IR (neat) ν (cm-1): 3304, 2978, 2935, 2858, 1671, 1601,
1517, 1442, 1366, 1272; 1H-NMR (400 MHz, DMSO-d6): δ 9.86/9.85* (s, 1H, C(O)NHPh),
8.25 (t, J = 5.6 Hz, 1H, C(O)NHCH2C(O)), 8.06 (d, J = 7.4 Hz, 1H, CH3C(O)NHCH), 8.01–
7.97 (m, 1H, C(O)NHCHC(O)NHPh), 7.61–7.58 (m, 2H, ArH), 7.53/7.52* (s, 1H, ArH),
7.32–7.28 (m, 3H, ArH), 7.07–7.03 (m, 1H, ArH), 5.55 (q, J = 6.4 Hz, 1H, ArCHCH3),
4.38–4.31 (m, 1H, C(O)NHCHC(O)NHPh), 4.25–4.19 (m, 1H, H3C(O)NHCH), 3.89–3.85
(m, 6H, 2 x OCH3), 3.75–3.56 (m, 3H, C(O)NHCH2C(O), CH2CH’H”NC(O)), 3.23–
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3.07 (m, 1H, CH2CH’H”NC(O)), 2.11–2.02 (m, 1H, NC(O)CH – CH2CH2 – ), 1.830/1.827*
(s, 3H, CH3C(O)NH), 1.65–1.40 (m, 10H, CH3C(O)NHCHCH2CH, NHCHCH2CH2CH2,
ArCHCH3), 0.88–0.63 (m, 10H, NC(O)CH – CH2CH2 – , CH(CH3)2); 13C-NMR (101 MHz,
DMSO-d6): δ 174.5, 172.85/172.82*, 170.18/170.16*, 169.6, 168.8, 152.88/152.85*, 148.2,
140.8, 138.7, 130.2, 128.7, 123.5, 119.3, 109.7, 107.4, 77.1, 56.3/56.2*, 56.1, 53.1, 51.4, 46.5
(observed by HSQC) 42.0, 40.6, 29.3/29.2*, 24.1, 23.1/23.0*, 22.9, 22.4, 21.6, 20.65/20.59*,
10.5, 7.9, 7.7; MS (ESI) m/z: calcd. for C35H49N6O10+ [M + H]+ 713.4, found 713.8; HRMS
(ESI) m/z: calcd. for C35H49N6O10+ [M + H]+ 713.3505, found 713.3516.
(2S)-2-(2-((S)-2-acetamido-4-methylpentanamido)acetamido)-6-(N-(1-(4,5-dimethoxy-2-
nitrophenyl)ethoxy)butyramido)-N-phenylhexanamide (3.88)
N
(S)N
H O
H
N
OH
N
O
(S)N
H
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O
NO2MeO
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O
According to the general procedure for Boc-deprotection, the
Boc-protected aniline amide 3.85 (519 mg, 0.84 mmol, 1.0
equiv.) was stirred in TFA:CH2Cl2 (3:7) (13.4 mL) for 1.5
h. Volatiles were removed under reduced pressure and co-
evaporated from toluene and CH2Cl2. The round-bottomed
flask was placed under vacuum for a couple of hours be-
fore a nitrogen atmosphere was established. According to the general procedure for
coupling reagent acylation, TBTU (351 mg, 1.09 mmol, 1.3 equiv.) and NEM (741
µL, 5.89 mmol, 7.0 equiv.) were added to a stirring solution of acetyl-L-leucylglycine
3.37 (233 mg, 1.01 mmol, 1.2 equiv.) in DMF (2.0 mL) and stirred for 15 min, be-
fore the crude TFA salt in DMF (6.4 mL) was added and stirred overnight. The re-
action mixture was diluted with EtOAc (25 mL), and the organic layer was washed
with brine (5 x 25 mL), sat. NaHCO3 (aq., 25 mL), and 1.0 M HCl (aq., 25 mL).
The combined organic phases were dried over Na2SO4, filtered, and concentrated in
vacuo. The photo-protected tripeptide 3.89 was isolated by flash column chromatog-
raphy (CH2Cl2 → CH2Cl2:MeOH 19:1) as a pale green foam (502 mg, 82%). A trace
amount of CH2Cl2 was observed by 1H-NMR. A diastereomeric mixture of 1:1 ratio was
observed in the NMR spectra. Two resonances for nuclei denoted with a star(*) were
observed and both chemical shifts are reported. Multiplicity for each diastereomer is
reported if possible. Rf = 0.24 (CH2Cl2:MeOH (19:1); UV);
1H-NMR (400 MHz, DMSO-
d6): δ 9.88/9.87* (s, 1H, C(O)NHPh), 8.28–8.24 (m, 1H, C(O)NHCH2C(O)), 8.07 (d, J =
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7.4 Hz, 1H, CH3C(O)NHCH), 7.94/7.92* (d, J = 5.1 Hz, 1H, C(O)NHCHC(O)NHPh),
7.60 (m, 2H, ArH), 7.52 (s, 1H, ArH), 7.31–7.27 (m, 3H, ArH), 7.07–7.03 (m, 1H,
ArH), 5.47–5.41 (m, 1H, ArCHCH3), 4.35–4.28 (m, 1H, C(O)NHCHC(O)NHPh), 4.24–
4.19 (m, 1H, H3C(O)NHCH), 3.92/3.90 (s, 3H, OCH3), 3.845/3.843* (s, 3H, OCH3),
3.76–3.65 (m, 2H, C(O)NHCH2C(O)) 3.56–3.48 (m, 1H, CH2CH’H”NC(O)), 3.06–2.99
(m, 1H, CH2CH’H”NC(O)), 2.25–2.22 (m, 2H, NC(O)CH2CH2CH3), 1.833/1.827* (s, 3H,
CH3C(O)NH), 1.66–1.37 (m, 12H, CH3C(O)NHCHCH2CH, NHCHCH2CH2CH2CH’H”,
ArCHCH3, NC(O)CH2CH2CH3), 1.23–1.12 (m, 2H, NHCHCH2CH2CH2), 0.88–0.77 (m,
9H, CH(CH3)2, NC(O)CH2CH2CH3); 13C-NMR (101 MHz, DMSO-d6): δ 174.0, 172.8,
170.39/170.36*, 169.6, 168.8, 152.8, 148.2, 140.8, 138.8, 130.6, 128.7, 123.4, 119.3, 109.7,
107.3, 77.0, 56.2, 56.1, 53.3/53.2*, 51.4, 46.5, 42.0, 40.5, 33.8, 31.6, 26.1, 24.1, 22.9, 22.5,
22.4, 21.6, 20.80/20.77*, 17.6, 13.6; MS (ESI) m/z: calcd. for C36H53N6O10+ [M + H]+ 729.4,
found 729.8.
N-((S)-6-(2-((S)-2-acetamido-4-methylpentanamido)acetamido)-7-oxo-7-(phenyl-
amino)heptyl)-N-(1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)cyclopropanecarboxamide
(3.89)
N
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According to the general procedure for Boc-deprotection,
the Boc-protected aniline amide 3.86 (685 g, 1.09 mmol, 1.0
equiv.) was stirred in TFA:CH2Cl2 (3:7) (17.4 mL) for 1.5
h. Volatiles were removed under reduced pressure and co-
evaporated from toluene and CH2Cl2. The round-bottomed
flask was placed under vacuum for a couple of hours, be-
fore a nitrogen atmosphere was established. According to
the general procedure for coupling reagent acylation, TBTU (455 g, 1.42 mmol, 1.3
equiv.) and NEM (959 µL, 7.62 mmol, 7.0 equiv.) were added to a stirring solution
of acetyl-L-leucylglycine 3.37 (301 mg, 1.30 mmol, 1.2 equiv.) in DMF (2.0 mL) and
stirred for 15 min, before the crude TFA salt in DMF (8.9 mL) was added and stirred
overnight. The reaction mixture was diluted with EtOAc (25 mL), and the organic layer
was washed with brine (5 x 25 mL), sat. NaHCO3 (aq., 25 mL), and 1.0 M HCl (aq.,
25 mL). The combined organic phases were dried over Na2SO4, filtered, and concen-
trated in vacuo. The photo-protected tripeptide 3.89 was isolated by flash column chro-
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matography (CH2Cl2 → CH2Cl2:MeOH 93:7) as a pale green foam (663 mg, 82%). A
trace amount of CH2Cl2 was observed by 1H-NMR. A diastereomeric mixture of 1:1 ra-
tio was observed in the NMR spectra. Two resonances for nuclei denoted with a star(*)
were observed and both chemical shifts are reported. Multiplicity for each diastere-
omer is reported if possible. Rf = 0.21 (CH2Cl2:MeOH (19:1); UV);
1H-NMR (400 MHz,
DMSO-d6): δ 9.87 (s, 1H, C(O)NHPh), 8.30–8.26 (m, 1H, C(O)NHCH2C(O)), 8.08 (d, J
= 7.1 Hz, 1H, CH3C(O)NHCH), 7.91 (d, J = 7.8 Hz, 1H, C(O)NHCHC(O)NHPh), 7.61
(d, J = 8.2 Hz, 2H, ArH), 7.53 (s, 1H, ArH), 7.32–7.28 (m, 3H, ArH), 7.06–7.03 (m, 1H,
ArH), 5.53 (q, J = 6.5 Hz, 1H, ArCHCH3), 4.35–4.30 (m, 1H, C(O)NHCHC(O)NHPh),
4.21 (m, 1H, CH3C(O)NHCH), 3.91/3.90* (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.76–
3.65 (m, 2H, C(O)NHCH2C(O)), 3.58–3.51 (m, 1H, CH2CH’H”NC(O)), 3.14–3.04 (m, 1H,
CH2CH’H”NC(O)), 2.11–2.03 (m, 1H, – CH2CH2 – CHC(O)N), 1.83 (m, 3H, CH3C(O)NH),
1.67–1.09 (m, 14H, CH3C(O)NHCHCH2CH, NHCHCH2CH2CH2CH2, ArCHCH3), 0.88–
0.64 (m, 10H, CH(CH3)2, – CH2CH2 – CHC(O)N); 13C-NMR (101 MHz, DMSO-d6): δ
174.5, 172.8, 170.51/170.48*, 169.6, 168.8, 152.8, 148.2, 141.0, 138.8, 130.3, 128.7, 123.4,
119.3, 109.8, 107.3, 77.2, 56.3, 56.1, 53.4, 51.4, 47.0, 42.1, 40.5, 31.8, 26.3, 25.9, 25.10/25.06*,
24.1, 22.9, 22.4, 21.6, 20.6 10.5, 7.9, 7.6; MS (ESI) m/z: calcd. for C36H51N6O10+ [M + H]+
727.4, found 727.8.
N-(Cyclopropylmethyl)-O-(1-(4,5-dimethoxy-2-nitrophenyl)ethyl)hydroxylamine
(3.90)
OMe
MeO
O
NO2
NH
According to the general procedure for reductive alkylation, cyclo-
propanecarboxaldehyde (670 µL, 8.97 mmol, 1.0 equiv.) and 2.7 (2.00
g, 8.97 mmol, 1 equiv.) in dry EtOH (36.0 mL) at rt afforded the cor-
responding oxime (1 h) that subsequently was reduced by the addition
of NaBH3CN (733 mg, 11.7 mmol, 1.3 equiv.) (4 h). The residues were
purified by a basic work-up and flash chromatography (EtOAc:heptane 1:3) providing
N-alkylated hydroxylamine 3.90 (2.27 g, 85%) as a neon-green oil. A trace amount of
CH2Cl2 was observed by 1H-NMR. Rf = 0.21 (EtOAc:heptane (1:3); UV); IR (neat) ν (cm-1):
3278, 3080, 3001, 2978, 2935, 2913, 2849, 1580, 1513, 1461, 1332, 1267; 1H-NMR (400 MHz,
DMSO-d6): δ 7.54 (s, 1H, ArH), 7.17 (s, 1H, ArH), 6.46 (t, J = 6.3 Hz, 1H, CHCH2NHO),
5.22 (q, J = 6.4 Hz, 1H, ArCHCH3), 3.94 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 2.59 (t, J = 6.3
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Hz, 2H, CHCH2NH), 1.38 (d, J = 6.4 Hz, 3H, ArCHCH3), 0.88–0.78 (m, 1H, CH2CHNH),
0.43–0.33 (m, 2H, – CH’H”CH’H” – ), 0.16–0.04 (m, 2H, – CH’H”CH’H” – ); 13C-NMR
(101 MHz, DMSO-d6): δ 153.4, 147.2, 140.1, 135.7, 108.9, 107.3, 75.6, 56.2, 56.04, 56.01, 21.5,
9.0, 3.4, 3.1; MS (ESI) m/z: calcd. for C14H21N2O5+ [M + H]+ 297.1, found 297.0.
N-(cyclobutylmethyl)-O-(1-(4,5-dimethoxy-2-nitrophenyl)ethyl)hydroxylamine (3.91)
OMe
MeO
O
NO2
NH
According to the general procedure for reductive alkylation, cyclobu-
tanecarboxaldehyde (323 µL, 3.59 mmol, 1.0 equiv.) and 2.7 (1.00 g, 3.59
mmol, 1 equiv.) in dry EtOH (14.4 mL) at rt afforded the corresponding
oxime (3 h) that subsequently was reduced by the addition of NaBH3CN
(226 mg, 3.59 mmol, 1.0 equiv.) (1 h). The residues were purified by ba-
sic work-up and flash chromatography (EtOAc:heptane 2:3) providing N-
alkylated hydroxylamine 3.91 (683 mg, 61%) as a neon-green oil. Rf = 0.21
(EtOAc:heptane (1:3); UV); IR (neat) ν (cm-1): 3283, 2965, 2934, 2859, 1578, 1508, 1454,
1324, 1270; 1H-NMR (400 MHz, DMSO-d6): δ 7.52 (s, 1H, ArH), 7.14 (s, 1H, ArH), 6.45 (t, J
= 5.3 Hz, 1H, CHCH’H”NH), 5.09 (q, J = 6.4 Hz, 1H, ArCHCH3), 3.93 (s, 3H, OCH3), 3.84
(s, 3H, OCH3), 2.85–2.79 (m, 1H, CHCH’H”NH), 2.73–2.66 (m, 1H, CHCH’H”NH), 2.40
(sept, J = 7.6 Hz, 1H, CHCH’H”NH), 1.98–1.89 (m, 2H, – CH”’H””CH2CH”H”” – ), 1.85–
1.71 (m, 2H, – CH”’H””CH2CH”’H””-), 1.65–1.54 (m, 2H, – CH”’H””CH2CH”’H”” – ),
1.35 (d, J = 6.4 Hz, 3H, ArCHCH3); 13C-NMR (101 MHz, DMSO-d6): δ 153.3, 147.2, 140.1,
135.6, 108.9, 107.2, 75.6, 57.2, 56.02, 56.01, 33.0, 26.03, 26.01, 21.4, 18.2; MS (ESI) m/z: calcd.
for C15H23N2O5+ [M + H]+ 311.2, found 311.3.
O-(1-(4,5-dimethoxy-2-nitrophenyl)ethyl)-N-neopentylhydroxylamine (3.92)
NO2
OMe
MeO
O
NH
According to the general procedure for reductive alkylation, trimethylac-
etaldehyde (546 µL, 5.02 mmol, 1 equiv.) and 2.7 (1.40 g, 5.02 mmol, 1
equiv.) in dry EtOH (20.1 mL) at rt afforded the corresponding oxime (7
h) that subsequently was reduced by the addition of NaBH3CN (410 mg,
6.53 mmol, 1.3 equiv.) (1.5 g). The residues were purified by basic work-
up and flash chromatography (EtOAc:heptane 3:7) providing N-alkylated
hydroxylamine 3.92 (1.16 g, 74%) as a light yellow semi solid. Rf = 0.35 (EtOAc:heptane
(3:7); UV); IR (neat) ν (cm-1): 3272, 3009, 2959, 2937, 2900, 2867, 1580, 1514, 1457, 1334,
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1268; 1H-NMR (400 MHz, DMSO-d6): δ 7.53 (s, 1H, ArH), 7.15 (s, 1H, ArH), 6.47 (t, J =
6.8 Hz, 1H, CCH’H”NH), 5.17 (q, J = 6.4 Hz, 1H, ArCHCH3), 3.93 (s, 3H, OCH3), 3.84
(s, 3H, OCH3), 2.64–2.52 (overlap with DMSO-d6) (m, 2H, CCH’H”NH), 1.36 (d, J = 6.4
Hz, 3H, ArCHCH3), 0.79 (s, 9H, C(CH3)3); 13C-NMR (101 MHz, DMSO-d6): δ 153.8, 147.7,
140.7, 135.8, 109.5, 107.7, 75.5, 63.3, 56.51, 56.47, 31.2, 28.4, 21.9; MS (ESI) m/z: calcd. for
C15H25N2O5+ [M + H]+ 313.2, found 313.1.
N-(cyclopentylmethyl)-O-(1-(4,5-dimethoxy-2-nitrophenyl)ethyl)hydroxylamine (3.93)
NO2
OMe
MeO
O
NH
According to the general procedure for reductive alkylation, cyclopen-
tanecarboxaldehyde (307 µL, 2.87 mmol, 1 equiv.) and 2.7 (0.80 g, 2.87
mmol, 1.0 equiv.) in dry EtOH (11.5 mL) at rt afforded the corresponding
oxime (4.5 h) that subsequently was reduced by the addition of NaBH3CN
(235 mg, 3.73 mmol, 1.3 equiv.) (1.5 h). The residues were purified by
basic work-up and flash chromatography (EtOAc:heptane 1:4) provid-
ing N-alkylated hydroxylamine 3.93 (811 mg, 87%) as a pale green semi
solid. Rf = 0.19 (EtOAc:heptane (1:4); UV); IR (neat) ν (cm-1): 3275, 3089, 2956, 2937,
2865, 1578, 1507, 1462, 1454, 1333, 1270; 1H-NMR (400 MHz, DMSO-d6): δ 7.53 (s, 1H,
ArH), 7.15 (s, 1H, ArH), 6.47 (t, J = 6.0 Hz, 1H, CHCH2NH), 5.14 (q, J = 6.4 Hz, 1H,
ArCHCH3), 3.93 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 2.74–2.68 (m, 1H, CHCH’H”NH),
2.61–2.54 (m, 1H, CHCH’H”HNH), 1.95 (m, 1H, HNCH’H”CH), 1.63–1.56 (m, 2H,
– CH”’H””CH2CH2CH”’H”” – ), 1.52–1.39 (m, 4H, – CH”’H””CH2CH2CH”’H”” – ),
1.37 (d, J = 6.4 Hz, 3H, ArCHCH3), 1.14–1.05 (m, 2H, – CH”’H””CH2CH2CH”” – ); 13C-
NMR (101 MHz, DMSO-d6): δ 153.3, 147.2, 140.2, 135.6, 108.9, 107.2, 75.5, 56.8, 56.0
(two overlapping signals), 37.0, 30.43, 30.37, 24.73, 24.66, 21.4; MS (ESI) m/z: calcd. for
C16H25N2O5+ [M + H]+ 325.2, found 325.2.
2-(Chloromethyl)thiophene (3.95)198
S
Cl
In an oven-dried round-bottomed flask containing a magnetic stirring bar,
SOCl2 (1.78 mL, 24.42 mmol, 2.0 equiv.) was slowly added to a cold solution
of 2-thiophenemethanol (2.49 mL, 12.21 mmol, 1.0 equiv.) in CH2Cl2 (48.8 mL)
at 0 °C and stirred overnight at rt under a nitrogen atmosphere. The following day, the
reaction mixture was concentrated under reduced pressure. The residues were dissolved
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in CH2Cl2 (100 mL) and washed with sat. NaHCO3 (aq., 3 x 100 mL). The organic layer
was dried over Na2SO4, filtered, and concentrated in vacuo. The title compound (3.0536
g, 58%) was used without further purification. Spectral data in correspondence with re-
ported literature values.198 1H-NMR (400 MHz, DMSO-d6): δ 7.32 (dd, J = 5.1 Hz, 1.2, 1H,
ArH), 7.10–7.08 (m, 1H, ArH), 6.96 (dd, J = 5.1 Hz, 3.5, 1H, ArH), 4.82 (s, 1H, ArCH2Cl).
O-(1-(4,5-dimethoxy-2-nitrophenyl)ethyl)-N-(thiophen-2-ylmethyl)hydroxylamine
TFA salt 3.96
NHF3CCOOH
O
NO2
OMe
MeO
S
According to the general procedure for alkylation procedure, NaH
(60% in oil) (596 mg, 14.9 mmol, 1.7 equiv.) was added to a cold
solution of N-Boc protected hydroxylamine 2.6 (3.00 g, 8.76 mmol,
1.0 equiv.) in MeCN (43.7 mL) at 0 °C and stirred overnight at rt.
The reaction mixture was quenched by the addition of H2O (50 mL),
and extracted with CH2Cl2 (3 x 150 mL). The combined organic layers
were dried over Na2SO4, filtered, and concentrated in vacuo. The N-
Alkylated N-Boc-hydroxylamine was purified flash chromatography (EtOAc:heptane 1:4
→ 2:3) to afforded 2.71 g (71%) of thiophene-2-methyl N-Boc hydroxylamine. According
to the general procedure for Boc-deprotection, the alkylated Boc-hydroxylamine (2.58 g,
5.88 mmol, 1.0 equiv.) was stirred in TFA:CH2Cl2 (3:7) (58.8 mL) for 3 h before volatiles
were removed under reduced pressure and co-evaporated from toluene and CH2Cl2 to
provide the TFA salt in quant. yield (2.6598 g). Rf = 0.38 (EtOAc:heptane (1:1); UV); IR
(neat) ν (cm-1): 2951, 2943, 2943, 2915, 2848, 1664, 1575, 1515, 1465, 1364, 1141; 1H-NMR
(400 MHz, DMSO-d6): δ 8.40 (br. s, 2H, ArCH2NH2), 7.54 (s, 1H, ArH), 7.43–7.41 (dd, J
= 5.0, 1.3 Hz, 1H, ArH), 7.13 (s, 1H, ArH), 7.00–6.95 (m, 2H, ArH), 5.21 (q, J = 6.4 Hz,
1H, ArCHCH3), 4.14 (q, J = 14.7, 5.3 Hz, 2H, ArCH2NH2), 3.91 (s, 3H, OCH3), 3.85 (s,
3H, OCH3), 1.36 (m, J = 6.4 Hz, 3H, ArCHCH3); 13C-NMR (101 MHz, DMSO-d6): δ 153.4,
147.4, 140.2, 140.0, 134.7, 126.6, 126.5, 125.7, 108.9, 107.3, 76.1, 56.04, 56.01, 49.7, 21.5; MS
(ESI) m/z: calcd. for C15H19N2O5S+ [M - TFA + H]+ 339.1, found 399.5.
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Methyl (2S)-2-(bis(tert-butoxycarbonyl)amino)-6-((cyclobutylmethyl)(1-(4,5-dime-
thoxy-2-nitrophenyl)ethoxy)amino)-6-oxohexanoate (3.98)
OMe
MeO
NO2
O
N
O
(S)
O
O
N O
OO
O
According to the general procedure for BTC acylation, 2,4,6-
collidine (3.01 mL, 22.8 mmol, 7.0 equiv.) was dropwise added
to a solution of BTC (676 mg, 2.28 mmol, 0.7 equiv.) and the
carboxylic acid 3.57 (1.47 g, 3.91 mmol, 1.2 equiv.) in dry THF
(61.4 mL) followed by the addition of the N-alkylated hydrox-
ylamine 3.91 (1.01 g, 3.26 mmol, 1.0 equiv.) in THF (20.0 mL)
and stirred overnight. The organic phase was washed with sat.
NaHCO3 (aq., 100 mL), 1.0 M HCl (aq., 2 x 100 mL), and brine
(100 mL). The residues were purified by flash column chromatography (EtOAc:heptane
1:9→ 7:13) to afford the hydroxamate 3.98 (756 mg, 35%) as a green oil. A trace amount
of CH2Cl2 and impurities were observed by 1H-NMR. A diastereomeric mixture of 1:1
ratio was observed in the NMR spectra. Two resonances for nuclei denoted with a star(*)
were observed and both chemical shifts are reported. Multiplicity for each diastereomer
is reported if possible. Rf = 0.26 (EtOAc:heptane (3:7); UV); IR (neat) ν (cm-1): 2978, 2937,
2871, 1742, 1699, 1668, 1520, 1457, 1366, 1272; 1H-NMR (400 MHz, DMSO-d6): δ 7.53
(s, 1H, ArH), 7.28/7.27* (s, 1H, ArH), 5.46–5.40 (m, 1H, ArCHCH3), 4.84–4.75 (m, 1H,
CH’H”CHN), 3.93 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.64–3.56 (m, 4H, CHCH’H”NC(O),
C(O)OCH3), 3.17–3.08 (m, 1H, CHCH’H”NC(O)), 2.52–2.48 (overlap with DMSO-d6)
(m, 1H, CHCH2HNC(O)), 2.35–2.30 (m, 2H, C(O)CH2CH2CH’H”CHN), 1.99–1.55 (m,
9H, – CH2CH2CH2 – CH, ArCHCH3), 1.48–1.34 (m, 20H, C(O)CH2CH2CH’H”CH, 2 x
C(CH3)3); 13C-NMR (101 MHz, DMSO-d6): δ 174.1, 170.51/170.48*, 152.8, 151.6, 148.2,
140.8/140.7*, 130.5, 109.8, 107.3, 82.57/82.54*, 77.1, 57.3, 56.2, 56.1, 52.0, 51.5, 33.2, 31.6,
28.76/28.66*, 27.48/27.45*, 25.89/25.87*, 25.53/25.51*, 21.6, 20.7, 17.9; MS (ESI) m/z: calcd.
for C22H34N3O8+ [M - 2 x Boc + 3 x H]+ 468.2, found 468.8.
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Methyl (2S)-2-(bis(tert-butoxycarbonyl)amino)-6-((cyclopentylmethyl)(1-(4,5-dime-
thoxy-2-nitrophenyl)ethoxy)amino)-6-oxohexanoate (3.99)
OMe
MeO
NO2
O
N
O
(S)
N O
OO
O
O
O
According to the general procedure for BTC acylation, 2,4,6-
collidine (2.94 mL, 22.22 mmol, 7.0 equiv.) was dropwise
added to a solution of BTC (660 mg, 2.22 mmol, 0.7 equiv.) and
the carboxylic acid 3.57(1.43 g, 3.84 mmol, 1.2 equiv.) in dry
THF (59.4 mL) followed by the addition of the N-alkylated hy-
droxylamine 3.93 (1.03 g, 3.18 mmol, 1 equiv.) in THF (20.0
mL) and stirred overnight. The organic phase was washed
with sat. NaHCO3 (aq., 100 mL), 1.0 M HCl (aq., 2 x 100
mL), and brine (100 mL). The residues were purified by flash column chromatography
(EtOAc:heptane 1:9→ 9:11) to afford the hydroxamate 3.99 (743 mg, 34%) as a green oil.
A trace amount of CH2Cl2 and impurities were observed by 1H-NMR . A diastereomeric
mixture of 1:1 ratio was observed in the NMR spectra. Two resonances for nuclei de-
noted with a star(*) were observed and both chemical shifts are reported. Multiplicity
for each diastereomer is reported if possible. Rf = 0.21 (EtOAc:heptane (3:7); UV); IR
(neat) ν (cm-1): 2977, 2949, 2870, 1744, 1699, 1519, 1456, 1366, 1272; 1H-NMR (400 MHz,
DMSO-d6): δ 7.53 (s, 1H, ArH), 7.30/7.29* (s, 1H, ArH), 5.47–5.41 (m, 1H, ArCHCH3),
4.84–4.77 (m, 1H, CH2CHN), 3.93 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.63 (s, 3H,
C(O)OCH3), 3.53–3.46 (m, 1H, CHCH’H”NC(O)), 3.00–2.91 (m, 1H, CHCH’H”NC(O)),
2.37–2.33 (m, 2H, NC(O)CH2CH2), 2.15–2.08 (m, 1H, CHCH2HNC(O)), 1.99–1.89 (m,
1H, CH2CH2CH”’H””CHN), 1.84–1.75 (m, 1H, CH2CH2CH”’H””CHN), 1.61–1.41 (m,
29H, – CH2CH””’H”””CH””’H”””CH2 – CH, 2 x C(CH3)3, ArCHCH3, NC(O)CH2C-
H2CHH”’H””CHN), 1.11–1.00 (m, 2H, CH – CH2CH””’H””’CH””’H””’CH2 – ); 13C-NMR
(101 MHz, DMSO-d6): δ 174.4, 170.5, 152.8, 151.63/151.60*, 148.2, 140.8/140.7*, 130.5,
109.8, 107.3, 82.57/82.53*, 77.5, 57.3, 56.2, 56.1, 52.0, 50.5 (observed by HSQC) 37.5, 31.5,
29.71/29.68*, 29.6, 28.8, 27.5, 24.4, 20.9, 20.8; MS (ESI) m/z: calcd. for C23H36N3O8+ [M - 2
x Boc + 3 x H]+ 482.2, found 482.8.
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Methyl (2S)-2-(bis(tert-butoxycarbonyl)amino)-6-(butyl(1-(4,5-dimethoxy-2-ni-
trophenyl)ethoxy)amino)-6-oxohexanoate (3.101)
OMe
MeO
NO2
O
N
O
(S)
N O
OO
O
O
O
According to the general procedure for BTC acylation, 2,4,6-
collidine (2.91 mL, 22.03 mmol, 7.0 equiv.) was dropwise
added to a solution of BTC (654 mg, 2.20 mmol, 0.7 equiv.) and
the carboxylic acid 3.57 (1.42 g, 3.78 mmol, 1.2 equiv.) in dry
THF (58.7 mL) followed by the addition of the N-alkylated hy-
droxylamine 3.92 (939 mg, 3.15 mmol, 1.0 equiv.) in THF (20.0
mL) and stirred overnight. The organic phase was washed
with sat. NaHCO3 (aq., 100 mL), 1.0 M HCl (aq., 2 x 100
mL), and brine (100 mL). The residues were purified by flash column chromatography
(EtOAc:heptane 1:9→ 1:1) to afford the hydroxamate 3.101 (498 mg, 24%) as a brown oil.
A trace amount of CH2Cl2 and impurities were observed by 1H-NMR . A diastereomeric
mixture of 1:1 ratio was observed in the NMR spectra. Two resonances for nuclei denoted
with a star(*) were observed and both chemical shifts are reported. Multiplicity for each
diastereomer is reported if possible. Rf = 0.44 (EtOAc:heptane (1:1); UV); IR (neat) ν (cm-1):
2798, 2955, 2936, 2873, 1744, 1699, 1667, 1520, 1336, 1272; 1H-NMR (400 MHz, DMSO-d6):
δ 7.54 (s, 1H, ArH), 7.299/7-293* (s, 1H, ArH), 5.46–5.40 (m, 1H, ArCHCH3), 4.83–4.77
(m, 1H, CH2CHN), 3.93 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.63 (s, 3H, C(O)OCH3),
3.55–3.49 (m, 1H, CH2CH’H”NC(O)), 3.03–2.93 (m, 1H, CH2CH’H”NC(O)), 2.38–2.32
(m, 2H, NC(O)CH2CH2CH2CH), 2.01–1.89 (m, 1H, NC(O)CH2CH2CH”’H””CHN), 1.84–
1.74 (m, 1H, NC(O)CH2CH2CH”’H””CHN), 1.61–1.23 (m, 25H, 2 x C(CH3)3, ArCHCH3,
CH3CH2CH2CH2NC(O)CH2CH2CH”’H””CHN), 1.15–1.02 (m, 2H, CH3CH2CH2), 0.77
(m, 3H, CH3CH2CH2CH2NC(O)); 13C-NMR (101 MHz, DMSO-d6): δ H’H”NC(O)CH2
is missing, 170.5, 152.8, 151.6, 148.2, 140.7, 130.6 (observed by HMBC), 109.7, 107.3, 82.5,
77.5 (observed by HSQC), 57.3, 56.2, 56.1, 52.0, 46.3 (observed by HSQC), 31.5, 28.8, 28.4,
27.5, 20.9, 20.8/20.7*, 19.3, 13.5; MS (ESI) m/z: calcd. for C21H34N3O8+ [M - 2 x Boc + 3 x
H]+ 456.2, found 456.8.
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Methyl (2S)-2-(bis(tert-butoxycarbonyl)amino)-6-((1-(4,5-dimethoxy-2-nitrophenyl)-
ethoxy)(neopentyl)amino)-6-oxohexanoate (3.102)
OMe
MeO
NO2
O
N
O
(S)
N O
OO
O
O
O
According to the general procedure for BTC acylation, 2,4,6-
collidine (2.53 mL, 19.1 mmol, 7.0 equiv.) was dropwise added
to a solution of BTC (565 mg, 1.90 mmol, 0.7 equiv.) and the
carboxylic acid 3.57 (1.23 g, 3.27 mmol, 1.2 equiv.) in dry THF
(58.0 mL) followed by the addition of the N-alkylated hydrox-
ylamine 3.92 (850 mg, 2.72 mmol, 1 equiv.) in THF (20.0 mL)
and stirred overnight. The organic phase was washed with sat.
NaHCO3 (aq., 100 mL), 1.0 M HCl (aq., 2 x 100 mL), and brine
(100 mL). The residues were purified by flash column chromatography (EtOAc:heptane
1:9→ 9:11) to afford the hydroxamate 3.102 (552 mg, 30%) as a green oil. A trace amount
of CH2Cl2 and impurities were observed by 1H-NMR. A diastereomeric mixture of 1:1
ratio was observed in the NMR spectra. Two resonances for nuclei denoted with a
star(*) were observed and both chemical shifts are reported. Multiplicity for each di-
astereomer is reported if possible. Rf = 0.16 (EtOAc:heptane (3:7); UV); IR (neat) ν (cm-1):
2977, 2953, 2872, 1743, 1699, 1520, 1458, 1366, 1273; 1H-NMR (400 MHz, DMSO-d6): δ
7.52 (s, 1H, ArH), 7.25 (s, 1H, ArH), 5.54–5.48 (m, 1H, ArCHCH3), 4.84–4.74 (m, 1H,
CH2CHN), 3.92 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.62 (s, 3H, C(O)OCH3), 3.46 (m, 1H,
CCH’H”NC(O)), 3.07 (m, 1H, CCH’H”NC(O)), 2.38–2.16 (d, 2H, C(O)CH2CH2), 2.00–1.73
(m, 2H, C(O)CH2CH2CH2CHN), 1.59 (d, J = 6.1 Hz, 3H, ArCHCH3), 1.48–1.35 (m, 20H,
2 x OC(CH3)3, C(O)CH2CH2CH2CHN), 0.84 (m, 9H, CH2C(CH3)3); 13C-NMR (101 MHz,
DMSO-d6): δ 174.1, 170.45/170.45*, 152.7, 151.63/151.60*, 148.3, 141.1/141.0*, 129.3, 110.2,
107.3, 82.5, 75.6, 57.28/57.25*, 56.14, 56.10/56.08*, 54.3 (observed by HSQC), 52.0, 33.1,
31.5, 28.2, 27.5, 27.4, 21.1, 20.4; MS (ESI) m/z: calcd. for C21H34N3O8+ [M - 2 x Boc + 3 x
H]+ 456.2, found 456.8.
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Methyl (2S)-2-(bis(tert-butoxycarbonyl)amino)-6-((1-(4,5-dimethoxy-2-nitrophenyl)-
ethoxy)(thiophen-2-ylmethyl)amino)-6-oxohexanoate (3.103)
OMe
MeO
NO2
O
N
O
(S)
S
N O
OO
O
O
O
According to the general procedure for BTC acylation, 2,4,6-
collidine (3.22 mL, 24.4 mmol, 8.0 equiv.) was dropwise added
to a solution of BTC (634 mg, 2.14 mmol, 0.7 equiv.) and car-
boxylic acid 3.57 (1.37 g, 3.04 mmol, 1.2 equiv.) in dry THF
(56.3 mL) followed by the addition of the N-alkylated hydrox-
ylamine 3.96 (1.37 g, 3.04 mmol, 1.0 equiv.) in THF (20.0 mL)
and stirred overnight. The organic phase was washed with sat.
NaHCO3 (aq., 100 mL), 1.0 M HCl (aq., 2 x 100 mL), and brine
(100 mL). The residues were purified by flash column chromatography (EtOAc:heptane
1:4 → 7:13) to afford the hydroxamate 3.103 (683 mg, 32%) as a brown oil. A trace
amount of CH2Cl2 was observed by 1H-NMR. A diastereomeric mixture of 1:1 ratio
was observed in the NMR spectra. Two resonances for nuclei denoted with a star(*)
were observed and both chemical shifts are reported. Multiplicity for each diastere-
omer is reported if possible. Rf = 0.19 (EtOAc:heptane (3:7); UV); IR (neat) ν (cm-1):
2978, 2937, 2873, 1743, 1697, 1519, 1366, 1272; 1H-NMR (400 MHz, DMSO-d6): δ 7.52 (s,
1H, ArH), 7.38 (m, 1H, ArH), 7.222/7.216* (s, 1H, ArH), 6.91–6.88 (m, 1H, ArH), 6.82–
6.78 (m, 1H, ArH), 5.58–5.52 (m, 1H, ArCHCH3), 4.88–4.75 (m, 2H, ArCH’H”NC(O),
C(O)CH2CH2CH”’H””CHN), 4.52–4.45 (m, 1H, ArCH’H”NC(O)), 3.86 (d, 6H, 2 x OCH3),
3.63 (s, 3H, C(O)OCH3), 2.44–2.33 (m, 2H, NC(O)CH2CH2CH”’H””), 1.96–1.89 (m, 1H,
NC(O)CH2CH2CH”’H””CHN), 1.84–1.74 (m, 1H, NC(O)CH2CH2CH”’H””CHN), 1.60 (d,
J = 6.4 Hz, 3H, ArCHCH3), 1.48–1.37 (m, 20H, NC(O)CH2CH2CH2CH2NBoc2, 6 x CH3);
13C-NMR (101 MHz, DMSO-d6): δ 174.8, 170.48/170.46*, 152.9, 151.60/151.58*, 148.1,
140.4, 138.6, 130.7, 126.63/126.60*, 126.4, 125.8, 109.7, 107.4, 82.5, 78.0, 57.3, 56.1, 52.0,
46.2, 31.7/31.6*, 28.7, 27.5, 21.1, 20.6/20.5*; MS (ESI) m/z: calcd. for C22H30N3O8S+ [M - 2
x Boc + 3 x H]+ 496.2, found 496.7. HRMS (ESI) m/z: calcd. for C32H45N3NaO12S+ [M +
Na]+ 718.2616, found 718.2626;
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Methyl (2S)-2-((tert-butoxycarbonyl)amino)-6-((cyclopropylmethyl)(1-(4,5-dimethoxy-
2-nitrophenyl)ethoxy)amino)-6-oxohexanoate (3.109)
OMe
MeO
NO2
O
N
O
(S)
O
O
HN O
O According to the general procedure for Boc-deprotection, TFA
(403 µL, 5.27 mmol, 2.6 equiv.) was added to carboxylic acid
3.57 (1.41 g, 3.77 mmol, 1.3 equiv.) and stirred in CH2Cl2
(17.1 mL) for 3.0 h. Volatiles were removed under reduced
pressure and co-evaporated from toluene and CH2Cl2. The
round-bottomed flask was placed under vacuum for a couple
of hours before a nitrogen atmosphere was established. Ac-
cording to the general procedure for BTC acylation, 2,4,6-collidine (2.68 mL, 20.3 mmol,
7.0 equiv.) was dropwise added to a solution of BTC (604 mg, 2.04 mmol, 0.7 equiv.)
and the crude mono-Boc carboxylic acid in THF (50.0 mL) followed by the addition of
N-alkylated hydroxylamine 3.90 (858 mg, 2.90 mmol, 1.0 equiv.) in THF (20.0 mL) and
stirred for 3.0 h. The organic phase was washed with H2O (100 mL), sat. NaHCO3 (aq.,
100 mL), 1.0 M HCl (aq., 100 mL), and brine (100 mL). The residues were purified by flash
column chromatography (EtOAc:heptane 3:7 → 9:11) to afford the hydroxamate 3.109
(783 mg, 49%) as a pale green oil. A trace amount of impurities, CH2Cl2 and, EtOAc
were observed by 1H-NMR. A diastereomeric mixture of 1:1 ratio was observed in the
NMR spectra. Two resonances for nuclei denoted with a star(*) were observed and both
chemical shifts are reported. Multiplicity for each diastereomer is reported if possible.
Rf = 0.51 (EtOAc:heptane (2:3); UV); IR (neat) ν (cm-1): 3346, 2976, 2936, 2853, 1743,
1710, 1663, 1517, 1440, 1335, 1272; 1H-NMR (400 MHz, DMSO-d6): δ 7.54 (s, 1H, ArH),
7.323/7.316* (s, 1H, ArH), 7.23 (m, 1H, CHNHC(O)O), 5.50–5.46 (m, 1H, ArCHCH3), 3.95–
3.89 (m, 4H, OCH3, CH2CH2CHNHC(O)O), 3.86 (s, 3H, OCH3), 3.61 (s, 3H, C(O)OCH3),
3.36–3.29 (overlap with H2O) (m, 1H, – CH2CH2 – CHCH’H”NC(O)), 3.13–3.06 (m,
1H, – CH2CH2 – CHCH’H”NC(O)), 2.36–2.29 (m, 2H, C(O)CH2CH2CH2CHNHBoc),
1.67–1.32 (m, 16H, C(O)CH2CH2CH2, ArCHCH3, OC(CH3)3), 0.99–0.85 (m, 1H,
– CH2CH2 – CHC), 0.40–0.36 (m, 2H, – CH”’H””CH”’H”” – CH), 0.16–0.13 (m, 2H,
– CH”’H””CH”’H”” – CHCH2NC(O)); 13C-NMR (101 MHz, DMSO-d6): δ 174.6, 173.1,
155.6/155.5*, 152.8, 148.1, 140.7, 130.7, 109.8, 107.3, 78.2, 77.3, 56.2, 56.1, 53.23/53.20*,
51.7, 51.4 (observed by HSQC), 31.5/31.4*, 30.04/29.97*, 28.2, 20.81, 20.79, 9.2, 3.5, 3.2; MS
(ESI) m/z: calcd. for C26H40N3O10+ [M + H]+ 554.3, found 554.7.
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methyl (2S)-2-((tert-butoxycarbonyl)amino)-7-((cyclopropylmethyl)(1-(4,5-dimethoxy-
2-nitrophenyl)ethoxy)amino)-7-oxoheptanoate (3.110)
OMe
MeO
NO2
O
N
O
(S)
O
O
NHO
O
According to the general procedure for Boc-deprotection, TFA
(496 µL, 6.49 mmol, 2.6 equiv.) was added to the carboxylic
acid 3.65 (1.80 g, 4.63 mmol, 1.3 equiv.) and stirred in CH2Cl2
(21.1 mL) for 3.0 h. Volatiles were removed under reduced
pressure and co-evaporated from toluene and CH2Cl2. The
round-bottomed flask was placed under vacuum for a couple
of hours, before a nitrogen atmosphere was established. According to the general pro-
cedure for BTC acylation, 2,4,6-collidine (3.30 mL, 24.9 mmol, 7.0 equiv.) was dropwise
added to a solution of BTC (740 mg, 2.50 mmol, 0.7 equiv.) and the crude mono-Boc car-
boxylic acid in dry THF (70.0 mL) followed by the addition of N-alkylated hydroxylamine
3.90 (1.06 g, 3.57 mmol, 1.0 equiv.) in THF (19.1 mL) and stirred for 3.0 h. The organic
phase was washed with H2O (100 mL), sat. NaHCO3 (aq., 100 mL), 1.0 M HCl (aq., 100
mL), and brine (100 mL). The residues were purified by flash column chromatography
(EtOAc:heptane 1:3→ 2:3) to afford the hydroxamate 3.110 (898 mg, 44%) as a neon-green
oil. A trace amount of CH2Cl2 was observed by 1H-NMR. A diastereomeric mixture of
1:1 ratio was observed in the NMR spectra. Two resonances for nuclei denoted with a
star(*) were observed and both chemical shifts are reported. Multiplicity for each diastere-
omer is reported if possible. Rf = 0.49 (EtOAc:heptane (2:3); UV); IR (neat) ν (cm-1): 3344,
2976, 2937, 2864, 1743, 1711, 1662, 1517, 1456, 1335, 1272; 1H-NMR (400 MHz, DMSO-d6):
δ 7.53 (s, 1H, ArH), 7.32 (s, 1H, ArH), 7.20/7.19* (d, J = 7.7, Hz, 1H, CHNHC(O)O),
5.51–5.46 (m, 1H, ArCHCH3), 3.94–3.86 (m, 7H, 2 x OCH3, CH2CH2CHNC(O)O),
3.61 (s, 3H, C(O)OCH3), 3.34–3.29 (m, 1H, – CH2CH2 – CHCH’H”NC(O)), 3.14–3.07
(m, 1H, – CH2CH2 – CHCH’H”NC(O)), 2.31–2.28 (m, 2H, NC(O)CH2CH2), 1.64–1.19
(m, 16H, C(O)CH2CH2CH2CHNHC(O)O, ArCHCH3, C(CH3)3), 0.99–0.89 (m, 1H,
– CH2CH2 – CHCH2), 0.40–0.36 (m, 2H, – CH”’H””CH”’H”” – CHCH2NC(O)), 0.16–0.13
(m, 2H, – CH”’H””CH”’H”” – CHCH2NC(O)); 13C-NMR (101 MHz, DMSO-d6): δ 173.4
(observed by HMBC), 173.2, 155.5, 152.8, 148.2, 140.8, 130.4, 109.9, 107.3, 78.2, 77.2, 56.2,
56.1, 53.4, 51.7, 51.3, 31.9, 30.5, 28.2, 25.2, 23.8, 20.8, 9.2, 3.5, 3.2; MS (ESI) m/z: calcd. for
C27H42N3O10+ [M + H]+ 567.3, found 567.7; HRMS (ESI) m/z: calcd. for C27H42N3O10+ [M
+ H]+ 568.2865, found 568.2870.
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tert-Butyl ((2S)-6-((cyclopropylmethyl)(1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)-
amino)-1,6-dioxo-1-(phenylamino)hexan-2-yl)carbamate (3.111)
OMe
MeO
NO2
O
N
O
(S)
O
H
N
NH
O
O
According to the general procedure for LiOH hydrolysis,
LiOH (96.2 mg, 4.02 mmol, 3.0 equiv.) was added to the
methyl ester 3.109 (741 mg, 1.34 mmol, 1.0 equiv.) in
THF:H2O (4:1) (33.5 mL). After 2.15 h, the reaction mixture
was diluted with EtOAc and acidified to pH ≈ 3-4 by the
addition of 1.0 M HCl (aq., 5.4 mL) and immediately the
aqueous phase was extracted with EtOAc (3 x 25 mL). The
combined organic phases were dried over Na2SO4, filtered,
and concentrated in vacuo and left under vacuum for a couple of hours before a nitro-
gen atmosphere was established. According to the general procedure for TBTU-DIPEA
aniline amidation, TBTU (497 mg, 1.55 mmol, 1.0 equiv.) was added to a stirring so-
lution of the carboxylic acid in CH2Cl2 (12.6 mL). After 10 min, DIPEA (1.40 mL, 8.03
mmol, 6.0 equiv.) and aniline (134 µL, 1.47 mmol, 1.1 equiv.) were added and stirred
overnight. Full conversion was not observed after 23.5 h, and therefore additionally DI-
PEA (699 µL, 4.02 mmol, 1.5 equiv.) was added and stirred for 15 min before TBTU (215
mg, 0.70 mmol, 0.5 equiv.) and aniline (67.1 µL, 0.74 mmol, 0.55 equiv.) were added and
stirred overnight. The reaction mixture was evaporated under reduced pressure, and
the organic layer was dissolved in EtOAc (25 mL) and washed with H2O (25 mL), sat.
NaHCO3 (aq., 25 mL), 1.0 M HCl (aq., 25 mL), and brine (25 mL). The organic phase
was dried over Na2SO4, filtered, and concentrated in vacuo. The desired product was
purified by flash column chromatography (EtOAc:heptane 3:7→ 9:11) to provide the ani-
line amide 3.111 (720 mg, 88%) as a light yellow foam. A trace amount of CH2Cl2 and
EtOAc were observed by 1H-NMR. A diastereomeric mixture of 1:1 ratio was observed
in the NMR spectra. Two resonances for nuclei denoted with a star(*) were observed and
both chemical shifts are reported. Multiplicity for each diastereomer is reported if possi-
ble. Rf = 0.07 (EtOAc:heptane (3:7); UV); IR (neat) ν (cm-1): 3291, 2977, 2934, 2871, 1667,
1600, 1518, 1334, 1272; 1H-NMR (400 MHz, DMSO-d6): δ 9.92 (s, 1H, C(O)NHPh), 7.60–
7.53 (m, 3H, ArH), 7.32–7.26 (m, 3H, ArH), 7.06–6.98 (m, 2H, ArH, CHNHC(O)O), 5.50–
5.46 (m, 1H, ArCHCH3), 4.09–4.02 (m, 1H, C(O)CH2CH2CH2CHNHC(O)O), 3.93/3.92*
(s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.36–3.30 (m, 1H, – CH”’H””CH”’H”” – CHCH’H”N),
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3.11–3.02 (m, 1H, – CHH”’H””CH”’H”” – CHCH’H”N), 2.42–2.30 (m, 2H, C(O)CH2CH2),
1.68-1.48 (m, 7H, C(O)CH2CH2CH2CH, ArCHCH3), 1.38 (m, 9H, C(CH3)3), 0.97–0.89
(m, 9H, – CH”’H””CH”’H”” – CHCH2), 0.38–0.33 (m, 2H, – CH”’H””CH”’H”” – CH),
0.16–0.10 (m, 2H, – CH”’H””CH”’H”” – CH); 13C-NMR (101 MHz, DMSO-d6): δ 174.7,
171.2 155.4, 152.8, 148.1, 140.70/140.67*, 139.3/139.0*, 130.7, 128.7/128.6*, 123.2/122.9*,
119.2/118.9*, 109.8, 107.3, 78.1, 77.1 (observed by HSQC), 56.23/56.22*, 56.1, 55.0/54.9*,
51.4, 31.9/31.8*, 31.4, 28.2, 21.1/21.0*, 20.83/20.76*, 9.2, 3.5/3.4*, 3.22/3.20*; MS (ESI) m/z:
calcd. for C27H42N3O10+ [M + H]+ 567.3, found 567.7.
tert-Butyl ((2S)-6-(butyl(1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)amino)-1,6-dioxo-1-
(phenylamino)hexan-2-yl)carbamate (3.112)
OMe
MeO
NO2
O
N
O
(S)
O
H
N
NH
O
O
According to the general procedure for Boc-deprotection,
the Boc-protected methyl ester 3.101 (498 mg, 0.76 mmol,
1.0 equiv.) was stirred in TFA:CH2Cl2 (3:7) (12.1 mL) for
1.5 h. Volatiles were removed under reduced pressure and
co-evaporated from toluene and CH2Cl2. According to the
general procedure for one-pot LiOH hydrolysis and Boc-
protection, LiOH (127 mg, 5.32 mmol, 7.0 equiv.) was added
to a stirring solution of the crude TFA salt in THF:H2O (4:1,
19.0 mL). After 2.0 h, Boc2O (390 mg, 1.79 mmol, 2.4 equiv.) was added and stirred for
2.0 h. The reaction mixture was diluted with EtOAc (20 mL), and pH adjusted to ≈ 3-4
by the addition of 1.0 M HCl (aq., 5.0 mL), and extracted with EtOAc (3 x 20 mL). The
combined organic phases were dried over Na2SO4, filtered, and concentrated in vacuo.
The carboxylic acid was placed under vacuum for a couple of hours before a nitrogen
atmosphere was established. According to the general procedure for TBTU-DIPEA ani-
line amidation, TBTU (244 mg, 0.76 mmol, 1.0 equiv.) was added to a stirring solution
of the carboxylic acid in CH2Cl2 (6.0 mL). After 10 min, DIPEA (793 µL, 4.56 mmol, 6.0
equiv.) and aniline (76.2 µL, 0.84 mmol, 1.1 equiv.) were added and stirred overnight.
The reaction mixture was evaporated under reduced pressure, and the organic layer
was dissolved in EtOAc (25 mL) and washed with H2O (25 mL), sat. NaHCO3 (aq., 25
mL), and 1.0 M HCl (aq., 2 x 50 mL). The organic phase was dried over Na2SO4, filtered,
and concentrated in vacuo. The residues were purified by flash column chromatography
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(EtOAc:heptane 1:1 → 9:11) to provide the hydroxamate 3.112 (247 mg, 53%) as a pale
green oil. A trace amount of CH2Cl2 and EtOAc were observed by 1H-NMR. A diastere-
omeric mixture of 1:1 ratio was observed in the NMR spectra. Two resonances for nuclei
denoted with a star(*) were observed and both chemical shifts are reported. Multiplicity
for each diastereomer is reported if possible. Rf = 0.38 (EtOAc:heptane (1:1); UV); IR (neat)
ν (cm-1): 3305, 2959, 2934, 2872, 1668, 1601, 1517, 1442, 1366, 1272; 1H-NMR (400 MHz,
DMSO-d6): δ 9.92 (br. s, 1H, C(O)NHPh), 7.60–7.58 (m, 2H, ArH), 7.53 (m, 1H, ArH), 7.32–
7.28 (m, 3H, ArH), 7.06–6.98 (m, 2H, ArH, CHNHC(O)O), 5.45–5.40 (m, 1H, ArCHCH3),
4.09–3.99 (m, 1H, CH2CHNHC(O)O), 3.923/3.920* (s, 3H, OCH3), 3.85 (s, 3H, OCH3),
3.56–3.49 (m, 1H, CH2CH’H”NC(O)), 3.00–2.87 (m, 1H, CH2CH’H”NC(O)), 2.40–2.29 (m,
2H, NC(O)CH2CH2CH2), 1.68–1.48 (m, 7H, NC(O)CH2CH2CH2CHN, ArCHCH3), 1.42–
1.24 (m, 11H, CH3CH2CH2CH2NC(O), C(CH3)3), 1.13–1.02 (m, 2H, CH3CH2), 0.76 (m,
3H, CH3CH2); 13C-NMR (101 MHz, DMSO-d6): δ NC(O)CH2 missing, 171.2, 155.4, 152.9,
148.2, 140.71/140.68*, 139.0, 130.6, 128.7, 123.2, 119.2, 109.7, 107.3, 78.1, 77.5 (observed
by HSQC), 56.2, 56.1, 54.9, 46.3 (observed by HSQC), 31.74/31.69*, 31.5, 28.4, 28.2, 20.9,
20.85/20.77*, 19.3 13.5; MS (ESI) m/z: calcd. for C31H45N4O9+ [M + H]+ 617.3, found 617.8.
tert-Butyl ((2S)-6-((cyclobutylmethyl)(1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)amino)-
1,6-dioxo-1-(phenylamino)hexan-2-yl)carbamate (3.113)
OMe
MeO
NO2
O
N
O
(S)
O
H
N
NH
O
O
According to the general procedure for Boc-deprotection,
the Boc-protected methyl ester 3.98 (756 mg, 1.15 mmol,
1.0 equiv.) was stirred in TFA:CH2Cl2 (3:7) (18.3 mL) for
1.5 h. Volatiles were removed under reduced pressure and
co-evaporated from toluene and CH2Cl2. According to the
general procedure for one-pot LiOH hydrolysis and Boc-
protection, LiOH (194 mg, 8.10 mmol, 7.0 equiv.) was added
to a stirring solution of the crude TFA salt in THF:H2O (4:1,
28.8 mL). After 1.5 h, Boc2O (0.5033 mg, 2.31 mmol, 2.0 equiv.) was added and stirred
for 2.0 h. The reaction mixture was diluted with EtOAc (25 mL), and pH adjusted to
≈ 3-4 by the addition of 1.0 M HCl (aq., 8.1 mL), and extracted with EtOAc (3 x 50
mL). The combined organic phases were dried over Na2SO4, filtered, and concentrated
in vacuo. The carboxylic acid was placed under vacuum for a couple of hours before
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a nitrogen atmosphere was established. According to the general procedure for TBTU-
DIPEA aniline amidation, TBTU (407 mg, 1.27 mmol, 1.1 equiv.) was added to a stirring
solution of the carboxylic acid in CH2Cl2 (5.5 mL). After 10 min, DIPEA (1.20 mL, 6.92
mmol, 6.0 equiv.) and aniline (126 µL, 1.38 mmol, 1.2 equiv.) were added and stirred
overnight. The reaction mixture was evaporated under reduced pressure, and the or-
ganic layer was dissolved in EtOAc (25 mL) and washed with H2O (25 mL), sat. NaHCO3
(aq., 25 mL), and 1.0 M HCl (aq., 2 x 25 mL). The organic phase was dried over Na2SO4,
filtered, and concentrated in vacuo. The residues were purified by flash column chro-
matography (EtOAc:heptane 3:7→ 7:3) to provide the aniline amide 3.113 (241 mg, 34%)
as a pale green oil. A trace amount of CH2Cl2 and EtOAc were observed by 1H-NMR.
A diastereomeric mixture of 1:1 ratio was observed in the NMR spectra. Two resonances
for nuclei denoted with a star(*) were observed and both chemical shifts are reported.
Multiplicity for each diastereomer is reported if possible. Rf = 0.07 (EtOAc:heptane (3:7);
UV); IR (neat) ν (cm-1): 3306, 2976, 2935, 2865, 1668, 1601, 1518, 1441, 1334, 1272; 1H-
NMR (400 MHz, DMSO-d6): δ 9.92 (br. s, 1H, C(O)NHPh), 7.59–7.57 (m, 2H, ArH), 7.53
(s, 1H, ArH), 7.32–7.26 (m, 3H, ArH), 7.06–7.02 (m, 1H, ArH), 6.98 (d, J = 7.8 Hz, 1H,
CHNHC(O)O), 5.45–5.40 (m, 1H, ArCHCH3), 4.09–4.00 (m, 1H, CH2CHNH), 3.919/3.917*
(s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.64–3.57 (m, 1H, CHCH’H”NC(O)), 3.13–3.04 (m, 1H,
CHCH’H”NC(O)), 2.53–2.44 (overlap with DMSO-d6) (m, 1H, CHCH2NC(O)), 2.37–2.28
(m, 2H, C(O)CH2CH2CH2), 1.91–1.45 (m, 13H, C(O)CH2CH2CH2CH, – CH2CH2CH2 –
CH, ArCHCH3), 1.31 (m, 9H, C(CH3)3); 13C-NMR (101 MHz, DMSO-d6): δ NC(O)CH2
missing, 171.2, 155.4, 152.8, 148.1, 140.72/140.67*, 139.0, 130.4, 128.7, 123.2, 119.2, 109.8,
107.3, 78.1, 76.8, 56.2, 56.1, 54.9, 51.6 (observed by HSQC), 33.2, 31.8/31.7*, 31.5, 28.2,
25.9/25.8*, 25.5, 21.1/21.0*, 20.8/20.7*, 17.8; MS (ESI) m/z: calcd. for C32H45N4O9+ [M +
H]+ 629.3, found 629.8.
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tert-Butyl ((2S)-6-((1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)(neopentyl)amino)-1,6-
dioxo-1-(phenylamino)hexan-2-yl)carbamate (3.114)
OMe
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O
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According to the general procedure for Boc-deprotection,
the Boc-protected methyl ester 3.102 (552 mg, 0.82 mmol,
1.0 equiv.) was stirred in TFA:CH2Cl2 (3:7) (13.1 mL) for
1.5 h. Volatiles were removed under reduced pressure and
co-evaporated from toluene and CH2Cl2. According to the
general procedure for one-pot LiOH hydrolysis and Boc-
protection, LiOH (140 g, 5.84 mmol, 7.0 equiv.) was added
to a stirring solution of the crude TFA salt in THF:H2O (4:1,
20.6 mL). After 1.5 h, Boc2O (360 mg, 1.65 mmol, 2.0 equiv.) was added and stirred for 2.0
h. The reaction mixture was diluted with EtOAc (25 mL), and pH adjusted to≈ 3-4 by the
addition of 1.0 M HCl (aq., 9.0 mL), and extracted with EtOAc (3 x 50 mL). The combined
organic phases were dried over Na2SO4, filtered, and concentrated in vacuo. The car-
boxylic acid was placed under vacuum for a couple of hours before nitrogen atmosphere
was established. According to the general procedure for TBTU-DIPEA aniline amidation,
TBTU (291 mg, 0.91 mmol, 1.1 equiv.) was added to a stirring solution of the carboxylic
acid in CH2Cl2 (3.9 mL). After 10 min, DIPEA (860 µL, 4.94 mmol, 6.0 equiv.) and aniline
(90.1 µL, 0.99 mmol, 1.2 equiv.) were added and stirred overnight. The reaction mixture
was evaporated under reduced pressure, and the organic phase was dissolved in EtOAc
(25 mL) and washed with H2O (25 mL), sat. NaHCO3 (aq., 25 mL), and 1.0 M HCl (aq., 2
x 25 mL). The organic phase was dried over Na2SO4, filtered, and concentrated in vacuo.
The residues were purified by flash column chromatography (EtOAc:heptane 3:7→ 7:3)
to provide the aniline amide 3.114 (219 g, 54%) as a pale green oil. A trace amount of
CH2Cl2 and EtOAc were observed by 1H-NMR. A diastereomeric mixture of 1:1 ratio was
observed in the NMR spectra. Two resonances for nuclei denoted with a star(*) were
observed and both chemical shifts are reported. Multiplicity for each diastereomer is re-
ported if possible. Rf = 0.09 (EtOAc:heptane (3:7); UV); IR (neat) ν (cm-1): 3301, 2956,
2937, 2870, 1668, 1601, 1519, 1442, 1366, 1273; 1H-NMR (400 MHz, DMSO-d6): δ 9.90 (br.
s, 1H, C(O)NHPh), 7.58 (m, 2H, ArH), 7.52 (m, 1H, ArH), 7.32–7.24 (m, 3H, ArH), 7.06–
7.02 (m, 1H, ArH), 6.98 (m, 1H, CHNHC(O)O), 5.53–5.48 (m, 1H, ArCHCH3), 4.09–4.00
(m, 1H, CH2CHNHC(O)O), 3.915/3.911* (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.52–3.46
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(m, 1H, (CH3)3CCH’H”NC(O)), 3.05–2.97 (m, 1H, (CH3)3CCH’H”NC(O)), 2.43–2.21 (m,
2H, NC(O)CH2CH2CH2), 1.64–1.48 (m, 7H, NC(O)CH2CH2CH2CHN, ArCHCH3), 1.37
(s, 9H, OC(CH3)3), 0.83 (s, 9H, CH2C(CH3)3), 13C-NMR (101 MHz, DMSO-d6): δ 173.2
171.20/171.18*, 155.4, 152.7, 148.3, 141.0, 139.0, 129.1, 128.7, 123.2, 119.2, 110.2, 107.3,
78.1, 56.2, 56.1, 54.9, 54.3, 33.3, 31.6, 31.5, 28.2, 28.0, 21.3, 20.4; MS (ESI) m/z: calcd. for
C32H47N4O9+ [M + H]+ 631.3, found 631.8.
tert-Butyl ((2S)-6-((cyclopentylmethyl)(1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)-
amino)-1,6-dioxo-1-(phenylamino)hexan-2-yl)carbamate (3.115)
OMe
MeO
NO2
O
N
O
(S)
O
H
N
NH
O
O
According to the general procedure for Boc-deprotection,
the Boc-protected aniline amide 3.99 (743 g, 1.13 mmol, 1.0
equiv.) was stirred in TFA:CH2Cl2 (3:7) (18.0 mL) for 1.5
h. Volatiles were removed under reduced pressure and co-
evaporated from toluene and CH2Cl2. According to the
general procedure for one-pot LiOH hydrolysis and Boc-
protection, LiOH (191 mg, 7.98 mmol, 7.1 equiv.) was added
to a stirring solution of the crude TFA salt in THF:H2O (4:1,
28.3 mL). After 1.5 h, Boc2O (495 mg, 2.27 mmol, 2.0 equiv.) was added and stirred for
2.0 h. The reaction mixture was diluted with EtOAc (25 mL), and pH adjusted to ≈ 3-4
by the addition of 1.0 M HCl (aq., 8.8 mL), and extracted with EtOAc (3 x 50 mL). The
combined organic phases were dried over Na2SO4, filtered, and concentrated in vacuo.
The carboxylic acid was placed under vacuum for a couple of hours before nitrogen at-
mosphere was established. According to the general procedure for TBTU-DIPEA aniline
amidation, TBTU (364 mg, 1.13 mmol, 1.1 equiv.) was added to a stirring solution of
the carboxylic acid in CH2Cl2 (5.4 mL). After 10 min, DIPEA (1.18 mL, 6.80 mmol, 6.0
equiv.) and aniline (114 µL, 1.25 mmol, 1.2 equiv.) were added and stirred overnight.
The reaction mixture was evaporated under reduced pressure, and the organic layer
was dissolved in EtOAc (25 mL) and washed with H2O (25 mL), sat. NaHCO3 (aq., 25
mL), and 1.0 M HCl (aq., 2 x 25 mL). The organic phase was dried over Na2SO4, filtered,
and concentrated in vacuo. The residues were purified by flash column chromatography
(EtOAc:heptane 3:7 → 6:4) to provide the aniline amide 3.115 (415 mg, 59%) as a pale
green oil. A trace amount of CH2Cl2 and EtOAc were observed by 1H-NMR. A diastere-
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omeric mixture of 1:1 ratio was observed in the NMR spectra. Two resonances for nuclei
denoted with a star(*) were observed and both chemical shifts are reported. Multiplic-
ity for each diastereomer is reported if possible. Rf = 0.07 (EtOAc:heptane (3:7); UV); IR
(neat) ν (cm-1): 3304, 2939, 2867, 1668, 1601, 1518, 1442, 1366, 1272; 1H-NMR (400 MHz,
DMSO-d6): δ 9.92 (br. s, 1H, C(O)NHPh), 7.58 (m, 2H, ArH), 7.53 (s, 1H, ArH), 7.32–
7.28 (m, 3H, ArH), 7.06–6.98 (m, 2H, ArH, CHNHC(O)), 5.46–5.41 (m, 1H, ArCHCH3),
4.10–4.02 (m, 1H, CH2CHNHC(O)O), 3.92/3.91* (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.53–
3.47 (m, 1H, CHCH’H”NC(O)), 2.98–2.85 (m, 1H, CHCH’H”NC(O)), 2.41–2.30 (m, 2H,
NC(O)CH2CH2), 2.14–2.06 (m, 1H, – CH”’H””CH2CH2CH”’H”” – CH), 1.67–1.23 (m,
22H, CH2CH2CHN, ArCHCH3, C(CH3)3, – CH”’H””CH2CH2CH”’H”” – CH), 1.10–0.98
(m, 2H, – CH”’H””CH2CH2CH”’H”” – CH), 13C-NMR (101 MHz, DMSO-d6): δ 174.0,
171.2, 155.4, 152.8, 148.2, 140.75/140.71*, 139.0, 130.4, 128.7, 123.2, 119.2, 109.8, 107.3, 78.1,
77.2, 56.2, 56.1, 54.9, 50.6, 37.5, 31.8/31.7*, 31.5, 29.6, 28.2, 24.4, 21.1, 20.8; MS (ESI) m/z:
calcd. for C33H47N4O9+ [M + H]+ 643.3, found 643.8.
tert-butyl ((2S)-6-((1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)(thiophen-2-ylmethyl)-
amino)-1,6-dioxo-1-(phenylamino)hexan-2-yl)carbamate (3.116)
OMe
MeO
NO2
O
N
O
(S)
S
O
H
N
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O
According to the general procedure for Boc-deprotection,
the Boc-protected aniline amide 3.103 (683 g, 0.98 mmol,
1.0 equiv.) was stirred in TFA:CH2Cl2 (3:7) (15.6 mL) for
1.5 h. Volatiles were removed under reduced pressure and
co-evaporated from toluene and CH2Cl2. According to the
general procedure for one-pot LiOH hydrolysis and Boc-
protection, LiOH (164 mg, 6.87 mmol, 7.0 equiv.) was added
to a stirring solution of the crude TFA salt in THF:H2O (4:1,
24.5 mL). After 1.5 h, Boc2O (428 mg, 1.96 mmol, 2.0 equiv.) was added and stirred for 2.0
h. The reaction mixture was diluted with EtOAc (25 mL), and pH adjusted to≈ 3-4 by the
addition of 1.0 M HCl (aq., 6.1 mL), and extracted with EtOAc (3 x 50 mL). The combined
organic phases were dried over Na2SO4, filtered, and concentrated in vacuo. The car-
boxylic acid was placed under vacuum for a couple of hours before a nitrogen atmosphere
was established. According to the general procedure for TBTU-DIPEA aniline amidation,
TBTU (347 g, 1.08 mmol, 1.1 equiv.) was added to a stirring solution of the N-protected
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amino acid in CH2Cl2 (4.6 mL). After 10 min, DIPEA (1.02 mL, 5.89 mmol, 6.0 equiv.) and
aniline (107 µL, 1.18 mmol, 1.2 equiv.) were added and stirred overnight. The reaction
mixture was evaporated under reduced pressure, and the organic layer was dissolved in
EtOAc (25 mL) and washed with H2O (25 mL), sat. NaHCO3 (aq., 25 mL), and 1.0 M HCl
(aq., 2 x 25 mL). The organic phase was dried over Na2SO4, filtered, and concentrated
in vacuo. The residues were purified by flash column chromatography (EtOAc:heptane
3:7 → 7:3) to provide the aniline amide 3.116 (528 mg, 82%) as a pale green oil. A trace
amount of CH2Cl2 and EtOAc were observed by 1H-NMR. A diastereomeric mixture of
1:1 ratio was observed in the NMR spectra. Two resonances for nuclei denoted with a
star(*) were observed and both chemical shifts are reported. Multiplicity for each di-
astereomer is reported if possible. Rf = 0.07 (EtOAc:heptane (3:7); UV); IR (neat) ν (cm-1):
3307, 2976, 2934, 2852, 1667, 1600, 1517, 1441, 1334, 1272; 1H-NMR (400 MHz, DMSO-d6): δ
9.92 (s, 1H, C(O)NHPh), 7.59 (d, J = 8.1 Hz, 2H, ArH), 7.52 (s, 1H, ArH), 7.35–7.28 (m, 3H,
ArH), 7.20 (s, 1H, ArH), 7.06–7.02 (m, 1H, ArH), 6.99 (d, J = 7.8 Hz, 1H, CHNHC(O)O),
6.89–6.86 (m, 1H, ArH), 6.78 (m, 1H, ArH), 5.55/5.54* (q, J = 6.5 Hz, 1H, ArCHCH3),
4.87/4.86* (d, J = 16.3 Hz, 1H, CH’H”NC(O)), 4.47–4.40 (m, 1H, CH’H”NC(O)), 4.09–
4.02 (m, 1H, CH2CHNHc(O)O), 3.85 (s, 6H, 2 x OCH3), 2.45–2.36 (m, 2H, C(O)CH2CH2),
1.66–1.49 (m, 7H, CH2CH2CH2CHN, ArCHCH3), 1.38 (m, 9H, CC(H3)3); 13C-NMR (101
MHz, DMSO-d6): δ 174.9, 171.2, 155.4, 152.9, 148.1, 140.4/140.3*, 139.0, 138.6, 130.7, 128.7,
126.59/126.55*, 126.4, 125.80/125.79*, 123.2, 119.2 109.7, 107.4, 78.1, 78.0 (observed by
HSQC), 56.11, 56.09, 54.9, 45.8, 31.9/31.8*, 31.42/31.40*, 28.2, 21.1/21.0*, 20.9/20.8*; MS
(ESI) m/z: calcd. for C32H41N4O9S+ [M + H]+ 657.3, found 657.8.
tert-Butyl ((2S)-7-((cyclopropylmethyl)(1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)-
amino)-1,7-dioxo-1-(phenylamino)heptan-2-yl)carbamate (3.117)
OMe
MeO
NO2
O
N
O
(S)
O
N
HNHO
O
According to the general procedure for LiOH hydrolysis,
LiOH (111 mg, 4.64 mmol, 3.0 equiv.) was added to the
methyl ester 3.110 (878 mg, 1.55 mmol, 1.0 equiv.) in
THF:H2O (4:1) (38.7 mL). After 2.15 h, the reaction mix-
ture was diluted with EtOAc and acidified to pH ≈ 3-4
by the addition of 1.0 M HCl (aq., 5.4 mL) and immedi-
ately the aqueous phase was extracted with EtOAc (3 x 25 mL). The combined organic
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phases were dried over Na2SO4, filtered, and concentrated in vacuo and left under vac-
uum for a couple of hours before a nitrogen atmosphere was established. According to
the general procedure for TBTU-DIPEA aniline amidation, TBTU (0.4967 g, 1.55 mmol,
1.0 equiv.) was added to a stirring solution of the carboxylic acid in CH2Cl2 (14.6 mL).
After 10 min, DIPEA (1.62 mL, 9.28 mmol, 6.0 equiv.) and aniline (155 µL, 1.70 mmol,
1.1 equiv.) were added and stirred overnight. Incomplete conversion was observed
(23.5 h), therefore additionally DIPEA (808 µL, 4.64 mmol, 3.0 equiv.) was added and
stirred for 15 min, before TBTU (248 mg, 0.77 mmol, 0.5 equiv.) and aniline (77.5 µL,
0.85 mmol, 0.55 equiv.) were added and stirred overnight. The reaction mixture was
evaporated under reduced pressure, and the organic layer was dissolved in EtOAc (25
mL) and washed with H2O (25 mL), sat. NaHCO3 (aq., 25 mL), 1.0 M HCl (aq., 25 mL),
and brine (25 mL). The organic phase was dried over Na2SO4, filtered, and concentrated
in vacuo. The residues were purified by flash column chromatography (EtOAc:heptane
3:7 → 9:11) to provide the aniline amide 3.111 (864 g, 89%) as a pale yellow foam. A
trace amount of CH2Cl2 was observed by 1H-NMR. A diastereomeric mixture of 1:1 ra-
tio was observed in the NMR spectra. Two resonances for nuclei denoted with a star(*)
were observed and both chemical shifts are reported. Multiplicity for each diastereomer
is reported if possible. Rf = 0.07 (EtOAc:heptane (3:7); UV); IR (neat) ν (cm-1): 3304,
2977, 2935, 2861, 1667, 1601, 1518, 1441, 1334, 1272; 1H-NMR (400 MHz, DMSO-d6): δ
9.93/9.92* (s, 1H, C(O)NHPh), 7.60–7.58 (m, 2H, ArH), 7.53/7.52* (s, 1H, ArH), 7.31–7.27
(m, 3H, ArH), 7.05–7.01 (m, 1H, ArH), 6.97–6.94 (m, 1H, CHNHC(O)O), 5.50–5.46 (q,
J = 7.8 Hz, 1H, ArCHCH3), 4.06–4.01 (m, 1H, CH2CHNHC(O)O), 3.92 (s, 3H, OCH3),
3.854/3.848* (s, 3H, OCH3), 3.34–3.29 (m, 1H, – CH”’H”’CH”’H”” – CHCH’H”N),
3.12–3.05 (m, 1H, – CH”’H”’CH”’H”” – CHCH’H”N), 2.34–2.31 (m, 2H, C(O)CH2CH2),
1.60–1.23 (m, 18H, CH2CH2CH2CH2CHN, ArCHCH3, C(CH3)3), 0.97–0.88 (m, 1H, –
CH”’H”’CH”’H”” – CHCH2), 0.37–0.36 (m, 2H, – CH”’H””CH”’H”’ – CHCH2), 0.15–0.11
(m, 2H, – CH”’H””CH”’H”” – CHCH2); 13C-NMR (101 MHz, DMSO-d6): δ 174.8, 171.4,
155.5, 152.8, 148.1, 140.7, 139.0, 130.7, 128.7, 123.2, 119.1, 109.8, 107.3, 78.0, 77.1, 56.2, 56.1,
54.9. 51.6, 32.0 31.7, 28.2, 25.2, 23.9, 20.8, 9.2, 3.5, 3.2; MS (ESI) m/z: calcd. for C27H42N3O10+
[M + H]+ 567.3, found 567.7.
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(2S)-2-(2-((S)-2-acetamido-4-methylpentanamido)acetamido)-N6-(cyclopropylmethyl)-
N6-(1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)-N1-phenylhexanediamide (3.118)
N
(S)N
H O
H
N
OH
N
O
(S)N
H
O
O
NO2MeO
MeO
O
According to the general procedure for Boc-deprotection, the
Boc-protected aniline amide 3.111 (708 mg, 1.15 mmol, 1.0
equiv.) was stirred in TFA:CH2Cl2 (3:7) (18.6 mL) for 1.0
h. Volatiles were removed under reduced pressure and co-
evaporated from toluene and CH2Cl2. The round-bottomed
flask was placed under vacuum for a couple of hours before
a nitrogen atmosphere was established. According to the general procedure for coupling
reagent acylation, TBTU (481 g, 1.50 mmol, 1.3 equiv.) and NEM (1.014 mL, 8.06 mmol,
7.0 equiv.) was added to a stirring solution of acetyl-L-leucylglycine 3.37 (318 mg, 1.38
mmol, 1.2 equiv.) in DMF (3.0 mL) and stirred for 20 min, before the crude TFA salt in
DMF (8.5 mL) was added and stirred overnight. Incomplete conversion was observed,
and therefore a new batch of acetyl-L-leucylglycine 3.37, TBTU, and NEM were prepared
in DMF (2.0 mL) and after stirring for 15 min added to the reaction mixture followed by
stirring overnight. The reaction mixture was diluted with EtOAc (25 mL), and the or-
ganic layer was washed with brine (5 x 25 mL), sat. NaHCO3 (aq., 25 mL), and 1.0 M
HCl (aq., 25 mL). The combined organic phases were dried over Na2SO4, filtered, and
concentrated in vacuo. The photo-protected tripeptide 3.118 was isolated by flash col-
umn chromatography (CH2Cl2 → CH2Cl2:MeOH 47:3) as a pale yellow foam (583 mg,
70%). A trace amount of CH2Cl2 was observed by 1H-NMR. A diastereomeric mixture
of 1:1 ratio was observed in the NMR spectra. Two resonances for nuclei denoted with
a star(*) were observed and both chemical shifts are reported. Multiplicity for each di-
astereomer is reported if possible. Rf = 0.18 (CH2Cl2:MeOH (19:1); UV);
1H-NMR (400
MHz, DMSO-d6): δ 9.89 (s, 1H, C(O)NHPh), 8.28 (t, J = 5.7 Hz, 1H, C(O)NHCH2C(O)),
8.09 (d, J = 7.4 Hz, 1H, CH3C(O)NHCH), 7.96 (d, J = 7.6 Hz, 1H, C(O)NHCHC(O)NHPh),
7.61 (d, J = 7.8 Hz, 2H, ArH), 7.53 (s, 1H, ArH), 7.32–7.28 (m, 3H, ArH), 7.07–7.03
(m, 1H, ArH), 5.50–5.45 (m, 1H, ArCHCH3), 4.39–4.33 (m, 1H, C(O)NHCHC(O)NHPh),
4.25–4.19 (m, 1H, H3C(O)NHCH), 3.92 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.77–
3.67 (m, 2H, C(O)NHCH2C(O)), 3.35–3.29 (overlap with H2O) (m, 1H, NCH’H”CH –
CH”’H””CH”’H”” – ), 3.11–3.04 (m, 1H, NCH’H”CH – CH”’H””CH”’H”” – ), 2.41–2.33
(m, 2H, NHCHCH2CH2CH2C(O)N), 1.84/1.82 (s, 3H, CH3C(O)NH), 1.77–1.42 (m, 10H,
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CH3C(O)NHCHCH2CH, NHCHCH2CH2CH2, ArCHCH3), 0.97–0.82 (m, 7H, CH(CH3)2,
NCH2CH – CH”’H””CH”’H”” – ), 0.36–0.35 (m, 2H, CH – CH”’H””CH”’H”” – C), 0.14–
0.12 (m, 2H, CH – CH”’H””CH”’H”” – C); 13C-NMR (101 MHz, DMSO-d6): δ NC(O)CH2
missing, 172.8, 170.39/170.36*, 169.6, 168.9/168.8*, 152.8, 148.1, 140.7, 138.8, 130.6, 128.7,
123.4, 119.3, 109.8, 107.3, 77.0, 56.2, 56.1, 53.43/53.37*, 51.44, 51.38, 42.0, 40.5, 31.9, 31.5,
24.2, 22.9, 22.4, 21.6, 20.8, 20.7, 9.2, 3.50/3.46*, 3.23/3.22*;
MS (ESI) m/z: calcd. for C36H51N6O10+ [M + H]+ 727.4, found 727.8; HRMS (ESI) m/z:
calcd. for C36H51N6O10+ [M + H]+ 727.3661, found 727.3665.
(2S)-2-(2-((S)-2-acetamido-4-methylpentanamido)acetamido)-N6-butyl-N6-(1-(4,5-di-
methoxy-2-nitrophenyl)ethoxy)-N1-phenylhexanediamide (3.119)
N
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According to the general procedure for Boc-deprotection, the
Boc-protected aniline amide 3.112 (233 mg, 0.38 mmol, 1.0
equiv.) was stirred in TFA:CH2Cl2 (3:7) (6.0 mL) for 1.5
h. Volatiles were removed under reduced pressure and co-
evaporated from toluene and CH2Cl2. The round-bottomed
flask was placed under vacuum for a couple of hours be-
fore a nitrogen atmosphere was established. According to the general procedure for
coupling reagent acylation, TBTU (159 mg, 0.49 mmol, 1.3 equiv.) and NEM (333 µL,
2.65 mmol, 7.0 equiv.) were added to a stirring solution of acetyl-L-leucylglycine 3.37
(106 mg, 0.46 mmol, 1.2 equiv.) in DMF (1.0 mL) and stirred for 15 min, before the
crude TFA salt in DMF (2.8 mL) was added and stirred overnight. Incomplete con-
version was observed, and therefore a new batch of acetyl-L-leucylglycine 3.37, TBTU,
and NEM were prepared in DMF (2.0 mL) and after stirring for 15 min added to the re-
action mixture followed by stirring overnight. The reaction mixture was diluted with
EtOAc (25 mL), and the organic layer was washed with brine (5 x 25 mL), sat. NaHCO3
(aq., 25 mL), and 1.0 M HCl (aq., 25 mL). The combined organic phases were dried
over Na2SO4, filtered, and concentrated in vacuo. The photo-protected tripeptide 3.119
was isolated by flash column chromatography (CH2Cl2 → CH2Cl2:MeOH 93:7) as a
pale green semi-solid (239 mg, 87%). A trace amount of CH2Cl2 was observed by 1H-
NMR. A diastereomeric mixture of 1:1 ratio was observed in the NMR spectra. Two
resonances for nuclei denoted with a star(*) were observed and both chemical shifts
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are reported. Multiplicity for each diastereomer is reported if possible. Rf = 0.17
(CH2Cl2:MeOH (19:1); UV); 1H-NMR (400 MHz, DMSO-d6): δ 9.90 (br. s, 1H, C(O)NHPh),
8.29 (t, J = 5.8 Hz, 1H, C(O)NHCH2C(O)), 8.08 (d, J = 7.4 Hz, 1H, CH3C(O)NHCH),
7.96 (d, J = 8.0 Hz, 1H, C(O)NHCHC(O)NHPh), 7.63–7.61 (m, 2H, ArH), 7.53 (s, 1H,
ArH), 7.32–7.28 (m, 3H, ArH), 7.07–7.03 (m, 1H, ArH), 5.42/5.41* (q, J = 5.8 Hz, 1H,
ArCHCH3), 4.39–4.33 (m, 1H, C(O)NHCHC(O)NHPh), 4.25–4.19 (m, 1H, H3C(O)NHCH),
3.921/3.920* (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.77–3.67 (m, 2H, C(O)NHCH2C(O)),
3.57–3.49 (m, 1H, C(O)NCH’H”CH2), 3.00–2.89 (m, 1H, C(O)NCH’H”CH2), 2.40–2.32
(m, 2H, NHCHCH2CH2CH2C(O)N), 1.84/1.83* (s, 3H, CH3C(O)NH), 1.77–1.23 (m, 12H,
CH3C(O)NHCHCH2CH, NHCHCH2CH2CH2, ArCHCH3, CH2CH2CH3), 1.14–1.03 (m,
2H, H2CH2CH3), 0.89–0.73 (m, 9H, CH2CH3, CH(CH3)2); 13C-NMR (101 MHz, DMSO-d6):
δ NC(O)CH2 missing, 172.8, 170.39/170.37*, 169.7, 168.9/168.8*, 152.87/152.86*, 148.2,
140.69/140.66*, 138.8, 130.7, 128.7, 123.4, 119.3, 109.7, 107.3, 77.5, 56.2, 56.1, 53.41/53.36*,
51.4, 46.4, 42.1, 40.5, 31.72/31.67*, 31.5, 28.42/28.39*, 24.2, 22.9, 22.4, 21.6, 20.9/20.8*,
20.70/20.68*, 19.3, 13.5; MS (ESI) m/z: calcd. for C36H53N6O10+ [M + H]+ 729.4, found
729.9.
(2S)-2-(2-((S)-2-acetamido-4-methylpentanamido)acetamido)-N6-(cyclobutylmethyl)-
N6-(1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)-N1-phenylhexanediamide (3.120)
N
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According to the general procedure for Boc-deprotection, the
Boc-protected aniline amide 3.113 (280 mg, 0.45 mmol, 1.0
equiv.) was stirred in TFA:CH2Cl2 (3:7) (7.1 mL) for 1.0
h. Volatiles were removed under reduced pressure and co-
evaporated from toluene and CH2Cl2. The round-bottomed
flask was placed under vacuum for a couple of hours be-
fore a nitrogen atmosphere was established. According to the general procedure for
coupling reagent acylation, TBTU (186 mg, 0.58 mmol, 1.3 equiv.) and NEM (392
µL, 3.12 mmol, 7.0 equiv.) were added to a stirring solution of acetyl-L-leucylglycine
3.37 (124 mg, 0.53 mmol, 1.2 equiv.) in DMF (2.0 mL) and stirred for 15 min, be-
fore the crude TFA salt in DMF (2.45 mL) was added and stirred overnight. The re-
action mixture was diluted with EtOAc (25 mL), and the organic layer was washed
with brine (5 x 25 mL), sat. NaHCO3 (aq., 25 mL), and 1.0 M HCl (aq., 25 mL). The
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combined organic phases were dried over Na2SO4, filtered, and concentrated in vacuo.
The photo-protected tripeptide 3.120 was isolated by flash column chromatography
(CH2Cl2 → CH2Cl2:MeOH 47:3) as a pale green foam (247 g, 75%). A trace amount
of CH2Cl2 was observed by 1H-NMR. A diastereomeric mixture of 1:1 ratio was ob-
served in the NMR spectra. Two resonances for nuclei denoted with a star(*) were ob-
served and both chemical shifts are reported. Multiplicity for each diastereomer is re-
ported if possible. Rf = 0.24 (CH2Cl2:MeOH (19:1); UV);
1H-NMR (400 MHz, DMSO-
d6): δ 9.89 (s, 1H, C(O)NHPh), 8.28 (t, J = 5.8 Hz, 1H, C(O)NHCH2C(O)), 8.09 (d, J
= 7.3 Hz, 1H, CH3C(O)NHCH), 7.97/7.96 (d, J = 7.8 Hz, 1H, C(O)NHCHC(O)NHPh),
7.62–7.60 (m, 2H, ArH), 7.53 (s, 1H, ArH), 7.32–7.27 (m, 3H, ArH), 7.07–7.03 (m, 1H,
ArH), 5.45–5.40 (m, 1H, ArCHCH3), 4.39–4.32 (m, 1H, C(O)NHCHC(O)NHPh), 4.25–
4.19 (m, 1H, CH3C(O)NHCH), 3.92 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.77–3.67 (m,
2H, C(O)NHCH2C(O)), 3.61 (dd, J = 14.5, 8.0 Hz, 1H, NCH’H”CH – CH2CH2CH2 – ),
3.13–3.04 (m, 1H, NCH’H”CH – CH2CH2CH2 – ), 2.52–2.44 (overlap with DMSO-d6)
(m, 1H, NCH2CH – CH2CH2CH2 – ), 2.37–2.29 (m, 2H, CHCH2CH2CH2C(O)N), 1.90–
1.40 (m, 18H, CH3C(O)NHCH2CH, CHCH2CH2CH2C(O)N, ArCHCH3, – CH2CH2CH2–
, CH3C(O)NHCH), 0.88–0.83 (m, 6H, CH(CH3)2); 13C-NMR (101 MHz, DMSO-d6): δ
NC(O)CH2 missing, 172.8, 170.4, 169.7, 168.9/168.8*, 152.8, 148.1, 140.7, 138.8, 130.4, 128.7,
123.4, 119.3, 109.8, 107.3, 77.0, 56.2, 56.1, 53.4/53.3*, 51.89, 51.86 (observed by HSQC), 42.0,
40.5, 33.2, 31.8, 31.5, 25.88/25.86*, 25.5, 24.2, 22.9, 22.4, 21.6, 20.8, 20.7, 17.8; MS (ESI) m/z:
calcd. for C37H53N6O10+ [M + H]+ 741.4, found 741.9.
((2S))-2-(2-((S)-2-acetamido-4-methylpentanamido)acetamido)-N6-(1-(4,5-dimethoxy-2-
nitrophenyl)ethoxy)-N6-neopentyl-N1-phenylhexanediamide (3.121)
N
(S)N
H O
H
N
OH
N
O
(S)N
H
O
O
NO2MeO
MeO
O
According to the general procedure for Boc-deprotection, the
Boc-protected aniline amide 3.114 (271 mg, 0.43 mmol, 1.0
equiv.) was stirred in TFA:CH2Cl2 (3:7) (6.9 mL) for 1.0
h. Volatiles were removed under reduced pressure and co-
evaporated from toluene and CH2Cl2. The round-bottomed
flask was placed under vacuum for a couple of hours be-
fore a nitrogen atmosphere was established. According to
the general procedure for coupling reagent acylation, TBTU (180 mg, 0.57 mmol, 1.3
158
3.13. Experimental Section
equiv.) and NEM (379 µL, 3.01 mmol, 7.0 equiv.) were added to a stirring solution
of acetyl-L-leucylglycine 3.37 (119 mg, 0.52 mmol, 1.2 equiv.) in DMF (2.0 mL) and
stirred for 15 min, before the crude TFA salt in DMF (2.30 mL) was added and stirred
overnight. The reaction mixture was diluted with EtOAc (25 mL), and the organic
layer was washed with Brine (5 x 25 mL), sat. NaHCO3 (aq., 25 mL), and 1.0 M HCl
(aq., 25 mL). The combined organic phases were dried over Na2SO4, filtered, and con-
centrated in vacuo. The photo-protected tripeptide 3.121 was isolated by flash column
chromatography (CH2Cl2 → CH2Cl2:MeOH 93:7) as a pale green foam (283 g, 88%). A
trace amount of CH2Cl2 was observed by 1H-NMR. A diastereomeric mixture of 1:1 ra-
tio was observed in the NMR spectra. Two resonances for nuclei denoted with a star(*)
were observed and both chemical shifts are reported. Multiplicity for each diastere-
omer is reported if possible. Rf = 0.20 (CH2Cl2:MeOH (19:1); UV);
1H-NMR (400 MHz,
DMSO-d6): δ 9.88 (s, 1H, C(O)NHPh), 8.28–8.26 (m, 1H, C(O)NHCH2C(O)), 8.07 (d, J
= 7.5 Hz, 1H, CH3C(O)NHCH), 7.97 (d, J = 7.6 Hz, 1H, C(O)NHCHC(O)NHPh), 7.61
(d, J = 8.1 Hz, 2H, ArH), 7.52 (s, 1H, ArH), 7.32–7.25 (m, 3H, ArH), 7.07–7.03 (m, 1H,
ArH), 5.53–5.48 (m, 1H, ArCHCH3), 4.39–4.32 (m, 1H, C(O)NHCHC(O)NHPh), 4.25–
4.19 (m, 1H, CH3C(O)NHCH), 3.912/3.909* (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.77–
3.67 (m, 2H, NHCH2C(O)), 3.50–3.46 (m, 1H, NCH’H”CH – CH2CH2CH2 – ), 3.05–2.99 (m,
1H, NCH’H”CH – CH2CH2CH2 – ), 2.43–2.21 (m, 2H, CHCH2CH2CH2C(O)N), 1.84/1.83*
(s, 3H, CH3C(O)N), 1.74–1.39 (m, 10H, CH3C(O)NHCHCH2CH, NHCHCH2CH2CH2,
ArCHCH3), 0.88–0.82 (m, 15H, C(CH3)3, CH(CH3)2); 13C-NMR (101 MHz, DMSO-d6):
δ NC(O)CH2 missing, 172.8, 170.4/170.3*, 169.6, 168.9/168.8*, 152.7, 148.3, 141.0, 138.8,
129.1, 128.7, 123.4, 119.3, 110.2/110.1*, 107.3, 75.6, 56.2, 56.1, 54.3 (observed by HSQC)
53.4/53.3*, 51.4, 42.0, 40.5, 33.2, 31.58, 31.56, 28.2, 24.1, 22.9, 22.4, 21.6, 21.0, 20.4; MS (ESI)
m/z: calcd. for C37H55N6O10+ [M + H]+ 743.4, found 743.8; HRMS (ESI) m/z: calcd. for
C37H55N6O10+ [M + H]+ 743.3974, found 743.3989.
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(2S)-2-(2-((S)-2-acetamido-4-methylpentanamido)acetamido)-N6-(cyclopentylmethyl)-
N6-(1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)-N1-phenylhexanediamide (3.122)
N
(S)N
H O
H
N
OH
N
O
(S)N
H
O
O
NO2MeO
MeO
O
According to the general procedure for Boc-deprotection, the
Boc-protected aniline amide 3.115 (407 mg, 0.63 mmol, 1.0
equiv.) was stirred in TFA:CH2Cl2 (3:7) (10.1 mL) for 1.0
h. Volatiles were removed under reduced pressure and co-
evaporated from toluene and CH2Cl2. The round-bottomed
flask was placed under vacuum for a couple of hours be-
fore a nitrogen atmosphere was established. According to the general procedure for
coupling reagent acylation, TBTU (265 mg, 0.82 mmol, 1.3 equiv.) and NEM (557 µL,
4.43 mmol, 7.0 equiv.) were added to a stirring solution of acetyl-L-leucylglycine 3.37
(175 mg, 0.76 mmol, 1.2 equiv.) in DMF (3.0 mL) and stirred for 15 min, before the
crude TFA salt in DMF (6.33 mL) was added and stirred overnight. The reaction mix-
ture was diluted with EtOAc (25 mL), and the organic layer was washed with brine (5
x 25 mL), sat. NaHCO3 (aq., 25 mL), and 1.0 M HCl (aq., 25 mL). The combined or-
ganic phases were dried over Na2SO4, filtered, and concentrated in vacuo. The photo-
protected tripeptide 3.122 was isolated by flash column chromatography (CH2Cl2:MeOH
99:1 → 93:7) as a pale green semi-solid (427 mg, 89%). A trace amount of CH2Cl2 was
observed by 1H-NMR. A diastereomeric mixture of 1:1 ratio was observed in the NMR
spectra. Two resonances for nuclei denoted with a star(*) were observed and both chemi-
cal shifts are reported. Multiplicity for each diastereomer is reported if possible. Rf = 0.23
(CH2Cl2:MeOH (19:1); UV); 1H-NMR (400 MHz, DMSO-d6): δ 9.89 (s, 1H, C(O)NHPh),
8.28 (t, J = 5.8 Hz, 1H, C(O)NHCH2C(O)), 8.08 (d, J = 7.2 Hz, 1H, CH3C(O)NHCH),
7.97/7.96* (d, J = 7.7 Hz, 1H, C(O)NHCHC(O)NHPh), 7.62–7.60 (m, 2H, ArH), 7.53 (s,
1H, ArH), 7.32–7.28 (m, 3H, ArH), 7.07–7.03 (m, 1H, ArH), 5.46–5.41 (m, 1H, ArCHCH3),
4.39–4.33 (m, 1H, C(O)NHCHC(O)NHPh), 4.25–4.19 (m, 1H, CH3C(O)NHCH), 3.92/3.92*
(s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.77–3.67 (m, 2H, C(O)NHCH2C(O)), 3.49–
3.47 (dd, J = 14.2, 8.4 Hz, 1H, C(O)NCH’H”CH – CH”’H””CH2CH2CH”’H”” – ),
2.97–2.86 (m, 1H, C(O)NCH’H”CH – CH”’H””CH2CH2CH”’H”” – ), 2.40–2.31 (m,
2H, CHCH2CH2CH2C(O)N), 2.13–2.05 (m, 1H, CH – CH”’H””CH2CH2CH”’H”” –
), 1.84/1.83* (s, 3H, CH3C(O)NH), 1.77–1.37 (m, 16H, CH3C(O)NHCHCH2CH,
NHCHCH2CH2CH2, ArCHCH3, CH – CH”’H””CH2CH2CH”’H”” – ), 1.09–0.97 (m, 2H,
160
3.13. Experimental Section
CH – CH”’H””CH2CH2CH”’H”” – ), 0.87 (d, J = 6.5 Hz, 3H, CHCH3), 0.83 (d, J =
6.5 Hz, 3H, CHCH3); 13C-NMR (101 MHz, DMSO-d6): δ NC(O)CH2 missing, 172.8,
170.39/170.38*, 169.7, 168.9/168.8*, 152.8, 148.2, 140.72/140.69*, 138.8, 130.6, 128.7, 123.4,
119.3, 109.8, 107.3, 77.2, 56.2, 56.1, 53.44/53.37*, 51.4, 50.5 (observed by HSQC) 42.1, 40.5,
37.5, 31.8/31.7*, 31.6/31.5*, 29.69/29.67* 24.4, 24.2, 22.9, 22.4, 21.6, 20.9/20.8*; MS (ESI)
m/z: calcd. for C38H55N6O10+ [M + H]+ 755.4, found 755.9.
(2S)-2-(2-((S)-2-acetamido-4-methylpentanamido)acetamido)-N6-(1-(4,5-dimethoxy-2-
nitrophenyl)ethoxy)-N1-phenyl-N6-(thiophen-2-ylmethyl)hexanediamide (3.123)
N
(S)N
H O
H
N
OH
N
O
(S)N
H
O
O
NO2MeO
MeO
O
S
According to the general procedure for Boc-deprotection, the
Boc-protected aniline amide 3.116 (510 mg, 0.78 mmol, 1.0
equiv.) was stirred in TFA:CH2Cl2 (3:7) (12.3 mL) for 1.0
h. Volatiles were removed under reduced pressure and co-
evaporated from toluene and CH2Cl2. The round-bottomed
flask was placed under vacuum for a couple of hours be-
fore a nitrogen atmosphere was established. According to the general procedure for
coupling reagent acylation, TBTU (325 mg, 1.01 mmol, 1.3 equiv.) and NEM (684
µL, 5.44 mmol, 7.0 equiv.) were added to a stirring solution of acetyl-L-leucylglycine
3.37 (216 mg, 0.94 mmol, 1.2 equiv.) in DMF (3.0 mL) and stirred for 15 min, be-
fore the crude TFA salt in DMF (4.33 mL) was added and stirred overnight. The re-
action mixture was diluted with EtOAc (25 mL), and the organic layer was washed
with brine (5 x 25 mL), sat. NaHCO3 (aq., 25 mL), and 1.0 M HCl (aq., 25 mL). The
combined organic phases were dried over Na2SO4, filtered, and concentrated in vacuo.
The photo-protected tripeptide 3.123 was isolated by flash column chromatography
(CH2Cl2:MeOH 99:1 → 93:7) as a brown semi-solid (500 mg, 84%). A trace amount
of CH2Cl2 was observed by 1H-NMR. A diastereomeric mixture of 1:1 ratio was ob-
served in the NMR spectra. Two resonances for nuclei denoted with a star(*) were ob-
served and both chemical shifts are reported. Multiplicity for each diastereomer is re-
ported if possible. Rf = 0.19 (CH2Cl2:MeOH (19:1); UV);
1H-NMR (400 MHz, DMSO-
d6): δ 9.90 (s, 1H, C(O)NHPh), 8.28 (t, J = 5.8 Hz, 1H, C(O)NHCH2C(O)), 8.084/8.080*
(d, J = 7.5 Hz, 1H, CH3C(O)NHCH), 7.96 (d, 1H, C(O)NHCHC(O)NHPh), 7.63–7.61
(m, 2H, ArH), 7.51 (s, 1H, ArH), 7.35–7.28 (m, 3H, ArH), 7.21/7.20* (s, 1H, ArH), 7.07–
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7.03 (m, 1H, ArH), 6.89–6.86 (m, 1H, ArH), 6.79–6.77 (m, 1H, ArH), 5.57–5.52 (m, 1H,
ArCHCH3), 4.86 (d, J = 16.3 Hz, 1H, C(O)NCH’H”Ar), 4.48–4.32 (m, 2H, C(O)NCH’H”Ar,
C(O)NHCHC(O)NHPh), 4.25–4.19 (m, 1H, CH3C(O)NHCH), 3.86 (s, 6H, 2 x OCH3),
3.77–3.67 (m, 2H, C(O)NHCH2C(O)), 2.46–2.33 (m, 2H, CHCH2CH2CH2C(O)N), 1.83–1.41
(m, 13H, CH3C(O)NHCHCH2CH, NHCHCH2CH2CH2, ArCHCH3), 0.88–0.82 (m, 6H,
CH(CH3)2); 13C-NMR (101 MHz, DMSO-d6): δ NC(O)CH2 missing, 172.8, 170.37/170.35*,
169.7, 168.9/168.8*, 152.93/152.92*, 148.1, 140.33/140.29*, 138.8, 138.6, 130.7, 128.7,
126.6/126.5*, 126.4, 125.8, 123.4, 119.3, 109.7, 107.4, 78.0, 56.12, 56.09, 53.43/53.37*, 51.4,
45.9, 42.0, 40.5, 31.9/31.8*, 31.5, 24.2, 22.9, 22.43/22.42*, 21.6, 21.1/21.0*, 20.6/20.5*; MS
(ESI) m/z: calcd. for C37H49N6O10S+ [M + H]+ 769.3, found 769.8.
(2S)-2-(2-((S)-2-acetamido-4-methylpentanamido)acetamido)-N7-(cyclopropylmethyl)-
N7-(1-(4,5-dimethoxy-2-nitrophenyl)ethoxy)-N1-phenylheptanediamide (3.124)
N
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H O
H
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According to the general procedure for Boc-deprotection, the
Boc-protected aniline amide3.117 (850 mg, 1.35 mmol, 1.0
equiv.) was stirred in TFA:CH2Cl2 (3:7) (21.5 mL) for 1.0
h. Volatiles were removed under reduced pressure and co-
evaporated from toluene and CH2Cl2. The round-bottomed
flask was placed under vacuum for a couple of hours before a
nitrogen atmosphere was established. According to the gen-
eral procedure for coupling reagent acylation, TBTU (565 mg,
1.76 mmol, 1.3 equiv.) and NEM (1.19 mL, 9.47 mmol, 7.0
equiv.) were added to a stirring solution of acetyl-L-leucylglycine 3.37 (374 mg, 1.62
mmol, 1.2 equiv.) in DMF (3.0 mL) and stirred for 20 min, before the crude TFA salt in
DMF (10.5 mL) was added and stirred overnight. Incomplete conversion was observed,
and therefore a new batch of acetyl-L-leucylglycine 3.37, TBTU, and NEM were prepared
in DMF (2.0 mL) and after stirring for 15 min added to the reaction mixture followed by
stirring overnight. The reaction mixture was diluted with EtOAc (25 mL), and the or-
ganic layer was washed with brine (5 x 25 mL), sat. NaHCO3 (aq., 25 mL), and 1.0 M
HCl (aq., 25 mL). The combined organic phases were dried over Na2SO4, filtered, and
concentrated in vacuo. The photo-protected tripeptide 3.124 was isolated by flash column
chromatography (CH2Cl2 → CH2Cl2:MeOH 93:7) as a light yellow foam (790 mg, 79%).
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A trace amount of CH2Cl2 was observed by 1H-NMR. A diastereomeric mixture of 1:1
ratio was observed in the NMR spectra. Two resonances for nuclei denoted with a star(*)
were observed and both chemical shifts are reported. Multiplicity for each diastereomer
is reported if possible. Rf = 0.24 (CH2Cl2:MeOH (19:1); UV);
1H-NMR (400 MHz, DMSO-
d6): δ 9.92/9.91* (s, 1H, C(O)NHPh), 8.29–8.26 (m, 1H, C(O)NHCH2C(O)), 8.08 (d, J =
7.6 Hz, 1H, CH3C(O)NHCH), 7.93 (d, J = 7.8 Hz, 1H, C(O)NHCHC(O)NHPh), 7.62 (d, J
= 8.0 Hz, 2H, ArH), 7.53/7.53* (s, 1H, ArH), 7.31–7.27 (m, 3H, ArH), 7.06–7.03 (m, 1H,
ArH), 5.48 (d, J = 6.5 Hz, 1H, ArCHCH3), 4.38–4.33 (m, 1H, C(O)NHCHC(O)NHPh),
4.25–4.19 (m, 1H, H3C(O)NHCH), 3.91 (s, 3H, OCH3), 3.853/3.847* (s, 3H, OCH3),
3.77–3.66 (m, 2H, C(O)NHCH2C(O)) 3.34–3.28 (m, 1H, C(O)NCH’H”CH), 3.11–
3.04 (m, 1H, C(O)NCH’H”CH), 2.34 (m, 2H, CH2CH2CH2C(O)N), 1.84 (s, 3H,
CH3C(O)NH), 1.76–1.55 (m, 6H, CH3C(O)NHCHCH2CH, NHCHCH2CH2, ArCHCH3),
1.51–1.41 (m, 4H, CH3C(O)NHCHCH2CH, CH2CH2CH2C(O)), 1.36–1.21 (m, 2H,
NHCHCH2CH2CH2), 0.93–0.82 (m, 7H, CH(CH3)2, C(O)NCH2CH), 0.36–0.34 (m, 2H,
– CH”’H””CH”’H”” – CHC(O)N), 0.16–0.09 (m, 2H, – CH”’H””CH”’H”” – CHC(O)N);
13C-NMR (101 MHz, DMSO-d6): δ NC(O)CH2 missing, 172.8, 170.5, 169.6, 168.8, 152.8,
148.1, 140.7, 138.9, 130.6, 128.7, 123.4, 119.3, 109.8, 107.3, 77.1, 56.2, 56.1, 53.2, 51.4, 51.3
(observed by HSQC) 42.1, 40.5, 32.0, 31.7, 25.0, 24.2, 23.94/23.90*, 22.9, 22.4, 21.6, 20.8, 9.2,
3.5, 3.2; MS (ESI) m/z: calcd. for C37H53N6O10+ [M + H]+ 741.4, found 741.8.
Methyl (2S)-2-(bis(tert-butoxycarbonyl)amino)-6-((1-(4,5-dimethoxy-2-nitrophenyl)-
ethoxy)amino)-6-oxohexanoate (3.125)
OMe
MeO
NO2
O
HN
O
(S)
O
O
N O
OO
O
According to the general procedure for coupling reagent acy-
lation, HATU (1.48 g, 3.89 mmol, 1.2 equiv.) and DIPEA (3.93
mL, 22.6 mmol, 7.0 equiv.) were added to a stirring solution of
the carboxylic acid 3.57 (1.33 g, 3.55 mmol, 1.1 equiv.) in DMF
(32.3 mL) and stirred for 15 min, before the hydroxylamine
hydrochloride 2.7 (900 mg, 3.23 mmol, 1.0 equiv.) was added
and stirred for 6 h. The organic layer was washed with brine
(6 x 100 mL). The hydroxamate 3.125 (1.78 g, 92%) was iso-
lated by flash column chromatography (EtOAc:heptane 1:1→ 3:2) as a pale green foam.
A diastereomeric mixture of 1:1 ratio was observed in the NMR spectra. Two resonances
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for nuclei denoted with a star(*) were observed and both chemical shifts are reported.
Multiplicity for each diastereomer is reported if possible. Rf = 0.25 (EtOAc:heptane (1:1);
UV); IR (neat) ν (cm-1): 3241, 2978, 2937, 1743, 1697, 1518, 1366, 1272; 1H-NMR (400 MHz,
DMSO-d6): δ 10.772/10.764* (s, 1H, HNC(O)), 7.57/7.56* (s, 1H, ArH), 7.37/7.37* (s, 1H,
ArH), 5.45 (q, J = 6.3 Hz, 1H, ArCHCH3), 4.74 (dd, J = 9.9, 4.9 Hz, 1H, CH’H”CH2CHN),
3.95 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.61 (s, 1H, C(O)OCH3), 1.88–1.77 (m, 3H,
NC(O)CH2CH2CH’H”CHN), 1.74–1.64 (m, 1H, CH’H”CHN), 1.47 (d, J = 6.3 Hz, 3H,
ArCHCH3), 1.46–1.31 (m, 20H, NC(O)CH2CH2CH2, 2 x C(CH3)3); 13C-NMR (101 MHz,
DMSO-d6): δ 170.4, 169.0, 153.4, 151.6, 147.7, 140.1/140.0*, 132.6, 109.2, 107.4, 82.5, 77.4,
57.2, 56.03, 56.01, 52.0, 31.7, 28.9, 27.4, 21.5, 21.0; MS (ESI) m/z: calcd. for C27H41N3NaO12+
[M + Na]+ 622.3, found 622.7; HRMS (ESI) m/z: calcd. for C27H41N3NaO12+ [M + Na]+
622.2582, found 622.258.
Methyl (2S)-2-(bis(tert-butoxycarbonyl)amino)-7-((1-(4,5-dimethoxy-2-nitrophenyl)-
ethoxy)amino)-7-oxoheptanoate (3.126)
OMe
MeO
NO2
O
HN
O
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O
O
NO
O
O
O
According to the general procedure for coupling reagent acy-
lation, HATU (1.25 g, 3.29 mmol, 1.2 equiv.) and DIPEA (3.34
mL, 19.2 mmol, 7.0 equiv.) were added to a stirring solution
of the carboxylic acid 3.65 (1.74 mg, 3.01 mmol, 1.1 equiv.)
in DMF (27.4 mL) and stirred for 20 min, before the hydrox-
ylamine hydrochloride 2.7 (765 mg, 2.74 mmol, 1.0 equiv.)
was added and stirred overnight. The organic layer was washed with brine:H2O (1:1,
6 x 100 mL). The hydroxamate 3.126 (1.28 g, 76%) was isolated by flash column chro-
matography (EtOAc:heptane 2:3→ 13:7) as a pale green foam. A diastereomeric mixture
of 1:1 ratio was observed in the NMR spectra. Two resonances for nuclei denoted with
a star(*) were observed and both chemical shifts are reported. Multiplicity for each di-
astereomer is reported if possible. Rf = 0.24 (EtOAc:heptane (2:3); UV); IR (neat) ν (cm-1):
3228, 2978, 2937, 2868, 1743, 1697, 1518, 1457, 1366, 1272; 1H-NMR (400 MHz, DMSO-d6):
δ 10.73 (s, 1H, HNC(O)), 7.56/7.55* (s, 1H, ArH), 7.36 (s, 1H, ArH), 5.47–5.41 (m, 1H,
ArCHCH3), 4.74–4.69 (m, 1H, CH2CHN), 3.95 (s, 3H, OCH3), 3.849/3.856* (s, 3H, OCH3),
3.62 (s, 1H, C(O)OCH3), 1.92–1.77 (m, 3H, NC(O)CH2CH2CH’H”CHN), 1.72–1.62 (m, 1H,
CH2CH’H”CHN), 1.48–1.31 (m, 23H, NC(O)CH2CH2CH2, 2 x C(CH3)3, ArCHCH3), 1.13–
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1.02 (m, 2H, CH2CH2CH2CHN), 13C-NMR (101 MHz, DMSO-d6): δ 170.5, 169.0, 153.4,
151.6, 147.7, 140.22/140.19*. 132.6, 109.24/109.20* 107.4/107.3*, 82.5, 77.3, 57.3, 56.03,
55.99, 52.0, 31.9, 28.9, 27.5, 24.8, 24.5, 21.0; MS (ESI) m/z: calcd. for C28H43N3NaO12+ [M +
Na]+ 636.3, found 636.8.
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Chapter 4
Itaconimides as Novel Quorum Sensing
Inhibitors of Pseudomonas aeruginosa
During my external stay, I was given the opportunity to go to Singapore and work with
Assistant Professor Liang Yang at SCELSE and Professor Choon-Hong Tan at the Division
of Chemistry and Biological Chemistry at NTU.
4.1 Cell Biology, Quorum Sensing, and the Battle against
Antibiotic Resistant Bacteria
Sir Alexander Fleming discovered penicillin in 1928, and later, Professor Ernst Boris
Chain and Sir Howard Walter Florey developed a useful large scale synthesis of the com-
pound. Together, in 1945, Flemming, Chain, and Florey received the Nobel Prize for their
achievements.199 In his Nobel lecture, Sir Alexander Fleming addressed several issues:
“And we are not at the end of the penicillin story. Perhaps we are only just at the beginning. We
are in a chemical age and penicillin may be changed by the chemists so that all its disadvantages
may be removed and a newer and a better derivative may be produced.... There may be a danger,
though, in underdosage. It is not difficult to make microbes resistant to penicillin in the laboratory
by exposing them to concentrations not sufficient to kill them, and the same thing has occasionally
happened in the body.... Moral: If you use penicillin, use enough”200
Today, we face the consequence of misused antibiotics, as uncontrolled usage has resulted
in a large amount of bacteria becoming resistant toward common antibiotics. In South
European countries, antibiotics can be bought without a prescription, often resulting in
over- or misuse due to lack of council.201,202 In the Northern countries, such as Denmark,
antibiotics can only be bought with a prescription, lowering the risk of improper use.203
In 1990, Woese et al. revised the taxonomic classification of all living cells and subdi-
vided the cells into three domains in the phylogenetic tree of life: Bacteria, Archaea, and
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Eukaryota.204 Archaea and Bacteria consists of prokaryote cells, whereas Eukaryota, as
the name implies, is eukaryote cells. Bacteria can also be divided into two independent
classes. In 1884, a Danish bacteriologist, Hans Christian Joachim Gram, found that differ-
ent bacteria had a significant color variation when subjected to the Crystal violet dye. He
classified the bacteria as Gram-negative or Gram-positive.
Gram-negative bacteria are composed of three membranes: an outer membrane, a pepti-
doglycan cell wall, and an inner membrane, Figure 4.1. Whereas Gram-positive bacteria
does not have the outer membrane. This membrane acts as an outer barrier, and is one
of the reasons why, Gram-negative bacteria display a higher degree of resistance and are
difficult to target. The outer membrane is composed of two layers consisting of phospho-
lipids and lipopolysaccharide, respectively.205,206
(a) Composition of Gram-negative cells (b) Composition of Gram-positive cells
Figure 4.1: Illustrating the differences between Gram-negative and Gram-postive cells. Adapted from Brown et al.206
For decades bacteria were believed to be organized as colonies in a free-floating (plank-
tonic) state, but it has later been shown that under 0.1% of the total microbial biomass
is found in this planktonic state.207 The bacteria tend to aggregate into communities and
produce a protecting layer, called the biofilm.208 Healy et al. describe that biofilm forma-
tion renders the bacteria more than 500 times less susceptible to antibiotics.207 Biofilms
are a problem in the medical treatment, as they tend to appear on the surfaces with a
weakened immune defense, and in particular on foreign objects, such as implants. The
lungs of cystic fibrosis patients often show high biofilm formation.209 Development of
highly resistant strains have been observed. Recently, an American female was infected
with resistant Klebsiella pneumoniae, and showed resistance towards 26 antibiotics,210 even
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against carbapenem, which is considered to be one of the ”last resort” drugs.211 In another
case, a strain of Escherichia coli showed resistance towards carbapenem and another last
resort antibiotics, colistin.212
Livestock also show signs of severe antibiotic resistance. The poor regulation of antibi-
otics in livestock and the constant pressure for the farmers to gain more revenue per
animal is to blame of this. An article in the Guardian reported that around two thirds of
all Danish pig farms are infected with the feared antibiotic resistance staphylococcus bac-
teria, namely methicillin resistant Staphylococcus aureus (MRSA) CC398 strain. In British
supermarkets it was found that 9% of the tested pork meat was infected with CC398,
among those 89% of the meat came from Danish farms. If this food is handled in the
right way, there is little risk of the strain being transferred to humans, but working with
the animals pose a higher risk of infection, as prolonged exposure heightens the risk of
mutations.213
Antibiotics are classified as bactericides, which means they kill the bacteria.214 The bacte-
ria develops resistance in order to survive. Therefore, it is important to develop antibi-
otics that targets mechanisms with a lower tendency to develop resistance. Another ap-
proach for targeting bacteria, is antipathogenic treatment.215 Biofilm need a well-organized
signal network to enable cell-to-cell communication within the bacteria, so-called quorum
sensing (QS).216 The course of the biofilm formation, developing, and dispersion into the
extracellular matrix are shown in Figure 4.2.
Figure 4.2: Biofilm formation, development, and the dispersion of bacteria into the extracellular matrix. Adapted
from [217]
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The quorum sensing apparatus monitors the bacteria growth by producing and releasing
small signal molecules called autoinducers. The concentration of these molecules in the
environment is proportional to the bacteria growth. When biofilms with high-density of
bacteria cells are obtained, a procedure induces the signal molecules to bind to their acti-
vated cognate receptors which expresses various virulence factors.218
P. aeruginosa is a opportunistic pathogen that is found in chronic cystic fibrosis infec-
tions, one of the most investigated pathogens displaying intrinsic multidrug resistance.
It exhibits a well-established biofilm formation, and has a broad tolerance profile.209,219
Furthermore, WHO has recently placed P. aeruginosa in the top three of the 12 most crit-
ical antibiotic-resistance bacteria on its global priority list with urgent demand for new
therapies.220
Gram-negative bacteria employ N-acyl homoserine lactones (AHLs) as autoinducers.
AHLs are structurally different between the Gram-negative bacteria, in both the length
and the substitution pattern of the acyl chain. The las system employs two proteins for
its mode of action, Figure 4.4. LasI, an autoinducer synthase that catalyzes the synthesis
of N-(3-oxo-dodecanoyl)-L-homoserine lactone (OdDHL), Figure 4.3, whereas lasR is a
transcriptional regulatory protein, controlling the expression of various virulence factors,
LasB elastase, LasA protease, and basic protease.
For the rhl system, RhlI is an autoinducer synthase, mediating the synthesis of N-butanoyl-
L-homoserine lactone (BHL), Figure 4.3. Furthermore, RhlR activates the transcription of
other virulence factors, the rhamnolipid biosynthesis genes (rhlAB).214,221
(S)
O
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O
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O
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BHL
Figure 4.3: Autoinducers applied by the las quorum sensing network
The communication process is sketched in Figure 4.4.219,221,222
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Figure 4.4: LasR and RhlR bind autoinducers to get activated as the corresponding LasR* and RhlR*. The Las system
regulates the RhlR system. Modified from Glansdorp et al.223
Small molecules that induces a disruption of the quorum sensing communication net-
work, also known as quorum quenchers, have been heavily investigated over the years,
due to their low resistance tendency. It is believed that mutations will not be able to
communicate with the rest of the group in the biofilm. Not only has there been a strong
interest in the development of inhibitors (antagonists) against the quorum sensing sys-
tem. Also, quorum sensing agonists (superagonists) has been studied.224–226 These mimic
a high-density state and prematurely induce dispersion of the biofilm, so the immune
system is more likely to destroy the pathogens.
Modifying the acyl chain of homoserine lactone, has been the preferred choice, but sev-
eral non-AHL synthesis programs have also been published. We will not describe all of
the published inhibitors, but several good papers and reviews have already been men-
tioned in this dissertation. For more information see references [225, 227–229]. Quorum
sensing inhibitors (QSis) have been found in food sources, two examples are ajoene from
garlic230 and iberin from horseradish231, Figure 4.5.
S
O
S S S
O
N C S
ajoene iberin
Figure 4.5: Naturally occuring QSis found in extracts from garlic and horseraddish
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4.2 Hit Compound and Covalent Modifiers
July Fong from the Yang group found six hit compounds that displayed activity against
the quorum sensing network in P. aeruginosa. The most promising inhibitor was the 2-
mercaptobenzothiazole disulfide allyl 4.1, Figure 4.6, with an IC50 of 0.98 µM against a
green fluorescent protein (gfp) tagged P. aeruginosa reporter strain,214 PAO1-lasB-gfp1. The
incorporation of the gfp tag makes it possible to detect the amount of produced LasB and
thereby to detect LasR activity. A decrease in fluorescence, compared to a reference sam-
ple, show inhibition of OdDHL formation, and hereby restricted formation of gfp-tagged
lasB.219 LasB is a metalloprotease which acts by destroying the surrounding environment
which liberates nutrition important for the growth of biofilm, as well as for initiating
biofilm formation.232
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4.1 4.2 4.3 4.4
Figure 4.6: Four hit compounds found to be active against quorum sensing. Adapted from Fong et al.1
The goal of my project, was to synthesize analogues of the N-napthyl itaconimide 4.5a,
Figure 4.7, to evaluate their quorum sensing properties. July found that 4.5a has an IC50
value of 4.16 µM against PAO1-lasB-gfp. The scaffold is advantageous due to the easy
accessibility to analogues, furthermore they can be synthesized at low costs.
N
O
O
4.5a
Figure 4.7: The fifth hit compound found in a screen of less than 500 compounds performed by J. Fong.
Itaconimides have been used to make polymers233 and in 1999 a patent was filed on the
synthesis and biological screening of itaconimides and citraconimides for activity against
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mycobacteria.234 The reported compounds demonstrated minimum inhibitory concentra-
tion (MIC) values of ≤ 20 µg/mL in a M. tuberculosis strain. Both the itaconimide- and
citraconimide N-octyl analogues was synthesized and tested in the patent.
Itaconimide and citraconimide contain a α,β-conjugated double bond, and due to their
Michael acceptor nature, these compounds could act as covalent modifiers. Covalent
modifiers, reversible or irreversible, have been one of the most influential classes of drugs
over time.235 Singh et al. described, that three of the ten most selling drugs in America in
2009 were covalent inhibitors. Over time, a total of 39 covalent drugs have been approved
by FDA, two well-known drugs are aspirin and β-lactams, such as penicillin,236 Figure 4.8.
A short timeline of covalent modifiers is illustrated in Figure 4.8.
Figure 4.8: A selection of known covalent modifier and some of the recent approved. Afatinib, not drawn in the
figure, was approved by FDA in 2013,237 and neratinib is likely to be approved in 2017238. Adapted from Whitty et al.235
Omeprazole and clopidogrel becomes active in vivo by metabolic modifications.236,239 Ner-
atinib contains an acrylamide group, which is one of the most applied moieties,240 that
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are shown to react with cystein residues via a Michael addition/1,4-addition of the β-
position.
4.3 Synthesis of Quorum Sensing Inhibitors
The general procedure used for synthesis of itaconimide analogues, was originally pub-
lished by Cava et al. in the 1960s for the synthesis of N-phenylmaleimide.241 A primary
amine (1.0 equiv.) is added to itaconic anhydride 4.6 in CHCl3 which forms the corre-
sponding α-itaconamic acid,242 Table 4.1. In most cases, the precipitate was collected by
filtration. For reactions with no precipitate or low yields, all volatiles were removed un-
der reduced pressure. The α-itaconamic acid was added Ac2O (3.5 equiv.) and NaOAc
(0.5 equiv.) followed by stirring at elevated temperature. The imidization reactions af-
forded both the desired itaconimide and the citraconimide. The latter side-product prob-
ably arise from an isomerization reaction of the itaconimides. The citraconimides and
the itaconimides was separated, and both included in the screening. All the synthesized
compounds are listed in Table 4.1.
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Table 4.1: Synthesized itaconimides and citraconimides
O
O
OH
O
O
N R
O
O
N R+
a b
O
O
O
NHR
NaOAc, Ac2O
45 min, 100 oCCHCl3
RNH2
Itaconimide
Itaconimide Citraconimide
Itaconimide
4.6
Entry R a (%) a b (%) a Entry R a (%) a b (%) a
1 4.6 4.5a (50) 4.5b (14) 11
Cl
4.6 4.16a (61) 4.16b (9)
2 4.6 4.7a (37) 4.7b (-)b 12 Br4.6 4.17a (37) 4.17b (20)
3 4.6 4.8a (17) 4.8b (-)b 13 F4.6 4.18a (40) 4.18b (19)
4 24.6 4.9a (10) 4.9b (-)b 14 NO24.6 4.19a (-)b 4.19b (-) b
5 4.6 4.10a (47) 4.10b (-)b 15 44.6 4.20a (8) 4.20b (14)
6 4.6 4.11a (49) 4.11b (29) 16 64.6 4.21a (16) 4.21b (-)b
7 OMe4.6 4.12a (-)c 4.12b (-)d 17 84.6 4.22a (13) 4.22b (10)
8 Cl4.6 4.13a (31) 4.13b (40) 18 104.6 4.23a (4) 4.23b (12)
9
F
Cl
4.6 4.14a (24) 4.14b (14) 19 124.6 4.24a (2) 4.24b (11)
10
Cl
4.6 4.15a (35) 4.15a (15)
a) Isolated yields b) not able to isolate c) a sample was available from the Tan lab d) not available
Generally, low yields were observed, and in some cases, it was not possible to isolate the
citraconimide side-products.
For the biological screening, the compounds were tested in duplicates at three different
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concentrations: 50 µM, 25 µM, and 12.5 µM. Each compound was tested for its effect on
the bacteria growth, indicated by the optical density at 600 nm (OD600), OD-AVE corre-
sponds to the average value of the duplicates. Compounds causing decreased amounts
of bacteria, display bactericidal activity and were discarded.
N-ortho-chlorophenyl 4.13a and N-octyl 4.21a showed more active than the original hit
compound, 4.5a. Due to these findings, the project was divided into two groups: N-
aliphatic itaconimides and N-arylated itaconimides. All the inhibition curves of the ita-
conimides and the citraconimides are included in experimental section, Section 4.5.
To investigate the effect of aliphatic N-alkyl chain, we synthesized the hexyl, decyl, do-
decyl, and tetradecyl analogues, Figure 4.9. Indeed, a correlation between the aliphatic
chain length and the activity was found: tetradecyl (4.24a) > dodecyl (4.23a) > decyl
(4.22a) > octyl (4.21a), Figure 4.9. We found that 4.24a was the most active of all the
synthesized compounds, Figure 4.9. At 50 µM, 4.24a almost eradicated quorum sensing.
However, antibiotic activity was observed by the OD600 measurement at 50 µM. This ef-
fect was significantly decreased at 12.5 µM.
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4.21a 4.20b 4.22b 4.23b 4.24b
Figure 4.9: Synthesis of selected N-aliphatic itaconimides
The second part of this project involved the synthesis of N-arylated itaconimides with fo-
cus on using anilines functionalized with electron-withdrawing groups (EWGs), Figure
Figure 4.10. This could potentially afford more reactive Michael acceptors. The syn-
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thesized compounds are listed in Figure 4.10. The bromo substituted analogue 4.17a
showed highest activity. Brom is less electronegative than chlor. This means that the
conjugated exo-cyclic alkene analogue 4.17a is less electrophilic compared to the chloro
analogue 4.13a. This could indicate that the activity is not only affected by inductive ef-
fects. It was observed that both the meta-chloro 4.15a and the para-chlor 4.16a analogues
had poorer activity. The decreased reactivity of 4.16a could be a consequence of a chloro-
carbonyl repulsion, constraining the spacial rotation around the N-C bond. We synthe-
sized and tested the ortho-fluorophenyl analogue 4.18a (not included in Figure 4.10), but
remarkably a poor inhibition profile was observed, see Section 4.5, which emphasizes the
statement that the inductive effect is not the only actor to afford strong inhibitors. Unfor-
tunately, we did not synthesize the para-iodophenyl analogue, which could have given
us more information about the electronegativity-dependency profile.
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Cl
4.5a 4.15a 4.16a4.14a 4.17a
4.13a 4.15b 4.16b4.14b 4.17b
Figure 4.10: Synthesis of selected N-arylated itaconimides
Finally, the most active compounds were tested against each other for the inhibition of P.
aeruginosa, Figure 4.11. We clearly observed that the tetradecyl compound 4.24a was the
most active of all the synthesized compounds.
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Figure 4.11: A screen including the most active compounds synthesized to find the most potent inhibitor
4.4 Conclusion
With the synthesis of 4.13a and 4.21a we found compounds with higher activity than the
original hit compound 4.5a. All inhibition curves are included in the Section 4.5. As high-
lighted earlier, QSis often have a long aliphatic chain that resembles the natural produced
autoinducer. The EWG properties would afford a stronger Michael acceptor. However,
the para-fluor analogue 4.18a displayed decreased activity than the para-bromophenyl
arylated itaconimide 4.17a. It could imply that the fluorine analogue made the Michael
acceptor too reactive, resulting in unspecific reactivity. The N-tetradecyl analogue 4.24a
was identified as the most active compound in this study. Fong recently found that the
IC50 values for the para-bromophenyl itaconimide 4.17a and the N-tetradecyl itaconimide
4.24a against PAO1-lasB-gfp are 3.40 µM and 0.21 µM, respectively. These are very promis-
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ing results. The tetradecyl analogue display almost 20 fold higher reactivity than the
napthyl analogue and shows almost five-fold increased activity compared to the the re-
cently published 2-mercaptobenzothiazole disulfide allyl 4.1 QSi by July Fong. More bio-
logical testing is currently being conducted in Singapore to establish its mode of action.
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4.5 Experimental Section
4.5.1 General Methods
NMR spectra were recorded on BrukerAvance III-400 spectrometer operating at 400 MHz
for 1H-NMR and 100 MHz for 13C-NMR. The specific deuterated solvent is stated for each
compound. Chemical shifts (δ) are given in ppm and the coupling constants (J) in Hz.
Mass spectrometric data were recorded on a ThermoFinnigan PolarisQ MS/ThermoFinnigan
LCQ Fleet MS. The values were reported in the unit of mass to charge ratio (m/z).
For TLC, Merck C-60 F254 silica gel plates were used and developed using UV-light or a
suitable stain. Flash chromatography was performed using a glass column packed with
Merck 60 silica gel (40-63 µm particles) as stationary phase. All liquid phases are specified
in experimental procedures.
Melting points were measured using a Stuart SMP30 melting point apparatus.
4.5.2 P. aeruginosa QS Inhibition Assay1,243
Compounds were prepared in 96-well microtiter plate (Nunc, Denmark) at concentra-
tion of 10 mM in 100% biograde DMSO. Test compounds were then mixed with ABTGC
medium and serial diluted to give a final concentration of 20 µM in the first well. An
overnight culture of PAO1-lasB-gfp strain (grown in LB medium at 37 °C, 200 rpm) was
diluted in ABTGC medium to a final optical density at 600 nm (OD600) of 0.02 (2.5 ×
108 CFU/mL). An equal amount of the bacterial suspension was added to the wells to
reach final inhibitor concentration of 10 µM. DMSO control (0.1% final concentration)
and blank control were used. The microtiter plate was incubated at 37 °Cin Tecan Infi-
nate 200 Pro plate reader (Tecan Group Ltd., Ma¨nnedorf, Switzerland) to measure the cell
density (OD600) and GFP fluorescence (excitation at 485 nm, emission at 535 nm) with 15
min intervals for at least 12 h. The inhibition assay for all test compounds and controls
were done in duplicate manner. Originally, a compound, G10, was found to be active
against P. aeruginosa, in the beginning this compound was used as a benchmark.
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4.5.3 General Procedure: Synthesis of Imides
In a round-bottomed flask containing a magnetic stirring bar, the primary amine was
slowly added to a vigorously stirring solution of itaconic anhydride 4.6 (1.0 equiv.) in
CHCl3 (0.1–0.2 M) and stirred for 1 h. In most cases, precipitation was observed within
minutes. The carboxylic amide intermediate was collected by filtration and washed with
a minimum CHCl3. When the intermediate did not precipitate, all volatiles were removed
under reduced pressure, and used without further purification. In a round-bottomed
flask equipped with a plastic stopper, Ac2O (3.5 equiv.) and NaOAc (0.5 equiv) was added
to the intermediate and stirred for 45 min at 100 °C. The dark solution was cooled to rt and
poured into ice cold H2O and extracted with EtOAc (3 x). The combined organic phases
were dried over Na2SO4, filtered, and concentrated in vacuo. The crude residues were pu-
rified immediately by flash chromatography. During the imide-formation isomerization
occurred, and for some of the reactions it was possible to isolate this compound.
3-Methylene-1-(naphthalen-1-yl)pyrrolidine-2,5-dione (4.5a) and
3-methyl-1-(naphthalen-1-yl)-1H-pyrrole-2,5-dione (4.5b)
According to the general procedure for synthesis of imides, 1-naphthylamine (639 mg,
4.46 mmol, 1.0 equiv.) and itaconic anhydride 4.6 (500 mg, 4.46 mmol, 1.0 equiv.) in
CHCl3 (42.8 mL) afforded a pale pink solid that was treated with Ac2O (1.48 mL, 15.6
mmol, 3.5 equiv.) and NaOAc (146 mg, 1.78 mmol, 0.4 equiv.) and heated at 100 °C. The
dark reaction mixture was cooled and poured into ice cold H2O (25 mL) and extracted
with EtOAc (3 x 25 mL). Purified by flash chromatography (EtOAc:hexane 1:4).
3-Methylene-1-(naphthalen-1-yl)pyrrolidine-2,5-dione (4.5a)
N
O
O
528 mg, 50%; pale yellow solid; Rf = 0.11 (EtOAc:hexane 1:4; UV); IR (neat)
ν (cm – 1): 3069, 3051, 2969, 2921, 1710, 1662, 1597, 1468; 1H-NMR (400 MHz,
CDCl3): δ 7.99–7.92 (m, 2H, ArH), 7.60–7.50 (m, 4H, ArH), 7.38 (dd, J = 7.3,
1.0 Hz, 1H, ArH), 6.53 (t, J = 2.3 Hz, 1H, CCHH), 5.81 (t, J = 2.3 Hz, 1H,
CCHH), 3.67 (m, 2H, C(O)CH2C(CH2)C(O)); 13C-NMR (101 MHz, CDCl3): δ 173.3, 169.0,
134.6, 133.3, 130.3, 129.4, 128.8, 128.7, 127.4, 126.8, 126.4, 125.5, 122.2, 122.1, 34.4;
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3-Methyl-1-(naphthalen-1-yl)-1H-pyrrole-2,5-dione (4.5b)
N
O
O
151 mg, 14%; yellow solid; Rf = 0.16 (EtOAc:hexane 1:4; UV); IR (neat) ν
(cm – 1): 3091, 3059, 3013, 2960, 1702, 1637, 1597, 1465, 1374; 1H-NMR (400
MHz, CDCl3): δ 7.96–7.91 (m, 2H, ArH), 7.57–7.50 (m, 4H, ArH), 7.36 (dd,
J = 7.3, 1.3 Hz, 1H, ArH), 6.60 (q, J = 1.6 Hz, 1H, C(O)CHC(CH3)C(O)), 2.25
(d, J = 1.6 Hz, 3H, C(O)CHC(CH3)C(O)); 13C-NMR (101 MHz, CDCl3): δ 171.3, 170.2,
146.3, 134.6, 130.6, 129.9, 128.7, 128.2, 127.9, 127.2, 127.0, 126.7, 125.5, 122.5, 11.5;
1-Mesityl-3-methylenepyrrolidine-2,5-dione (4.7a)
N
O
O
According to the general procedure for synthesis of imides, 2,4,6-
trimethylaniline (376 µL, 2.68 mmol, 1.0 equiv.) and itaconic anhydride
4.6 (300 mg, 2.68 mmol, 1.0 equiv.) in CHCl3 (12.8 mL) afforded a white
solid that was treated with Ac2O (886 µL, 9.37 mmol, 3.5 equiv.) and
NaOAc (110 mg, 1.34 mmol, 0.5 equiv.) and heated at 100 °C. The dark reaction mixture
was cooled and poured into ice cold H2O (25 mL) and extracted with EtOAc (3 x 25 mL).
The residues were purified by flash chromatography (EtOAc:hexane 1:3) to afford 4.7a
(226 mg, 37%) as a light brown solid. Rf = 0.19 (EtOAc:hexane 1:3; UV); IR (neat) ν (cm
– 1):
3095, 2984, 2952, 2919, 2858, 1707, 1660, 1485, 1371; 1H-NMR (400 MHz, CDCl3): δ 6.98
(s, 2H, ArH), 6.47 (t, J = 2.3 Hz, 1H, CCHH), 5.74 (t, J = 2.3 Hz, 1H, CCHH), 3.55 (t, J =
2.3 Hz, 2H, C(O)CH2C(CH2)C(O)), 2.31 (s, 3H, ArCH3), 2.07 (s, 6H, 2 x ArCH3); 13C-NMR
(101 MHz, CDCl3): δ 172.8, 168.5, 139.5, 135.3, 133.2, 129.4, 127.5, 121.6, 34.1, 21.1, 17.8;
1-(3,5-Dimethylphenyl)-3-methylenepyrrolidine-2,5-dione (4.8a)
N
O
O
According to the general procedure for synthesis of imides, 3,5-
dimethylaniline (334 µL, 2.68 mmol, 1.0 equiv.) and itaconic anhydride
4.6 (301 mg, 2.68 mmol, 1.0 equiv.) in CHCl3 (25.6 mL) afforded a pale
brown solid that was treated with Ac2O (886 µL, 9.37 mmol, 3.5 equiv.)
and NaOAc (110 mg, 1.34 mmol, 0.5 equiv.) and heated at 100 °C. The cooled reaction
mixture was poured into ice cold H2O (25 mL) and extracted with EtOAc (3 x 25 mL).
Flash chromatography (EtOAc:hexane 1:4) provided of 4.8a (99 mg, 17%) as a pale or-
ange solid. Rf = 0.17 (EtOAc:hexane 1:3; UV); IR (neat) ν (cm
– 1): 2998, 2958, 2922, 1706,
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1664, 1595, 1469, 1382; 1H-NMR (400 MHz, CDCl3): δ 7.04 (s, 1H, ArH), 6.91 (m, 2H,
ArH), 6.46 (t, J = 2.3 Hz, 1H, CCHH), 5.72 (t, J = 2.3 Hz, 1H, CCHH), 3.49 (t, J = 2.3 Hz,
2H, C(O)CH2C(CH2)C(O)), 2.35 (s, 6H, 2 x ArCH3); 13C-NMR (101 MHz, CDCl3): δ 173.2,
168.8, 139.2, 133.2, 131.7, 130.8, 124.3, 121.7, 34.1, 21.4;
1-Butyl-3-methylenepyrrolidine-2,5-dione (4.9a)
N
O
O
According to the general procedure for synthesis of imides, n-butylamine
(265 µL, 2.68 mmol, 1.0 equiv.) and itaconic anhydride 4.6 (301 mg, 2.68
mmol, 1.0 equiv.) in CHCl3 (12.8 mL) afforded after evaporation a white
residue that was treated with Ac2O (886 µL, 9.37 mmol, 3.5 equiv.) and
NaOAc (110 mg, 1.34 mmol, 0.5 equiv.) and heated at 100 °C. The dark reaction mixture
was cooled and poured into ice cold H2O (25 mL) and extracted with EtOAc (3 x 25 mL).
Flash chromatography (EtOAc:hexane 1:3) provided 4.9a (47 mg, 10%) as a red oil. IR
(neat) ν (cm – 1): 2959, 2935, 2873, 1698, 1663; 1H-NMR (400 MHz, CDCl3): δ 6.33 (t, J = 2.4
Hz, 1H, CCHH), 5.61 (t, J = 2.4 Hz, 1H, CCHH), 3.57 (t, J = 7.5 Hz, 2H, NCH2CH2), 3.30 (t, J
= 2.4 Hz, 2H, C(O)CH2C(CH2)C(O)), 1.61–1.54 (m, 2H, NCH2CH2CH2CH3), 1.37–1.28 (m,
2H, NCH2CH2CH2CH3), 0.92 (m, 3H, NCH2CH2CH2CH3); 13C-NMR (101 MHz, CDCl3):
δ 174.0, 169.7, 133.5, 120.5, 38.8, 33.9, 29.9, 20.2, 13.7;
1-(2,3-Dimethylphenyl)-3-methylenepyrrolidine-2,5-dione (4.10a)
N
O
O
According to the general procedure for synthesis of imides, 2,3-
dimethylaniline (327 µL, 2.68 mmol, 1.0 equiv.) and itaconic anhydride 4.6
(300 mg, 2.68 mmol, 1.0 equiv.) in CHCl3 (25.6 mL) afforded a pink solid
that was treated with Ac2O (886 µL, 9.37 mmol, 3.5 equiv.) and NaOAc (110
mg, 1.34 mmol, 0.5 equiv.) and heated at 100 °C. The dark reaction mixture was cooled
and poured into ice cold H2O (25 mL) and extracted with EtOAc (3 x 25 mL). Purification
by flash column chromatography (EtOAc:hexane 1:3) gave 4.10a (286 mg, 47%) as a light
yellow solid. Rf = 0.14 (EtOAc:hexane 1:3; UV); IR (neat) ν (cm
– 1): 3088, 3005, 2983, 2953,
2923, 1706, 1662, 1601, 1469, 1373; 1H-NMR (400 MHz, CDCl3): δ 7.26-7.19 (m, 2H, ArH),
6.95 (d, J = 7.4 Hz, 1H, ArH), 6.47 (t, J = 2.3 Hz, 1H, CCHH), 5.74 (t, J = 2.3 Hz, 1H, CCHH),
3.54 (m, 2H, C(O)CH2C(CH2)C(O)), 2.33 (s, 3H, ArCH3), 2.01 (s, 3H, ArCH3); 13C-NMR
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(101 MHz, CDCl3): δ 173.1, 168.8, 138.6, 134.3, 133.6, 131.3, 131.0, 126.5, 125.6, 121.8, 34.2,
20.5, 14.5;
3-Methylene-1-phenylpyrrolidine-2,5-dione (4.11a) and
3-methyl-1-phenyl-1H-pyrrole-2,5-dione (4.11b)
According to the general procedure for synthesis of imides, aniline (244 µL, 2.68 mmol,
1.0 equiv.) and itaconic anhydride 4.6 (301 mg, 2.68 mmol, 1.0 equiv.) in CHCl3 (12.8 mL)
afforded a white solid that was treated with Ac2O (886 µL, 9.37 mmol, 3.5 equiv.) and
NaOAc (110 mg, 1.34 mmol, 0.5 equiv.) and heated at 100 °C. The dark reaction mixture
was cooled and poured into ice cold H2O (25 mL) and extracted with EtOAc (3 x 25 mL).
Purified by flash chromatography (EtOAc:hexane 1:3).
3-Methylene-1-phenylpyrrolidine-2,5-dione (4.11a)
N
O
O
245 mg, 49%; off white solid; Rf = 0.12 (EtOAc:hexane 1:3; UV); IR (neat) ν
(cm – 1): 3096, 3069, 2992, 2957, 1701, 1661, 1593, 1496; 1H-NMR (400 MHz,
CDCl3): δ 7.52–7.47 (m, 2H, ArH), 7.43–7.39 (m, 1H, ArH), 7.35–7.32 (m,
2H, ArH), 6.48 (t, J = 2.3 Hz, 1H, CCHH), 5.75 (t, J = 2.3 Hz, 1H, CCHH),
3.52 (t, J = 2.3 Hz, 2H, C(O)CH2C(CH2)C(O)); 13C-NMR (101 MHz, CDCl3): δ 173.0, 168.6,
133.1, 132.0, 129.3, 128.8, 126.5, 121.9, 34.1;
3-Methyl-1-phenyl-1H-pyrrole-2,5-dione (4.11b)
N
O
O
147 mg, 29%; pale yellow solid; Rf = 0.29 (EtOAc:hexane 1:3; UV); IR (neat)
ν (cm – 1): 3086, 3072, 2926, 1693, 1639, 1594, 1395; 1H-NMR (400 MHz,
CDCl3): δ 7.48–7.44 (m, 2H, ArH), 7.37–7.33 (m, 3H, ArH), 6.48 (q, J = 1.7
Hz, 1H, C(O)CHC(CH3)C(O)), 2.18 (d, J = 1.7 Hz, 3H, C(O)CHC(CH3)C(O));
13C-NMR (101 MHz, CDCl3): δ 170.8, 169.7, 145.9, 131.8, 129.2, 127.9, 127.6, 126.1, 11.3;
1-(4-Chlorophenyl)-3-methylenepyrrolidine-2,5-dione (4.13a) and
1-(4-chlorophenyl)-3-methyl-1H-pyrrole-2,5-dione (4.13b)
According to the general procedure for synthesis of imides, 4-chloroaniline (341 mg, 2.68
mmol, 1.0 equiv.) and itaconic anhydride 4.6 (300 mg, 2.68 mmol, 1.0 equiv.) in CHCl3
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(12.8 mL) afforded a white solid that was treated with Ac2O (886 µL, 9.37 mmol, 3.5 equiv.)
and NaOAc (110 mg, 1.34 mmol, 0.5 equiv.) and heated at 100 °C. The dark reaction
mixture was cooled and poured into ice cold H2O (25 mL) and extracted with EtOAc (3 x
25 mL). Purified by flash chromatography (EtOAc:hexane 1:3).
1-(4-Chlorophenyl)-3-methylenepyrrolidine-2,5-dione (4.13a)
N
O
O
Cl
182 mg, 31%; off-white solid; Rf = 0.1 (EtOAc:hexane 1:3; UV); IR (neat)
ν (cm – 1): 3095, 3063, 1705, 1665, 1493; 1H-NMR (400 MHz, CDCl3): δ
7.48–7.44 (m, 2H, ArH), 7.33–7.30 (m, 2H, ArH), 6.49 (t, J = 2.3 Hz,
1H, CCHH), 5.76 (t, J = 2.3 Hz, 1H, CCHH), 3.51 (t, J = 2.3 Hz, 2H,
C(O)CH2C(CH2)C(O)); 13C-NMR (101 MHz, CDCl3): δ 172.6, 168.3, 134.6, 132.8, 130.4,
129.5, 127.7, 122.3, 34.1;
1-(4-Chlorophenyl)-3-methyl-1H-pyrrole-2,5-dione (4.13b)
N
O
O
Cl
237 mg, 40%; pale yellow solid Rf = 0.24 (EtOAc:hexane 1:3; UV);
IR (neat) ν (cm – 1): 3083, 2928, 1696, 1644, 1495, 1400; 1H-NMR (400
MHz, CDCl3): δ 7.44–7.41 (m, 2H, ArH), 7.33–7.30 (m, 2H, ArH),
6.49 (q, J = 1.8 Hz, 1H, C(O)CHC(CH3)C(O)), 2.17 (t, J = 1.8 Hz, 3H,
C(O)CHC(CH3)C(O)); 13C-NMR (101 MHz, CDCl3): δ 170.4, 169.4, 146.1, 133.5, 130.3,
129.4, 127.7, 127.1, 11.3;
1-(4-Chloro-2-fluorophenyl)-3-methylenepyrrolidine-2,5-dione (4.14a) and
1-(4-chloro-2-fluorophenyl)-3-methyl-1H-pyrrole-2,5-dione (4.14b)
According to the general procedure for synthesis of imides, 4-chloro-2-fluoroaniline (297
µL, 2.68 mmol, 1.0 equiv.) and itaconic anhydride 4.6 (300 mg, 2.68 mmol, 1.0 equiv.)
in CHCl3 (12.8 mL) afford a white solid that was treated with Ac2O (886 µL, 9.37 mmol,
3.5 equiv.) and NaOAc (110 mg, 1.34 mmol, 0.5 equiv.) and heated at 100 °C. The dark
reaction mixture was cooled and poured into ice cold H2O (25 mL) and extracted with
EtOAc (3 x 25 mL). Purified by flash chromatography (EtOAc:hexane 1:3).
1-(4-Chloro-2-fluorophenyl)-3-methylenepyrrolidine-2,5-dione (4.14a)
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N
O
O
F
Cl
157 mg, 24%; off-white solid; Rf = 0.13 (EtOAc:hexane 1:3; UV); IR (neat)
ν (cm – 1): 3119 3065, 2925, 1713, 1663, 1586, 1498; 1H-NMR (400 MHz,
DMSO): δ 7.29–7.20 (m, 3H, ArH), 6.49 (t, J = 2.3 Hz, 1H, CCHH), 5.77
(t, J = 2.3 Hz, 1H, CCHH), 3.72–3.53 (m, 2H, C(O)CH2C(CH2)C(O))); 13C-
NMR (101 MHz, DMSO): δ 171.9, 167.7, 157.4 (d, JCF = 256.3 Hz), 136.5 (d, JCF = 10.0 Hz),
132.9, 131.15, 131.14, 125.4 (d, JCF = 3.9 Hz), 122.8, 117.9 (d, JCF = 23.1 Hz), 34.32;
1-(4-Chloro-2-fluorophenyl)-3-methyl-1H-pyrrole-2,5-dione (4.14b)
N
O
O
F
Cl
87 mg, 14 % off-white solid IR (neat) ν (cm – 1): 3102, 2993, 2957, 2923,
1709, 1641, 1585, 1500, 1388; 1H-NMR (400 MHz, CDCl3): δ 7.27–7.18 (m,
3H, ArH), 6.53–6.52 (q, J = 1.8 Hz, 1H, C(O)CHC(CH3)C(O)), 2.18 (d, J =
1.8 Hz, 3H, C(O)CHC(CH3)C(O)); 13C-NMR (101 MHz, CDCl3): δ 169.7,
168.5, 157.7 (d, JCF = 255.9 Hz), 146.7, 135.7 (d, JCF = 9.3 Hz), 130.49, 130.48, 128.2 125.2 (d,
JCF = 3.9 Hz), 117.7 (d, JCF = 23.1 Hz), 11.4;
1-(3-Chlorophenyl)-3-methylenepyrrolidine-2,5-dione (4.15a) and
1-(3-chlorophenyl)-3-methyl-1H-pyrrole-2,5-dione (4.15b)
According to the general procedure for synthesis of imides, 3-chloroaniline (283 µL, 2.68
mmol, 1.0 equiv.) and itaconic anhydride 4.6 (300 mg, 2.68 mmol, 1.0 equiv.) in CHCl3
(12.8 mL) afforded a off-white solid that was treated with Ac2O (886 µL, 9.37 mmol, 3.5
equiv.) and NaOAc (110 mg, 1.34 mmol, 0.5 equiv.) and heated for 45 min. The dark
reaction mixture was cooled and poured into ice cold H2O (25 mL) and extracted with
EtOAc (3 x 25 mL). Purified by flash chromatography (EtOAc:hexane 1:3).
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1-(3-Chlorophenyl)-3-methylenepyrrolidine-2,5-dione (4.15a)
N
O
O
Cl 206 mg, 35%; off-white solid; Rf = 0.1 (EtOAc:hexane 1:3; UV); IR (neat) ν
(cm – 1): 3119, 3079, 3011, 2922, 1706, 1659, 1593, 1477, 1381; 1H-NMR (400
MHz, DMSO): δ 7.44–7.37 (m, 3H, ArH), 7.28–7.26 (m, 1H, ArH), 6.49 (t,
J = 2.3 Hz, 1H, CCHH), 5.77 (t, J = 2.3 Hz, 1H, CCHH), 3.51 (t, J = 2.3
Hz, 2H, C(O)CH2C(CH2)C(O)); 13C-NMR (101 MHz, DMSO): δ 172.5, 168.2, 134.8, 132.1,
132.7, 130.2, 129.0, 126.8, 124.7, 122.4, 34.1;
1-(3-Chlorophenyl)-3-methyl-1H-pyrrole-2,5-dione (4.15b)
N
O
O
Cl 90 mg, 15%; off-white foam; Rf = 0.24 (EtOAc:hexane 1:3; UV); IR
(neat) ν (cm – 1): 3093, 2963, 2925, 1706, 1642, 1594, 1478, 1388; 1H-NMR
(400 MHz, CDCl3): δ 7.41–7.27 (m, 4H, ArH), 6.49 (q, J = 1.8 Hz, 1H,
C(O)CHC(CH3)C(O)), 2.18 (d, J = 1.8 Hz, 3H, C(O)CHC(CH3)C(O)); 13C-
NMR (101 MHz, CDCl3): δ 170.3, 169.2, 146.1, 134.7, 132.9, 130.1, 127.9, 127.7, 126.0, 123.9,
11.3;
1-(2-Chlorophenyl)-3-methylenepyrrolidine-2,5-dione (4.16a) and
1-(2-chlorophenyl)-3-methyl-1H-pyrrole-2,5-dione (4.16b)
According to the general procedure for synthesis of imides, 2-chloroaniline (282 µL, 2.68
mmol, 1.0 equiv.) and itaconic anhydride 4.6 (300 mg, 2.68 mmol, 1.0 equiv.) in CHCl3
(12.8 mL) afforded a off-white solid that was treated with Ac2O (886 µL, 9.37 mmol, 3.5
equiv.) and NaOAc (110 mg, 1.34 mmol, 0.5 equiv.) and heated at 100 °C. The dark
reaction mixture was cooled and poured into ice cold H2O (25 mL) and extracted with
EtOAc (3 x 25 mL). Purified by flash chromatography (EtOAc:hexane 1:3).
1-(2-Chlorophenyl)-3-methylenepyrrolidine-2,5-dione (4.16a)
N
O
O
Cl 362 mg, 61%; off-white solid; Rf = 0.13 (EtOAc:hexane 1:3; UV); IR (neat)
ν (cm – 1): 3101, 2960, 2932, 1710, 1662, 1483; 1H-NMR (400 MHz, DMSO):
δ 7.57–7.53 (m, 1H, ArH), 7.44–7.37 (m, 2H, ArH), 7.28–7.23 (m, 1H, ArH),
6.48 (t, J = 2.3 Hz, 1H, CCHH), 5.76 (t, J = 2.3 Hz, 1H, CCHH), 3.63–3.48
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(m, 2H, C(O)CH2C(CH2)C(O)); 13C-NMR (101 MHz, DMSO): δ 172.3, 168.0, 133.2, 132.5,
131.0, 130.7, 130.1, 130.0, 128.0, 122.4, 34.4;
1-(2-Chlorophenyl)-3-methyl-1H-pyrrole-2,5-dione (4.16b)
N
O
O
Cl 55 mg, 9%; light yellow solid; Rf = 0.28 (EtOAc:hexane 1:3; UV); IR (neat)
ν (cm – 1): 3095, 3070, 3042, 1702, 1642, 1488, 1392; 1H-NMR (400 MHz,
DMSO): δ 7.54–7.52 (m, 1H, ArH), 7.42–7.35 (m, 2H, ArH), 7.27–7.24 (m,
3H, ArH), 6.51 (q, J = 1.8 Hz, 1H, C(O)CHC(CH3)C(O)), 2.19 (d, J = 1.8
Hz, 3H, C(O)CHC(CH3)C(O)); 13C-NMR (101 MHz, DMSO): δPeak ν(F1) [ppm] Intensity
[abs] Annotation 170.1, 169.0, 146.4, 133.3, 130.8, 130.7, 130.5, 129.6, 128.0, 127.8, 11.4;
1-(4-Bromophenyl)-3-methylenepyrrolidine-2,5-dione (4.17a) and
1-(4-bromophenyl)-3-methyl-1H-pyrrole-2,5-dione (4.17b)
According to the general procedure for synthesis of imides, 4-bromoaniline (460 mg, 2.68
mmol, 1.0 equiv.) and itaconic anhydride 4.6 (300 mg, 2.68 mmol, 1.0 equiv.) in CHCl3
(12.8 mL) afforded a white solid that was treated with Ac2O (886 µL, 9.37 mmol, 3.5 equiv.)
and NaOAc (110 mg, 1.34 mmol, 0.5 equiv.) and heated at 100 °C. The dark reaction
mixture was cooled and poured into ice cold H2O (25 mL) and extracted with EtOAc (3 x
25 mL). Purified by flash chromatography (EtOAc:hexane 1:3).
1-(4-Bromophenyl)-3-methylenepyrrolidine-2,5-dione (4.17a)
N
O
O
Br
267 mg, 37%; off-white solid; Rf = 0.09 (EtOAc:hexane 1:3; UV); IR (neat)
ν (cm – 1): 3093, 3062, 2994, 1705, 1665, 1490; 1H-NMR (400 MHz, DMSO):
δ7.62–7.59 (m, 2H, ArH), 7.27–7.23 (m, 2H, ArH), 6.48 (t, J = 2.3 Hz,
1H, CCHH), 5.76 (t, J = 2.3 Hz, 1H, CCHH), 3.54 (t, J = 2.3 Hz, 2H,
C(O)CH2C(CH2)C(O))); 13C-NMR (101 MHz, DMSO): δ172.6, 168.2, 132.8, 132.5, 130.9,
128.0, 122.6, 122.3, 34.1;
1-(4-Bromophenyl)-3-methyl-1H-pyrrole-2,5-dione (4.17b)
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N
O
O
Br
142 mg, 20%; light yellow solid; Rf = 0.28 (EtOAc:hexane 1:3; UV); IR
(neat) ν (cm – 1): 3087, 2962, 2923, 2843, 1697, 1646, 1592, 1491, 1375; 1H-
NMR (400 MHz, DMSO): δ7.59–7.56 (m, 2H, ArH), 7.28–7.24 (m, 2H,
ArH), 6.48 (q, J = 1.8 Hz, 1H, C(O)CHC(CH3)C(O)), 2.17 (d, J = 1.8 Hz,
3H, C(O)CHC(CH3)C(O)); 13C-NMR (101 MHz, DMSO): δ170.4, 169.3, 146.1, 132.4, 130.9,
127.7, 127.3, 121.4, 11.3;
1-(4-Fluorophenyl)-3-methylenepyrrolidine-2,5-dione (4.18a) and
1-(4-fluorophenyl)-3-methyl-1H-pyrrole-2,5-dione (4.18b)
According to the general procedure for synthesis of imides, 4-fluoroaniline (254 µL, 2.68
mmol, 1.0 equiv.) and itaconic anhydride 4.6 (300 mg, 2.68 mmol, 1.0 equiv.) in CHCl3
(12.8 mL) afforded a white solid that was treated with Ac2O (886 µL, 9.37 mmol, 3.5 equiv.)
and NaOAc (110 mg, 1.34 mmol, 0.5 equiv.) and heated at 100 °C. The dark reaction mix-
ture was cooled and poured into ice cold H2O (25 mL) and extracted with EtOAc (3 x 25
mL). Purified by flash chromatography (EtOAc:hexane 1:3). affording 1-(4-fluorophenyl)-
3-methylenepyrrolidine-2,5-dione 4.18a as a off white solid () and 1-(4-fluorophenyl)-3-
methyl-1H-pyrrole-2,5-dione 4.18b as a white solid.
1-(4-Fluorophenyl)-3-methylenepyrrolidine-2,5-dione (4.18a)
N
O
O
F
222 mg, 40%; off-white solid; Rf = 0.08 (EtOAc:hexane 1:3; UV); IR (neat)
ν (cm – 1): 3067, 2962, 2928, 1703, 1664, 1602, 1511, 1386; 1H-NMR (400
MHz, CDCl3): δ 7.36–7.31 (m, 2H, ArH), 7.20–7.14 (m, 2H, ArH), 6.48 (t,
J = 2.4 Hz, 1H, CCHH), 5.75 (t, J = 2.4 Hz, 1H, CCHH), 3.51 (t, J = 2.4 Hz,
2H, C(O)CH2C(CH2)C(O))); 13C-NMR (101 MHz, CDCl3): δ 172.9, 168.5, 162.3 (JCF = 248.6
Hz), 132.9, 128.4 (JCF = 8.6 Hz), 127.9 (JCF = 3.25 Hz), 122.2, 116.3 (JCF = 23.0 Hz), 34.0;
1-(4-Fluorophenyl)-3-methyl-1H-pyrrole-2,5-dione (4.18b)
N
O
O
F
107 mg, 19%; off-white solid; Rf = 0.24 (EtOAc:hexane 1:3; UV); IR (neat)
ν (cm – 1): 3093, 3078, 2997, 2931, 1698, 1640, 1602, 1513, 1405; 1H-NMR
(400 MHz, CDCl3): δ 7.34–7.29 (m, 2H, ArH), 7.17–7.11 (m, 2H, ArH),
6.48 (q, J = 1.8 Hz, 1H, C(O)CHC(CH3)C(O)), 2.17 (d, J = 1.8 Hz, 3H,
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C(O)CHC(CH3)C(O)), 13C-NMR (101 MHz, CDCl3): δ 170.7, 169.6, 161.8 (d, JCF = 247.6
Hz), 146.01, 127.86 (d, JCF = 8.5 Hz), 127.70 (d, JCF = 3.1 Hz), 127.61, 116.18 (d, JCF = 22.7
Hz), 11.3;
1-Hexyl-3-methylenepyrrolidine-2,5-dione (4.20a) and
1-hexyl-3-methyl-1H-pyrrole-2,5-dione (4.20b)
According to the general procedure for synthesis of imides, hexylamine (1.95 mL, 8.92
mmol, 1.0 equiv.) and itaconic anhydride 4.6 (1.00 g, 8.92 mmol, 1.0 equiv.) in CHCl3
(42.8 mL) afforded after evaporation a white residue that was treated with Ac2O (3.0 mL,
31.2 mmol, 3.5 equiv.) and NaOAc (366 mg, 4,46 mmol, 0.5 equiv.) and heated at 100 °C.
The dark reaction mixture was cooled and poured into ice cold H2O (50 mL) and extracted
with EtOAc (3 x 50 mL). Purified by flash chromatography (hexane→ 1:7 EtOAc:Hexane).
1-Hexyl-3-methylenepyrrolidine-2,5-dione (4.20a)
N
O
O
Me
145 mg, 8%; red oil; Rf = 0.13 (EtOAc:hexane 1:7; UV); IR (neat) ν (cm
– 1):
2930, 2859, 1701, 1663, 1391; 1H-NMR (400 MHz, CDCl3): δ 6.32 (t, J = 2.3
Hz, 1H, CCHH), 5.60 (t, J = 2.3 Hz, 1H, CCHH), 3.55 (t, J = 7.5 Hz, 2H,
NCH2CH2), 3.29 (t, J = 2.3 Hz, 2H, C(O)CH2C(CH2)C(O)), 1.61-1.54 (m, 2H,
NCH2CH2), 1.30-1.27 (m, 6H, CH2CH2CH2), 0.86 (t, J = 6.8 Hz, 3H, CH3); 13C-NMR (101
MHz, CDCl3): δ174.0, 169.7, 133.5, 120.4, 39.0, 33.9, 31.4, 27.8, 26.6, 22.6, 14.1;
1-Hexyl-3-methyl-1H-pyrrole-2,5-dione (4.20b)
N
O
O
246 mg, 14%; red oil; Rf = 0.34 (EtOAc:Heptane (1:7); UV); IR (neat)
ν (cm – 1): 3100, 2956, 2930, 2859, 1702, 1643, 1376; 1H-NMR (400 MHz,
CDCl3): δ 6.29 (q, J = 1.8 Hz, 1H, C(O)CHC(CH3)C(O)), 3.46 (t, J = 7.3 Hz,
2H, NCH2CH2), 2.06 (d, J = 1.8 Hz, 3H, C(O)CHC(CH3)C(O)), 1.58–1.51 (m,
2H, NCH2CH2), 1.28-1.24 (m, 6H, CH2CH2CH2); 0.86 (t, J = 6.7 Hz, 3H, CH3); 13C-NMR
(101 MHz, CDCl3): δ 172.1, 171.1, 145.6, 127.3, 38.1, 31.4, 28.7, 26.5, 22.6, 14.1, 11.1;
3-Methylene-1-octylpyrrolidine-2,5-dione (4.21a)
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N
O
O Me
According to the general procedure for synthesis of imides, octylamine
(442 mg, 2.68 mmol, 1.0 equiv.) and itaconic anhydride 4.6 (300 mg,
2.68 mmol, 1.0 equiv.) in CHCl3 (12.8 mL) afforded after evaporation
a white residue that was treated with Ac2O (886 µL, 9.37 mmol, 3.5
equiv.) and NaOAc (110 mg, 1.34 mmol, 0.5 equiv.) and heated at 100 °C. The dark
reaction mixture was cooled and poured into ice cold H2O (25 mL) and extracted with
EtOAc (3 x 25 mL). Purification by flash chromatography (1:3 EtOAc:Hexane) provided
4.21a (98 mg, 16%) as a off white solid. Rf = 0.27 (EtOAc:hexane 1:3; UV); IR (neat) ν
(cm – 1): 2925, 2855, 1703, 1664. 1367; 1H-NMR (400 MHz, CDCl3): δ 6.33 (t, J = 2.3 Hz,
1H, CCHH), 5.61 (t, J = 2.3 Hz, 1H, CCHH), 3.56 (t, J = 7.5 Hz, 2H, NCH2CH2), 3.30 (t, J =
2.3 Hz, 2H, C(O)CH2C(CH2)C(O)), 1.59 (p, J = 7.3 Hz, 2H, NCH2CH2), 1.29–1.25 (m, 10H,
CH2CH2CH2CH2CH2), 0.87 (t, J = 6.7 Hz, 3H, CH2CH3); 13C-NMR (101 MHz, CDCl3): δ
174.0, 169.7, 133.5, 120.5, 39.1, 33.9, 31.9, 29.35, 27.9, 27.0, 22.8, 14.2;
1-Decyl-3-methylenepyrrolidine-2,5-dione (4.22a) and
1-decyl-3-methyl-1H-pyrrole-2,5-dione (4.22b)
According to the general procedure for synthesis of imides, decylamine (1.78 mL, 8.92
mmol, 1.0 equiv.) and itaconic anhydride 4.6 (1.00 g, 8.92 mmol, 1.0 equiv.) in CHCl3 (42.8
mL) afforded after evaporation a white residue that was treated with Ac2O (2.95 mL, 31.2
mmol, 3.5 equiv.) and NaOAc (366 mg, 4,46 mmol, 0.5 equiv.) and heated at 100 °C. The
dark reaction mixture was cooled and poured into ice cold H2O (50 mL) and extracted
with EtOAc (3 x 50 mL). Purified by flash chromatography (hexane → EtOAc:hexane
1:9).
1-Decyl-3-methylenepyrrolidine-2,5-dione (4.22a)
N
O
O
Me
287 mg, 13%; red oil; Rf = 0.11 (EtOAc:hexane 1:9; UV); IR (neat) ν (cm
– 1):
3093, 2913, 2847, 1697, 1662, 1390; 1H-NMR (400 MHz, CDCl3): δ 6.33 (t, J
= 2.5 Hz , 1H, CCHH), 5.60 (t, J = 2.0 Hz , 1H, CCHH), 3.56 (t, J = 7.5 Hz
, 2H, NCH2CH2), 3.30 (t, J = 2.2 Hz , 2H, C(O)CH2C(CH2)C(O)), 1.62–1.55
(m, 2H, NCH2CH2), 1.28–1.24 (m, 14H, CH2CH2CH2CH2CH2CH2CH2), 0.87 (t, J = 6.9 Hz,
3H, CH2CH3); 13C-NMR (101 MHz, CDCl3): δ 174.0, 169.7, 133.5, 120.4, 39.1, 33.9, 32.0,
29.63, 29.59, 29.4, 29.3, 27.9, 27.0, 22.8, 14.2;
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1-Decyl-3-methyl-1H-pyrrole-2,5-dione (4.22b)
N
O
O
Me
226 mg, 10%; pink semi-solid; Rf = 0.30 (EtOAc:hexane 1:9; UV); IR (neat)
ν (cm – 1): 2923, 2854, 1704, 1643, 1375; 1H-NMR (400 MHz, CDCl3): δ
6.29 (q, J = 1.8 Hz, 1H, C(O)CHC(CH3)C(O)), 3.47 (t, J = 7.4 Hz, 2H,
NCH2CH2), 2.06 (d, J = 1.8 Hz, 3H, C(O)CHC(CH3)C(O)), 1.59–1.52 (m,
2H, NCH2CH2), 1.27–1.24 (m, 14H, CH2CH2CH2CH2CH2CH2CH2), 0.87 (t, J = 6.9 Hz,
3H, CH2CH3); 13C-NMR (101 MHz, CDCl3): δ 172.1, 171.1, 145.6, 127.3, 38.1, 32.0, 29.64,
29.61, 29.4, 29.3, 28.7, 26.9, 22.8, 14.2, 11.1;
1-Dodecyl-3-methylenepyrrolidine-2,5-dione (4.23a) and
1-dodecyl-3-methyl-1H-pyrrole-2,5-dione (4.23b)
According to the general procedure for synthesis of imides, dodecylamine (2.05 mL, 8.92
mmol, 1.0 equiv.) and itaconic anhydride 4.6 (1.00 g, 8.92 mmol, 1.0 equiv.) in CHCl3 (64.2
mL) afforded a white solid that was treated with Ac2O (2.95 mL, 31.2 mmol, 3.5 equiv.)
and NaOAc (366 mg, 4,46 mmol, 0.5 equiv.) and heated at 100 °C. The dark reaction
mixture was cooled and poured into ice cold H2O (50 mL) and extracted with EtOAc (3 x
50 mL). Purified by flash chromatography (EtOAc:hexane 1:9).
1-Dodecyl-3-methylenepyrrolidine-2,5-dione (4.23a)
N
O
O
Me
92 mg, 4% dark red semi-solid; Rf = 0.28 (EtOAc:hexane 1:9; UV);
IR (neat) ν (cm – 1): 3093, 2914, 2847, 1695, 1663, 1344; 1H-NMR (400
MHz, CDCl3): δ 6.33 (t, J = 2.2 Hz, 1H, CCHH), 5.61 (t, J = 2.2
Hz, 1H, CCHH), 3.56 (t, J = 7.5 Hz, 2H, NCH2CH2), 3.30 (t, J =
2.2 Hz, 2H, C(O)CH2C(CH2)C(O)), 1.62-1.55 (m, 2H, NCH2CH2), 1.28-1.24 (m, 18H,
CH2CH2CH2CH2CH2CH2CH2CH2CH2), 0.87 (t, J = 6.9 Hz, 3H, CH2CH3); 13C-NMR (101
MHz, CDCl3): δ 174.0, 170.0, 133.5, 120.5, 39.1, 33.9, 32.1, 29.76, 29.75, 29.7, 29.6, 29.5, 29.3,
27.9, 27.0, 22.8, 14.2;
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1-Dodecyl-3-methyl-1H-pyrrole-2,5-dione (4.23b)
N
O
O
Me
295 mg, 12%; pink semi-solid; Rf = 0.29 (EtOAc:hexane 1:9; UV); IR
(neat) ν (cm – 1): 3081, 2915, 2848, 1685, 1638, 1376; 1H-NMR (400 MHz,
CDCl3): δ 6.29 (q, J = 1.8 Hz, 1H, C(O)CHC(CH3)C(O)), 3.47 (t, J = 7.3
Hz, 2H, NCH2CH2), 2.07 (d, J = 1.8 Hz, 3H, C(O)CHC(CH3)C(O)), 1.59–
1.52 (m, 2H, NCH2CH2), 1.27–1.24 (m, 18H, CH2CH2CH2CH2CH2CH2CH2CH2CH2), 0.87
(t, J = 1.8 Hz, 3H CH2CH3); 13C-NMR (101 MHz, CDCl3): δ 172.0 171.0 145.4 127.2 38.0
32.0 29.61, 29.55, 29.5, 29.3, 29.1, 28.6, 26.8, 22.7, 14.1, 11.0;
3-Methylene-1-tetradecylpyrrolidine-2,5-dione (4.24a) and
3-methyl-1-tetradecyl-1H-pyrrole-2,5-dione (4.24b)
According to the general procedure for synthesis of imides, tetradecylamine (1.90 g, 8.92
mmol, 1.0 equiv.) and itaconic anhydride 4.6 (1.00 g, 8.92 mmol, 1.0 equiv.) in CHCl3
(68.2 mL) afforded at white white solid that was treated with Ac2O (2.95 mL, 31.2 mmol,
3.5 equiv.) and NaOAc (366 mg, 4,46 mmol, 0.5 equiv.) and heated at 100 °C. The dark
reaction mixture was cooled and poured into ice cold H2O (50 mL) and extracted with
EtOAc (3 x 50 mL). Purified by flash chromatography (hexane→ EtOAc:hexane 1:9).
3-Methylene-1-tetradecylpyrrolidine-2,5-dione (4.24a)
N
O
O
Me
63 mg, 2%; light brown solid; IR (neat) ν (cm – 1): ; 1H-NMR (400 MHz,
CDCl3): δ 6.33 (t, J = 2.5 Hz , 1H, CCHH), 5.61 (t, J = 2.0 Hz , 1H,
CCHH), 3.56 (t, J = 7.5 Hz , 2H, NCH2CH2), 3.30 (t, J = 2.2 Hz , 2H,
C(O)CH2C(CH2)C(O)), 1.61–1.55 (m 2H, NCH2CH2), 1.29–1.24 (m 22H
CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2), 0.88 (t, J = 6.8 Hz, 3H CH2CH3); 13C-
NMR (101 MHz, CDCl3): δ 174.0, 170.0, 133.5, 120.4, 39.1, 33.9, 32.0, 29.82, 29.79, 29.76,
29.7, 29.6, 29.6, 29.3, 27.9, 27.0, 22.8, 14.2;
3-Methyl-1-tetradecyl-1H-pyrrole-2,5-dione (4.24b)
N
O
O
Me
316 mg, 11%; light pink solid; IR (neat) ν (cm – 1): 3081, 2914, 2848,
1683, 1638, 1376; 1H-NMR (400 MHz, CDCl3): δ 6.29 (q, J = 1.8 Hz, 1H,
C(O)CHC(CH3)C(O)), 3.47 (t, J = 7.3 Hz, 2H, NCH2CH2), 2.07 (d, J = 1.8
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Hz, 3H, C(O)CHC(CH3)C(O)), 1.57–1.54 (m, 2H, NCH2CH2), 1.29–1.24
(m, 22H, CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2), 0.87 (t, J = 6.8 Hz, 3H, CH3);
13C-NMR (101 MHz, CDCl3): δ 172.0, 171.0, 145.5, 127.2, 38.0, 31.9, 29.7, 29.64, 29.62,
29.55, 29.5, 29.3, 29.1, 28.6, 26.8, 22.7, 14.1, 11.0;
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P. aeruginosa QS Inhibition Curves
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Appendix B: Inhibition curves
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ABSTRACT  
We herein present broadly useful and readily available non-integral hydroxylamine linkers for 
the routine solid-phase synthesis of hydroxamic acids. The developed protocols enable the 
 1 
efficient synthesis and release of a wide range of hydroxamic acids from various resins, relying 
on high control and flexibility with respect to reagents and synthetic processes. A trityl-based 
hydroxylamine linker was used to synthesize a library of peptide hydroxamic acids. The 
inhibitory effects of the compounds were examined for seven HDAC enzyme subtypes using a 
chemiluminescence-based assay. 
 
Introduction 
Hydroxamic acids belong to an important class of compounds with a plethora of biological 
properties, including antibacterial, antifungal and anticancer activity (Fig. 1).1,2  The ability of 
hydroxamates to chelate metal ions, such as Fe3+ and Zn2+, has been widely explored in biology 
and medicine, The siderophore desferrioxamene B (Desferal, 1) is used medically to treat iron 
overdose, which can arise either due to multiple blood transfusions or an underlying genetic 
blood disease.3 A large number of recent studies have dealt with hydroxamic acids as potent 
inhibitors of Zn2+-containing enzymes, such as matrix metallo-proteinases (MMPs), and histone 
deacetylases (HDACs). HDAC inhibitors represent a promising class of anticancer agents, with 
two hydroxam acid-based inhibitors now approved for cutaneous and peripheral T-cell 
lymphoma, respectively.  Recognizing the diverse anti-cancer activities of Vorinostat (SAHA, 
3)4 and Belonistat (4)5, huge efforts have been made to explore hydroxamic acids for the 
treatment of various cancers. In addition to promising anticancer effects, HDAC inhibitors have 
also been suggested for the treatment of a range of other diseases, such as internal fibrosis, 
autoimmune, inflammatory diseases, metabolic disorders and many more. However, disruption 
of multiple pathways by these inhibitors, and the lack of specificity by these inhibitors to a target 
 2 
enzyme, may contribute to the cytotoxicity observed in many clinical trials. Therefore, there is 
an increasing need to develop more potent and isoform-selective HDAC inhibitors.  Following 
the observation of clinical benefits of HDAC inhibitors in various diseases, there has been a 
substantial refocus on the organic chemistry and biomedical properties of the hydroxamic acid 
class of compounds. 
  
Figure 1. Clinically important hydroxamic acids. 
Discussions. 
Although a high number of potent hydroxamic acids have been identified in drug and probe 
discovery efforts,5 only few general methods for the parallel and combinatorial synthesis of 
hydroxamic acids have been reported. There have been notable reports describing the solid-phase 
synthesis of hydroxamic acids,6 e.g. hydroxylamine derivatives, being either N-tethered to 
MBHA,7 and Tentagel resins,8 or O-tethered to Wang,9 Sasrin,10 and trityl resins,11 have served 
as the starting point for the synthesis of a range of hydroxamic acids.  Alternatively, a reported 
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stepwise method relies on the hydrolysis of ester-bound compounds, followed by attachment of 
the formed carboxylic acids to a hydroxylamine resin using a peptide coupling agent, before final 
cleavage to generate hydroxamic acids.12 The solid-phase synthesis of hydroxamic acids via 
direct hydroxyaminolysis of ester-linked substrates has also been reported.13  
The use of non-integral linkers is usually preferred because these provide control and flexibility 
for the synthetic process,14 and exact degree of loading and functionalization may easily be 
controlled and assessed. Along these lines, any functionalized solid support can be used with 
such linkers. When the linker is attached through an amide or ester bond, the quality of the 
starting resin can be assured by controlling the purity of the linker. When the first building block 
is attached to the linker through a more demanding bond, this may advantageously be formed in 
solution before attaching the linker construct to the solid support.15 The majority of linkers used 
in solid-phase synthesis are thus of the non-integral type. 
Results 
As part of ongoing efforts to synthesize hydroxamic acids, we set out to develop a non-integral 
hydroxylamine linker for the solid-phase synthesis and release of hydroxamic acids. Important 
criteria comprise the applicability to protocols that effectively may lead to a wide variety of 
structurally diverse hydroxamic acids, notably with high control and flexibility for the synthetic 
process, on any kind of solid support. Initially, the p-methoxybenhydryl-linker 10 was 
investigated for the solid-phase synthesis of hydroxamic acids. The p-methoxybenhydryl-linker 
system was first reported by Walter16 and Brown,17 for the preparation of primary and secondary 
amides, respectively.   
 4 
To construct linker 10, phenylmagnesium bromide was added to vanillin, followed by 
alkylation with 4-bromobutanoate. Subsequent treatment with AcBr gave the bromide 6 in high 
yield. However, much to our surprise, reaction with FmocNHOH in the presence of DIPEA gave 
the N-alkylated derivative 7 as the sole product. Chan et al.18 had previously reported a related 
synthetic sequence using Fmoc-NR-OH (R = alkyl chain), where O-alkylation was forced. To 
synthesize the desired O-alkylated hydroxylamine-linker 10, bromide 6 was treated with N-
hydroxyphthalimide, followed by removal of the phthalimide with hydrazine. Fmoc-protection 
followed by treatment with Novozyme-435 led to the desired linker 10.  Using standard reagents 
for solid-phase peptide synthesis, the linker was immobilized and synthetically elaborated on an 
amino-functionalized PEGA resin. Hydroxamic acids were released when the resin was treated 
with CH2Cl2/TFA (1:1) for 24 hours. The linker resists 20% TFA (aq) for 1 hour, and is thereby 
compatible with removal of highly acid-labile protecting groups.  However, fluctuating yields 
and purities were generally observed with this linker system, often as a result of hydroxamate 
hydrolysis during periods of prolonged acidic treatment.  
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Scheme 1. Synthesis of p-methoxybenhydryl-based linker 10 for the solid-phase synthesis and 
release of hydroxamic acids 
In search of a more acid-labile construct, we became interested in a linker based on the trityl-
group (linker 16). The trityl-group was pioneered in linkers for solid-phase synthesis by 
Leznoff19 and Fréchet.20 Cleavage hereby becomes more straightforward, relying on either dilute 
TFA or HBr.20 More detailed studies indicated that anhydrous 0.3 M HCl (dioxane) was 
sufficient for cleavage. 19 Since then, trityl linker constructs have been generated for the release 
of a variety of functionalized molecules from solid support, particularly in integral linker 
constructs, e.g. peptides,21 hydroxamic acids,18 amines, acids, thiols,22 and as a non-integral 
linker through 4-carboxy derivatives.23  
Starting with 4-hydroxybenzophenone 11, addition of phenylmagnesium bromide24 gave trityl 
alcohol 12, which was alkylated with ethyl 4-bromobutanoate at the phenolic position to provide 
intermediate trityl ester 13 in high yield. Bromination with acetylbromide in toluene followed by 
treatment with Fmoc-NHOH in CH2Cl2 in the presence of DIPEA generated Fmoc-protected 
hydroxylamine ester 15. In this case, only O-substitution was observed with a sterically 
demanding alkylating reagent. Exposing ester 15 to hydrolysis with Novozyme-435 completed 
the synthesis of the trityl linker 16.  
 6 
 Scheme 2. Synthesis of trityl-based linker 16 for the solid-phase synthesis and release of 
hydroxamic acids 
Using standard reagents for solid-phase peptide synthesis, the linker was easily immobilized and 
synthetically elaborated on an amino-functionalized PEGA resin (Table 1). Rewardingly, 
hydroxamic acids were cleanly released when cleavage was performed with TFA/CH2Cl2 (1:10) 
in the presence of 2% (v/v) TIPS (Triisopropylsilane) for 5 min. In comparison, the commercially 
available amino-functionalised polystyrene resin functionalized with the hydroxylamine linker   
16 was tested under the same conditions. Here, hydroxamic acids were cleanly released after 5 
min. of treatment with 1% TFA (CH2Cl2). The reduced reactivity of linker 16 at the PEGA resin 
is explained by a reduced proton activity in the polyethylene glycol polyacrylamide-
functionalised resin (PEGA). The PEG based resins serve as proton sponges.   
For preliminary biological screening of small-molecule and peptide hydroxamic acids, we 
generated a library of potential HDAC inhibitors (19 A–BV; Table 1). In previous studies, we 
have identified the thiophene-group as a promising sub-structure in HDAC-inhibitors, generally 
leading to inhibitors of good activity and selectivity.25 Based on these results, further 
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investigation into thiophene-hydroxamic acids was chosen as the focus of this study. The library 
was synthesized using 4 different thiophene spacer-groups 20,26 21, 22, 23 which was used in 
combination with various terminating moieties (Scheme 3).  
 
Scheme 3. Application of a trityl-based linker for the solid-phase synthesis and release of 
thiophene hydroxamic acids. 
Much to our delight the synthesized hydroxamic acids 19A–BV showed activity against 
HDAC subtype enzymes as well as a marked isoform-selectivity, thus indicating the potential of 
the compound collection to identify important binding interactions through stereostructure–
 8 
activity studies. Specifically, 11 compounds (19N, 19R, 19S, 19AB, 19AD, 19AF, 19AJ, 19AN, 
19AX, 19BK, 19Bl) were found to selectively inhibit HDAC6. HDAC6 itself plays a role in 
degradation and clearance of misfolded proteins, as well as cell protection in response to 
environmental stress by interaction with stress granules.27 Thus, the multiple functions of 
HDAC6 modulate many cellular pathways, which are relevant to tumor cell biology and 
malignant behavior. On the basis of these functions, HDAC6 appears to be one of the most 
attractive targets among HDACs for cancer treatment. 
 
Conclusions. 
In summary, we have developed two broadly useful non-integral hydroxylamine linkers, based 
on a trityl and a biphenyl group, respectively. The developed protocols enable the efficient 
synthesis and release of a wide variety of hydroxamic acids, and show high control and 
flexibility for the synthetic process, including solid phase composition. A proof-of-concept 
collection of 72 skeletally diverse hydroxamic acids compounds was prepared. The inhibitory 
effects of the compounds were examined against 7 HDAC enzyme subtypes using a 
Chemiluminescence-based assay. 
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 Table 1. Chemical and biological data for hydroxamic acids. 
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 Table 1 continued 
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